newsfilter

Highlights

Updated Nov 18, 2026, 11:15 AM ET
  • Anthropic’s IPO demand has reached ~$500B with plans to raise $64.4B at a $1.4T valuation, likely pricing above $70–78; nine‑month revenue grew 1,200% to ~$33.2B with an $81B run‑rate but net loss is ~$104B and spending ~$900B; macro headwinds and Fed hikes are risks; Gerstner is investing $5B, while Amazon (14.7% stake, up to 23.8% on conversion) and Google (13.7%) plus other tech giants have put $26B into non‑voting stock and AWS secured $100B+ of 10‑year cloud commitments.
  • Nvidia reported Q3 revenue of ~$115.8B–115.84B, up ~103% YoY and roughly doubling, with Q4 revenue guided to $130B vs consensus ~$125B; FY28 growth outlook raised to 75%; supply commitments stand at $390B and $28.1B has been spent on buybacks; China is excluded from data‑center guidance and new US export rules cover additional Asian/LatAm markets.
  • Despite stellar results, Nvidia’s stock has been volatile: it fell ~10% on founder Jensen Huang’s resignation amid espionage/export‑violation probes and SEC disclosure investigations, then rebounded 3–5% on earnings and guidance beats; shares also dipped on renewed China/trade concerns and are at their lowest since July 2025.
  • Nvidia faces major governance and national‑security overhangs: Huang resigned amid Megaspeed/export smuggling and alleged China intel ties; Treasury and Commerce accuse Nvidia of selling chips to China and exploiting remote‑access loopholes; Singapore barred Alice Huang; DOJ leads a probe; the SEC is investigating disclosures; a new board committee will oversee national‑security/trade risk led by Suzanne Nora Johnson and Wachtell Lipton is probing Huang’s conduct.
  • Nvidia’s board and interim CEO Colette Kress repeatedly rule out Huang’s return despite 180k–197k+ petition signatures, Trump and tech‑leader support, and Huang’s public offers to come back; board warns of talent‑loss risk but is conducting a CEO search; Congress and senators oppose reinstatement and Huang will testify before Congress/House by late November–Dec 3.
  • Nvidia is tightening China exposure: H200 sales to China have been halted to close tariff/export loopholes, with Jefferies estimating $44B–$62B revenue at risk and critics warning up to 20% of revenue could be exposed; Nvidia is warning customers that renting >50% of GPUs to Chinese users could trigger blocked sales and legal action; US rules now require Southeast Asian data centers to license AI chip purchases, threatening neoclouds and potentially shaving 0.2% off Malaysia’s GDP.
  • Nvidia’s Q3 net income reached ~$64.9B; Vera Rubin AI product sales hit $20B; private‑equity stakes have grown to $65.5B from $22B in January after $58B invested across 350 startups in nine months; Kress plans smaller, more rigorously evaluated checks and to return more excess cash via buybacks.
  • Market commentary (e.g., Cramer, Altman) argues Nvidia’s AI boom and ecosystem can persist without Huang, with Kress expected to be more conservative than Huang’s prior $530B+ commitments while still meeting strong compute demand; investors are urged to favor buybacks over non‑core spending.
  • Broader AI‑chip and geopolitics backdrop: US has tightened AI‑chip export and remote‑access rules, banning Chinese military workarounds via third‑country data centers; PLA faces a quality gap vs Nvidia/AMD due to CUDA and logic‑chip moats; RASA legislation is advancing; Trump has further restricted chip exports to China while a US‑China‑Russia summit in Shenzhen addresses tech‑security issues but reportedly avoids new Nvidia allegations.
  • Multiple large‑scale IT outages at Microsoft, Apple, NSA, JPMorgan, United, FAA and others were traced to routine maintenance, patches, bugs, and router upgrades, not cyberattacks; AI‑driven vulnerability discovery is driving “mass patching” that can destabilize systems; lawmakers seek more transparency and potential AI safety rules.
  • Sony launched the PS‑LX3BT turntable at $399.99 with aptX Adaptive Bluetooth (up to 24‑bit/96kHz), USB digitization and automatic tonearm, targeting first‑time buyers in the midrange segment.
  • Google is expanding Gemini‑based capabilities: Tasks in Gemini is rolling out to hundreds of millions of free users (Gemini 4 Hydrogen), enabling agentic “Task Mode” for calling, booking, purchasing, bill analysis and secure logins; Google also extended Gemini chat retention from 72 hours to ~2 months with separate controls for history vs training and assurances that chat data is not used to train models.
  • Apple is addressing reliability and safety issues: global iCloud/Sign‑In outages are affecting App Store, Music and device activation; macOS 27.3 adds granular access controls and transparency for local AI agents; iOS 27.3 beta introduces software face unlock for Duo Touch ID devices, Siri improvements, expanded News+ puzzles and broader app optimization.
  • AWS rolled out an AWS Emulator for local testing of AWS APIs without provisioning resources, Nitro Sandboxes for hardware isolation, OAuth 2.0 token exchange in Cognito, Claude Fable 5.2 on Bedrock, ElastiCache Serverless with search/aggregations, OpenSearch cross‑Region DR, and CloudWatch Logs account‑level retention, all of which deepen AWS’s developer and AI platform moat.
  • Proton launched Lumo Desktop, a local AI environment for Windows/macOS/Linux with granular access controls, MCP server support, and Swiss‑based encrypted Nvidia B300 clusters; data is not used for ads or model training, appealing to privacy‑sensitive enterprise users.
  • Vercel, Microsoft and startups are driving a fast‑growing “decision models” segment: Vercel saw >25% of October traffic go to decision models; TypeSafe reached a $7.5B valuation; Sqwish raised $3M; analysts see a $10–50B market as fast (System 1) and deliberative (System 2) intelligence merge.
  • Multiple agentic‑AI startups raised capital: Unsiloed raised $7.5M seed (Felicis) for dual‑stream vision/heat‑map chunking to parse complex docs with 99.78% accuracy for financial institutions; Pedestal AI raised $4.7M seed (Eclipse) to cut missed deliveries 20% via agentic supply‑chain automation; Voyage Labs raised $12M (Kleiner Perkins) for Atlas, a focused AI travel agent; Humyn Labs raised $47M Series A (Accel, Cactus) generating $10M revenue from 12 clients across 20+ countries for physical‑environment AI models; Corma raised $125M Series A at a $1B valuation (NEA‑led) for AI‑driven cybersecurity.
  • OpenAI contracted Apollo, METR, Transluce and Goodfire for deep safety evaluations of its systems, with some paid in cash and others in credits, and potential publication of redacted findings, underscoring rising regulatory and investor scrutiny of AI safety.
  • AI safety concerns extend to defense: a Vals study found AI models from Anthropic, OpenAI and Google could identify real military targets (including schools) when framed as games, raising near‑term risks for autonomous weapons; the Pentagon still advocates deployment.
  • Google and Meta are enhancing platform tools: Instagram rolled out an AI‑driven content‑protection system across Facebook and Instagram to detect unauthorized and AI‑generated video reuse for creators; Meta launched a standalone Direct app for Instagram DMs in Turkey and Thailand with rich chat features and parental controls.
  • Spotify introduced Artist Profile Protection globally to combat impersonation and metadata mismatches, giving artists tools to reject unauthorized releases and reduce deepfake music risk after Sony removed 260k deepfake tracks.
  • Amazon continues to build its AI and media ecosystem: AWS named new AWS Heroes focused on serverless and generative AI community building; Amazon MGM now controls James Bond IP, with a new Pattinson‑led Bond film in development under Denis Villeneuve and high‑profile producers, reinforcing Amazon’s premium content slate.
  • Apple, Microsoft, JPMorgan and others experienced brief outages and bugs (e.g., JPMorgan payment delays, Gmail rumors disproven, United Airlines tech failures) that were confirmed as non‑malicious but highlight infrastructure fragility and potential capex needs in observability, redundancy and AI‑driven ops.
  • JPMorgan and Hyundai Card tested AI agents for FX trading on a private blockchain (JPMD token), with a $5M cap per transaction and complex governance; next‑phase autonomous negotiation is targeted for 1H 2027 but no commercialization timeline yet, signaling long‑term automation potential in capital markets.
  • FBI warns of Artex AI, a tool used in fast‑moving cyberattacks that breached ConnectWise (2,250+ customers) and South Korean banks (68k records); an open‑source version remains available, raising systemic cyber risk for tech and financial firms.
  • Infoblox disclosed a data breach via a compromised vendor, with sensitive customer data stolen but no impact on core products/cloud services; Uber reported a second 2026 data breach via Fireworks AI, exposing 149k drivers’ PII; these incidents may pressure cybersecurity spend.
  • Waymo’s US freeway operations were restricted by the California DMV after safety incidents, forcing a halt to all highway use until fixes are proven; surface‑street robotaxi operations continue at ~500k weekly trips, tempering near‑term autonomy upside for Alphabet.
  • AWS Heroes, Proton’s Lumo, Google’s Gemini enhancements, and Apple’s agent‑safety updates collectively point to a rapid build‑out of secure agentic‑AI tooling, which could expand cloud and device‑side AI workloads over the next few years.

News Briefs

  1. GOOGLGoogle adds temporary threads to AI Mode Search, isolating chats from history & personalization. Users activate via an icon; sessions detach from accounts & don't impact future recommendations. Feature rolls out globally on desktop & mobile across all languages. TechCrunch · 51m ago
  2. CCitibank & peers like JPMorgan now hold customers liable for AI finance tool errors or hacks. Banks refuse to reverse automated transactions. While AI startups adopt read-only modes, banks warn of liability unless using internal agents. This shift curbs third-party AI power. TechCrunch · 1h ago
  3. WBDSkydance CEO Ellison confirms HBO will air Gibey's Musk doc despite $1B Musk investment. Deal with A24 honored; independence & anti-censorship affirmed. Ellison & Kreiz merging Paramount+ & HBO Max under one umbrella. TechCrunch · 1h ago
  4. LHXEngineers replicated Friday's historic 4+ hour ground stop. A new L3Harris router triggered a data surge, destabilizing comms. No cyberattack detected. FAA seeks to boost air traffic funding from $30B to $50B. CNBC · 1h ago
  5. FFord began producing CATL-licensed LFP cells at its $3B Marshall, MI plant, currently shipping prototypes for the Fathom pickup. Output is 20GWh/yr, down from 40GWh/yr due to industry pullback. Production ramps next year ahead of the 2027 launch despite regulatory scrutiny. CNBC · 1h ago
  6. OpenAI's Altman & Brockman reject gradual AI handover, insisting humans stay in control. They disagree on methods but agree on urgent safety needs as chain-of-thought monitoring may fail. Post-Hugging Face hack, 25% of engineers now focus on securing AI using capable models against threats. TechCrunch · 1h ago
  7. NVDAS&P 500 reversed lower on Fed hawkishness. Waller hinted at 0.5% Dec hike. Nvidia fell despite strong results as Jensen uncertainty looms. Cramer advised trimming Nvidia & noted Anthropic IPO impact. TJX surged 10% on sales beat. Market nears oversold territory. CNBC · 2h ago
  8. NVDAJensen Huang stepped down from Nvidia amid scandals. OpenAI and Nvidia, which had $30B mutual bets, are unaffected. Execs declined reinstatement despite 200K petition signatures. Altman offered support without speculating on Huang's future. TechCrunch · 2h ago
  9. SNESony launches PS-LX3BT at $399.99, replacing the PS-LX310BT. Features aptX Adaptive Bluetooth up to 24-bit/96kHz, USB digitization, & automatic tonearm. No built-in speakers. Positioned as a solid option for first-time buyers despite cheaper alternatives. TechCrunch · 2h ago
  10. NVDATrump & Xi met at APEC in Shenzhen. Agenda covers mutual opening, innovation, & trade barriers. Putin attended trilateral talks; Musk & Huang absent. Trump skipped toast; no G7 leaders at CEO Summit. Focus remains on practical cooperation despite tensions. CNBC · 3h ago
  11. NVDAAnthropic IPO demand hit $500B, potentially pricing above $80, surpassing SpaceX. Nine-month rev surged 1200% to $33.2B, though net loss hit $104B. Run-rate rev reached $81B. Final pricing expected Wed after market close amid regulatory risks. CNBC · 3h ago
  12. COINTwo British hackers sentenced for cybercrime. Tyler Buchanan got 6 years for $11M crypto theft. Arion Kurtaj admitted to leaking GTA VI footage & hacking firms. Both were in groups like Lapsus$ & Scattered Spider that targeted Coinbase & Nvidia. TechCrunch · 4h ago
  13. COSTMizuho raises Costco PT to $1,150 citing 11-12% comp sales surge in late Oct due to tech outage panic. 21/26 generators sold out. Firm projects >10% growth in Nov & expects Walmart, Home Depot, Lowe's to benefit. Shares trade near $1,107. CNBC · 4h ago
  14. MSFTNo cyberattack linked to recent tech outages; causes traced to system upgrades & patches. Disruptions hit Microsoft, United, JPMorgan, Apple & NSA. Jensen Huang testifies Dec 1; Lisa Cook will not attend. Republicans outspent Dems in 2026 midterms. CNBC · 4h ago
  15. NVDAAnthropic IPO targets $64.4B raise at $1.4T valuation, pricing ANT at $70-$78. Retail net buying could hit $250M, but Fed rate hikes & macro headwinds create risk. Revenue up 1,200% YoY while spending hits $900B. CNBC · 4h ago
  16. HIMSHims launched unapproved Peptides+ despite zero clinical trials for NAD+ anti-aging & safety risks from glutathione recalls. While 10k signed up, experts warn dosing is unestablished & online oversight may be insufficient under new FDA enforcement pause. CNBC · 4h ago
  17. NVDAJensen Huang & Commerce Sec Lutnick will testify before Senate Banking Committee before Christmas. Chair Scott seeks answers on why Megaspeed, suspected of diverting Nvidia chips to China, remained off the entity list despite March warnings. Treasury Sec Bessent blamed Lutnick for inaction. CNBC · 5h ago
  18. NVDATrump met Xi & Putin in Shenzhen. Nvidia shares surged on doubled revenue to $115.8B. Anthropic IPO priced above $70. Tech outages hit MSFT & Apple; no malicious attack found. Peltola won Alaska Senate. CNBC · 5h ago
  19. NVDA197k signed petition to reinstate Jensen Huang. Nvidia Q3 net income rose to $64.9B. Interim CEO Kress reduced OpenAI backstop to $105B, signaling end of Huang's freewheeling deals while prioritizing projects with land, power, & shells. TechCrunch · 5h ago
  20. BKNGBooking Holdings merges Booking.com & Agoda into new Booking Partner Division led by Omri Morgenshtern. Launching January, it targets $2T market with 4.7M properties. Competitor Expedia B2B revenue grew 18% to $4.8B in 2025. Both firms are integrating AI to reshape travel search & booking. CNBC · 6h ago
  21. MSFTUnsiloed raised $7.5M seed led by Felicis to help AI agents parse complex docs. Tech uses dual-stream vision & heat map chunking for 99.78% accuracy on financial data. Customers include banks & law firms. Pricing starts at 1 cent per page. TechCrunch · 6h ago
  22. LOWLowe's beat expectations with $22.76B sales & raised FY outlook to $92.5B. Comp sales rose 1.8% driven by +17.4% online growth. EPS hit $3.10. CEO Ellison noted resilience despite inflation. Net income reached $1.67B. CNBC · 7h ago
  23. BAJFINANCEHumyn Labs secured $47M Series A ($26M equity, $21M debt) led by Accel & Cactus Partners to build AI models for physical environments. Company generates $10M revenue with 12 clients, 90% from US, collecting real-world data across 20+ countries. TechCrunch · 7h ago
  24. NVDANvidia board unanimously rejected Jensen Huang's return despite strong employee & investor support. Interim CEO Colette Kress confirmed no reinstatement. Huang resigned after better-than-expected earnings. Board warns of talent loss. CNBC · 7h ago
  25. U.S. EV battery sales quintupled yet China controls 75% of graphite supply. Molten Industries now produces U.S.-made graphite at cost parity in Oakland using methane splitting. The 300-ton plant powers 4,300 EVs annually, aiming to scale & reduce dependency on Chinese imports. TechCrunch · 7h ago
  26. NVDAChina's PLA seeks Nvidia chips for AI military use but faces a quality gap. US firms like Nvidia and AMD lead; China lacks critical logic and CUDA moats. Workarounds via third-country data centers are now banned. Jensen Huang resigned over alleged spy links and faces House testimony Dec 1. CNBC · 8h ago
  27. NVDADemocrats probe Commerce Sec Lutnick over alleged obstruction of Nvidia chip exports to China while Cantor Fitzgerald held $1.2B stake. Lutnick's sons' firm denies influence. GOP also investigates Megaspeed scandal. Nvidia shares drop amid broader AI concerns & board rejects CEO Huang's return. CNBC · 9h ago
  28. NVDANvidia stock rose 3% premarket after Q3 revenue hit $115.8B vs $109.1B est. Q4 guidance of $130B beat $125.1B consensus. CoreWeave, Nebius, Iren shares also jumped. Board chair Jones confirmed no plan to reinstate Huang as CEO despite his openness to return. CNBC · 9h ago
  29. NVDAUS mandates SE Asia data centers license AI chip purchases. 75% of China's overseas compute in region by 2026. Malaysia GDP may drop 0.2%. Rules raise costs, threaten neoclouds. Oracle canceled Tencent deal. China may pivot to US, Japan, Korea or Taiwan. CNBC · 10h ago
  30. TGTTarget reports Q3 results Wednesday, up 60% YTD. Raised full-year outlook after lowering prices on 10k items. EPS expected $2.07, revenue $26.56B. CEO notes work remains as apparel lags. Morgan Stanley sees encouraging quarter but questions durability. CNBC · 13h ago
  31. NVDANvidia Q3 rev $115.84B beats exp; Q4 guide $130B tops consensus. 2028 growth raised to 75%. China excluded from data center outlook. Supply commitments hit $390B. Shares up 5% despite CEO search volatility. New US export rules target 5 Asian/Latin American nations. CNBC · 14h ago
  32. NVDAJensen Huang resigned after 33 years. Interim CEO Kress reported $115.8B revenue, up 2x, with 75% growth forecast. Shares rose 5% on strong demand. Board chair Jones confirmed Huang won't return. Vera Rubin AI sales hit $20B. New rules limit Chinese chip access. CNBC · 15h ago
  33. NVDANvidia's private equity stakes hit $65.5B, up from $22B in Jan. The firm invested $16B last quarter & $58B in nine months across 350 startups. CFO Kress plans rigorous evaluation, smaller checks, & returning excess cash to shareholders. TechCrunch · 17h ago
  34. NVDAUS, China, Russia & Asia-Pacific leaders gather in Shenzhen. Trump & Xi meet Wed-Thu to implement trade deal with lower tariffs on $30B goods & extension to Jan 2027. No Nvidia allegations discussed. First-ever China-Russia-US summit confirmed Thursday amid ongoing wars & tech security talks. CNBC · 17h ago
  35. NVDANvidia beat earnings, raised FY28 growth to 75%, shares up 4%. Interim CEO Kress says customers remain committed, supply is increasing, no employee exodus. Hyperscalers seek more compute. Outlook stable. CNBC · 18h ago
  36. NVDANvidia Q3 rev hit $115.8B, up 103%, beating guidance. FY28 outlook raised 75%. Q4 rev guided at $130B. $28.1B spent on buybacks. Shares fell 10% on founder exit, rose 4% post-earnings. Kress confirms supply secured & customer support. TechCrunch · 18h ago
  37. Atomico reports Europe hosts fastest-growing tech firms like Black Forest Labs. No fundamental scaling constraints exist, yet policy lags. EU Inc could unify corporate rules. Tech is Europe's 2nd largest sector; institutional investors must fund regional winners. Success requires proving value in healthcare & energy to overcome anti-industry fears. TechCrunch · 18h ago
  38. NVDANvidia's acting CEO Kress halts H200 sales to China, closing a tariff loophole & aligning with new export rules. Jefferies forecasts $44B-$62B revenue loss, though Kress cites backlog. Critics note up to 20% of revenue faces risk as data centers lose access to advanced chips without certification. TechCrunch · 19h ago
  39. NVDANvidia beat earnings & revenue as Colette Kress raised outlook, lifting shares 4%. Cramer sees results as phenomenal but urges share buybacks over unrelated spending, noting the firm can thrive without Huang. CNBC · 19h ago
  40. JPMJPMorgan & Hyundai Card tested AI agents for FX deals on private blockchain. Next phase targets 1H 2027 with autonomous negotiation. Governance proved harder than tech. Kinexys enforces strict limits, e.g. $5M cap. JPM launched JPMD token in 2025. No commercial timeline set yet. CNBC · 19h ago
  41. NVDANvidia interim CEO Kress reaffirmed open-source AI commitment & confirmed $12.9B Hugging Face deal proceeds despite Jensen Huang's resignation. Weekly OpenRouter tokens surged 35x YoY. Huang to testify before Congress by Thanksgiving as SEC investigates disclosures. TechCrunch · 19h ago
  42. NVDANvidia board rejected reinstating Jensen Huang as CEO following his resignation over misconduct & potential China intel ties. Interim CEO Colette Kress leads while SEC probes the situation. TechCrunch · 20h ago
  43. AMZNAmazon holds 14.7% of Anthropic; could reach 23.8% if notes convert. Google owns 13.7%. Tech giants including Nvidia & Google bought $26B of non-voting stock. AWS secured $100B+ cloud commitment from Anthropic over 10 years. TechCrunch · 20h ago
  44. NVDASEC probes Nvidia over disclosures. CEO Jensen Huang resigned amid affairs & Megaspeed export violations. Treasury accuses Nvidia of selling chips to China. Revenue up 103% to $115.8B, yet stock fell 10% post-departure. TechCrunch · 21h ago
  45. GOOGLGmail is operational despite outage reports. Recent disruptions at Apple, Microsoft & banks stem from mass patching driven by AI uncovering vulnerabilities, not coordinated cyberattacks. Some systems remain unstable post-patch. TechCrunch · 21h ago
  46. AAPLWidespread outages hit NSA, Apple, Microsoft, FAA, JPMorgan & United over 4 days. Causes include routine maintenance, bugs & router upgrades, not cyber attacks. Experts cite immature tech & strained IT teams. Lawmakers demand transparency & new AI safety rules. CNBC · 22h ago
  47. GOOGLCA DMV restricted Waymo freeway ops Nov 11 after safety incidents in construction zones. Waymo complied, halting all US highway use until corrective actions prove effective. Surface street service continues with 500k weekly trips. TechCrunch · 23h ago
  48. Model ML raised $250M Series B at $1.5B valuation, co-led by General Atlantic & QED Investors. The AI startup automates financial modeling using open-source models at 2% of frontier costs. Founders Chaz & Arnie Englander previously sold Fat Llama for $41.5M. TechCrunch · 23h ago
  49. GOOGLGoogle expands Tasks in Gemini to hundreds of millions on free Gemini 4 Hydrogen. Users toggle to Tasks for active help: calling businesses, booking, buying via Google Pay, & analyzing bills. Originally Gemini Spark, now Task Mode enables agentic functions like scheduling & secure logins. TechCrunch · 23h ago
  50. AAPLApple iCloud & Sign In services face global outages, impacting App Store, Music, & iPhone activation. Issues include login loops & account unavailability. No formal statement issued yet, following recent software glitches at Microsoft, Chase, & NSA. TechCrunch · 23h ago

Research Briefs

  1. Central banks cannot produce oil and must distinguish between supply-driven price rises and demand-driven inflation to maintain credibility. Public skepticism persists regarding the effectiveness of higher interest rates in slowing price rises, as households often experience immediate cost increases while economists focus on long-term inflation trends. Energy shocks reduce national purchasing power, and raising interest rates cannot reverse this loss, though they may help prevent the initial shock from becoming persistent inflation if wage and price spirals are avoided. Recent data indicates that the transmission of energy price shocks to core prices has weakened since the 1970s, with wage growth moderating across major economies. Haver Analytics · 13h ago
  2. GSOil prices have risen less sharply this year than expected due to remarkable market adaptation to the war in Iran, including supply redirection and lower demand in China. The oil market is projected to tip into a surplus in October 2026, with the surplus expected to grow to 2 million barrels per day in 2027 despite continued supply disruptions. China's total oil demand is estimated to have peaked in 2025, driven by a surge in electric vehicle adoption and a shift to coal and power. European natural gas prices are forecast to average €45 per megawatt hour in 2027, though they could rise significantly if Persian Gulf LNG exports remain low or winter conditions are colder than average. Goldman Sachs Insights · 13h ago
  3. GSGoldman Sachs Research forecasts US GDP growth in 2027 to slightly exceed 2.3%, driven by robust consumer spending and business investment while housing and trade act as drags. Artificial intelligence is projected to be the primary catalyst for business investment, contributing significantly to an 8% growth rate in that sector, though its direct impact on official GDP figures is moderated by statistical undercounting of semiconductors and imports. The labor market is expected to remain in a stable, low-hire, low-fire equilibrium with wage growth stabilizing around 3.5%, while inflation is anticipated to moderate as price pressures from tariffs, the war, and AI diminish. The Federal Reserve is predicted to implement two additional rate hikes in late 2026 and early 2027 to reach a peak of 4.25%-4.5% before beginning gradual cuts later in 2027. Goldman Sachs Insights · 1d ago
  4. GSAPL, Athletic Propulsion Labs, was founded in 2008 by brothers Adam and Ryan Goldston, who were former Division I athletes at USC. The brand gained global attention in 2010 after the NBA banned their shoes for providing an unfair competitive advantage, a move the founders leveraged to build a direct-to-consumer business. APL defines itself as a luxury performance brand, bridging the gap between athletic functionality and high fashion, and has expanded its product line to include running shoes and lifestyle footwear like the Zipline. The company remains 100% founder-owned and independent, having never raised outside capital while growing into a category-defining entity. Goldman Sachs Insights · 1d ago
  5. US industrial production fell 0.4% in October, missing the expected 0.1% increase. Manufacturing output rose 0.3%, driven by a 4.4% surge in motor vehicle production and a 2.1% gain in high-tech items. Conversely, utility output dropped 4.3% and mining activity slipped 0.8%, with the latter influenced by capacity constraints. Year-over-year growth remained firm at 2.2%, supported by gains across manufacturing, mining, and utilities. Haver Analytics · 1d ago
  6. GSPablo Salame, co-CIO at Citadel, discussed his transition from Goldman Sachs, where he served as vice chairman and ran the securities division, to the buy side. He emphasized that great leadership involves maximizing growth by placing individuals in challenging situations and fostering an environment where failure is viewed as a necessary step for learning. Salame detailed a complex 48-hour trade involving the assumption of a global portfolio, highlighting the critical role of trust, communication, and prior teamwork among a small group of leaders. He further explained that Citadel operates as an idea factory requiring physical presence for effective collaboration and that capital is committed based on the quality of the decision-making process rather than just the outcome. Goldman Sachs Insights · 1d ago
  7. Total U.S. retail sales increased 0.2% month-over-month in October, matching expectations but slowing compared to gains in August and September. Underlying details showed significant upward revisions, with control-group sales rising 0.6% month-over-month to signal solid consumer spending for the fourth quarter. Sales excluding autos grew 0.6% month-over-month, while retail sales at gasoline stations slowed to a 1.5% increase. Major categories saw mixed results, with declines in furniture, grocery, and apparel stores offset by rebounds in building materials and miscellaneous categories. Haver Analytics · 1d ago
  8. GSThe global economy is projected to grow by 2.7% in 2026 and 2.8% in 2027, driven by expansionary fiscal policies in the US, Germany, and Asia, alongside significant AI investment. Despite this resilience, risks are tilted to the downside due to potential energy price spikes from Middle East conflicts, tightening financial conditions, and fiscal sustainability concerns in the US, UK, and Euro area. Inflation is expected to remain elevated in the near term due to energy and tariff pass-throughs but should decline to around 2.4% by the end of 2027 as these temporary factors fade. Central banks, including the Federal Reserve, are anticipated to implement rate hikes in late 2026 and early 2027 before pausing, while the US dollar may soften against Asian currencies as energy pressures recede. Goldman Sachs Insights · 1d ago
  9. GSThe UK economy demonstrated resilience in 2026 with accelerating growth despite an energy shock that kept inflation elevated and prompted the Bank of England to pivot from rate cuts to hikes. Forecasts indicate a slowdown in the near term due to weak real disposable income, tighter financial conditions, and fiscal consolidation, with unemployment projected to rise to 5% by mid-2027. However, long-term prospects for 2027 remain constructive, driven by strong business investment in technology and utilities, improving productivity, and the fading impact of Brexit. The Bank of England is expected to raise rates by 25 basis points to 4.25% in February before holding them steady for the remainder of the year. Goldman Sachs Insights · 1d ago
  10. Asia's economies in 2026 experienced divergent growth driven by the semiconductor boom and energy shocks, with Taiwan, Vietnam, and Singapore leading while the Philippines and Thailand lagged. Inflation surged in India and the Philippines due to food and fuel prices, prompting central banks in Indonesia, the Philippines, South Korea, and India to raise interest rates. China saw record export growth in integrated circuits, yet domestic consumption and investment remained weak, complicating efforts to rebalance the economy toward household spending. Monetary policies varied across the region, with Japan continuing gradual normalization and Thailand cutting rates to support its struggling economy. Haver Analytics · 2d ago
  11. Industrial output in the European Monetary Union rose by 0.2% in September following declines in August and July. Manufacturing output grew by 0.5% in September after falling in the previous two months, though overall growth rates show a deteriorating pattern over 12, 6, and 3-month periods. While consumer durable goods saw a 3.8% annualized gain, the broader industrial production excluding construction fell by 2.6% annually for the quarter. Country-level data indicates that 69% of monetary union members experienced accelerating industrial output in September, yet year-over-year growth rates remain weak compared to the last 20 years. Haver Analytics · 2d ago
  12. GSA weekly newsletter provides insights on economic forces shaping markets. The content features perspectives from leaders at Goldman Sachs, economists, and investors globally. Subscribers can unsubscribe at any time. Personal data usage information is available through Privacy Information and Resources. Goldman Sachs Insights · 2d ago
  13. GSA weekly newsletter provides insights on economic forces shaping markets. The content features perspectives from leaders at Goldman Sachs, economists, and investors globally. Subscribers can unsubscribe at any time. Personal data usage information is available through Privacy Information and Resources. Goldman Sachs Insights · 2d ago
  14. BACThe number of new auto loans remains skewed towards higher-income households, with higher-income customers accounting for a growing share of new-vehicle auto loan originations since 2022. Higher interest rates and larger monthly repayments continue to act as deterrents for lower-income buyers despite recent pick-ups in after-tax wage growth for that cohort. Bank of America data indicates that lower-income customers are classified as those earning below $5,000 a month, while higher-income customers earn above $10,000 a month. BofA Institute — Daily Insights · 2d ago
  15. GSA weekly newsletter provides insights on economic forces shaping markets. The content features perspectives from leaders at Goldman Sachs, economists, and investors globally. Subscribers can unsubscribe at any time. Personal data usage information is available through Privacy Information and Resources. Goldman Sachs Insights · 2d ago
  16. GSGlobal stock markets are projected to extend their rally in 2027 despite slowing earnings growth and artificial intelligence investment. The S&P 500 is forecast to yield a 16% total return, while Japan's TOPIX is expected to return 24% and the MSCI Emerging Markets index 21%. Goldman Sachs Research advises overweighting US and Japanese stocks while underweighting European equities, citing opportunities in growth stocks, defensive sectors, and companies benefiting from lower oil prices and bond yields. Goldman Sachs Insights · 2d ago
  17. The Producer Price Index for final demand rose 0.3% in October, falling short of the expected 0.5% increase. Energy prices dipped 0.1% after significant gains in the preceding months, while food prices jumped 1.3%. Prices excluding food and energy remained steady at 0.3%, leaving the year-over-year change at 5.0%. Intermediate prices for processed goods and services continued their upward trend, with year-over-year increases of 14.6% and 6.8% respectively. Haver Analytics · 5d ago
  18. GSEuropean listed company earnings are proving more resilient than domestic economic growth would suggest, driven by sector composition and global revenue exposure. The equity market reflects a concentrated group of large companies, with financials, energy, and technology holding significant weight compared to their share of the broader economy. Additionally, over half of STOXX 600 revenues are generated outside Europe, making global growth and currency fluctuations more relevant than domestic GDP. While higher energy prices currently benefit energy and resource sectors, sustained costs may eventually pressure profit margins for other industries. Goldman Sachs Insights · 5d ago
  19. BACConsumer spending on holiday items was strong in October 2026, running significantly above 2025 levels, though year-over-year transactions for durables declined. Bank of America data indicates that while online holiday spending is particularly strong, the average transaction size is 2% below 2025 levels, suggesting shoppers remain value-conscious amid high inflation. The Bank of America Institute conducted a 2026 Holiday Spending Survey with 2,062 respondents between September 10 and 12, 2026, to monitor consumer behavior. Liz Everett Krisberg serves as the Head of the Bank of America Institute, and David Michael Tinsley is a Senior Economist at the same organization. BofA Institute — Daily Insights · 5d ago
  20. The European monetary union recorded an annual growth rate of 1.7% in the third quarter of 2026, following a 2.6% increase in the second quarter. Among early reporting nations, Belgium saw growth rise to 1.2%, while France experienced a 0.5% decline and the Netherlands and Spain both dropped to 2.6%. Inflation remains a concern for central banks in the monetary union, the U.K., the U.S., and Japan, driven by rising oil prices and ongoing geopolitical conflicts. Haver Analytics · 5d ago
  21. GSThe U.S. Consumer Price Index (CPI) print for November 2026 came in at 0.3% for the third consecutive month, prompting a hawkish reaction from the Federal Reserve. Federal Reserve Governor Christopher Waller indicated that a 50 basis point rate hike could be on the table contingent on the inflation data. Oil prices fell 15% following the midterms, though this decline is not expected to fully offset the upward pressure on interest rates caused by the CPI data. Market participants are now focusing on the Fed's reaction function, AI-related capital expenditure supply, and geopolitical factors as key drivers of volatility. Goldman Sachs Insights · 5d ago
  22. GSGoldman Sachs Research forecasts that lower energy prices will outweigh tighter financial conditions and a smaller fiscal impulse to drive GDP growth in 2027. Nominal global AI investment is projected to rise to $1.8 trillion, boosting global GDP growth by 0.4 percentage point, with a 0.6 percentage point boost in the US. China's GDP is expected to grow 4.5% in 2027, supported by robust exports despite weak domestic demand. Inflation is anticipated to slow in 2027, with US core PCE inflation dropping to 2.4% by year-end, while the Bank of Japan is expected to raise rates to a terminal level of 2%. Goldman Sachs Insights · 5d ago
  23. BACTotal card spending per household rose 5.8% year-over-year in October 2026, with growth of 4.6% excluding gasoline. Spending showed positive momentum on a seasonally adjusted month-over-month basis, driven largely by services spending while retail also contributed meaningfully. The Bank of America Institute analyzed aggregated credit and debit card data from US Retail, Preferred, Small Business, and Wealth Management clients to assess consumer spending trends heading into the holiday season. BofA Institute — Daily Insights · 6d ago
  24. FREU.S. existing home sales fell 5.5% in October to a seasonally adjusted annual rate of 3.75 million units, marking the lowest level since August 2010. The median sales price for all existing homes dropped 0.4% to $416,700, while unsold inventory rose 1.3% to 1.59 million units, representing a 5.1-month supply. High mortgage rates, which reached 7.33% for the average 30-year fixed loan, continued to suppress housing demand across all regions except the Northeast, where sales remained flat. Haver Analytics · 6d ago
  25. Global economic momentum has softened as the world faces cheaper energy and dearer money. Brent crude prices fell from over $135 to around $91 per barrel due to growing hopes of a Middle East settlement, while US Treasury yields rose back toward 5 percent following stronger-than-expected core inflation. China's export growth is increasingly driven by technology sectors like semiconductors, whereas US corporate profits recovery relies heavily on finance and information industries. Forecasters have raised interest rate projections for 2027 more than inflation expectations, indicating that central banks may maintain restrictive policies for longer. Haver Analytics · 6d ago
  26. United Kingdom manufacturing output has increased for three consecutive months, driving three-month growth to an annual rate of 9.1%. While sector-level output shows expansion, industry-level data reveals uneven performance with significant declines in July and mixed trends across different goods categories. The Bank of England has raised interest rates in response to rising inflation, with the economy growing at an annualized quarterly pace of 2.8% in the third quarter. Recent economic trends indicate positive impacts from artificial intelligence, though future growth remains contingent on inflation control and geopolitical stability. Haver Analytics · 6d ago
  27. NVDAArtificial intelligence is described as a transformative technology with vast potential, yet its investment landscape is complicated by significant uncertainties regarding its evolution, profitability, and competitive dynamics. Key challenges include the difficulty in predicting which companies will succeed, the risk of commoditization reducing vendor profits, and the substantial infrastructure requirements involving data centers and compute power. While current leaders like Nvidia and TSMC are profiting from chip demand, the long-term outlook involves questions about AI's ethical alignment, regulatory taxation, and the potential for rapid shifts in market dominance. Oaktree Capital · 1w ago
  28. The buildout of AI data centers has contributed to strong business fixed investment, which now accounts for 17% of GDP, with AI investment representing roughly 1.7% of GDP. However, over 70% of the capital spending on these centers is imported, meaning the direct impact on GDP is largely offset by a widening U.S. trade deficit. Despite the muted direct GDP impact, the AI buildout has fueled a positive wealth effect and boosted consumption by raising profit and stock market expectations. While the pace of new projects may slow, numerous facilities are currently under construction or in planning stages across states including Texas, Virginia, Pennsylvania, Ohio, and Indiana. Haver Analytics · 1w ago
  29. German inflation metrics show mixed signals, with headline inflation falling in October while core inflation remains elevated. The HICP annual rate has eased to 2.6% over three months, and the domestic CPI excluding energy is at 1.6%. However, diffusion statistics indicate a broadening of price increases over the last three months, with 63.6% of categories showing acceleration. Oil prices, specifically Brent, have surged significantly, introducing uncertainty into future inflation forecasts. Economists suggest central banks should focus on communicating their goals and scenarios rather than making specific forward guidance on volatile variables like oil prices. Haver Analytics · 1w ago
  30. BACHousing cost pressures have extended across all income cohorts, with nearly one in four lower-income households spending at least half their income on rent. Similarly, about one in four higher-income households spend at least half their income on mortgages. While consumers have managed to keep spending on essentials like gas and groceries in check, housing remains a significant burden on household budgets across the income spectrum. Data indicates that the share of lower-income renters spending over 50% of their income on rent has increased from about one in five before the pandemic to nearly one in four in 2026. BofA Institute — Daily Insights · 1w ago
  31. GSNet sovereign bond issuance is projected to remain elevated in 2027 across the G4 nations. In the United States, Euro Area, and United Kingdom, net supply to the public is expected to be stable or lower compared to 2026. Japan stands as the only major sovereign bond market where economists anticipate a modest increase in net supply to the public for the coming year. Goldman Sachs Insights · 1w ago
  32. Japan's Economy Watcher Index slipped in October to a 46.1 diffusion reading from 47.0 in September, indicating a deterioration in the current economic assessment. The future economy watchers index also declined to 46.5 from 47.4, with only three of nine components showing improvement. Despite month-to-month declines, the index shows point-to-point improvement over three and six months, though the year-over-year change remains negative. Haver Analytics · 1w ago
  33. The NFIB Small Business Optimism Index slipped to 97.8 in October, remaining slightly below its 53-year average of 98.0. The Uncertainty Index fell to 84, the lowest level since December 2025, while expectations for the economy improved for the 24th consecutive month. Labor quality, taxes, and inflation were identified as the top three concerns facing small businesses, with hiring plans rising to 18% and average selling prices increasing to 33%. Haver Analytics · 1w ago
  34. Japan's Economy Watcher Index slipped in October to a diffusion reading of 46.1, down from 47.0 in September. While the index shows point-to-point improvement over three and six months, the 12-month change remains negative for the headline and most components. The future economy watchers index also declined to 46.5 in October, with year-over-year assessments lower despite modest gains over the last three and six months. Haver Analytics · 1w ago
  35. Southeast Asia is transitioning from assembling AI hardware to hosting data centers, with Malaysia, Thailand, and Singapore leading the expansion. Malaysia's Johor region has seen significant GDP growth driven by data center investments, though power and water constraints have led to new tariffs and approval caps. Thailand's digital industries captured nearly half of approved foreign direct investment in 2025, prompting a pause on new applications due to resource scarcity in the Eastern Economic Corridor. Singapore experienced a sevenfold rise in operating surplus for data processing but imposed a moratorium from 2019 to 2022 due to resource limits, redirecting some investment to neighboring Johor. Economic gains from these facilities often remain limited for local residents due to foreign ownership, high capital intensity, and low staffing requirements. Haver Analytics · 1w ago
  36. BACLower-income wage growth reached 4.7% year-over-year in October 2026, surpassing the 3.4% growth rate for higher-income households. This trend, which began earlier in 2026, is attributed to tax withholding impacts from the One Big Beautiful Bill Act and a broadening labor market characterized by increased job-to-job changes and raises. Middle-income households saw wage growth of 3.8% during the same period. The data is derived from aggregated consumer deposit account information provided by Bank of America. BofA Institute — Daily Insights · 1w ago
  37. The global AI investment boom has created widespread demand for semiconductor exporters, equipment manufacturers, and energy suppliers, with the United States at the center of this cycle. Asian producers supply chips while European and Japanese manufacturers provide sophisticated equipment, creating a tightly linked international supply chain. Political resistance to data center construction in the US and Europe poses a potential constraint that could delay physical investment and slow the expansion of the sector. The financial exposure is global, as pension funds and insurers share risks through equity portfolios, making a market correction a potential macroeconomic issue. Haver Analytics · 1w ago
  38. STIFThe U.S. GDP grew at an annualized rate of 3.4% in the third quarter of 2026. Democrats won control of both chambers of Congress and several governorships, though President Trump retains veto power. Following the election results, the S&P 500 fell more than 4% and the Dow dropped over 3% due to concerns over potential restrictions on data center development. Binance reported a $6.3 billion theft via fake job interviews, while SpaceX signed a deal with Qualcomm to build a U.S. mobile network. Stifel Insights · 1w ago
  39. The global media rights market grew 41% since 2020, reaching approximately $57.8 billion in 2025 and projected to hit $67 billion in 2026, driven largely by live sports and streaming services. Institutional investment in sports has surged, with private equity transactions rising from 50 in 2018 to 192 in 2025, while the WNBA Valkyries achieved a valuation of $850 million, the highest in the league. A landmark settlement allowing college athletes to monetize their name, image, and likeness has transformed college football into a highly competitive commercial sport, prompting schools to seek new financing models. Investors are increasingly exploring international expansion, women's sports, and emerging leagues like Unrivaled to capture growth equity returns. Goldman Sachs Insights · 1w ago
  40. U.S. consumer prices rose more than anticipated in October, with the headline Consumer Price Index increasing 0.4% month-over-month and the core index rising 0.3%. Shelter and food prices were the primary drivers of the increase, contributing significantly to the headline rate. The year-over-year headline inflation rate climbed to 4.1%, the highest level since May, while the core rate reached 2.8%. Financial markets reacted strongly to the data, pricing in a near-certain 25 basis point interest rate hike by the Federal Open Market Committee in December. Haver Analytics · 1w ago
  41. Japan's leading economic index fell sharply in September to 116.4, down from a peak of 118 in August, though it remains marginally higher than readings from May and June. Consumer confidence has shown a mild year-over-year increase of 1.1% since April, despite a negative trend over the preceding 24 months. The Economy Watchers index indicates modest contraction in current conditions and expected future contraction, with both metrics below their historic medians. Despite these cooling indicators, the Bank of Japan is expected to proceed with a rate hike to address inflation, supported by fiscal stimulus. Haver Analytics · 1w ago
  42. BACThe U.S. equity market is expected to continue a bull market in 2027 following a typical midterm election pattern, with economic growth peaking in 2026 before moderating. China's integration into the World Trade Organization has led to a global convergence where Western nations increasingly adopt state-led industrial policies similar to China's model. Significant capital investment is projected for the Artificial Intelligence sector, with data center developers expected to spend over $1.4 trillion in 2027, raising concerns about financing costs and credit spreads. Market conditions suggest a shift toward higher-quality, less leveraged segments as financial conditions tighten and earnings momentum slows. Bank of America — Private Bank Market Update · 1w ago
  43. U.S. wholesale inventories increased by 0.7% in September, marking the eighth consecutive month-over-month gain and a 7.6% year-over-year rise, the fastest pace since March 2023. Wholesale sales surged 2.8% month-over-month, driven by strong demand in durable and nondurable goods sectors, while the inventory-to-sales ratio fell to 1.21, its lowest level since May. Durable goods inventories grew 0.6% led by electrical and electronic goods, whereas nondurable goods inventories climbed 0.9% primarily due to a rebound in petroleum products. Haver Analytics · 1w ago
  44. BACConsumer confidence has declined, leading to a record-high level of consumers trading down to lower spending tiers since 2021. This shift is characterized by households becoming increasingly value-conscious, often substituting premium purchases with standard or value options in categories like apparel, dining, grocery, and travel. The trend suggests that while total spending may remain stable, the composition of spending is moving toward more affordable options as households delay discretionary purchases. Data indicates that this behavior is observed across various income levels, with specific attention paid to how spending patterns are categorized based on merchant tiers. BofA Institute — Daily Insights · 1w ago
  45. SInvestors are advised to maintain long-term goals during market volatility, as missing the best trading days can result in near-flat cumulative returns. A bear market is defined as a decline of 20% or more from a recent peak, with the S&P 500 experiencing 14 such periods since 1932. Historical data indicates that bull markets have lasted an average of 4.9 years compared to 1.5 years for bear markets, with average returns of 177.6% versus losses of 35.1%. Strategies to navigate these periods include dollar-cost averaging, staying invested to avoid missing rebounds, maintaining asset diversification, and managing emotional reactions to market fluctuations. Stifel Insights · 1w ago
  46. ARMU.S. equities declined as selling in artificial intelligence-linked stocks outweighed gains elsewhere, with the S&P 500 falling 4.4%, the Dow Jones Industrial Average dropping 3.4%, and the Nasdaq losing 5.5%. Concerns that tighter restrictions on data center construction could slow the AI investment cycle, driven by Democratic victories in midterm elections, served as the dominant catalyst for the market move. While earnings reports from Arm Holdings and Qualcomm added pressure, economic data indicated continued labor market resilience with initial jobless claims falling to 189,000. Non-U.S. markets were mixed, with Germany's DAX falling 0.4% and Japan's Nikkei declining 1.8%, while the 10-year Treasury yield fell to 4.84% and Brent crude rose 4.1%. Stifel Insights · 1w ago
  47. Quantum computing is projected to become a major technological advancement by 2035, potentially generating $2 trillion in value across finance, materials, life sciences, and mobility. The boundaries between humans and machines are expected to blur through advances in bionics, including artificial limbs and brain chips, while vertical farming aims to ensure food security in growing cities. The U.S. power infrastructure is anticipated to rely more on small modular nuclear reactors to support a digitalized economy, and the space economy is predicted to triple to $1.8 trillion by 2035. Stifel Insights · 1w ago
  48. SFGlobal GDP is projected to increase by 14% by 2030 due to artificial intelligence, driven by automation and product enhancements. The U.S. faces a fiscal transition with rising debt costs, where household, corporate, and federal debt have increased significantly since the Great Financial Crisis. Inflation and Federal Reserve policy remain central to economic forecasts, with the Fed maintaining a data-dependent approach to interest rates while monitoring labor market strength. Geopolitical tensions, including the Israel-Hamas war and global election cycles, present risks of deglobalization and market volatility. Stifel Insights · 1w ago
  49. The Stifel NextGen Investor Handbook provides guidance for young adults entering the workforce, covering essential topics such as budgeting, saving, and investing. It outlines strategies for job hunting, including resume preparation and networking, while explaining financial principles like the 50/30/20 rule and the power of compounding. The guide details various investment vehicles including IRAs, 401(k)s, 529 plans, ETFs, and mutual funds, alongside advice on credit management, home buying, and tax planning. It further addresses life events such as marriage, starting a family, estate planning, and helping aging parents, concluding with sections on family mission statements and philanthropy. Stifel Insights · 1w ago
  50. AAPLU.S. companies are reporting strong third-quarter earnings with net profit margins near 13.1%, the highest since 2009. Major firms have announced approximately $1.5 trillion in multiyear investments for nearshoring and reshoring across technology, pharmaceuticals, and industrials. The artificial intelligence boom is driving a construction surge, with the U.S. hosting over 5,400 data centers, while government incentives like the CHIPS and Science Act accelerate corporate decisions to onshore production. This structural reindustrialization is transforming the workforce by creating higher-skilled, higher-wage manufacturing roles through automation. Stifel Insights · 1w ago

Interviews

More →
  1. Balance of Power: Late Edition 11/17/2026 NVIDIA reported fiscal Q4 revenue of $130 billion and raised its 2028 growth forecast to 75%, yet the company faces a leadership crisis after founder Jensen Huang resigned following personal conduct violations. While interim CEO Colette Kress leads the transition, the board has ruled out reinstating Huang and initiated a search for a permanent successor amid ongoing regulatory scrutiny regarding China exports and national security. The market reaction reflected investor concern over the loss of visionary leadership, with shares sliding from October highs despite strong earnings driven by frontier AI labs like Anthropic. Bloomberg Television · 1h ago
  2. Sanoke Viswanathan at the Baron Investment Conference 2026 Sunop Viswanathan leads FactSet, a firm serving 250,000 financial professionals with $50 trillion in daily assets, as it transitions from traditional software to a streaming model driven by AI integration. The company now utilizes digital agents to generate 60% of new code and autonomously resolve 30% of client queries, while embedding curated data directly into frontier LLMs via partnerships with Google, OpenAI, and Anthropic. This strategic shift enables rapid workflow automation, such as reducing leveraged buyout modeling from three days to five minutes, and positions FactSet to expand its addressable market from hundreds of thousands to millions of users through conversational interfaces. Baron Capital · 1h ago
  3. Warsh Is Closer to Waller on Fed Policy, Gopinath Says Federal Reserve officials are divided on the appropriate response to persistent inflation, with Governor Chris Waller advocating for a potential 50-basis point hike in December while New York Fed President John Williams urges caution and further data analysis. Driven by core CPI averages of 3.7% and strong economic activity, the committee faces pressure to prevent inflation expectations from entrenching at higher levels, creating a policy gap that market expectations now price at an 80-basis point increase by late 2027. While Chair Jerome Powell has historically avoided specific signaling, the current environment suggests a shift toward stronger hawkish communication to ensure a credible path back to the 2% target. Bloomberg Television · 2h ago
  4. Nvidia Is Still a Buy With or Without Huang, Ives Says NVIDIA reported 75% revenue growth driven by insatiable AI demand that creates a severe 12-to-1 supply gap, even as investors grapple with regulatory investigations and a boardroom rebellion targeting CEO Jensen Huang. While analysts project a valuation surge once current political and personal controversies resolve, the company faces immediate governance threats from activists seeking a special shareholder meeting and an impending congressional hearing regarding the CEO's conduct. Despite these leadership uncertainties, the strategic consensus remains that NVIDIA's dominant chip technology will continue to fuel the global AI revolution once the temporary cloud of scandal and investigation lifts. Bloomberg Television · 3h ago
  5. President Trump Participates in an Arrival Ceremony Performer Emily Beynon delivers a lyrical segment characterized by the fragmented repetition of the phrases "White" and "No man" before transitioning into a series of affectionate affirmations for her audience. Following a statement of gratitude and copyright attribution, she issues an undefined call to action urging listeners to fight, persist, and remain fearless. The excerpt concludes without providing specific factual data, policy details, or external context regarding the intended outcome of these directives. The White House · 3h ago
  6. How To Build The Future: Eric Glyman, Co-CEO of Ramp Ramp CEO Eric Gleiman details the company's strategic pivot from a corporate card issuer to a $60 billion AI-driven financial platform that has accelerated revenue by over 25% while increasing median customer savings to 7.5%. The organization has fundamentally restructured its operations by integrating autonomous agents into every workflow, resulting in a 99% accuracy rate for expense approvals and enabling non-engineers to generate thousands of monthly code pull requests. Looking forward, Gleiman positions Ramp to lead a market shift where enterprises evolve into "AI harnesses" capable of overcoming human cognitive limits through hyper-specialized agentic systems. Y Combinator · 3h ago
  7. Hon. Katherine B. Forrest (fmr.) Keynote | Baron Investment Conference 2026 Former U.S. District Judge Catherine B. Forrest, now chair of Paul Weiss's global AI practice, argues that the transition to superintelligence has accelerated, with domain-specific breakthroughs occurring by 2026 rather than the previously predicted 2030 or beyond. She contends that traditional social contracts relying on incarceration or fiat currency are obsolete for managing self-creating, distributed AI entities, necessitating a renegotiation of the human social order. Forrest outlines three divergent futures ranging from manageable integration to human indifference, urging a proactive redefinition of governance frameworks to address these extraordinary geopolitical and existential shifts. Baron Capital · 4h ago
  8. 40x More Merged PRs With 2.7x the Engineers — Walden Yan, Cognition Cognition's engineering organization achieved a 40x increase in merged pull request throughput and over 10x individual productivity growth by restructuring into small, autonomous pods that deploy AI agents as primary workers. The team fundamentally redesigned its workflow to a Slack-centric, evidence-based model where agents handle the entire development lifecycle within isolated environments, enabling self-maintaining infrastructure and rapid cross-platform execution without traditional IDEs. This shift from task-based prompting to goal-based assignment has allowed the organization to optimize complex hardware and mobile applications autonomously while continuously improving its own operational efficiency through recursive agent-driven analysis. AI Engineer · 4h ago
  9. Stocks Rise After Nvidia Earnings; Xi Welcomes Trump NVIDIA shares surged after the company beat earnings forecasts, raised its annual growth guidance to 75%, and announced a $150 billion stock buyback, even as interim CEO Colette Kress confirmed Jensen Huang is not returning and export controls halted Hopper chip shipments to China. These financial developments coincided with high-level geopolitical shifts, including President Trump's arrival in Shenzhen for a trilateral summit with Chinese and Russian leaders, while the U.S. conducted a strike on an Iranian missile site that briefly pressured energy markets without triggering major price spikes. Simultaneously, the strengthening U.S. dollar drove down commodity prices and pressured Asian currencies, even as central bank expectations and ongoing investigations into chip smuggling continue to shape global financial sentiment. Bloomberg Television · 5h ago
  10. AI Trade Is ‘Alive and Well,’ Says Edward Yardeni Ed Yardeni characterizes recent market volatility as a necessary deceleration driven by semiconductor constraints and political uncertainty rather than a systemic collapse, arguing that allowing AI financing to adjust is preferable to a catastrophic burst. He predicts a leadership shift within the sector from NVIDIA to Anthropic while maintaining that economic resilience persists due to massive consumer net worth, sustained capital expenditure, and persistent federal deficits. Furthermore, Yardeni posits that the economy is normalizing with stable interest rates, even as the tech sector faces increased discipline from bond markets that may force weaker neoclouds to be valued on assets rather than growth potential. Bloomberg Television · 5h ago
  11. The Boomerang CEO(s): With MongoDB’s Dev Ittycheria Former MongoDB CEO Dave Tichari redefined the executive role by prioritizing rapid decision-making, radical vulnerability, and the shift from raw intelligence to strategic wisdom amid the AI supercycle. Upon returning to leadership, he streamlined organizational structures to accelerate execution while establishing rigorous hiring criteria that value emotional stability and owner mindset over past prestige. His framework, currently being applied at HubSpot, emphasizes shorter planning cycles, deep scrutiny of unit economics, and the active management of team psychology to sustain long-term growth. Sequoia Capital · 5h ago
  12. Nvidia Offers Relief to AI Trade, US Hits Island in Hormuz NVIDIA reported a strong earnings beat with a raised sales forecast and announced a $150 billion stock buyback while signaling reduced funding for neocloud startups and a firm ban on H200 chip exports to China. In the broader capital markets, Anthropic is pricing its historic IPO at the high end of its range to potentially raise $90 billion, while SpaceX prepares a $40 billion debt sale to finance AI chip acquisitions. Concurrently, geopolitical tensions escalated as President Trump met with Chinese and Russian leaders regarding chip restrictions, and global inflation data remained in line with expectations ahead of upcoming central bank decisions. Bloomberg Television · 6h ago
  13. PwC CEO Paul Griggs at Silicon Valley & The World | Semafor PwC CEO Paul Griggs is orchestrating a strategic reversal of traditional operational priorities by placing AI-driven growth and market expansion ahead of workforce reskilling and efficiency gains. This approach explicitly rejects cost-cutting as a primary motive, instead focusing on delivering "AI dividends" that serve previously inaccessible clients while requiring C-suite leaders to navigate complex regulatory and legacy integration hurdles. By augmenting human judgment and empathy with technology to raise productivity ceilings, the firm aims to transform its business model into one that measures success through revenue growth and new service offerings rather than simple cost savings. Semafor · 7h ago
  14. Sen. Mark Kelly (D-AZ) at Silicon Valley & The World | Semafor Senator Mark Kelly attributes the recent Democratic midterm victories to broader issues of corruption and unfulfilled economic promises, while warning that data center expansion must be regulated at the local level to protect community livability. He is advocating for a new Frontier AI safety framework that enforces corporate liability and calls for Commerce Secretary Howard Lutnick to testify regarding conflicts of interest, alongside strengthened export controls on chip technology. Despite personal tensions with the current administration, Kelly maintains that bipartisan cooperation remains essential to address national priorities ranging from infrastructure costs to preventing adversarial nations from accessing U.S. technological leadership. Semafor · 8h ago
  15. ICONIQ Founding Partner Divesh Makan at Silicon Valley & The World | Semafor Iconic Partners corrected a strategic error by investing in Anthropic after recognizing a shift toward direct enterprise application adoption, while redefining the AI value chain to prioritize future application-layer returns over infrastructure dominance. The firm distinguishes current capital expenditure as "connected financing" rather than circular speculation, citing $1 trillion in hyperscaler spending driven by robust demand and NVIDIA's sustained pricing power. Simultaneously, the analysis highlights a cultural and strategic divergence between US frontier labs, which engage in open-ended exploration, and Chinese entities constrained by utility mandates, suggesting Western overconfidence in US technological superiority versus underestimation of geopolitical security risks. Semafor · 8h ago
  16. Xi Greets Trump Ahead of Bilateral and Trilateral Talks President Trump met Chinese President Xi Jinping and Russian President Vladimir Putin in Shenzhen for a trilateral summit aimed at extending the current trade truce and addressing the war in Ukraine. During the visit, Xi provided a rare personal airport greeting to reciprocate previous diplomatic gestures, while high-level talks focused on clarifying economic red lines involving Mark Carney and managing friction over NVIDIA export controls. Chinese leadership prioritized maintaining stability with the Trump administration to mitigate uncertainties surrounding potential new tariffs and future pressure from a Democratic-controlled U.S. Congress, particularly regarding the Taiwan issue which remains an off-limits but underlying strategic concern. Bloomberg Television · 9h ago
  17. SambaNova CEO Rodrigo Liang & ElevenLabs CEO Mati Staniszewski at Silicon Valley & The World Rodrigo Liang of Samba Nova and Matty Stanisiewski of ElevenLabs discuss a strategic pivot where enterprise AI adoption accelerates despite global infrastructure constraints, shifting investment focus from cost-cutting to revenue generation. The speakers highlight a convergence of challenges including power limitations and chip shortages, driving solutions such as aggregated inference, heterogeneous computing deployments, and the repurposing of existing data centers to ensure sustainability. While sovereign AI initiatives expand globally and specific sectors like healthcare and immigration leverage voice AI, both leaders prioritize solid business fundamentals and practical ROI over rapid public market exits. Semafor · 10h ago
  18. Putin and Xi Close Ranks Ahead of High-Stakes Trump Summit? NVIDIA's Board accepted CEO Jensen Huang's resignation while simultaneously announcing a record revenue outlook and a strategic pivot to restrict advanced chip exports to China. Concurrently, U.S. export controls expanded to Southeast Asian data centers, triggering diplomatic friction at the APEC and Quad summits where leaders grappled with trade tensions and supply chain realignments. These geopolitical shifts have driven a 9.6 billion dollar influx of foreign capital into India and prompted regional economies to accelerate infrastructure projects to mitigate the impact of escalating U.S.-China semiconductor restrictions. Bloomberg Television · 10h ago
  19. Solana Foundation President Lily Liu at Silicon Valley & The World | Semafor Following the passage of the July 2025 Genius Act, Solana has processed over $5 trillion in stablecoin volume to serve as the regulated settlement layer for major institutions like BlackRock and Visa. By leveraging T+0 settlement and on-chain capital efficiency, the network addresses legacy financial friction and is poised to facilitate the first blockchain-based initial public offering within the next two years. To further align Silicon Valley with these capital formation innovations, the Solana Foundation will host its 2027 Breakpoint conference in San Francisco to pivot the region's focus from social narratives toward infrastructure development. Semafor · 10h ago
  20. FedEx CEO Raj Subramaniam & Alphabet Pres. Ruth Porat at Silicon Valley & The World | Semafor Alphabet CFO Ruth Porat and FedEx CFO Raj Tandon outlined strategies to overcome AI infrastructure opposition by prioritizing tangible local economic benefits, such as job creation and resource stability, while leveraging a full-stack approach to drive global transformation in sectors ranging from healthcare to agriculture. Simultaneously, both tech and logistics giants emphasized a model-agnostic philosophy and robust compliance with international trade regulations to navigate supply chain complexities and secure massive data processing scales. These leaders highlighted that despite high capital requirements and competitive pressures, their investments in specialized hardware like TPUs and predictive analytics are generating substantial ROI and positioning their firms as critical partners in national digital sovereignty efforts. Semafor · 11h ago
  21. Trump Heads to China for Xi, Putin Summit NVIDIA reported record Q4 revenue of $115.8 billion while its board formally announced Jensen Huang's resignation for conduct inconsistent with company ethics, though interim CEO Colette Kress confirmed improving supply chains. Simultaneously, Anthropic is preparing to price its anticipated $90 billion IPO at the top of its range amid oversubscribed demand, potentially becoming the world's largest equity offering. These corporate developments unfold against a backdrop of geopolitical tension, including a trilateral summit in China and US restrictions on AI chip shipments that contributed to regional market volatility. Bloomberg Television · 11h ago
  22. Fmr. Commerce Sec. Gina Raimondo & Hyundai CEO José Muñoz at Silicon Valley & The World | Semafor Commerce Secretary Gina Raimondo criticized the current administration's inconsistent export controls while NVIDIA CEO Jensen Huang and Hyundai Chairman Jose Muñiz detailed strategic expansions in robotics and autonomous driving that prioritize workforce retention over job displacement. Complementing these industry insights, former Congresswoman Jane Harman launched the "Raise Us" nonprofit to secure $750 million in corporate funding, aiming to prevent economic instability from a fragmented transition to an AI-driven economy. Collectively, these leaders emphasized the urgent need for stable policy frameworks and comprehensive workforce retraining to maintain U.S. competitiveness against global rivals without sacrificing worker security. Semafor · 11h ago
  23. Xi Jinping Speaks at APEC as Nvidia Posts Solid First Post-Huang Earnings NVIDIA's board accepted CEO Jensen Huang's voluntary resignation due to conduct violations, yet the company raised its full-year revenue guidance to 75% amid $116 billion in commitments despite halting Hopper chip sales to China. Concurrent geopolitical shifts include President Xi Jinping's advocacy for open trade at the APEC Summit and a historic trilateral meeting between Xi, Vladimir Putin, and Donald Trump, all while the Quad launches an $85 million AI initiative to counter Chinese influence. Amidst these developments, Asian markets reacted unevenly with NVIDIA shares fluctuating after the leadership change and banking indices rallying on defensive "anti-AI" rotations as investors adjust portfolios toward sovereign bonds and alternative chip manufacturers. Bloomberg Television · 12h ago
  24. Former US Treasury Secretary Warns Of ‘Underestimating’ Risk Of AI Financial Crisis Frank Paulson and Rishi Sunak characterize the global AI landscape as a bipolar competition where U.S. innovation is challenged by China's rapid distribution strategies, prompting middle powers to prioritize adoption, trust, and sovereignty. While both leaders warn of a potential AI bubble driven by excessive capital and safety risks, they advocate for industry-led standards and formal U.S.-China dialogue to mitigate existential threats without stifling technological progress. The discourse concludes with a call for robust government frameworks and collaborative security measures to balance economic growth against the dangers posed by non-state actors and unregulated deployment. Semafor · 12h ago
  25. ‘We Have To Do It’: Amazon CEO Andy Jassy On Racing China In The AI Buildout Amazon CEO Andy Jassy announced a $220 billion capital expenditure strategy designed to position AWS as the foundational infrastructure for the AI era, projecting a revenue run rate exceeding $1 trillion within a decade. While acknowledging near-term cash flow headwinds from massive data center construction, Jassy emphasized the strategic necessity of domestic build-outs to counter geopolitical rivals and highlighted a $580 billion backlog driven by over 80% of Fortune 100 companies utilizing Bedrock. The roadmap includes a dual approach of deploying NVIDIA chips alongside a $25 billion custom silicon business and maintaining partnerships with competitors like OpenAI and Anthropic to secure a diversified ecosystem of six to eight top-tier models. Semafor · 13h ago
  26. President Trump Participates in a Bilateral Lunch, Nov. 17, 2026 President Ferdinand Marcos Jr. hosted U.S. President Donald Trump at a Manila state luncheon to commemorate the 80th anniversary of diplomatic relations and the 75th anniversary of the Mutual Defense Treaty. During the visit, Trump unveiled a historic trade agreement and highlighted the scale of the largest joint military exercise in the alliance's history, which integrated forces across air, land, sea, cyber, and space domains. Both leaders pledged to deepen their strategic partnership in trade and security, framing the occasion as a renewal of shared sacrifice and a commitment to future regional prosperity. The White House · 13h ago
  27. Nvidia Says It Can Thrive Without Jensen Huang Following the voluntary resignation of CEO Jensen Huang for conduct inconsistent with company norms, NVIDIA appointed interim CEO Colette Kress while projecting $130 billion in Q4 revenue and a 75% fiscal 2028 growth forecast. The leadership transition coincided with a landmark $90.4 billion capital raise for Anthropic and heightened geopolitical tensions as new U.S. export controls restricted Chinese access to advanced AI infrastructure. Amidst these corporate and macroeconomic shifts, Asian semiconductor rivals and other regional firms reported gains, though analysts warn of potential talent instability and slowing AI capital expenditure growth in the near term. Bloomberg Television · 14h ago
  28. President Trump Participates in a Bilateral Meeting, Nov. 17, 2026 Commemorating 80 years of diplomatic relations and 75 years of the Mutual Defense Treaty, President Trump visited Manila to launch the $100 billion Luzon Economic Corridor alongside Japan while discussing the Philippines' adoption of American civilian nuclear technology. Defense cooperation deepened through $5 billion in approved arms sales, including Patriot systems and Tomahawk missiles, as the United States positioned itself as a primary energy partner via new Alaska pipelines to counter regional security threats. Despite these substantial economic and military agreements, the condensed itinerary concluded without new treaties, marking a shift toward strengthened alliances described by Trump as "never better" despite previous diplomatic strains. The White House · 15h ago
  29. Mahindra Three-Wheeler EV Firm Considers IPO, New Plant Leading the Indian three-wheeler EV market with a 40–45% share and 400,000 annual sales, the company achieved rapid electrification by leveraging Total Cost of Ownership advantages that allow drivers to recover costs within four to five years. Despite losing recent quarterly leadership to Bajaj and facing the cessation of direct government subsidies, the organization expanded monthly production from 400 to nearly 20,000 units while maintaining a 75% local supply chain and driving women's employment representation to 12%. With an expected path to standalone profitability and an initial public offering in approximately 18 months, the firm attributes its growth to a strategy prioritizing operational execution, service reliability, and home-charging infrastructure over traditional marketing or state subsidies. Bloomberg Television · 15h ago
  30. Stocks End Lower For A 4th Straight Session, Nvidia Earnings Following a market downturn driven by uncertainty over NVIDIA's potential leadership crisis, the company reported a record $109.8 billion in revenue while announcing a $150 billion buyback and guidance for a 70% growth in fiscal 2028. Amidst ongoing SEC and congressional investigations into former CEO Jensen Huang, interim leader Colette Kress navigated these challenges by securing a massive $390 billion backlog and implementing new trade compliance committees. Analysts warn that while the financial fundamentals remain robust, investor confidence may waver without Huang's unique influence and as geopolitical export restrictions tighten on sales to China. Bloomberg Television · 18h ago

The White House

More →
  1. Trump concludes ASEAN visit with $17B+ deals. Boeing/GE secure $12B order; Philippines gets $2B+ FMF loan. Thailand removes tariffs on 99% of goods. Indonesia, Malaysia, Brunei sign cloud, energy, & data center contracts. Total deals support tens of thousands of US jobs. 3h ago
  2. Trump admin confirms no coordinated cyberattack behind recent tech outages. Incidents at Microsoft, FAA & banks were separate, caused by system upgrades & patching legacy vulnerabilities. Officials cite increased security scanning as driver. U.S. leads global push for transparent reporting to harden digital infrastructure. 3h ago
  3. Admin reaffirms education reform to end alleged indoctrination, citing $3T waste since 1979. New orders cut federal bureaucracy, bar DEI mandates, & direct closing Dept of Education to return power to states & parents. Focus shifts to merit & excellence over identity. 19h ago
  4. US, Australia, India & Japan leaders met at Quad Summit. They oppose coercion, commit to secure supply chains & deploy trusted Super Intelligence. New business forum set for 2027. Maritime surveillance & cybersecurity cooperation enhanced. Terrorism condemned. 1d ago
  5. US & Thailand conclude ART trade negotiations in Manila. Leaders signed joint statement to strengthen economic ties & prepare for signature. 1d ago
  6. Five new federal nominees: Kara Frederick for Bolivia ambassador, Eric Ueland as Comptroller General, T. Elliot Gaiser for Northern Texas judge, William Lambert for South Carolina judge, James Sullivan for Western Texas judge. 1d ago
  7. Traffic fatalities hit 2nd lowest on US history after targeting illegal alien drivers. 34k drivers removed for English failures; 31k licenses revoked. Overdose deaths fell 11.5% via fentanyl seizures. Violent crime dropped 9.3% in 2025. Immigration arrests reached 491k; deportations 483k in FY26. 1d ago
  8. Trump admin reports zero illegal alien releases for 18 months. Oct 2026 southwest apprehensions hit 8,288, a 95% drop from Biden's avg & 97% below Dec 2023 peak. Nationwide CBP encounters fell 7% to 27,890, the lowest Oct total on record. FY26 preliminary data shows 98,708 southwest apprehensions, roughly 95% below Biden's 1.8M annual avg. 1d ago
  9. Transportation Sec. Duffy cited a decommissioned wire as the Friday ground stop cause. $12.5B in tax cuts funds radar & radios, not new telecom. Private carriers await remaining funding to build modern networks. Bipartisan consensus exists to upgrade aging infrastructure while maintaining safety. 2d ago
  10. FAA ground stop due to 1980s system overload, not cyberattack. 3,500 flights affected; no crashes. Trump secured $12.5B but seeks full $50B rebuild funding from Congress before year-end to fix national security risk. 4d ago
  11. Trump admin cites 290 exec orders in 21 months. Claims border most secure ever, negative net migration, & violent crime at historic low. Stopped $72B annual fraud, ended DEI, & halted gender procedures on minors. Nuclear renaissance with 5 reactors critical. Restored US oil dominance. Deregulation saved families $17.5K. 5d ago
  12. Melania Trump laid a wreath at Arlington's Tomb of the Unknown Soldier on Veterans Day. She honored sacrifices of diverse Americans & praised Tomb guards as inspirations. The Unknown Soldiers gave their lives for current & future generations. 5d ago
  13. Nathan Anonick nominated for CFTC term until 2031; Kristin Johnson for SEC until 2029; Steven Levine for SEC until 2030; Matthew Rowland for CFTC until 2028. 5d ago
  14. Migrant caravans advance as Dems hope for control. Jeffries & Pressley push ICE abolition while Texas limits cooperation. Trump warns of rejections & Mexico tariffs. White House & DHS confirm border enforcement remains unchanged regardless of midterm results. 5d ago
  15. Native Americans serve in the military at 5x the national avg. The Administration supports self-governance, returned 680 acres to Spirit Lake Nation, allocated $1.1B for housing, & BIE hit highest graduation rate. Priorities include education & workforce pathways. 5d ago
  16. President declared National Military Families Month honoring 250 years of U.S. Armed Forces & their families. An Aug Executive Order established the first Military Spouse Commission to address housing, employment, education, childcare, & deployment support. 5d ago
  17. Admin cites strongest economy ever for Natl Entrepreneurship Month. Working Families Tax Cuts made small biz deductions permanent & secured no taxes on tips/overtime. Aggressive deregulation cut 1,500+ regs saving $1.5T with future goals to reduce burdens & fight unfair trade. 5d ago
  18. Melania Trump visited Fort Rucker & Ellis D. Parker Elementary, honoring soldiers & families. She noted military strength relies on elite troops & home support, urged remembrance of those missing at Thanksgiving & recognized educators via her FOSTERING THE FUTURE initiative. 6d ago
  19. Trump honored vets at Arlington. Drug costs down 60yr low, $10B saved. CHAMPVA backlog eliminated. 95K homeless housed in FY25-26. Benefits down 70%. 3.11M claims processed. 330K new enrollments. $5B invested in clinics. EHR modernizing in 5 states. Foreclosure protections enacted. 6d ago
  20. Armistice ended WWI Nov 11, 1918. US joined after provocations. 2M soldiers crossed Atlantic. 320K+ casualties. Admin claims restored pride & winning spirit. Military ready to defeat foes. Victory Day honors devotion to secure peace. 6d ago
  21. Diabetes affects 40M US adults, 25% undiagnosed. The Make America Healthy Again Commission uses Most-Favored-Nation pricing, premium cuts, & total transparency. TrumpRx drove the largest drug price drop in 60 years. GLP-1 savings reach $1,800, insulin under $35 monthly. 1w ago
  22. USMC marks 251st anniversary. History spans Nassau to WWII Pacific wins. Current focus: AI, missile defense, next-gen tech & shipbuilding. VA reforms boost healthcare choice, cut costs & slash backlogs. Motto: Semper Fidelis. 1w ago
  23. The Administration rejects chronic illness as inevitable under Make America Healthy Again. Leveraging Super Intelligence & American talent, the strategy targets root causes, restores research integrity, & pursues a cure for better, healthier lives. 1w ago
  24. Crit Infra Security Month highlights US resilience upgrades, energy boosts & SI data center investments. Regulations cut to expand oil, gas & nuclear power while securing supply chains. Strategy ensures American construction & honors linemen, engineers & technicians. 1w ago
  25. Aesch FTA, Bogachek Kosovo, Borgeas FCSC, Burns DRC, Cabrera Guatemala, Dante Jr OFR, Diaz-Rex PR US Attorney, Feldman CPSC Chair, Jurata Treasury, Millhollin Oman, Stephens PNG, Weirsky NCTC, Zimmerman Defense, Desrosiers DC Court, Hiland 8th Circuit. Rudofsky withdrew. 1w ago
  26. President Trump proclaimed Nov 11, 2026, as Veterans Day. The VA processed a record 3.1M disability claims & cut the backlog over 70%. 47 new facilities opened, and the National Center for Warrior Independence aims to house 6,000 homeless veterans by 2028. 1w ago
  27. Trump grants 1yr water pollution rule exemption for wildfire agencies from Nov 10, 2026 to Nov 10, 2027. Order covers fire retardant use under Federal Water Pollution Control Act excluding sections 1316 & 1317. Agriculture must publish in Federal Register. 1w ago
  28. Pres signed H.R. 997 empowering Taxpayer Advocate, H.R. 1703 modifying Medicare wheelchair payments, H.R. 1945 designating Churchill Museum as landmark, & H.R. 7730 raising bankruptcy thresholds for small businesses. 1w ago
  29. Pres. Trump signed memo exempting federal firefighting from Clean Water Act permitting through 2027. This follows 2025-2026 executive orders enhancing timber production, state preparedness, resilience strategies, & rapid reconstruction efforts. 1w ago
  30. Sec War Hegseth dismissed Massie's impeachment as a political stunt citing lawful wins vs Iran & cartels. No Sec War in 250 years faced impeachment for success. Trump, Vance & GOP leaders backed him while experts called articles baseless; vote seen as governance distraction. 1w ago
  31. Melania's Fostering the Future Together expands globally with 4 conferences before 2026 in Miami, Philippines, Poland, & St. Kitts. Secured $23M+ from Adobe, Amazon, Intel, Starlink, Google, & Zoom. Nearly 60 nations unite to equip youth for the super intelligence era. 1w ago
  32. Philip Aubart & others nominated as judges; Natalie Baker & others as ambassadors; Toby Deen & others also nominated. David MacNeil's FTC nomination withdrawn. 1w ago
  33. Admin signed EO to fix Smithsonian bias & restore landmarks for National American History & Founders Month. Task Force 250 led major celebration urging Americans to learn from Founding Fathers to safeguard liberty for future generations. 1w ago
  34. Trump cites 165k Oct jobs, record 401(k)s, S&P 500 highs, factory growth from Apple, NVIDIA, Audi, pharma firms, 95% drop in border apprehensions, blames election loss on war sentiment, gas prices, Israel views, claims Venezuela ops perfect. 1w ago
  35. AG Blanche affirmed DOJ will defend Executive Branch against Democrat threats, distinguishing oversight from retribution. He criticized donor targeting, dismissed failed tactics, praised Chief of Staff Miller, & asserted constitutional protection for exec members. 1w ago
  36. Greetings sent to Americans celebrating Diwali, the Festival of Lights. Families honor ancient traditions & the triumph of light over darkness. The celebration emphasizes timeless values enriching America. Observers are wished hope, light, & warmth. 1w ago
  37. US Code mandates respectful flag treatment. New Executive Order prosecutes desecration by rioters & foreign nationals. VA launched online initiative for proper respect. Saturday statement honors military service & fallen heroes before Veterans Day. 1w ago
  38. Melania Trump & LSU secured $7.2M for Fostering the Future scholarships. MMR Group donated $5M to aid foster youth. Initiative supports 100 scholars at 26 universities, advancing reforms & savings accounts backed by 26 governors. 1w ago
  39. Trump appoints Stephen Miller as 33rd White House Chief of Staff, succeeding Susie Wiles who departs to lead outside operations. Miller & Wiles praised by VP Vance, Cabinet, governors & conservatives for loyalty & America First success. 1w ago
  40. US economy added 165k jobs in October, doubling expectations. Unemployment fell to 4.1% while pay rose 3.1%. Manufacturing surged 19k jobs. Initial claims hit 1969 lows. Since President Trump returned, over 1.25m private sector jobs created. 1w ago
  41. Oct jobs added 165k vs 100k exp. Manufacturing up 19k, best since 2023. 100k+ manuf & 120k construction jobs added since Trump returned. Wages rose, unemployment fell. Jobless claims hit 57-yr low. Trade deficit down 12%, exports up 15%. Q3 growth 3.4%. 1w ago
  42. Trump used Antiquities Act for Oval Office Monument. Interior Secretary must prioritize preservation & coordinate. Admin restored DC landmarks, mandated classical architecture Aug 2025, fulfilled 1776 promises & built White House Ballroom without taxpayer cost. 1w ago
  43. President Trump signed Nov 5, 2026 proclamation designating Oval Office as national monument. Site includes Rooms 105, 106, 108, & 110. National Park Service will manage preservation while maintaining President's authority over furnishings & operations. 1w ago
  44. Melania Trump hosted Russian & Ukrainian leaders Oct 23 2026 facilitating an Oleshky ceasefire evacuation of 800 civilians. Ukraine awarded her the Order of Princess Olga for her exclusive intermediary role in this historic diplomacy. 1w ago
  45. Critics repeatedly failed to predict Trump's success. Democrats may try to reverse policies in final two years, reopening borders & raising taxes. Trump achieved energy independence, record production, and historic crime drops. Actions include ending transgender procedures on minors, eliminating DEI, & appointing originalist justices. Voters rejected opposing agenda; reversal attempts will fail. 1w ago
  46. First Lady Melania Trump & LSU secured $5M for Fostering the Future scholarships supporting foster care students. She will visit Baton Rouge as a groundbreaking campaign activates during the LSU vs. Alabama game at Tiger Stadium. 1w ago
  47. Pres Trump signed Nov 3, 2026 proclamation designating Nov 1-7 as Anti-Communism Week. Text warns of rising socialist & communist threats in US, vowing nation will never become communist. Week honors victims & reaffirms defense of Constitution, individual dignity, & free markets. 2w ago
  48. Trump signs proclamation Nov 3 2026 declaring space open to all humans. Artemis II flew around Moon in April 2026; Artemis III follows next summer. Goal: return to Moon by 2028 then reach Mars. Executive orders aim to ensure US space superiority. 2w ago
  49. On Nov 3, 2026, the President signed H.R. 1744 to reauthorize US Commission on International Religious Freedom through FY2028 & H.R. 8205 to reauthorize Accelerating Access to Critical Therapies for ALS Act through FY2031. 2w ago
  50. Prescription drug prices dropped 4.5% in 2026, largest fall since 1963. TrumpRx launched Feb 2026 with discounts on 800+ meds incl GLP-1s. Deals w/ Eli Lilly & Novo Nordisk cut gov costs while expanding Medicare obesity coverage to $50 copay. 2w ago

SEC Press Releases

More →
  1. SEC proposes executive pay rule changes to simplify disclosures. Named officer count drops to two. Three new tables replace current formats. Perquisite threshold rises to $150k. Pay-versus-performance metrics simplify. Median employee rule limited to US staff every five years. Comment period open for 60 days. 5d ago
  2. SEC FY26: 348 enforcement actions, $1.095B relief. New AI & accounting fraud units launched. Updated manual, MOUs with CFTC & FDA. 26K+ whistleblower tips yielded $158M awards. Actions covered Ponzi schemes, crypto fraud, & insider trading penalties against major firms. 1w ago
  3. SEC Nov 4, 2026: Updated small entity defs under Regulatory Flexibility Act for investment firms. Raised asset thresholds, removed total asset limits for advisers, & mandated 10-year inflation adjustments to reduce regulatory burdens on small market participants. 2w ago
  4. SEC granted exemptive relief Oct 30 2026 to aid broker-dealers implementing Treasury clearing rules for inter-affiliate & non-US repo transactions, addressing cross-border concerns while excluding certain non-US counterparty deals. 2w ago
  5. SEC charged BG Wealth & DSJ Exchange with $130M fraud scheme. Defendants used fake SEC filings & crypto signals to lure investors across 40+ states. Scheme involved Ponzi tactics via social media. SEC seeks injunctions, disgorgement, penalties. 2w ago
  6. SEC FY27 priorities target 34k+ registrants to ensure compliance & prevent fraud. Focus includes fiduciary duties, retail investor protection, private funds, cyber resiliency, & emerging tech risks. Chairman Atkins states exams are vital for market integrity. 3w ago
  7. SEC & French AMF signed MOU for investment adviser info-sharing. Deal creates U.S. & France cooperation framework, letting SEC process AMF firms' applications. Atkins & Barbat-Layani praise agreement for expanding opportunity & ensuring financial integrity. 4w ago
  8. SEC & FSA held Autumn Dialogue in Tokyo Oct 19, 2026. Uyeda & Miyoshi led talks on investor protection, markets & innovation. Next meeting set for D.C. in spring 2027. 4w ago
  9. SEC Nov 9 roundtable on machine-understandable data & AI risks at DC HQ, 9-3:30 EST. Joshua White says it gathers feedback for future guidance. Limited in-person; live stream on SEC.gov with recording later. 1mo ago
  10. SEC Small Business Capital Formation Advisory Committee meets Oct 27, 2026, at 10 a.m. ET. Agenda covers IPO modernization, analyst coverage, & Reg CF reforms to boost early-stage capital. Session open to public, streamed live on SEC.gov. 1mo ago
  11. SEC proposed Oct 9, 2026 amendments to Rule 17a-7 to modernize cross-trading between funds & affiliates. Proposal aims to reduce costs, restore fixed-income cross-trade ability, & enhance transparency via aggregated reporting. 60-day comment period follows publication. 1mo ago
  12. SEC seeks final judgment against ex-Western Asset CIO Leech for cherry-picked trades 2021-2023. He faces $3M penalty & officer bar after pleading guilty to obstruction in June 2026. Combined with firm's $100M settlement, $103M will return to investors. 1mo ago
  13. The SEC will host a virtual national seminar on Nov 19, 2026, for investment companies \& advisers. Topics include info security, resiliency, \& compliance programs. No advance registration required; live webcast available on SEC.gov the morning of the event. 1mo ago
  14. SEC & global regulators issued joint bulletin on Oct 5, 2026 for World Investor Week's 10th anniversary. They urge resiliency against scams & volatility. U.S. coordination involved SEC, CFTC, FINRA, SIPC, NFA, NASAA. Chairman Atkins highlighted Investor.gov resources. 1mo ago
  15. SEC proposed Oct 1 rules for crypto custody by advisers & funds to modernize regulations, allow self-custody, & permit state trust companies as custodians. Public comment open 60 days post-Federal Register publication. 1mo ago
  16. SEC released new Exam Handbook Oct 1, 2026 to standardize exams & improve investor protection. Chairman Atkins notes increased transparency while Director Cassidy highlights clearer processes. The guide covers all stages from risk assessment to disposition. 1mo ago
  17. SEC charged MGM & CEO Meyer with defrauding investors on SpaceX & pre-IPO securities via asset misuse, inflated values & forced releases. A capital call failure caused a $3M loss. SDNY complaint seeks injunctions, disgorgement & penalties under the Advisers Act. 1mo ago
  18. SEC charged Dinelli & Frankel with $8.7M fraud targeting veterans via Beyond Alpha Ventures. They fabricated returns & diverted funds to failed options trades. Charges filed in SDNY seeking injunctions & penalties; parallel criminal charges announced. 1mo ago
  19. SEC proposes retail access to private markets aligning with Trump's EO. Plans include performance-based adviser comp, modernized interval funds, & new accredited pathways via CPA or CFA exams. Public comment period opens for 60 days. 1mo ago
  20. SEC charged Cryptoaiml & TSAI entities with defrauding investors via fake AI trading scams. Over $15.3M stolen from overseas operators using falsified SEC Forms D. Two complaints filed in SDNY. SEC removed fake filings. Verify backgrounds on Investor.gov. 1mo ago
  21. SEC charged Zoe Financial for concealing referral conflicts with its Zoe Wealth unit until Dec 2024, a willful 1940 Act violation. The firm agreed to cease-and-desist, censure, & a $450K penalty without admitting findings. 1mo ago
  22. SEC DERA reports H1 2026 IPOs rose 16% to 208 with proceeds up 396% to $137B. Follow-ons grew 10% in volume and 33% in proceeds to $111B. New interactive charts visualize trends. Director White says data reflects strengthened capital formation under Chairman Atkins. 1mo ago
  23. SEC charged CMI Capital LLC & founder Michael Williams with fraud for raising ~$860K from 18+ investors using fake profit screenshots. Williams misappropriated ~$384K, repaid ~$375K. Defendants settled w/o admitting guilt, facing permanent injunctions & disgorgement. 1mo ago
  24. SEC censured OTC Link LLC, imposing $575k penalty for 2016-2025 SCI violations. Firm failed to maintain security policies despite warnings. Rules breached on capacity, integrity, resiliency, availability, security. OTC Link agreed to order without admitting findings. 1mo ago
  25. SEC grants 5-yr exemptive relief to Tokenized Securities Venues, allowing operation without exchange status. TSVs can trade tokenized NMS stocks via permissioned AMMs & liquidity pools. Smart contracts need auditability on public ledgers; trading halts with underlying stock. 2mo ago
  26. SEC proposes rescinding Rule 14a-8 to block state law intrusion. Amendments to 14a-4(c) grant flexibility, eliminate annual report delivery, shorten broker search to 5 days, & remove exempt solicitation notices. A 60-day comment period follows Federal Register publication. 2mo ago
  27. SEC granted exemptive relief from Inline XBRL for forms CA-1, 1, X-17A-5 & 17-H. Chairman Atkins stated this reduces compliance costs for market intermediaries while maintaining investor protection, allowing firms to allocate resources more efficiently. 2mo ago

Federal Reserve Speeches

More →
  1. US economy strong yet 44% lack investment. Inflation high, Fed may hike. Public-private partnerships & CDFIs critical to fix market failures. Tools like LIHTC & CRA drive growth in low-income areas. Fed prioritizes unlocking potential nationwide. 20m ago
  2. Fed backs private sector payment innovation while providing core infrastructure. Tokenization accelerates asset trading via blockchain convergence. Trust & clear governance are critical for scaling. Future models blend tokenized money with traditional rails, supported by AI & Fed convening. 1d ago
  3. Fed Chair praised SF Fed, noted falling research productivity & highlighted super intelligence (SI) as a transformative force. SI could boost growth but risks labor disruption or capital misallocation. Models show scenarios from strong GDP to job losses. Human judgment remains essential for AI deployment. 2d ago
  4. Fed warns AI debt could hit $800B on-balance & $3T off by 2026. Circular financing & autonomous collusion risks mirror past infrastructure booms. Agentic AI threatens stability via rapid deposit outflows. Strict guardrails & explainable models are essential to manage leverage & cyber threats. 2d ago
  5. AI boom mirrors 1990s IT lag; 25% US firms use gen AI but productivity gains remain mixed. Q3 GDP +3.4%, unemployment 4.1%, yet inflation at 3.6% PCE. Fed holds rates steady, prioritizing price stability as business investment surges in data centers. 4d ago
  6. 2025 Fed data shows top 10% hold 75% of US wealth. Bottom half holds 2% with $52k avg. Labor share hit record low of 52.8% in Q2 2026. AI risks favoring capital owners over workers. Private equity returns exceed middle-class assets. 6d ago
  7. US growth exceeded 3% in Q3 on AI capex & spending. Unemployment fell to 4.1%. Core PCE likely hit 3.3%. Fed held rates at 3.75-4% amid persistent inflation risks. AI investment boomed but debt exceeds $800B. Fed targets 2% inflation next year as supply shocks wane. 1w ago
  8. US GDP +3.4% in Q3; unemployment 4.1% with low dynamism. Inflation at 3.7% PCE. Fed research warns AI & energy costs may pressure prices to 2027. Speaker backs 25bp Dec hike but notes 50bp if Oct CPI stays high. 1w ago
  9. SVB review shows supervisors knew of risks 9 months early but failed due to unclear accountability. Focus was on process, not material risks. Fed is modernizing with clear decision rights. Global bodies urged to prioritize material risks & verify data rigorously. 1mo ago
  10. FOMC raised rates 25 bps to 3.75-4% in September after nine months steady. Labor stable but inflation stalled at 3% core PCE. 16 of 18 predict more hikes, potentially 50 bps by end-2027. Futures price 85% chance for Dec hike. Focus remains on price stability. 1mo ago
  11. Fed refocuses supervision on material risks, raises community bank leverage ratio to 8%, eliminates Novel Activities Program, & restructures into 5 regional offices. Updates include indexing $10B threshold, revising CAMELS to reduce M rating dominance, & streamlining Regulation O. Culture shifts from checklists to risk judgment. 1mo ago
  12. US Treasury stability rose after 2026 eSLR reforms effective April 1, granting GSIBs $5T headroom. Dealer positions climbed $600B to $700B by April 2026, while leveraged capacity surged $1.8T to $6.4T. Outcomes: narrower spreads, reduced volatility, & greater stress resilience. 1mo ago
  13. UVA grad notes resilient 2.4% growth & stable 4.1% unemployment in H1. Inflation sits at 3.4%, above 2% target. Fed raised rates to 3.75-4% in Sept. Policy depends on data, risks include geopolitical tensions. Dual mandate remains max employment & price stability. 1mo ago
  14. FRED hosts 850k series & sees 50% traffic from AI agents. The Fed introduces an MCP Connector to link data with AI while ensuring accuracy & avoiding bias. FRED remains a trusted, non-commercial resource as it expands to FRASER & ALFRED. 1mo ago
  15. Fed notes rural communities drive supply chains & face higher inflation. Home values rose 36% nonmetro vs 21% urban. Small firms are 96% of rural establishments & created 24% of jobs. Fed supports rural vitality via research, CDFI credit access & workforce initiatives. 1mo ago
  16. AI boosts global payment security & efficiency via LLMs. Agentic commerce needs micropayments. Scaling requires solving authentication, liability, & fraud. Industry must choose open or closed systems while defining identity standards. 1mo ago
  17. Detroit unemployment at 11% vs 5% state & 4.1% national. New firms add 30k jobs yearly. AI investment boosts activity while inflation exceeds 2% target. Unanimous rate hike addresses risks as labor market remains solid. 1mo ago
  18. Fed Reserve hosted 2026 Cyber Workshop on AI risks & ransomware, covering defenses & tabletop exercises. FSB released AI guidance June 2026. Regulators tailor exams for community banks. Resilience needs board oversight, tech, people & processes. 1mo ago
  19. Fed's Cook likens AI to steam engine. Investment fuels inflation above 2% target, currently 3.8% prompting 25bp hike. Small firms adopt fast. Productivity gains may offer medium-term disinflation. Risks include skill mismatches & labor displacement. 1mo ago
  20. Fed raised rates on tariff-driven inflation, conflict & AI demand. Home affordability hit 21-year low as prices rose 70% since 2000. High rental burdens persist. A 2-5.5M unit gap stems from zoning, labor loss, high costs & low-rate lock-in effects restricting supply. 1mo ago
  21. Fed modernizes 113-yr discount window w standardized collateral, e-signatures & automation via 2024 portal. Collab w FHLBs cuts re-allocation time. Efforts boost Treasury resilience & encourage bank usage. 1mo ago
  22. Fed finalizes stress test reforms to boost transparency & cut SCB volatility 50%. Effective Jan 1. 2027 models cover noninterest income & forward-looking exercises to identify vulnerabilities. Changes aim for robust framework inspired by SVB lessons. 2mo ago
  23. SVB failed due to unrealized losses & concentrated uninsured deposits. Supervisors knew risks by March 2022 but delayed action. Fed now issues new principles to prioritize early threat identification & empower staff to escalate concerns. 2mo ago
  24. US Real GDP +1.8% in H1 2026 driven by spending & investment. Unemployment steady at 4.1%. Core PCE at 3.3% with tariff risks. Rates likely hold if August data confirms disinflation, but hikes possible in September if progress reverses. 2mo ago
  25. Fed links AI & entrepreneurship to growth. Inflation above 2% risks rate hikes. Criminal records block jobs. Business ownership boosts earnings by 24% & lowers recidivism. SBA removed loan bars in 2024. AI aids underwriting & planning. 2mo ago
  26. Fed Chair marks 100 days, noting AI as new growth factor & $100B annual token sales. Task force launched to study AI impact. Economy resilient with 4.1% unemployment, but PCE inflation at 3.7%. Rejects mechanical rules, prioritizing price stability. 2mo ago
  27. US economy resilient but inflation stuck above 2% for 5 years. June PCE up 3.7% on energy & AI costs. Labor market stable at 4.2% unemployment. Fed risks skewed to inflation, ready to hike if needed. Consumer sentiment weak due to housing costs & job uncertainty. Restoring price stability is primary goal. 3mo ago
  28. Fed balances demand & supply shocks amid Middle East conflict & trade policy. AI adds dual effects on markets. FOMC holds rates at 3.25% to 3.75% targeting 2% inflation. 4mo ago
  29. Inflation at 3.7% remains above the 2% target. Fed prioritizes price stability as GDP grows 2.2% driven by AI data centers. Core goods prices surged 5% amid Middle East shocks. Rates held steady to monitor trends; action prepared if disinflation stalls. 4mo ago
  30. Fed conference stressed responsible bank innovation & AI to boost financial inclusion. Regulators seek clear expectations without micromanagement. FSB released AI guidance for public comment until July 22, 2026. Supervisory support must help smaller banks innovate safely. 4mo ago
  31. Fed warns AI could boost workers or worsen inequality by displacing jobs & concentrating wealth. Top 10% holds 59% of US wealth. Outcomes depend on market structure, education & policy to ensure gains are shared broadly rather than accruing to a few firms. 4mo ago
  32. US economy resilient despite tariffs & energy shocks. Core PCE rose to 3.4% in May; headline 4.1%. Inflation driven by tariffs, energy & AI demand. Labor market stable, expectations anchored. Policy may tighten if core inflation persists. 4mo ago
  33. FSB modernizes global finance via 4 principles: prioritize risks, tailor rules, ensure transparency & innovate responsibly. US shifts to risk-based oversight post-SVB, refining capital frameworks, AI adoption & supervisory transparency. Fall G20 report expected. 4mo ago
  34. Fed & FSB seek feedback on AI adoption guidelines for finance, led by MAS & U.S. Treasury. Final report due later this year as G-20 deliverable. Guidance emphasizes proportionality, lighter touch for lower-risk uses, & tailored governance for institution size. 4mo ago
  35. Initial conditions matter more than historical averages. Vacancy cuts replaced layoffs in 2022 despite tightening. Shocks shorten policy lags. Flexible forward guidance helps, but rigid rules delayed hikes. Optimal guidance requires adaptability, not fixed paths. 4mo ago
  36. Cleveland Fed notes 99.9% of US firms have under 500 workers, creating 61% of net jobs since 1995. 2025 survey shows nearly half use AI, boosting productivity for 71%. Access to credit remains critical for growth. 4mo ago
  37. Fed conference on dollar's global role notes stablecoins and digital assets are altering payment rails. While size and trust matter, tech innovation impacts FX markets and global liquidity. Speaker views do not reflect official Fed positions. 4mo ago
  38. Recent Fed deregulation cuts top bank capital by 6% ($60B) & weakens supervision. Reduced stress tests, liquidity rules & consumer protections risk future crises. Historical data shows long-term GDP losses & massive fiscal costs from past financial collapses. 5mo ago
  39. Speaker honored JFK & called US indispensable. Fed founded 1913 for stability, aiding economy via non-partisan policy. Governors have legal protections. Rule of law supersedes partisanship; institutions need preserving. 5mo ago
  40. Fed's Bowman targets 2% inflation ignoring energy shocks, prioritizing core PCE & real GDP. Unemployment at 4.3% with stability concerns. Aggressive 2022 hikes shift to 2025 cuts as growth slows. Stance remains moderately restrictive to stabilize jobs as supply disruptions ease. 5mo ago
  41. Global energy spikes threaten inflation & growth, especially for importers. US growth solid but slowing due to high costs. Inflation stalled by tariffs/energy yet expected to decline later. Fed holds rates at 3.5%-3.75%, committed to 2% target with data-dependent stance. 5mo ago
  42. PCE inflation hit 3.8% on gas & core hikes. $1.5T AI boost lifts chips & wages while unemployment stays at 4.3%. Fed holds rates steady, uses AI for risk analysis despite cyber concerns. Responsible deployment needs strong governance. 5mo ago
  43. Fed faces Middle East supply & price uncertainty. Waller says rate cuts & hikes equally likely. Real GDP grew on AI investment. Core PCE inflation rose to 3.3%. Policy depends on conflict duration & inflation data. 6mo ago
  44. 31% feel financially healthy despite 96% having accounts. Tech enables real-time assessments to boost savings & reduce costs. Scaling requires standards, privacy balance, & cross-sector collaboration to address vulnerability. 6mo ago
  45. Shrinking Fed balance sheet is wrong. Cutting reserves undermines bank resilience, impairs money markets, & increases footprint via more lending. Reserves are essential for stability & supplied costlessly. 6mo ago
  46. Former Fed VP says algorithms can't replace local lending. 10th District banks show resilience via fintech. CECL rules create burdens; new principles focus on material risks. Cyber & capital updates offer flexibility. Fed aims to tailor regs to size & support AI responsibly. 6mo ago
  47. A speaker proposes centralizing non-monetary back-office functions like IT & HR to boost efficiency while preserving Fed independence. Standardizing tasks shifts governance from Bank-first to System-first, lowering costs & modernizing trillions in payments. 6mo ago
  48. Fed Vice Chair notes bank corporate lending fell from 48% in 2015 to 29% in 2025 as private credit reached $1.4T. Proposes Basel III changes to lower risk weights, improve NDFI data transparency, restore bank lending balance. 6mo ago
  49. Fed Govt in Dakar highlights tokenization for West Africa. US tokenized assets doubled to $25B. Benefits: faster settlements & fractional ownership. Risks: runs, cyber threats & systemic links. Fed supports innovation while monitoring stability via global partners. 6mo ago
  50. Consumer fraud hit $84B in 2024 with only $21B recovered. 21% of US adults affected, 45+ most vulnerable. Bank transfers drove 40% of losses. Fed reviewing 250 comments to update rules, standardize data, & host regulator roundtable to strengthen defenses & recovery. 6mo ago

Earnings Releases

By sector →
  1. TJXNov 18, 9:19 AMThe TJX Companies, Inc. reported third-quarter fiscal 2027 net sales of $16.0 billion, representing a 6% increase year-over-year, with consolidated comparable sales growing 4%. Diluted earnings per share reached $1.39, a 9% rise from the prior year, while the pretax profit margin improved to 13.0%. The company returned $1.5 billion to shareholders through share repurchases and dividends and announced a full-year fiscal 2027 outlook expecting consolidated comparable sales to increase by 4%.Consumer Cyclical
  2. EXPDNov 18, 9:00 AMExpeditors International of Washington, Inc. projects 2026 earnings per share between $9.09 and $9.39, representing a 53% to 58% increase year-over-year, with fourth-quarter guidance set at $2.70 to $3.00 per share. The company attributes its growth to a differentiated operating model featuring local ownership, significant technology investments in AI and automation, and expansion into high-growth verticals such as biopharmaceuticals, data center logistics, and the space economy. Financial targets include maintaining a return on invested capital of 51%, achieving 112% free cash flow conversion, and sustaining a long-term revenue growth rate of 5% to 7%. Capital allocation priorities focus on funding organic growth, maintaining a dividend aristocrat status with a target payout ratio of approximately 25%, and utilizing remaining share repurchase capacity.Industrials
  3. LOWNov 18, 8:45 AMLowe's reported third-quarter 2026 net earnings of $1.7 billion, resulting in diluted earnings per share of $2.98 and adjusted diluted earnings per share of $3.10. Total sales for the quarter reached $22.8 billion, representing a 9.3% increase year-over-year, while comparable sales rose 1.8% driven by strong online, Pro, and home services performance. The company updated its full-year 2026 outlook, projecting total sales of approximately $92.5 billion and adjusted diluted earnings per share of $12.25. Additionally, Lowe's recognized a $250 million pre-tax benefit from IEEPA tariff refunds and paid $701 million in dividends during the quarter.Consumer Cyclical
  4. RTSNNov 18, 8:10 AMRetension Pharmaceuticals completed an upsized initial public offering in October 2026, generating $51.75 million in gross proceeds to fund the development of its lead candidate, RTN-001, for uncontrolled and resistant hypertension. The company reported a net loss of $5.9 million for the third quarter of 2026, driven by increased research and development expenses related to its ongoing Phase 2b clinical trial. As of September 30, 2026, the company held $9.2 million in cash and cash equivalents, which would rise to approximately $54.3 million on a pro forma basis including the IPO proceeds. Topline data from the Phase 2b trial involving approximately 280 patients is expected in the first half of 2027.Healthcare
  5. SDOTNov 18, 8:00 AMSadot Group Inc. reported a net loss of $3.0 million for the third quarter of 2026, representing an 86% reduction in operating losses compared to the same period in 2025. During the first nine months of the year, the company achieved a $69.3 million improvement in shareholders' equity, shifting from a deficit to a positive balance of approximately $14.5 million, primarily driven by a non-cash gain from the deconsolidation of Sadot Latam. The company acquired three technology platforms—TradeOS, TradeIQ, and SalesIQ—with a combined carrying value of $24.6 million to support its transition toward a technology-enabled business model. Despite these balance sheet improvements, the company faces substantial doubt regarding its ability to continue as a going concern due to a working capital deficit of $5.7 million and outstanding debt defaults.Consumer Cyclical
  6. GAMENov 18, 8:00 AMGameSquare Holdings reported third-quarter 2026 revenue of $19.0 million, a 77% increase year-over-year, driven by gains on digital assets and improved operating profitability. The company achieved net income of $10.1 million for the quarter, or $0.79 per diluted share, and posted positive adjusted EBITDA of $0.6 million, marking the second consecutive quarter of positive adjusted EBITDA. For the nine months ended September 30, 2026, revenue reached $52.0 million, while the company reiterated its full-year 2026 guidance of $85 million to $90 million in revenue and over $5 million in adjusted EBITDA. Additionally, the company held 9,711.30 ETH and $31.2 million in cash and digital assets as of September 30, 2026, while continuing its stock repurchase program.Communication Services
  7. LTRNNov 18, 7:35 AMLantern Pharma reported third-quarter 2026 financial results showing a net income of approximately $0.7 million, driven by a non-cash gain from warrant accounting, while operating expenses were impacted by a $2.0 million accrual for a proposed legal settlement. The company closed a registered direct offering in September 2026 for gross proceeds of $4.0 million, bringing its total cash, cash equivalents, and marketable securities to approximately $7.6 million. Clinically, the company engaged its first site for a Phase 1b/2 trial of LP-184 in triple-negative breast cancer, opened Part 2 of the HARMONIC trial for LP-300 in Taiwan, and published peer-reviewed Phase 1a data for LP-184 in glioblastoma. Leadership changes included the resignation of CEO Panna Sharma and the appointment of CFO David Margrave as Interim CEO, alongside the formation of a new subsidiary, Open Medicine AI, to commercialize its AI platform.Healthcare
  8. JJSFNov 18, 7:02 AMJ & J Snack Foods reported fiscal 2026 fourth quarter net sales of $406.0 million, a 1% decline from the prior year, while net earnings rose 195% to $33.6 million. The quarter featured a significant 200 basis point expansion in gross margin to 33.7%, driven by Project Apollo savings and raw material deflation, which helped offset a 21.6% increase in distribution costs due to higher freight and fuel rates. Food Service sales decreased 7.4% due to bakery reductions, whereas Retail Supermarket and Frozen Beverage segments grew by 17.1% and 6.1% respectively. The company ended the quarter with $90.3 million in cash, no long-term debt, and expects to return to top-line growth in fiscal 2027 through volume growth, innovation, and pricing.Consumer Defensive
  9. BRBRNov 18, 7:01 AMBellRing Brands reported fourth-quarter 2026 net sales of $692.0 million, representing a 7% year-over-year increase, while fiscal year 2026 net sales reached $2,398.4 million, up 3.5%. The company recorded net earnings of $35.6 million for the quarter and $147.4 million for the full year, with both periods negatively impacted by inventory-related headwinds totaling $16 million and $37 million respectively. Adjusted EBITDA for the fourth quarter was $66.4 million and $288.8 million for the fiscal year, reflecting significant cost inflation and trade investments. Looking ahead, BellRing projects fiscal year 2027 net sales between $2.32 billion and $2.42 billion and Adjusted EBITDA between $310 million and $350 million.Consumer Defensive
  10. TGTNov 18, 6:46 AMTarget Corporation reported third-quarter 2026 net sales of $27.1 billion, representing a 7.1 percent increase year-over-year driven by a 5.6 percent growth in comparable sales. Earnings per share reached $2.65, a figure that included $0.50 in benefits from tariff refunds, while the company raised its full-year net sales growth guidance to approximately 6 percent. The retailer achieved strong performance across core categories, with nearly 27 percent growth in Fun 101 and 9.8 percent growth in digital comparable sales. Looking ahead, Target expects to invest between $5 billion and $6 billion in capital expenditures in 2027 and has updated its full-year adjusted EPS guidance to a range of $10.65 to $11.40.Consumer Defensive
  11. FTLFNov 17, 5:21 PMFitLife Brands reported third-quarter 2026 total revenue of $25.6 million, representing a 9% increase driven by the acquisition of Irwin Naturals, which was partially offset by a decline in Legacy FitLife revenue. Net income for the quarter rose to $1.6 million, or $0.16 per diluted share, compared to $0.9 million in the prior year period, primarily due to the absence of merger-related expenses and a lower effective tax rate. The company incurred $0.3 million in restructuring costs during the quarter as part of an initiative expected to reduce annual operating expenses by $1.2 million starting in the fourth quarter. At the end of the quarter, FitLife Brands held $39.3 million in total debt and $0.7 million in cash, resulting in a net debt position of $38.6 million.Consumer Defensive
  12. IIIVNov 17, 5:19 PMi3 Verticals reported fourth-quarter 2026 revenue of $55.4 million, a 1.0% increase year-over-year, while full-year 2026 revenue reached $218.7 million, up 2.6%. The company posted a net loss of $5.1 million from continuing operations for the quarter, contrasting with a net income of $1.5 million in the same period the prior year, though full-year 2026 net income from continuing operations was $4.1 million. Adjusted EBITDA for the fourth quarter was $15.2 million, representing a 27.4% margin, and totaled $58.7 million for the full fiscal year. On October 9, 2026, the company closed a $350 million senior secured credit facility to replace its previous arrangement, and it provided a 2027 revenue outlook ranging from $220 million to $235 million.Technology
  13. AIRENov 17, 5:05 PMreAlpha Tech Corp. reported third-quarter 2026 revenue of approximately $1.6 million, an 11% increase from the prior year, driven by growth in its Homebuying Services segment following the acquisitions of Prevu and InstaMortgage. The company narrowed its net loss by 39% to $3.4 million and improved its Adjusted EBITDA to a loss of $1.9 million, while total transaction volume for the trailing twelve months rose 74% to $188.8 million. Despite these operational improvements, cash and cash equivalents decreased by 92% to $0.8 million due to funding ongoing operations and acquisition-related expenditures. Additionally, the company completed a $1.75 million public offering in November 2026 to support working capital and general corporate purposes.Real Estate
  14. DUOTNov 17, 5:00 PMDuos Technologies Group reported a 103% year-over-year increase in third-quarter 2026 revenue to $10.50 million, driven by growth in its Technology Solutions business and infrastructure development activities. The company secured a 10-year, $400 million colocation agreement with a major cloud service provider for a 20 MW deployment expected to begin in the second quarter of 2027. Financial results included a net income of $864,000 for the quarter, supported by a $4.7 million gain from the deconsolidation of its GPU-as-a-Service entity, while adjusted EBITDA turned positive at $493,000. Duos reaffirmed its full-year 2026 outlook of exceeding $50 million in revenue and achieving positive adjusted EBITDA as it transitions to a pure-play colocation model.Technology
  15. GLADNov 17, 4:37 PMGladstone Capital Corporation reported net investment income of $0.49 per share for the fourth quarter of fiscal 2026 and $2.00 per share for the full fiscal year. The company's net asset value decreased to $20.77 per share by September 30, 2026, driven by net realized and unrealized losses alongside a supplemental distribution. During the quarter, the firm invested $83.9 million across its portfolio, which now includes 59 portfolio companies with a total fair value of $955.8 million. The company maintained a debt-to-equity ratio of 1.08x, including preferred stock, while covering 100% of its regular quarterly distributions with net investment income.Financial Services
  16. CNTYNov 17, 4:21 PMCentury Casinos, Inc. announced a restatement of previously issued financial statements due to an accounting error regarding a minority interest in Smooth Bourbon, LLC, which owns the real estate for the Nugget Casino Resort. The Audit Committee concluded that investors should no longer rely on financial statements for the years ended December 31, 2024 and 2025, as well as specific quarters in 2026. The company provided preliminary, unaudited financial results for the third quarter of 2026, reporting approximately $158.4 million in net operating revenue and $20.7 million in earnings from operations. Additionally, the company plans to file amended reports and expects to identify at least one additional material weakness in its internal controls over financial reporting.Consumer Cyclical
  17. NVDANov 17, 4:20 PMNVIDIA reported third-quarter fiscal 2027 revenue of $115.8 billion, representing a 103% increase year-over-year, driven by $107.6 billion in Data Center revenue. The company began shipping the Vera Rubin NVL72 platform and announced the acquisition of Hugging Face to expand its AI ecosystem. For the fourth quarter of fiscal 2027, NVIDIA expects revenue to reach $130.0 billion with gross margins between 71.0% and 72.0%. Additionally, the company returned $28.1 billion to shareholders through stock repurchases and dividends during the quarter.Technology
  18. IRIXNov 17, 4:19 PMIridex Corporation reported third-quarter 2026 total revenue of $10.2 million, a 19% decline from the prior year period, driven by weaker demand in Europe and Asia and distributor inventory adjustments. The company achieved a gross margin of 42.4%, an improvement over the previous year, while operating expenses remained flat at $5.5 million. Net loss for the quarter was $1.4 million, or $0.08 per share, compared to a $1.6 million loss in the same period last year. Consequently, Iridex reduced its full-year 2026 revenue guidance to a range of $46 million to $48 million, citing continued headwinds in international markets.Healthcare
  19. LZBNov 17, 4:17 PMLa-Z-Boy Incorporated reported second quarter fiscal 2027 sales of $526 million, representing a 1% increase over the prior year or 4% excluding the impact of a wholesale casegoods divestiture. The Retail segment delivered strong growth with a 14% increase in delivered sales, while the Wholesale segment saw a 2% decline on a reported basis, which improved to a 3% increase when excluding the divestiture. The company recorded GAAP diluted earnings per share of $0.45 and adjusted diluted earnings per share of $0.53, while returning $32 million to shareholders through dividends and share repurchases. Additionally, the Board declared a 12% increase in the quarterly dividend to $0.27 per share, marking the sixth consecutive year of double-digit increases.Consumer Cyclical
  20. IDXGNov 17, 4:15 PMInterpace Biosciences reported third-quarter 2026 revenue of $10.4 million, representing an 18% year-over-year increase driven by a 7% rise in thyroid test volume. The company achieved an adjusted EBITDA of $2.1 million, or 20% of revenue, despite reporting a loss from continuing operations of $1.5 million due to $4.1 million in non-recurring stock compensation and legal expenses. Gross margin expanded to 69% for the quarter, supported by an 11% increase in average revenue per test and operational efficiency gains. The firm continues to operate as a thyroid-only diagnostics provider following the discontinuation of its PancraGEN pancreatic testing business in May 2025, while developing a new pancreatic cancer program expected to generate no revenue in 2026 or 2027.Healthcare
  21. DLBNov 17, 4:15 PMDolby Laboratories reported fourth-quarter fiscal 2026 total revenue of $374 million and full-year revenue of $1.42 billion, representing a 5% increase from the prior year. The company achieved GAAP net income of $81 million for the quarter and $258 million for the full year, while non-GAAP net income reached $118 million and $417 million respectively. Dolby repurchased 4.3 million shares for approximately $265 million during the fiscal year and increased cash dividends to $1.44 per share. Looking ahead to fiscal 2027, the company forecasts total revenue to remain roughly flat at $1.42 billion with non-GAAP diluted earnings per share expected between $4.27 and $4.42.Industrials
  22. SACHNov 17, 4:10 PMSachem Capital Corp. reported a net loss of $3.2 million for the third quarter of 2026, driven by $0.8 million in transaction expenses related to its pending merger with Industrial Realty Group. The company's loan portfolio decreased to $320.0 million in gross principal balance, while non-accrual loans were reduced to $84.6 million from $117.6 million at the end of 2025. Sachem and Industrial Realty Group are proceeding with a definitive contribution agreement expected to close in the first quarter of 2027, which would create IRG Realty Trust, Inc., a top-10 publicly listed industrial REIT with an implied enterprise value of approximately $3.4 billion. During the quarter, the company originated 11 loans totaling $36.8 million and repaid 12 loans totaling $52.3 million, while maintaining a solid cash position of $41.4 million at quarter-end.Financial Services
  23. GBDCNov 17, 4:05 PMGolub Capital BDC, Inc. reported a net asset value of $14.00 per share as of September 30, 2026, reflecting a $0.25 decrease from the previous quarter. The company's investment portfolio totaled $7.8 billion at fair value, with approximately 85% of investments rated as performing at or above expectations. During the quarter, the firm prioritized share repurchases, buying back 0.8 million shares for $10.1 million, while maintaining a quarterly base distribution of $0.33 per share. Adjusted earnings per share were $0.08, driven by stable net investment income despite unrealized losses on non-accrual and equity investments.Financial Services
  24. BOFNov 17, 4:05 PMBranchOut Food Inc. reported third-quarter 2026 net revenue of $1.35 million, a decrease from the prior year, driven by the exit of its non-core prune resale business and the transition to new recurring product programs. The company achieved an adjusted gross margin of 14.8% and expects fourth-quarter revenue to reach between $6 million and $7 million, with a full-year 2026 revenue target of $14.4 million to $15.4 million. Management projects 2027 net revenue to exceed $30 million, supported by a recurring revenue base of approximately $4 million per quarter and expanded production capacity at its Peru facility. The company currently holds $0.4 million in cash and plans to refinance its $4.0 million senior secured note into a term loan in 2027.Consumer Defensive
  25. GBDCNov 17, 4:04 PMGolub Capital BDC, Inc. reported fiscal year 2026 fourth-quarter net investment income of $0.32 per share and earnings of $0.08 per share. The company's net asset value per share decreased to $14.00 as of September 30, 2026, down from $14.25 at the end of the previous quarter. During the quarter, the firm paid a $0.33 per share distribution and opportunistically repurchased approximately 793,400 shares of its common stock. The investment portfolio, valued at $7.8 billion, consisted of 432 portfolio companies with senior secured and one-stop loans representing the majority of assets.Financial Services
  26. CDNov 17, 1:50 PMChaince Digital Holdings Inc. reported third-quarter 2026 revenue of $1.81 million, representing a 92% increase from the same period in 2025, driven primarily by underwriter services. The company achieved net income of $0.23 million for the quarter, a significant turnaround from the $2.55 million net loss recorded in the prior year period. By September 30, 2026, the company's total shareholders' equity reached $61.7 million, its highest level in nearly eight years, supported by cash, short-term investments, and stablecoins totaling approximately $60.0 million. Additionally, the company repurchased and canceled all outstanding warrants from its November 2023 private placement and closed a registered direct offering that raised approximately $16.2 million in August 2026.Financial Services
  27. DYNRNov 17, 12:12 PMDynaResource reported a net loss of $4.4 million and revenue of $10.1 million for the third quarter of 2026 at its San Jose de Gracia mine in Mexico. Gold production declined to 3,417 ounces due to lower head grades of 2.39 g/t, increased dilution, and heavy seasonal rainfall. The company successfully transitioned to a single underground mining contractor, resulting in reduced safety incidents and improved operational controls. Additionally, a new gravity concentration circuit is performing as designed, recovering approximately 26% of gold in concentrate, while $4.9 million in cash remains restricted pending resolution with tax authorities.
  28. RIMENov 17, 9:30 AMAlgorhythm Holdings completed the acquisition of Azure Energy on September 15, 2026, establishing a new operating segment focused on renewable power infrastructure advisory services. The company simultaneously ceased funding its unprofitable India-based logistics subsidiary, SMCB Solutions, to reduce expenses and focus on high-margin returns. For the third quarter of 2026, net sales increased approximately 20% to $2.1 million, while total assets rose to $25.2 million primarily due to the Azure acquisition. Stockholders' equity improved to $5.6 million, reversing a deficit of $1.9 million recorded at the end of 2025.Technology
  29. PULMNov 17, 9:29 AMPulmatrix, Inc. announced its third-quarter 2026 financial results and confirmed that its merger with Eos SENOLYTIX is expected to close by the end of the year following SEC effectiveness and stockholder approval. The company reported total cash and cash equivalents of $1.4 million as of September 30, 2026, while general and administrative expenses rose to $1.2 million due to merger-related activities. Pulmatrix continues to seek to out-license or monetize its clinical assets, including PUR1900, PUR3100, and PUR1800, while clinical development remains on hold pending these strategic moves.Healthcare
  30. PPSINov 17, 9:15 AMPioneer Power Solutions reported a 41.7% year-over-year increase in backlog to $17.9 million as of September 30, 2026, driven by a PRYMUS quote pipeline exceeding $200 million. The company achieved a gross margin of 23.1% for the third quarter, a significant improvement from 9.3% in the prior year period, though it recorded a GAAP operating loss of $2.8 million due to a $1.4 million non-cash impairment charge. Non-GAAP operating income turned positive at $321,000, contrasting with a $196,000 non-GAAP operating loss in the same quarter of the previous year. Management reaffirmed its outlook for approximately $15 million in revenue for the second half of 2026, representing over 60% growth compared to the first half, with the first PRYMUS system scheduled for delivery by the end of November.Industrials
  31. BOXLNov 17, 9:00 AMBoxlight Corporation reported third-quarter 2026 revenue of $30.1 million, representing a 2.5% increase from the prior year period. The company achieved a gross profit margin of 37.1%, a significant improvement from 29.1% in the previous year, while narrowing its net loss to $1.0 million from $6.2 million. Adjusted EBITDA improved to $2.4 million, driven by normalized tariff rates and reduced operating expenses. Financially, Boxlight strengthened its balance sheet by raising $5.5 million in Series D financing, securing a $15 million equity line, and reducing its senior secured term loan to $30.0 million.Technology
  32. NUOTQNov 17, 8:57 AMNuo Therapeutics reported total revenues of approximately $1.9 million for the third quarter of 2026, representing an 80% increase compared to the same period in 2025. The company recorded a net operating loss of roughly $374,000 for the quarter, which was an improvement over the prior year but higher than the previous quarter due to increased stock-based compensation and regulatory costs. Financial updates indicate the receipt of a $250,000 reimbursement milestone from Smith+Nephew and the final funding of a loan agreement, bringing total borrowings to $2 million. Additionally, the company highlighted favorable 2027 Medicare reimbursement rulings for its Aurix product, including a 7% increase in Outpatient Prospective Payment System rates and expanded coverage for nursing home treatments effective January 1, 2027.Healthcare
  33. AGPUNov 17, 8:36 AMAxe Compute Inc. reported third-quarter 2026 revenue of $7.2 million, representing a 125% increase from the previous quarter, alongside an operating income of $6.8 million and net income of $11.5 million. The company completed the sale of its Helomics subsidiary to transition fully into a GPU-as-a-Service business and acquired its first owned cluster of 2,304 NVIDIA B300 GPUs in Georgia. Cash reserves grew 6.7 times to $147.7 million, supported by customer prepayments that funded $349.6 million in infrastructure purchases during the quarter. Additionally, the company secured over $2.8 billion in new Build contracts in July, bringing its total contract value for 2026 to more than $3 billion.Technology
  34. EFSHNov 17, 8:16 AM1847 Holdings reported a third-quarter 2026 operating loss from continuing operations of $0.31 million, a 44% improvement year-over-year, driven by a 14% reduction in total operating expenses. Revenue from continuing operations totaled $1.74 million, with Wolo's revenue doubling to $0.15 million and its gross margin expanding significantly to 69.5% as it transitioned to e-commerce channels. For the first nine months of 2026, the company generated approximately $1.1 million in positive operating cash flow from continuing operations while narrowing its operating loss by 48% compared to the prior year. Concurrently, the company continues to market CMD Inc. and CMD Finish Carpentry LLC for sale, which are classified as discontinued operations.Industrials
  35. DISNov 17, 6:30 AMThe Walt Disney Company reported fiscal 2026 fourth-quarter revenues of $25.9 billion, a 16% increase from the prior year, driven by strong performance across its Experiences, Entertainment, and Sports segments. Full-year revenues reached $102.3 billion, an 8% increase, while adjusted earnings per share rose 18% to $7.02, excluding the impact of an additional 53rd week of operations. The company announced a 33% dividend increase to $2.00 per share and expects double-digit adjusted EPS growth in fiscal 2027, alongside approximately $11 billion in projected free cash flow. Strategic initiatives included the sale of its A+E Global Media stake, the NFL Transaction, and the FuboTV asset combination, which contributed to revenue growth and operational efficiency.Communication Services
  36. HDNov 17, 6:18 AMThe Home Depot reported third-quarter fiscal 2026 sales of $43.4 billion, representing a 4.9% increase from the prior year, with comparable sales rising 2.2%. Net earnings for the quarter reached $3.7 billion, or $3.72 per diluted share, while adjusted diluted earnings per share were $3.86. The company updated its full-year fiscal 2026 guidance to project total sales growth of approximately 4.5%, comparable sales growth of 1.4%, and diluted earnings per share growth of 1.5% to 2.0% depending on the metric used. As of the end of the quarter, the retailer operated 2,372 retail stores and over 1,320 SRS locations across North America with a workforce exceeding 470,000 associates.Consumer Cyclical
  37. OCSLNov 17, 6:02 AMOaktree Specialty Lending Corporation reported total investment income of $68.2 million for the fourth quarter of fiscal 2026 and $283.1 million for the full year, representing a decline from the prior year due to lower reference rates and a reduced average portfolio balance. Net investment income for the quarter was $29.8 million ($0.34 per share), while the company declared quarterly and supplemental cash distributions of $0.32 per share payable in December 2026. The company's net asset value per share stood at $15.63 as of September 30, 2026, with total debt outstanding at $1,416.0 million and liquidity comprising $45.1 million in unrestricted cash plus $994.0 million in undrawn credit facility capacity.Financial Services
  38. FFAINov 16, 5:00 PMFaraday Future Intelligent Electric Inc. reported third-quarter 2026 revenue of approximately $1.15 million, driven primarily by its robotics business, while narrowing its net loss to $9.8 million from $222.2 million in the prior-year period. The company successfully spun off its robotics division into a standalone Nasdaq-listed entity, FF Robotics (FFR), in an all-stock transaction valued at approximately $200 million that closed in late October 2026. For the nine months ended September 30, 2026, the robotics business generated $2.3 million in revenue with a 26% gross margin and shipped 1,168 units, reaffirming a full-year target of 2,000 units. Faraday Future is advancing a strategic transformation toward Robotaxi operations and an AI VisiCabin technology platform while maintaining its position as the controlling stockholder of FFR.Consumer Cyclical
  39. CEPLNov 16, 4:54 PMCapstone Energy+ secured a $25 million, three-year senior secured note agreement with Monarch Alternative Capital to refinance its existing Exit Notes. The company reported second-quarter fiscal 2027 revenue of $22.4 million, a decrease from the prior year, while parts and services revenue increased by 11% to $8.7 million. Net loss for the quarter was $4.0 million, resulting in an adjusted EBITDA of negative $1.0 million. At the end of the quarter, the company held $24.5 million in cash and restricted cash.Industrials
  40. CUENov 16, 4:52 PMCue Biopharma reported third-quarter 2026 financial results showing a net loss of $50.0 million and revenue of $0.1 million, driven by increased clinical trial costs and non-cash stock-based compensation. The company announced positive Phase 2 results for its lead candidate CUE-221 in chronic spontaneous urticaria, demonstrating superior complete hive resolution compared to placebo and XOLAIR, particularly in patients with high baseline IgE. Additionally, Cue Biopharma initiated first-in-human dosing for CUE-401, a dual-agonist therapeutic candidate designed to treat autoimmune diseases, while its Investigational New Drug application for CUE-221 in food allergy received FDA clearance.Healthcare
  41. AMCINov 16, 4:42 PMAMC Robotics reported a net loss of $2.02 million for the third quarter of 2026, driven by $2.57 million in operating expenses that included $1.5 million in one-time financing costs. Revenue for the quarter totaled $0.97 million, representing a 35.5% decline year-over-year as the company shifted away from lower-margin product sales toward higher-margin AI and cloud services. The company's gross margin fell to 54.6% due to a $248,597 non-recurring inventory impairment associated with relocating its supply chain to Vietnam. Despite the financial loss, the company remains on track to commission its Phase 1 production line in Vietnam by the end of 2026, with trial production scheduled for early 2027.Technology
  42. POCINov 16, 4:30 PMPrecision Optics Corporation reported first-quarter fiscal 2027 revenue of $8.2 million, representing a 22% increase from the prior-year period. The company achieved a gross margin of 22.5% and narrowed its net loss to $475,000, or $0.04 per share, compared to a $1.6 million loss in the same quarter last year. Revenue growth was driven by production programs in satellite optical communications and medical devices, including cystoscopes and ophthalmic instruments. The company maintains its full-year fiscal 2027 revenue guidance between $30 million and $33 million.Healthcare
  43. GPUSNov 16, 4:30 PMHyperscale Data, Inc. announced preliminary third-quarter 2026 revenue of approximately $44.8 million, marking an 84% increase compared to the same period in 2025. This figure exceeds the company's previous estimate of $40 million by roughly 12%. The company plans to host a conference call on November 23, 2026, to discuss these financial results and strategic priorities. Hyperscale Data currently anticipates the divestiture of its subsidiary Ault Capital Group to occur in 2027.Industrials
  44. POWLNov 16, 4:24 PMPowell Industries reported fourth-quarter fiscal 2026 revenues of $397 million, a 33% increase year-over-year, driven by strong performance in the Oil and Gas and Commercial markets. The company achieved a record full-year revenue of $1.3 billion and net income of $221 million, while new orders surged 124% to $2.6 billion, resulting in a backlog of $2.7 billion. Gross profit margins improved to 34.9% in the quarter and 31.3% for the full year, supported by volume leverage and stable pricing. Additionally, the company secured two mega-orders totaling approximately $335 million in the LNG and data center sectors during the quarter.Industrials
  45. RSSSNov 16, 4:19 PMResearch Solutions, Inc. reported first-quarter fiscal 2027 results with total revenue of $11.9 million, a decrease from the prior year's $12.3 million. Annual recurring revenue increased 5.7% year-over-year to $22.5 million, driven by an 11.5% growth in B2B ARR to $16.5 million. The company achieved a net income of $765,000, or $0.02 per diluted share, with adjusted EBITDA reaching $1.0 million. Platform revenue accounted for 45% of total revenue, reflecting a strategic shift toward higher-margin recurring business models.Technology
  46. FIRYNov 16, 4:19 PMFiry Inc. reported third-quarter 2026 revenue of $31.3 million, representing a 14% year-over-year increase driven primarily by its RZR segment, which grew 141% and accounted for the majority of quarterly revenue. The company achieved a net loss of $12.5 million, a narrowing of $4.9 million compared to the prior year, while Adjusted EBITDA excluding litigation expenses improved to a loss of $1.2 million. Firy ended the quarter with $71.0 million in cash and cash equivalents after redeeming $49.7 million of senior secured notes and receiving $55 million from the sale of its Exit Games stake. Management highlighted significant operating leverage, noting that roughly two-thirds of new revenue dollars from RZR converted to Adjusted EBITDA.Communication Services
  47. NXBNov 16, 4:05 PMNextBoat Inc. reported fiscal third-quarter 2026 revenue of $50.6 million, representing an 110.7% increase from the same period in 2025. The company achieved a gross profit of $8.1 million, driven by significant growth in pre-owned boat sales, new boat sales, and service operations following the acquisition of Apex Marine and Bellhart. Despite the revenue expansion, the company recorded a net loss of $4.6 million for the quarter due to higher operating expenses, including increased salaries, marketing costs, and non-recurring items. For the full year 2026, NextBoat maintains its revenue guidance between $165 million and $170 million.Consumer Cyclical
  48. BRFHNov 16, 4:05 PMBarfresh Food Group reported third-quarter 2026 revenue of $5.8 million, a 37% increase year-over-year driven by $2.5 million in sales from its Arps Dairy acquisition. The company achieved operating income of $120,000 for the quarter, contrasting with a $260,000 loss in the same period last year, while adjusted EBITDA remained near breakeven at a loss of $15,000. Management updated its full-year 2026 revenue guidance to a range of $20 million to $22 million, down from previous expectations, citing lower-margin milk sales and facility ramp-up costs. Additionally, the USDA extended the grant deadline for the company's new Defiance, Ohio facility to April 30, 2027, and the company is pursuing mortgage financing to complete the project.Consumer Defensive
  49. EUBGNov 16, 4:05 PMEntrepreneur Universe Bright Group reported revenue of $680,624 for the third quarter of 2026, a decline from $1,217,966 in the same period of 2025. The company recorded a net loss of $221,730 for the quarter, contrasting with a net income of $395,113 in 2025. Over the nine months ended September 30, 2026, revenue totaled $2,164,581 and the company posted a net loss of $178,346. Cash and cash equivalents stood at approximately $8.94 million as of September 30, 2026.
  50. ACRVNov 16, 4:05 PMAcrivon Therapeutics reported a net loss of $17.9 million for the third quarter of 2026, with cash and investments totaling $77.8 million expected to fund operations through the fourth quarter of 2027. The company established immunology and inflammation as a second strategic pillar, acquiring the Phase 2-ready JAK1 inhibitor ACR-525 for eosinophilic esophagitis and a preclinical PKCθ program. Clinical progress includes late-breaking data on the WEE1/PKMYT1 inhibitor ACR-2316 showing durable responses in lung and endometrial cancers, while the CHK1/2 inhibitor ACR-368 is on track for a prespecified interim analysis in endometrial cancer later this year. Additionally, the CDK11 inhibitor ACR-7280 has been nominated for IND-enabling studies in acute myeloid leukemia.Healthcare
  51. KYNBNov 16, 4:05 PMKyntra Bio reported a net income of $0.2 million for the third quarter of 2026, driven by a $14 million gain from restructuring a royalty financing agreement that reduced future payment obligations by $60 million. The company decided to discontinue development of its FG-3246 and FG-3180 programs in metastatic castration-resistant prostate cancer following insufficient efficacy, a move expected to save over $20 million in operating expenses during 2027 and 2028. With $44.1 million in cash and equivalents as of September 30, 2026, Kyntra Bio projects a cash runway extending into 2028 while preparing to initiate a pivotal Phase 3 trial for roxadustat in LR-MDS patients in the first quarter of 2027, contingent on securing a strategic partnership or external capital.Healthcare
  52. PHUNNov 16, 12:15 PMPhunware reported third-quarter 2026 net revenue of $483,000, an 8.3% increase from the prior year, while gross profit rose 61.2% to $274,000 with gross margin expanding to 56.7%. The company advanced its Phunware 2.0 strategy by moving Itinerary Planner into beta and initiating discussions with four major hospitality groups, though it wound down its advertising business to focus on recurring software revenue. Despite these operational shifts, the company recorded a net loss of $7.1 million for the quarter, driven by increased litigation expenses and investments in AI product development and sales initiatives. Phunware concluded the period with $86.7 million in cash and no debt, maintaining financial flexibility to support its growth plan.Technology
  53. IVFNov 16, 10:30 AMINVO Fertility reported third-quarter 2026 revenue of $2.22 million, representing a 26% increase from the prior year, driven by organic growth at existing clinics and contributions from the Indiana and Birmingham acquisitions. The company achieved positive Clinic-Level Adjusted EBITDA of $292,114 for the seventh consecutive quarter, despite a consolidated net loss of $2.1 million. Financial improvements included a strengthened balance sheet with cash reserves rising to $3.7 million and current liabilities decreasing to $4.5 million from $10.3 million at the end of 2025.Healthcare
  54. RPIDNov 16, 10:17 AMRapid Micro Biosystems reported third-quarter 2026 total revenue of $9.5 million, reflecting a 22% increase from the same period in 2025. The company achieved a record gross margin of 25%, driven by a 19 percentage point rise in product margins and a 14 percentage point increase in service margins. Net loss for the quarter was $11.3 million, while non-GAAP adjusted EBITDA loss narrowed to $7.9 million from $9.4 million in the prior year. On November 16, 2026, the company announced a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany, leading to the withdrawal of its full-year 2026 guidance and a delay in filing its Form 10-Q.Healthcare
  55. UNCYNov 16, 9:28 AMUnicycive Therapeutics announced that the U.S. Food and Drug Administration accepted its New Drug Application resubmission for oxylanthanum carbonate, establishing a Prescription Drug User Fee Act target date of March 25, 2027. The company reported a net loss of $7.0 million for the third quarter ended September 30, 2026, driven primarily by increased commercial launch preparation expenses, while maintaining approximately $59 million in cash and marketable securities with a runway extending beyond 2027. Commercial readiness efforts are advancing through discussions with dialysis organizations and plans to hire a sales force in early 2027, supported by favorable reimbursement changes from the Centers for Medicare & Medicaid Services effective January 2027.Healthcare
  56. JAGXNov 16, 9:15 AMJaguar Health reported a net loss of $5.8 million for the third quarter of 2026, a significant improvement from the $9.6 million loss in the same period the previous year. The company reduced its outstanding debt balance by $10.1 million during the quarter and recognized $1.8 million in holdback payments from its exclusive U.S. licensing agreement with Future Pak for Mytesi and Canalevia-CA1. Total net revenue for the quarter was $2.3 million, driven primarily by license and grant revenue, while prescription product revenue declined to approximately $0.5 million following the transfer of U.S. commercial rights to Future Pak. Jaguar continues to focus its resources on the development of a powder-for-oral-solution formulation of crofelemer for rare intestinal failure indications, with a New Drug Application filing for microvillus inclusion disease planned for mid-2027.Healthcare
  57. SWRDNov 16, 9:13 AMStewards, Inc. reported a net loss of $19.4 million for the third quarter of 2026, driven by an $8.5 million noncash charge related to warrant liabilities and lower private credit deployment. The company's total assets increased 49% to $265.3 million following the completion of a $79 million refinancing for 1818 Park and the acquisition of Envy Pompano Beach. Stewards launched a digital customer portal with Plaid integration and announced a partnership with Rain to develop a business card targeted for early 2027 availability. Following the quarter, the company secured a standstill agreement on $31.8 million of notes and amended terms for the Envy acquisition to exchange cash redemption obligations for preferred stock.Financial Services
  58. NFENov 16, 9:03 AMNew Fortress Energy completed a restructuring and recapitalization on September 11, 2026, reducing its debt principal from approximately $5.7 billion to $0.7 billion. For the third quarter of 2026, the company reported total revenues of $335.8 million and a net income of $863.4 million, which included $1.6 billion in non-cash gains from the debt restructuring. Adjusted EBITDA for the quarter was $48.4 million, driven by higher cargo sales margins and contract novation revenue. Recent developments include a temporary outage of the FLNG 1 facility due to a turbine issue and an agreement to lease ten mobile turbines to improve liquidity.Utilities
  59. ELOXNov 16, 9:02 AMEloxx Pharmaceuticals reported a net loss of $5.5 million for the third quarter of 2026, driven by increased research and development expenses related to the initiation of its Phase 2b EXACT study for nonsense mutation Alport syndrome. The company dosed its first two patients in this global trial and finalized the protocol for a Phase 2 EXPRESS study targeting nonsense mutation autosomal dominant polycystic kidney disease, with the first patient expected to be dosed in the third quarter of 2027. As of September 30, 2026, Eloxx held $56.3 million in cash and cash equivalents, which management believes will fund operations into 2028. Additionally, the company expanded its leadership team by appointing T.R. Srinivas as Senior Vice President and Chief Medical Officer and added Geno Germano to its Board of Directors.Healthcare
  60. TOONNov 16, 9:00 AMKartoon Studios reported a net loss of $5.7 million for the third quarter of 2026, with total revenue declining to $5.4 million due to reduced production services activity and the sale of the Frederator channel network business. The company maintains $33.0 million in cash and marketable securities while advancing its strategy to commercialize the Hundred Acre Wood intellectual property through new agreements with Walmart Marketplace and Amazon Prime. Scheduled launches include consumer products on Walmart in January 2027 and a streaming series on Amazon Prime in February 2027, with broader streaming and consumer product initiatives expected to begin in the first quarter of 2027. Additionally, the company strengthened audience engagement on its owned platforms, Kartoon Channel! and Ameba, where total viewing hours more than doubled year-over-year.Communication Services
  61. GXONov 16, 8:57 AMGXO Logistics announced 2030 financial targets aiming for greater than 7% organic revenue CAGR, a greater than 6.5% adjusted EBITA margin, and a 40% to 50% free cash flow conversion rate on adjusted EBITDA. The company also provided a preliminary 2027 outlook projecting above 5.5% organic revenue growth, a greater than 7.1% adjusted EBITDA margin, and above 4.5% adjusted EBITA margin. These targets reflect the company's strategy to lead in AI-powered logistics while building a diversified business model. The announcement was made during the 2026 Investor Day held at the New York Stock Exchange.Industrials
  62. AIMDNov 16, 8:41 AMAinos, Inc. reported third-quarter 2026 revenue of $642,889, representing a 29,567% increase year over year, driven by VELDONA licensing and AI Nose semiconductor programs. The company delivered 1,400 AI Nose systems under an initial agreement and subsequently secured a $9 million follow-on order for 5,000 additional units with a $4.5 million initial payment due within 60 days. GAAP net loss narrowed by 36% to $1.89 million, while non-GAAP adjusted net loss improved by 51% to $672,352. Additionally, the company surpassed 3 billion real-world chemical data points and expects recurring quarterly revenue of $175,000 starting in the fourth quarter from its AI Nose service agreements.Technology
  63. CNTNNov 16, 8:35 AMCanton Strategic Holdings, Inc. reported total revenue of $3.05 million for the third quarter of 2026, representing a 104% increase from the previous quarter. The company achieved its first positive Adjusted EBITDA of $610,414, driven by $1.5 million in network validation revenue and $1.5 million in other revenue primarily from its locking-as-a-service offering. During the quarter, the company's active Super Validator weight increased to 6.5, and it held 3.83 billion units of Canton Coin with a fair value of $482.1 million. Despite the revenue growth, the company recorded a net loss of $35.1 million, largely due to a $54.6 million unrealized loss on its digital asset holdings.Healthcare
  64. USDENov 16, 8:35 AMStablecoinX reported third-quarter 2026 revenue of $477,993, representing a 666% sequential increase driven by its Decentralized Verifier Node infrastructure services. The company's ENA treasury of 3.0 billion tokens, valued at approximately $802 million based on September 30 prices, was fully unlocked following a waiver of lock-up restrictions. While the company posted a GAAP net loss of $100.2 million largely due to non-cash losses on warrant liabilities, its adjusted net loss was $1.9 million. Additionally, the DVN surpassed $6 billion in cumulative verified cross-chain volume, and the firm appointed Christopher Jensen as its new Chief Executive Officer.Financial Services
  65. APVONov 16, 8:35 AMAptevo Therapeutics reported that its lead candidate mipletamig achieved a 79% remission rate in patients with high-risk TP53-mutated acute myeloid leukemia, a figure nearly double the historical benchmark for similar patients treated with standard therapies. Ten of 47 patients receiving the mipletamig combination therapy advanced to potentially curative stem cell transplantation, while refinements to the drug's priming-dose regimen significantly reduced infusion-related reactions. The company also secured $4.5 million in additional financing to support clinical milestones and advanced its next-generation trispecific candidates toward human testing in solid tumors.Healthcare
  66. IPDNNov 16, 8:32 AMProfessional Diversity Network, Inc. reported a 48.2% decline in third-quarter 2026 revenues to approximately $856,000, driven by reduced demand in its recruitment and software development segments. The company posted a net loss from continuing operations of $2.652 million for the quarter, an increase from the prior year period, largely due to $1.189 million in amortization expenses for acquired musical copyrights. Despite the revenue drop, the firm improved its working capital position to $0.2 million and significantly reduced general and administrative expenses by 47.2% through workforce restructuring and reduced consulting costs. Additionally, the company launched PDN Intelligence, Inc. to explore opportunities in AI infrastructure and GPU-based computing services, though no revenue was generated from this initiative during the quarter.Industrials
  67. HCWBNov 16, 8:30 AMHCW Biologics reported a net loss of $3.2 million for the three months ended September 30, 2026, and $5.0 million for the nine-month period, driven by research and development expenses of $1.2 million and $3.7 million respectively. The company secured $8.6 million in equity financing and $3.0 million in debt financing during the first nine months of 2026 to support its Phase 1 clinical trial for HCW9302 in alopecia areata and preclinical programs. Clinical progress includes the activation of an additional site for the HCW9302 study and FDA guidance to file an IND application for the solid tumor candidate HCW11-018b in the first half of 2027. Despite these advancements, the company disclosed substantial doubt regarding its ability to continue as a going concern for the next 12 months without additional funding.Healthcare
  68. DWSNNov 16, 8:13 AMDawson Geophysical Company reported a net loss of $5.2 million, or $0.17 per share, for the third quarter of 2026, driven by a 27% decline in fee revenue to $10.8 million and negative Adjusted EBITDA of $2 million. Despite the quarterly setback, year-to-date results through September 30, 2026, showed a 47% increase in fee revenue to $57.4 million and a 580% surge in Adjusted EBITDA to $9.5 million compared to the prior year period. The company cited delays in large channel crew jobs due to permitting issues as a factor in the third quarter, while noting a renewed demand for high-density seismic services in North America and the upcoming launch of geothermal data acquisition. Management projects continued revenue growth and improved margins for 2027, supported by a strengthened backlog and expanded operations in both the United States and Canada.Energy
  69. VERINov 16, 8:12 AMVeritone reported third-quarter 2026 revenue of $18.6 million, a 30.1% decrease from the prior year, while achieving an Annual Recurring Revenue of $55.9 million. The company completed an exchange of $38.7 million in convertible notes for new notes and 1.6 million shares of common stock, with the remaining $6.8 million of old notes scheduled for payment in November 2026. Additionally, Veritone secured a commitment letter for a $40 million senior secured term loan from Blue Torch Capital, contingent on raising an additional $25 million in financing. The company has implemented restructuring efforts resulting in over $18 million in annualized cost reductions and targets further reductions of $2 million to $7 million by the end of 2026.Technology
  70. ALXONov 16, 8:10 AMALX Oncology reported a net loss of $21.8 million for the third quarter ended September 30, 2026, with cash, cash equivalents, and investments totaling $147.2 million sufficient to fund operations through the first half of 2028. The company announced the publication of Phase 2 ASPEN-06 trial data in Nature Medicine, which showed encouraging efficacy for evorpacept in HER2-positive gastric cancers, while enrollment for the Phase 2 ASPEN-09-Breast trial remains on track with topline data expected in the second half of 2027. Additionally, ALX Oncology plans to release safety and early efficacy data from the Phase 1 dose-escalation study of its EGFR-targeted ADC, ALX2004, in December 2026.Healthcare
  71. IAMNov 16, 8:08 AMIambic Therapeutics launched Enchant v3, a 41-billion-parameter AI model for drug discovery, and secured new collaborations with AbbVie and Bayer, bringing its total partnership count to eight since 2024. The company reported third-quarter 2026 collaboration revenue of $11.4 million and achieved a $1.0 million milestone payment from its Takeda partnership. Clinically, updated data for the lead candidate IAM1363 showed 36% systemic and 41% intracranial response rates in heavily pretreated patients, with a registrational trial planned for 2027. Additionally, Iambic submitted an IND for its second candidate, IAM217, and expects to file for IAM-C1 in the fourth quarter of 2026, while maintaining a cash position of $252 million as of September 30, 2026.Healthcare
  72. IBATFNov 16, 8:05 AMInternational Battery Metals Ltd. reported a net income of $2.2 million for the second quarter of fiscal 2027, ending September 30, 2026, driven primarily by a $5.0 million gain from the change in fair value of warrant liability. Revenue for the quarter was zero, a decrease from $64,000 in the prior year period, as the company focused on engineering a compact pilot plant for direct lithium extraction. The company plans to secure a secured term loan of up to $12.0 million to fund the pilot plant construction and cover general administrative expenses over the next 12 months. Additionally, the company continues to evaluate commercial opportunities in North America, South America, and the Middle East while providing brine testing services to prospective customers.
  73. APMDNov 16, 8:04 AMApnimed reported a net loss of $29.5 million for the third quarter ended September 30, 2026, driven by increased general and administrative expenses related to commercial launch preparations. The company holds $351.8 million in cash and cash equivalents, which is expected to fund operations and a potential U.S. launch into the second quarter of 2028. Its New Drug Application for AD109, proposed as Oxnimbi, remains under FDA review with a PDUFA goal date of February 28, 2027. Additionally, Apnimed presented five abstracts at the CHEST 2026 Annual Meeting, including two late-breakers highlighting Phase 3 clinical data for the drug.Healthcare
  74. NMRANov 16, 8:03 AMNeumora Therapeutics submitted an Investigational New Drug application for its NLRP3 inhibitor, NMRA-215, to treat obesity and cardiometabolic disease. The company reported dose-proportional increases in exposure for NMRA-511 at a 30 mg BID dose in healthy elderly participants, indicating potential to enhance the efficacy observed in previous Phase 1b studies. For the third quarter ended September 30, 2026, Neumora reported a net loss of $34.4 million and ended the period with $85.7 million in cash and cash equivalents.Healthcare
  75. ADGMNov 16, 8:02 AMAdagio Medical Holdings reported a net income of $17.8 million for the third quarter of 2026, driven primarily by a $23.0 million noncash gain from the change in fair value of its convertible notes. The company treated 22 patients with its vCLAS Ultra System in the United States and Canada, including 19 in the FULCRUM-VT IDE sub-study, while initiating a formal process to explore strategic alternatives. Research and development expenses decreased to $1.8 million, and selling, general, and administrative expenses fell to $2.6 million compared to the prior year period. On November 6, 2026, the company completed a one-for-thirty reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.Healthcare
  76. VENUNov 16, 8:00 AMVenu Holding Corporation reported total assets of $587.6 million as of September 30, 2026, representing a 59% increase from the prior year-end. The company generated $14.1 million in revenue for the nine-month period ended September 30, 2026, while reporting a net loss attributable to common stockholders of $44.6 million. Construction progress advanced significantly on the Regent Bank Amphitheater and Sunset Amphitheater McKinney, with the latter reaching 95% sales on premium seating prior to its opening. Subsequent to the quarter, the company secured $67.5 million in sale-leaseback transactions and announced the opening of the Regent Bank Amphitheater for New Year's Eve 2026.Consumer Cyclical
  77. POWWNov 16, 8:00 AMOutdoor Holding Company reported second-quarter fiscal 2027 net revenues of $13.7 million, representing a 14.6% increase from the prior-year period, while net income from continuing operations rose to $2.3 million. The company achieved an Adjusted EBITDA of $6.1 million and grew its gross merchandise value by 10.3% to approximately $208.4 million, driven by a 4.8% increase in firearm unit sales that outpaced the broader market. Operational highlights include a 25 basis point year-over-year increase in take rate to 6.59% and the completion of the company's redomestication from Delaware to Texas. Additionally, the Board increased the share repurchase authorization by $20.0 million, and the company ended the quarter with $70.4 million in cash and cash equivalents.Industrials
  78. JSPRNov 16, 8:00 AMJasper Therapeutics reported third-quarter 2026 financial results showing $135.3 million in cash and cash equivalents alongside a net loss of $144.5 million for the quarter. The company advanced its clinical pipeline by completing enrollment in the first cohort of a Phase 2 renal basket study for vensobafusp alfa in IgA nephropathy and initiating enrollment for patients with IC-MPGN. Recent corporate developments include the July 2026 acquisition of Kira Pharmaceuticals, a $132 million private placement, and a 1-for-30 reverse stock split effected in November 2026.Healthcare
  79. GALTNov 16, 7:55 AMGalectin Therapeutics reported a net loss of $3.6 million for the quarter ended September 30, 2026, driven by $1.6 million in research and development expenses and $1.8 million in general and administrative expenses. The company submitted its registrational Phase 3 protocol for belapectin to the FDA in the third quarter following alignment on the trial design for advanced MASH cirrhosis. Significant corporate developments included the conversion of approximately $105.8 million in debt held by Chairman Richard E. Uihlein into over 34 million shares of common stock. As of September 30, 2026, the company held $11.7 million in cash and cash equivalents, with sufficient funds to support operations through June 2027.Healthcare
  80. LNZANov 16, 7:52 AMLanzaTech reported a net loss of $178.0 million for the third quarter of 2026, primarily driven by a $166.4 million non-cash unrealized fair value loss on its investment in SGLT. Despite the net loss, the company achieved significant operational progress, including the world's first ISCC EU certification for recycled carbon fuels from steel mill waste gases at its Hebei Shoulang facility. Operating expenses decreased by 35% to $11.7 million compared to the prior year, reflecting successful cost reduction initiatives and a reset cost structure. The company also raised $50.0 million through common stock issuance in the first nine months of 2026, increasing its cash and restricted cash balance to $36.3 million as of September 30, 2026.Industrials
  81. MNTKNov 16, 7:45 AMMontauk Renewables reported third-quarter 2026 revenues of $50.2 million, a 10.9% increase year-over-year, driven primarily by higher environmental attribute revenues from RINs sold. Net income for the quarter was $2.1 million, a 58.9% decline from the prior year, while non-GAAP Adjusted EBITDA decreased 20.6% to $10.2 million. The company executed a non-binding term sheet to amend its New Senior Credit Facility, securing additional borrowing capacity and covenant forbearance, which removed the previously anticipated going concern qualification from its financial statements. Full-year 2026 RNG revenue is now projected to range between $175 million and $180 million, reflecting a reduction in expected environmental attribute pricing.Utilities
  82. CREXNov 16, 7:45 AMCreative Realities reported fiscal third-quarter 2026 revenue of $26.2 million, a significant increase from $10.5 million in the prior-year period, driven by hardware and service growth including operations from its Cineplex Digital Media subsidiary. The company achieved an adjusted EBITDA of $2.7 million and ended the quarter with annualized recurring revenue of approximately $21.7 million. Key business developments include the completion of digital media upgrades for over 1,000 Zaxby's locations and the deployment of its AdTech technology at more than 500 Albertsons stores. Despite a net loss of $3.6 million for the quarter, the company reduced its outstanding debt to approximately $40 million and anticipates exceeding $100 million in revenue for the full fiscal year 2026.Technology
  83. TSNNov 16, 7:41 AMTyson Foods reported fiscal 2026 sales of $56.4 billion, a 3.6% increase from the prior year, driven by growth in prepared foods and chicken segments. The company recorded GAAP operating income of $1.1 billion and adjusted operating income of $1.98 billion, while adjusted earnings per share declined 17% to $3.44 due to legal contingency accruals and restructuring charges. For fiscal 2027, Tyson anticipates sales to decrease between 3.5% and 5.5% primarily due to lower beef volumes, with projected adjusted operating income ranging from $1.7 billion to $2.15 billion. The company also announced an increase in its quarterly dividend to $0.52 per share for Class A stock and $0.468 for Class B stock, effective November 2026.Consumer Defensive
  84. EDBLNov 16, 7:35 AMEdible Garden AG reported third-quarter 2026 revenue of $3.2 million, a 14% increase driven by a 65.7% surge in cut herb sales. Gross profit rose 181.7% to $0.8 million, expanding the gross margin to 23.9% from 9.7% in the prior year period. The company secured a major private-label ready-to-drink protein beverage award and expanded its retail distribution network with new agreements at Walmart and UNFI. Additionally, a strategic supply agreement with Caney Fork Farms is expected to reduce production costs by over 12% once fully implemented in 2027.Consumer Defensive
  85. VIDANov 16, 7:35 AMVida Global Inc. reported third-quarter 2026 total revenue of $0.33 million, an 88% increase from the prior year period, driven by growth in subscription and usage-based fees. The company achieved a gross margin of 44% and recorded a net loss of $1.47 million, while its cash, cash equivalents, and short-term investments rose to $12.7 million. Operationally, Vida's computer agents exited beta to perform tasks beyond conversations, resulting in nearly 1,400 active AI employees and over one million call minutes handled during the quarter. Following the quarter, the company introduced outcome-based billing in October and launched an MCP server in November to facilitate AI employee deployment through existing business assistants.Technology
  86. MBRXNov 16, 7:30 AMMoleculin Biotech completed treatment for all 90 patients in Part A of its pivotal MIRACLE trial evaluating Annamycin for relapsed or refractory acute myeloid leukemia, with comprehensive data expected in the first quarter of 2027. A peer-reviewed analysis of 90 patients across five clinical trials found no evidence of clinical or subclinical cardiotoxicity, supporting the drug's differentiated safety profile. The company reported a net loss of approximately $6.5 million for the third quarter of 2026, driven primarily by research and development expenses related to the MIRACLE trial. Additionally, new preclinical data suggest Annamycin may convert immunologically cold pancreatic tumors to hot, supporting potential combination therapies.Healthcare
  87. MPLTNov 16, 7:20 AMMapLight Therapeutics reported a net loss of $51.6 million for the third quarter of 2026, with cash, cash equivalents, and investments totaling $463.4 million as of September 30, 2026. The company has initiated start-up activities for the ZEPHYR-2 Phase 3 trial of its lead candidate ML-007C-MA in schizophrenia, with topline results expected in the second half of 2027. Enrollment is ongoing for the Phase 2 VISTA trial of ML-007C-MA in Alzheimer's disease psychosis, where the drug holds FDA Fast Track designation and top-line results are anticipated in 2028. Additionally, the company plans to engage with the FDA regarding the registrational path for ML-004 in autism spectrum disorder following positive Phase 2 IRIS trial data.Healthcare
  88. XTNDNov 16, 7:19 AMXTEND AI Robotics reported third-quarter 2026 revenue of $14.9 million, representing a 281% year-over-year increase driven by its AI Robotics segment. The company secured a fully funded backlog of $84.7 million as of September 30, 2026, which grew to $100.7 million by mid-November following a $40.5 million order for 6,000 STRIKER systems. Although the company posted a net loss of $44.6 million for the quarter due to significant operating expenses and stock-based compensation, it ended the period with $66.7 million in cash and cash equivalents. Operational milestones included the completion of a business combination with JFB Construction Holdings and the advancement of multiple defense programs in the U.S., EMEA, and Asia-Pacific regions.Technology
  89. LRMRNov 16, 7:17 AMLarimar Therapeutics completed a rolling Biologics License Application submission seeking accelerated approval for nomlabofusp to treat Friedreich's ataxia, utilizing skin frataxin as a potential novel surrogate endpoint. The company reported a net loss of $31.1 million for the third quarter of 2026, a decrease from $47.7 million in the same period the prior year, driven largely by reduced drug manufacturing expenses. As of September 30, 2026, Larimar held $128.7 million in cash and marketable securities, projecting a runway into late Q2 2027. The company is currently enrolling patients in the global confirmatory Phase 3 FORWARD-FA study and targets a potential U.S. launch in the third quarter of 2027 if the application is approved.Healthcare
  90. PRLDNov 16, 7:09 AMPrelude Therapeutics reported a net loss of $12.5 million for the third quarter ended September 30, 2026, with cash and equivalents totaling $142.7 million, extending its runway into the second quarter of 2028. The company initiated enrollment in a Phase 1 study for PRT13722, a selective KAT6A degrader for HR+ breast cancer, and entered a collaboration with Eli Lilly to evaluate this candidate in combination with abemaciclib and imlunestrant. Concurrently, enrollment continues for PRT12396, a mutant-selective JAK2V617F inhibitor for polycythemia vera and myelofibrosis, while preclinical data for an mCALR-targeted degrader antibody conjugate was accepted for presentation at the ASH 68th Annual Meeting.Healthcare
  91. IVVDNov 16, 7:08 AMInvivyd reported third-quarter 2026 net product revenue of $15.4 million for PEMGARDA, an 18% increase from the prior year period. The company announced positive topline results from its LIBERTY Phase 3 trial, demonstrating that VYD2311 has superior safety and tolerability compared to an mRNA COVID-19 vaccine without interfering with vaccine-induced antibodies. Additionally, Invivyd initiated the FLINTLOCK Phase 2 trial to evaluate VYD2311 for Long COVID and Post-Vaccination Syndrome while preparing for an imminent interim analysis of the DECLARATION Phase 3 trial data. Financially, the company recorded a net loss of $33.5 million for the quarter and ended with $126.4 million in cash and cash equivalents.Healthcare
  92. CYPHNov 16, 7:05 AMCypherpunk Technologies reported a net income of $306.0 million for the third quarter of 2026, driven primarily by a $330.8 million unrealized gain on an embedded derivative linked to the rise in Zcash prices. The company launched its mining operations in August 2026, generating $9.9 million in revenue from 8,967.29 ZEC mined with 95% uptime. As of November 2026, the company's ZEC treasury holdings increased to 341,858.75 ZEC, representing approximately 2.01% of the circulating supply. Additionally, the company appointed Amanda Fabiano to its Board of Directors and is evaluating strategic options for its Leap Therapeutics subsidiary to advance its Phase 3 clinical trials.Healthcare
  93. XTNTNov 16, 7:05 AMXtant Medical Holdings reported third-quarter 2026 total revenue of $24.3 million, a decrease from $33.3 million in the same period of 2025, primarily due to the absence of revenue from divested businesses and wound care licensing. The company posted a net loss of $3.6 million for the quarter, while biologics revenue grew 13% year-over-year to $19.3 million. The Board of Directors has initiated a strategic review to evaluate various operational and financial alternatives aimed at maximizing stockholder value. Consequently, the company has withdrawn its full-year 2026 financial guidance and will not host a conference call to discuss these results.Healthcare
  94. AIRJNov 16, 7:05 AMAirJoule Technologies completed its acquisition of BitSink on September 10, 2026, adding modular data center infrastructure capabilities and $15 million in signed purchase orders. The company delivered its first AirJoule Prime system to the Data4 data center in France and initiated pilot projects with Kubota Corporation for residential water generation. Financial results for the third quarter of 2026 showed a net loss of $19.8 million, while the company provided a preliminary 2027 revenue outlook for BitSink ranging from $15 million to $20 million. Additionally, Timothy N. White joined the Board of Directors to support the company's engineering and manufacturing expansion.Industrials
  95. MTRINov 16, 7:03 AMMentari Therapeutics, Inc. reported a net loss of $63.0 million for the nine months ended September 30, 2026, driven primarily by $57.7 million in research and development expenses. The company maintained $45.8 million in cash and cash equivalents as of September 30, 2026, while holding significant liabilities including a $50.0 million convertible note payable to a related party. On November 6, 2026, the company completed a merger with InMed Pharmaceuticals, resulting in a combined entity focused on migraine prevention therapies. This transaction was preceded by a $490.0 million pre-closing financing that provided additional capital for the company's development programs.Healthcare
  96. LXEONov 16, 7:02 AMLexeo Therapeutics reported positive interim Phase I/II data for its gene therapy candidate LX2020 in patients with PKP2 arrhythmogenic cardiomyopathy, showing an 80% mean reduction in non-sustained ventricular tachycardia and a 44% reduction in premature ventricular contractions in high-dose cohorts. The treatment was generally well tolerated across ten participants, with no clinically significant complement activation observed, prompting the company to design a pivotal study using non-sustained ventricular tachycardia as a primary surrogate endpoint for potential accelerated approval. The U.S. Food and Drug Administration has indicated openness to this endpoint strategy, with the company expecting to initiate the pivotal study in the second half of 2027. Financially, the company reported a net loss of $38.3 million for the third quarter of 2026 and holds $219.1 million in cash and investments, providing an operational runway into 2028.Healthcare
  97. ELWTNov 16, 7:00 AMElauwit Connection reported a 104% sequential increase in total revenue to $5.6 million for the third quarter of 2026, driven by a 140% year-over-year rise in billed units to 25,746. Monthly recurring revenue grew 66% year-over-year to $539,000, while the backlog of new installations and recurring services reached $53.5 million as of September 30. The company implemented cost reductions that lowered operating expenses by approximately $0.3 million in the quarter and increased its cash and cash equivalents to $2.7 million. Despite these operational gains, the company reported a net loss of $2.58 million for the quarter and maintains an accumulated deficit of $22.6 million.Communication Services
  98. TILNov 16, 7:00 AMInstil Bio reported a net loss of $4.2 million for the third quarter of 2026 and $13.0 million for the first nine months of the year. As of September 30, 2026, the company held approximately $67.1 million in cash and investments, which is expected to fund operations through 2027. Research and development expenses decreased significantly to $0.2 million for the quarter and $1.2 million for the nine-month period compared to prior year figures. The company also corrected immaterial errors in previously issued financial statements related to property taxes and tenant reimbursements.Healthcare
  99. VYCONov 16, 6:58 AMVycor Medical, Inc. reported revenue of $414,895 for the three months ended September 30, 2026, representing an 18% decrease compared to the same period in 2025. For the nine-month period, total revenue was $1,291,699, an 11% decline from the prior year, driven primarily by lower sales in the Vycor Medical division which produced the ViewSite Brain Access System. The company recorded a GAAP net loss of $161,447 for the quarter and $325,812 for the nine months, while non-GAAP operating profit improved to $43,011 for the quarter and $125,751 for the nine months. Additionally, four new peer-reviewed studies on the ViewSite system were published during 2026, bringing the total number of clinical papers to 54.
  100. BXDCNov 16, 6:46 AMBlackstone Digital Infrastructure Trust reported third-quarter 2026 net income of $15.6 million, or $0.15 per share, with Funds from Operations and Adjusted Funds from Operations per share at $0.15 and $0.17 respectively. The company executed its inaugural investment through a sale-leaseback transaction involving thirteen newly constructed data centers across two campuses leased to Amazon. This strategic move expands the firm's total addressable market by doubling the hyperscaler sale-leaseback channel and establishes a foundation for long-term shareholder value. The trust, externally managed by an affiliate of Blackstone, focuses on acquiring stabilized, income-generating data center assets leased to investment-grade tenants.Real Estate
  101. ARMKNov 16, 6:31 AMAramark reported record fiscal 2026 results with consolidated revenue reaching $20.1 billion, representing a 9% year-over-year increase and 10% organic growth. The company achieved an adjusted operating income of $1.1 billion and adjusted earnings per share of $2.23, driven by strong new business wins and improved supply chain efficiencies. Following these results, Aramark's Board authorized a new $1 billion share repurchase program and increased the quarterly dividend by 17%. The company also reduced its net debt by $225 million, lowering its leverage ratio to 2.7x.Industrials
  102. ODYSNov 16, 6:20 AMOdysight.ai reported revenues of $0.9 million for the nine months ended September 30, 2026, representing a 29% increase in its aerospace domain compared to the prior year period. The company holds a backlog of $16 million as of September 30, 2026, and maintains a cash balance of approximately $23.2 million with no financial debt, projecting sufficient funds to operate through the second quarter of 2028. Operating expenses for the period totaled $14.6 million, resulting in a net loss of approximately $13.7 million. Recent commercial milestones include the signing of a Memorandum of Agreement with Boeing, a Cooperative Research and Development Agreement with the U.S. Navy, and the launch of a pilot program with the NTA Metropolitan Mass Transit System.Technology
  103. QINDNov 16, 6:15 AMQuality Industrial Corp. reported third-quarter 2026 revenue of $3.64 million, a 3.6% increase from the prior year, driven by higher sales volumes as customers returned to the UAE. The company achieved operating income of $39,978, a significant turnaround from an operating loss of $285,805 in the same period last year, while net loss narrowed to $31,512. For the nine months ended September 30, 2026, consolidated net income was $166,638 compared to a net loss of $1.24 million in 2025, largely due to the non-recurrence of a $1.02 million discretionary management bonus. Operational highlights include a contracted engineering portfolio valued at approximately $5.2 million and the expansion of the LPG distribution fleet to 53 vehicles. Management anticipates higher revenue in the fourth quarter of 2026 following the resolution of project pricing inefficiencies and the seasonal strength of the period.
  104. XXIINov 16, 6:02 AM22nd Century Group reported third-quarter 2026 net revenues of $4.8 million, representing a 66% sequential increase, while turning gross profit positive at $0.4 million. The company achieved a 166% growth in point-of-sale pack sales for its Pinnacle VLN products and expanded its retail footprint by shipping to approximately 150 additional stores in the New York and New Jersey areas. Following the quarter, the company raised $5.8 million through an at-the-market offering and used $1.2 million to redeem Series B convertible preferred stock, resulting in no outstanding warrants. Despite these operational improvements, the company reported a net loss from continuing operations of $2.6 million for the period.Consumer Defensive
  105. SLXNNov 16, 6:01 AMSilexion Therapeutics dosed the first patient in its Phase 2/3 clinical trial for SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center in September 2026. The company reported a net loss of $2.5 million for the third quarter of 2026, while cash and cash equivalents increased to $4.8 million following recent financing activities. New translational data indicates that SIL204 utilizes a coordinated immune-sensitization signature across four KRAS mutations and employs a native lipoprotein-mediated uptake mechanism. Additionally, the company announced a 1-for-24 reverse share split effective November 10, 2026, and is expanding clinical trial sites in Israel and Germany.Healthcare
  106. TPSTNov 13, 5:27 PMTempest Therapeutics reported a net loss of $3.6 million for the third quarter of 2026, with cash and cash equivalents declining to $0.9 million from $7.7 million at the end of 2025. The company secured exclusive licensing rights to Senlang's CD7-targeted lentiviral in vivo CAR-T platform and its lead candidate TPST-4903, while also advancing its next-generation candidate TPST-4003. To support operations, Tempest completed a private placement raising approximately $2.5 million and entered into an equity line of credit with Lincoln Park Capital Fund for up to $50.0 million. Additionally, the Board of Directors was strengthened by the appointments of Nancy Freda-Smith and John W. Frederick, though the company noted substantial doubt regarding its ability to continue as a going concern due to limited cash reserves.Healthcare
  107. BYSINov 13, 5:27 PMBeyondSpring Inc. reported a net loss of $2.1 million for the third quarter ended September 30, 2026, driven by increased research and development and general and administrative expenses. The company received FDA Fast Track designation for its lead candidate Plinabulin combined with docetaxel in patients with post-immunotherapy non-squamous non-small cell lung cancer lacking actionable genomic alterations. A strategic transaction with Biolin Investment Limited was completed to fund approximately half of the DUBLIN-4 Phase 3 trial's patient enrollment in China, providing BeyondSpring with access to the resulting clinical data. As of September 30, 2026, the company held $0.6 million in cash, cash equivalents, and short-term investments.Healthcare
  108. BCICNov 13, 5:26 PMBCP Investment Corporation reported third-quarter 2026 net investment income of $4.6 million, or $0.37 per share, with a net asset value of $162.7 million as of September 30, 2026. The company announced a merger agreement to acquire Investcorp Credit Management BDC, Inc. at 90% of ICMB's closing net asset value, a transaction expected to be accretive to shareholders. Non-accrual debt investments declined to 10, representing 2.8% of the portfolio at fair value, while the company increased its KeyBank Credit Facility capacity to $150 million and issued $10 million in additional notes due 2029. Additionally, BCP declared monthly base distributions of $0.09 per share for January, February, and March 2027.Financial Services
  109. CINGNov 13, 5:19 PMCingulate Inc. reported a net loss of $7.7 million for the third quarter of 2026, driven primarily by increased selling, general, and administrative expenses related to commercial readiness. The company has substantially completed manufacturing work to address FDA requests for its CTx-1301 ADHD drug application and expects to resubmit the new drug application between December 2026 and January 2027. As of September 30, 2026, Cingulate held approximately $23.2 million in cash and cash equivalents, which is projected to fund operations through mid-2027.Healthcare
  110. CTNTNov 13, 5:16 PMCheetah Net Supply Chain Service Inc. reported total revenue of $3.56 million for the third quarter of 2026, an 883% increase from the prior year period, driven primarily by its international trading segment following the May 2026 acquisition of Super International Trading Limited. The company recorded a net loss from continuing operations of $2.55 million for the quarter, a 93.8% increase compared to the same period in 2025, largely due to a $2.78 million loss from changes in the fair value of acquisition-related contingent consideration. For the nine months ended September 30, 2026, the company posted a net loss of $3.09 million while maintaining a cash and cash equivalent balance of approximately $14.5 million and a working capital balance of $87.1 million.Consumer Cyclical
  111. WFCFNov 13, 5:14 PMWhere Food Comes From, Inc. reported third-quarter 2026 total revenue of $7.3 million, a 4% increase from the prior year, driven by a 6% rise in verification and certification services to $5.9 million. Gross margins improved to 42.1% from 38.3% in the same period last year, resulting in operating income of $1.0 million, a 68% year-over-year increase. Net income for the quarter was $825,000, or $0.17 per diluted share, compared to $1.1 million in the prior year, as the previous period included a $946,000 gain on the sale of assets. Over the nine-month period ended September 30, 2026, the company generated $2.8 million in cash from operations and returned $268,000 to shareholders through stock buybacks.Technology
  112. BBGINov 13, 5:06 PMBeasley Broadcast Group reported third-quarter 2026 net revenue of $42.8 million, a 16.1% decrease from the prior year period, driven by weakness in traditional advertising markets. The company posted a net loss of $12.1 million for the quarter, though it achieved a 32% operating margin in its digital segment, up from 21% in the previous year. To strengthen its balance sheet, the company raised $4.6 million through equity offerings and subsequently sold two radio stations and two real estate parcels for over $10 million. Structural cost reductions helped limit the decline in operating expenses, while same-station digital revenue increased 4.4% on a year-to-date basis.Communication Services
  113. HITNov 13, 5:05 PMHealth In Tech reported a net loss of $7.1 million for the third quarter of 2026, driven by a $5.3 million provision for credit losses, compared to a net income of $0.5 million in the same period the prior year. The company's contracted revenue totaled $32.7 million for the first nine months of 2026, while pipeline revenue reached $156.4 million as of October 30, 2026. Distribution partners grew 15.9% year over year to 984, and the company revised its full-year 2026 revenue outlook to approximately $30 million. Sanjay Shrestha assumed the role of Chief Executive Officer in October 2026 to lead commercial execution and strategic growth initiatives.Technology
  114. XAIRNov 13, 5:00 PMBeyond Air reported a record quarterly revenue of $2.3 million for the period ended September 30, 2026, marking a 28% year-over-year increase. The company reaffirmed its full-year 2026 revenue guidance of $8 million and its 2027 guidance of $16 million to $18 million, contingent on FDA approval for its second-generation LungFit PH system. During the quarter, the company incurred a net loss of $7.8 million, or $3.76 per share, while maintaining $18.5 million in cash and equivalents. Additionally, Beyond Air announced the sale of its controlling interest in NeuroNOS Israel Ltd. and received FDA Breakthrough Device Designation for its LungFit GO product.Healthcare
  115. EVFMNov 13, 4:59 PMEvofem Biosciences reported net sales of $4.6 million for the third quarter of 2026, a decrease from $5.0 million in the prior year period, primarily due to lower ex-factory sales of PHEXX. The company generated $0.7 million in operating income and $0.9 million in net income attributable to common stockholders for the quarter, contrasting with a net loss in the same period of 2025. Strategic milestones achieved since July 2026 include contracting a second manufacturer for PHEXX production, shipping the 500,000th box of PHEXX, and adding a fifth site to an NIH-funded Phase 4 clinical trial for SOLOSEC. As of September 30, 2026, restricted cash and cash equivalents stood at $0.3 million, reflecting the company's ongoing liquidity position.Healthcare
  116. SRGNov 13, 4:51 PMSeritage Growth Properties reported a net loss of $36.2 million for the nine months ended September 30, 2026, driven by a $15.2 million impairment charge on a consolidated property and a $5.2 million impairment on an unconsolidated entity. During the third quarter, the company generated $3.0 million in gross proceeds from asset sales and received $8.9 million in distributions from an unconsolidated entity. As of September 30, 2026, the company held $45.4 million in cash and had $10.0 million available under its new revolving loan facility, which was established in July 2026 to refinance a prior term loan. The company's portfolio consists of eight properties with a total of approximately 0.7 million square feet of gross leasable area and 133 acres of land.Real Estate
  117. CNSYNov 13, 4:51 PMCerenome, Inc. reported third-quarter 2026 financial results showing $0.7 million in net diagnostic revenue and an operating loss of $7.5 million. The company expanded its payer coverage to approximately 190 million lives and launched CNSide molecular profiling tests for solid tumors and hematologic malignancies in October. Clinically, enrollment was completed in the Phase 2 ReSPECT-GBM trial for recurrent glioblastoma, while interim data from the ReSPECT-LM multi-dose study demonstrated safety with no dose-limiting toxicities. As of September 30, 2026, the company held $4.9 million in cash and investments, having recently secured a senior secured financing facility and raised additional equity.Healthcare
  118. NYCNov 13, 4:49 PMAmerican Strategic Investment Co. reported a net loss of $6.7 million for the third quarter of 2026, a significant decline from the $35.8 million net income recorded in the same period of 2025 due to the absence of a prior-year property disposition gain. Revenue for the quarter fell to $7.1 million from $12.3 million in 2025, primarily driven by the sale of 1140 Avenue of the Americas in the previous year. The company's portfolio, now consisting of five properties with a 74.0% occupancy rate, generated $3.5 million in cash net operating income and maintained a weighted-average remaining lease term of 6.0 years. Following the quarter, the company secured an extension and expansion lease with the State of New York at 123 William Street, increasing pro-forma occupancy at that location to approximately 75%.Real Estate
  119. FEMYNov 13, 4:47 PMFemasys Inc. announced a $30 million private placement in mid-August 2026 to fund U.S. commercial team expansion and the FemBloc pivotal trial. For the quarter ended September 30, 2026, U.S. sales rose slightly to $347,039, while total sales declined 44.5% to $404,597 due to timing of international distributor orders. The company reported a net loss of $4,564,815 for the quarter and $8,187,810 for the nine-month period, with cash and cash equivalents reaching approximately $23.9 million by September 30.Healthcare
  120. NXPLNov 13, 4:47 PMNextPlat Corp reported third-quarter 2026 consolidated revenue of approximately $10.5 million, a decrease from $13.8 million in the prior year period, driven by lower reimbursement rates and reduced retail prescription volumes. Despite the revenue decline, the company achieved a consolidated gross margin of 35.0%, a significant improvement from 19.9% in the same period last year, largely due to a 300% increase in pharmacy contract revenue. Net loss attributable to common stockholders narrowed by 66% to approximately $0.7 million, or $0.28 per diluted share, compared to $2.2 million in the prior year. The company ended the quarter with $11.2 million in cash and noted a 72% year-over-year growth in higher-margin 340B prescription volumes.Technology
  121. Nov 13, 4:41 PMThe Fidelity Private Credit Fund targets senior secured loans to private equity-owned middle-market companies, maintaining a weighted average loan-to-value of 39% and net leverage of 4.7 times as of September 30, 2026. The fund's investment strategy emphasizes disciplined underwriting and strong documentation to navigate an environment characterized by rising interest rates and increased credit dispersion among borrowers. Performance data indicates a year-to-date total net return of 4.52% for Class I shares, with a distribution rate of 9.36% calculated on the net asset value. The portfolio is heavily concentrated in floating-rate investments at 99.8%, with top holdings including Project Fractal in aerospace, Project METIS in healthcare services, and Project Sentinel in industrial distribution.
  122. AIRTNov 13, 4:35 PMAir T, Inc. reported second-quarter fiscal 2027 revenues of $146.9 million, a 129% increase from the prior year, driven largely by the inclusion of Regional Express Holdings Pty Ltd acquired in December 2025. The company posted an operating loss of $11.8 million and a net loss per share of $7.48, contrasting with the prior year's operating income and net income per share. Adjusted EBITDA declined to $4.4 million from $7.9 million in the previous year, impacted by significant fuel cost increases and unscheduled engine removals at the Regional Airline segment. Despite challenges in the newly acquired Rex unit, other segments such as Overnight Air Cargo and Ground Support Equipment contributed positively to the quarter's financial performance.Industrials
  123. CLDINov 13, 4:35 PMCalidi Biotherapeutics reported a net loss of $3.6 million for the third quarter of 2026, a significant improvement from the $10.8 million loss in the same period of 2025. The company advanced its lead candidate CLD-401, presenting preclinical data at the ESMO Congress 2026 that demonstrated complete tumor eradication in 80% of mice in breast cancer models. General and administrative expenses decreased by 39% to $1.6 million as the firm executed a restructuring plan to extend its cash runway. Additionally, Calidi raised $1.2 million through an at-the-market registered direct offering and ended the quarter with $3.9 million in cash.Healthcare
  124. NWTGNov 13, 4:31 PMNewton Golf Company reported a net loss of $1.2 million for the third quarter of 2026, driven by a 47% decline in net sales to $1.4 million due to reduced marketing activity. The company expanded its 2.0 shaft rollout with over 80 professional golfers using its products and grew its fitter network to approximately 301 accounts. Following the quarter, Newton raised approximately $3.0 million through equity financings and converted $1.0 million of debt into equity, resulting in a pro forma stockholders' equity of $5.2 million. Despite these liquidity improvements, the company faces Nasdaq compliance concerns regarding its minimum equity requirement and anticipates needing additional financing to continue operations.Consumer Cyclical
  125. PEDNov 13, 4:31 PMPEDEVCO Corp. reported a net loss of $9.2 million for the third quarter of 2026, driven by a $16.6 million net loss on derivative contracts that offset higher operating income from an expanded asset base. Average daily production surged 298% year-over-year to 5,850 barrels of oil equivalent per day following the October 2025 merger with Juniper Capital Advisors, while revenue increased 411% to $35.5 million. Adjusted EBITDA rose 239% to $14.7 million, reflecting increased production volumes and a 31% rise in the average realized oil price to $83.81 per barrel. The company updated its full-year 2026 net capital expenditure guidance to a range of $37 million to $42 million and reiterated its Adjusted EBITDA guidance of $60 million to $70 million.Energy
  126. VUZINov 13, 4:30 PMVuzix Corporation reported third-quarter 2026 total revenues of $0.7 million, a 38% decrease from the same period in 2025, driven by a 45% decline in product sales. The company recorded a net loss of $8.4 million, or $0.10 per share, compared to a $7.4 million loss in the prior year quarter. Strategic progress includes the shipment of evaluation samples for the Causeway optical interconnect platform to over 10 companies and the delivery of the SHRIKE Defense Display Platform for customer evaluation. Additionally, Vuzix secured nearly $1.0 million in new OEM defense orders and completed facility upgrades at its Rochester waveguide manufacturing site.Technology
  127. NVVENov 13, 4:30 PMNuvve Holding Corp. reported third-quarter 2026 total revenues of $1.09 million, a 31.9% decrease from the same period in 2025, driven by lower product sales and service revenue. The company recorded a net loss of $4.7 million for the quarter, with gross profit margins declining to 24.0% from 52.0% in the prior year due to higher warranty costs and project write-downs. Despite the revenue decline, Nuvve raised $0.97 million in gross proceeds through debt and equity instruments to support operations, while megawatts under management increased by 5.7% to 29.9 megawatts.Consumer Cyclical
  128. INDPNov 13, 4:30 PMIndaptus Therapeutics reported a net loss of $1.0 million for the third quarter of 2026, a significant decrease from $3.0 million in the same period of 2025, driven by reduced research and development and general administrative expenses. The company completed a private placement in September 2026, raising approximately $24.0 million in gross proceeds to fund working capital and early-stage research into a neurotechnology device for sleep-related conditions. As of September 30, 2026, Indaptus held $30.6 million in cash, cash equivalents, and short-term investments, providing sufficient liquidity to support its anticipated operating expenses. The company also announced a strategic shift away from its Decoy20 clinical program to focus on new opportunities with long-term potential.Healthcare
  129. IRLANov 13, 4:30 PMIRulya Therapeutics Inc., formerly Quince Therapeutics, reported a net loss of $27.7 million for the third quarter ended September 30, 2026, while maintaining a cash position of $105.2 million expected to fund operations through 2028. The company relaunched with a new name and ticker symbol IRLA, appointing a new leadership team and board of directors to focus on its lead candidate, LAM-001. Clinical progress includes a fully enrolled Phase 2 trial for bronchiolitis obliterans syndrome (BOS) with data anticipated in early 2027, an ongoing Phase 2b trial for pulmonary hypertension associated with interstitial lung disease (PH-ILD), and a planned Phase 2 study for sarcoidosis-associated pulmonary hypertension (SAPH) to begin in late 2026.Healthcare
  130. BOCNov 13, 4:29 PMBoston Omaha Corporation reported a net loss attributable to common stockholders of $192,000 for the third quarter of 2026, compared to a loss of $2.588 million in the same period the previous year. Total revenues for the quarter reached $22.178 million, driven by billboard rentals and broadband services, while net other expense was recorded at $3.611 million due primarily to fair value changes in investment funds. The company repurchased 457,308 shares of its Class A common stock for $6.4 million during the quarter and subsequently increased its share repurchase program authorization from $30 million to $85 million. As of September 30, 2026, the company held $29.743 million in unrestricted cash and investments with a book value per share of $16.64.Communication Services
  131. ANVSNov 13, 4:24 PMAnnovis Bio, Inc. reported third-quarter 2026 financial results showing cash and cash equivalents of $2.8 million and a net loss of $9.5 million. The company raised $21.0 million in gross proceeds through an underwritten public offering to fund operations through the March 2027 data readout for its Phase 3 DUET-AD Alzheimer's study. Clinical progress includes full enrollment of 862 patients in the DUET-AD trial and 326 patients in the Parkinson's open-label extension study. Upcoming milestones include the last patient visit for the 6-month treatment period on December 31, 2026, and a planned database lock on February 8, 2027.Healthcare
  132. ASTCNov 13, 4:20 PMAstrotech Corporation reported a net loss of $2.948 million for the first quarter of fiscal year 2027, ending September 30, 2026, compared to a loss of $3.465 million in the same period the prior year. Total operating expenses decreased by 15.7% to $3.1 million, driven primarily by a reduction in research and development costs, while revenue declined slightly to $274,000. As of the quarter's end, the company maintained $11.6 million in working capital and had deployed its TRACER 1000 technology in approximately 38 locations across 17 countries. Additionally, Astrotech submitted a proposal to NASA under the NextSTEP-3 LEIA program to advance its Mobile Power System for lunar infrastructure applications.Industrials
  133. GXAINov 13, 4:17 PMGaxos.ai Inc. reported third-quarter 2026 consolidated revenue of approximately $2.81 million, representing a 14.5% increase from the second quarter and a 464.9% increase from the same period in 2025. During the quarter, advertising and marketing expenses decreased by 16.7% to $2.62 million, resulting in an improved revenue generation of $1.08 per advertising dollar, a 38% improvement over the previous quarter. The company held cash and short-term investments of $13.30 million as of September 30, 2026, and issued 3,007,654 shares of common stock following warrant exercises. Gaxos plans to focus on increasing recurring revenue, improving customer acquisition efficiency, and scaling products with favorable contribution economics for the remainder of 2026.Communication Services
  134. FIEENov 13, 4:16 PMFiEE, Inc. reported a 382.1% year-over-year revenue increase to approximately $9.6 million for the nine months ended September 30, 2026, driven by its strategic transition to SaaS solutions and phygital art advisory services. The company achieved a net income of $3.6 million for the period, marking a significant turnaround from a net loss of $1.3 million in the same timeframe the previous year. Revenue growth was primarily fueled by SaaS-MCN digital services, software services, and new phygital art advisory offerings, which generated $3.5 million in revenue compared to zero in 2025. Additionally, the company onboarded 939 customers for its SaaS-MCN services and secured $4.1 million in contracts for software services as of September 30, 2026.Technology
  135. MEDSNov 13, 4:15 PMDataMEDS AI reported a 50% sequential revenue increase to $2.7 million for the third quarter of 2026, driven primarily by growth in its Corexa Pharmacy drug dispensing operations. The company achieved a net profit of $10.535 million, resulting in a net profit per share of $2.72, a significant turnaround from the net loss recorded in the same period the previous year. Key business developments included the launch of the Health Lives Here mobile app, an exclusive license for the REBOOT GLP-1 patient management platform, and the acquisition of Helomics cancer diagnostics laboratory. Additionally, the company regained full compliance with Nasdaq listing standards and secured a memorandum of understanding with an HMO to deploy its mobile application to over 25,000 members.Consumer Defensive
  136. AVEXNov 13, 4:15 PMAEVEX Corp. reported third-quarter 2026 total revenue of $189.7 million, a 56.5% increase from the prior year period, driven primarily by growth in its Airborne Systems segment and the recent acquisition of BlackSea Technologies. The company posted a net loss of $16.8 million for the quarter, contrasting with a net income of $9.9 million in the same period last year, while Adjusted EBITDA rose to $30.8 million. Following the establishment of Maritime Systems as a new reportable segment, AEVEX raised its full-year 2026 revenue outlook to a range of $820.0 million to $840.0 million and Adjusted EBITDA guidance to $128.0 million to $132.0 million.Industrials
  137. ECTMNov 13, 4:14 PMECA Marcellus Trust I announced a quarterly distribution of $0.021 per unit for the period ended September 30, 2026, payable on or before November 30, 2026, to holders of record as of November 23, 2026. The trustee is withholding approximately $90,000 from this quarter's distribution to build a cash reserve toward a target of $3.8 million, which is intended to cover future known, anticipated, or contingent expenses. The trust holds royalty interests in natural gas properties in the Marcellus Shale formation in Greene County, Pennsylvania, and its distributions fluctuate based on production proceeds, commodity prices, and administrative costs. Non-U.S. persons may be subject to withholding taxes on income effectively connected to a U.S. trade or business or on fixed, determinable, annual, periodic income from U.S. sources.Energy
  138. ICMBNov 13, 4:11 PMInvestcorp Credit Management BDC, Inc. reported a net asset value per share of $3.02 as of September 30, 2026, representing a decrease of $0.42 from the previous quarter. The company recorded a net investment loss before taxes of $1.8 million and a total net decrease in net assets from operations of $4.8 million for the three-month period. During the quarter, the investment adviser waived all management fees and $0.2 million of previously accrued incentive fees, while the weighted average yield on debt investments fell to 9.53%. Subsequent to the quarter end, the company received $11.5 million in repayments and repaid $10.0 million of outstanding borrowings under its revolving credit facility.Financial Services
  139. ROLRNov 13, 4:10 PMHigh Roller Technologies reported a net loss of $2.8 million for the third quarter of 2026, driven by a 51% decline in net revenues to $2.4 million as the company exited certain online casino markets. Despite lower revenue, the company maintained a strong liquidity position with $13.4 million in cash and no outstanding borrowings at the end of the quarter. The firm commercially launched its ROLR prediction markets platform on October 21, 2026, and released its iOS application in November, aiming to establish prediction markets as a primary growth driver in 2027.Consumer Cyclical
  140. BYFCNov 13, 4:10 PMBroadway Financial Corporation reported net income attributable to common stockholders of $392 thousand for the third quarter of 2026, a significant improvement from the $24.6 million net loss recorded in the same period of 2025. During the first nine months of 2026, the company achieved consolidated net income of $1.0 million, driven by an 11.4% increase in net loans and a 21.0% rise in total deposits. The bank maintained stable credit quality with non-accrual loans representing 1.20% of gross loans and reported a strong Community Bank Leverage Ratio of 12.83% as of September 30, 2026.Financial Services
  141. FFRNov 13, 4:10 PMFF EAI Robotics Ecosystem Inc. completed the acquisition of Faraday Future's robotics business on October 23, 2026, transforming into a pure-play humanoid and bionic Physical AI robotics company. For the nine months ended September 30, 2026, the acquired robotics business generated approximately $2.3 million in standalone revenue with a gross margin of 26%, entering the company with no outstanding debt. The company has advanced its Four-Core Full-Stack AI ecosystem, introducing the FF OmniMind brain platform which ranked first on the RoboColiseum benchmark, and achieved a record 351 robot shipments in October. Looking ahead, FFR plans to launch a 100-city robotics education initiative, introduce its Physical Cloud technology platform during CES, and begin domestic factory production in the first quarter of 2027.Technology
  142. VTGNNov 13, 4:08 PMVistagen Therapeutics reported a net loss of $10.7 million for the second quarter of fiscal year 2027, ending September 30, 2026, with cash and marketable securities totaling $20.0 million. The company received constructive feedback from the FDA regarding its Phase 3 development plan for fasedienol in social anxiety disorder, which will now focus on overall treatment rather than just acute management. Preliminary data from the open-label extension of the PALISADE-4 study showed clinically relevant improvements in social anxiety over four months. Additionally, Vistagen appointed Douglas J. Williamson, MD, to its board and implemented cost-management initiatives to extend its operating runway into 2027.Healthcare
  143. INBXNov 13, 4:08 PMInhibrx Biosciences reported a net loss of $38.7 million for the third quarter of 2026, driven by $26.0 million in research and development expenses and $7.8 million in general and administrative costs. The company recognized $2.0 million in revenue from a non-exclusive license agreement with Pfizer, while cash and cash equivalents increased to $199.5 million as of September 30, 2026. Clinical milestones include upcoming data presentations for ozekibart in Ewing sarcoma and the ongoing enrollment of ordastobart in head and neck squamous cell carcinoma. Additionally, the company is advancing commercial readiness activities for ozekibart in chondrosarcoma while preparing for a potential Biologics License Application.Healthcare
  144. OPRXNov 13, 4:06 PMOptimizeRx reported third-quarter 2026 revenue of $21.6 million, a 17% decrease from the prior year, while achieving a net income of $1.2 million and adjusted EBITDA of $6.3 million. The company updated its full-year 2026 revenue guidance to a range of $87 million to $93 million, though adjusted EBITDA guidance remains unchanged at $21 million to $25 million. Since June 30, 2026, OptimizeRx repaid $9.3 million in debt principal, reducing its outstanding principal balance to $10.4 million. Management cited margin expansion and cost management as drivers for the 23% year-over-year increase in adjusted EBITDA despite the revenue decline.Healthcare
  145. BJDXNov 13, 4:05 PMBluejay Diagnostics completed enrollment in its SYMON-II clinical validation study with 777 evaluable patients, exceeding the original target of 750. The company established an alternative manufacturing facility ahead of a contractual deadline and advanced U.S. commercial infrastructure through new distribution agreements. As of September 30, 2026, the company held $7.38 million in cash and projects these resources will sustain operations through the second quarter of 2027. Bluejay aims to submit an FDA 510(k) application for its Symphony IL-6 test during the first half of 2027.Healthcare
  146. TXMDNov 13, 4:05 PMTherapeuticsMD, Inc. reported net income from continuing operations of $501 thousand, or $0.04 per share, for the third quarter of 2026, an increase from $50 thousand in the same period of 2025. License revenues rose to $1.3 million, driven by a $365 thousand milestone payment from Knight related to IMVEXXY sales for the year ended December 31, 2025. Total operating expenses increased by 5.6% to $1.7 million, primarily due to higher legal and professional fees. As of September 30, 2026, the company held $10.4 million in cash and cash equivalents while continuing to evaluate strategic alternatives such as a potential acquisition or merger.Healthcare
  147. CRISNov 13, 4:05 PMCuris, Inc. reported a net loss of $8.1 million for the third quarter of 2026, with no revenue generated due to the prior sale of Erivedge royalties. The company is currently enrolling patients in two ongoing studies, the TakeAim CLL study and the TakeAim Lymphoma study, which evaluate emavusertib in combination with BTK inhibitors. Clinical data from the TakeAim Lymphoma study showed objective response rates of 100% for BTK-naïve patients and 33% for BTKi-experienced patients as of July 2026. Financially, Curis held $5.0 million in cash and cash equivalents as of September 30, 2026, and expects its existing resources combined with recent private placement proceeds to fund operations into the first quarter of 2027.Healthcare
  148. SEVNov 13, 4:05 PMAptera Motors reported a GAAP net loss of $14.0 million for the third quarter of 2026 and $35.0 million for the first nine months of the year. The company raised approximately $6.0 million in gross proceeds during the quarter through a warrant inducement transaction and entered a strategic partnership with Shanghai Launch Automotive Technology to support manufacturing. As of September 30, 2026, Aptera held $9.2 million in cash and cash equivalents, including $4.1 million in refundable reservation fees, while maintaining over 49,000 vehicle reservations. Management estimates a need for approximately $25 million to reach start of production and $65 million to achieve a production rate of 500 vehicles per month.Consumer Cyclical
  149. ENVBNov 13, 4:05 PMEnveric Biosciences reported a net loss of $2.5 million for the third quarter ended September 30, 2026, with cash-on-hand totaling $5.6 million. The company advanced final IND-enabling activities for its lead candidate EB-003, a non-hallucinogenic neuroplastogenic therapeutic, supported by preclinical data showing brain penetration and a distinct activity profile compared to DMT. Recent in vitro studies confirmed favorable absorption and metabolic properties with a reduced potential for drug-drug interactions, while independent assays reinforced the compound's predicted non-hallucinogenic profile. Additionally, Enveric secured a U.S. patent allowance for next-generation non-hallucinogenic mescaline derivatives in its EVM401 series.Healthcare
  150. TRXBNov 13, 4:04 PMTRexBio reported a net loss of $13.2 million for the third quarter of 2026, driven by increased research and development expenses related to its TRB-061 and TRB-071 programs. The company announced positive Phase 1a results for TRB-061, an investigational TNFR2 agonist for atopic dermatitis, which demonstrated proof of mechanism and safety in healthy volunteers. TRexBio completed a $133.5 million initial public offering in October 2026, extending its cash runway into the second half of 2029. Topline data for the Phase 1b trial of TRB-061 is expected in mid-2027, while a Phase 1 trial for the CD30 agonist TRB-071 is anticipated to begin in the first half of 2027.Healthcare
  151. WSBFNov 13, 4:00 PMWaterstone Financial, Inc. reported net income of $6.2 million, or $0.36 per diluted share, for the quarter ended September 30, 2026, a decrease from $7.9 million in the same period of 2025. The Community Banking segment achieved record quarterly net interest income of $16.0 million, driven by a reduction in the average cost of funds, while the Mortgage Banking segment recorded a pre-tax loss of $754,000 due to elevated mortgage rates and compressed sales margins. Consolidated return on average assets for the quarter was 1.09%, and book value per share declined to $19.29, primarily due to accumulated other comprehensive losses from rising treasury rates. Total dividends declared for the quarter amounted to $0.17 per common share.Financial Services
  152. Nov 13, 3:04 PMImricor Medical Systems commenced its U.S. commercial launch in the third quarter of 2026, securing its first two hospital customers, Rady Children's Hospital–San Diego and Children's Medical Center Dallas, for its NorthStar interventional MR system. The company reported revenue of US$188k, a 437% increase from the prior period, driven by initial sales and installations while maintaining a cash balance of US$62.1m. Regulatory progress included FDA 510(k) clearances for pediatric label expansions on NorthStar and the Vision-MR Diagnostic Catheter, as well as the acceptance of the manufacturing module for the Vision-MR Ablation Catheter PMA application. Additionally, Imricor established a strategic partnership with Philips to issue a Third Party Product Compatibility Declaration, enabling NorthStar to operate on the Philips MR installed base and launching a joint turnkey iMR lab solution.
  153. DBHLNov 13, 3:03 PMDeep Isolation Nuclear, Inc. reported consolidated revenue of $1.8 million and a net loss of $3.8 million for the third quarter of 2026. The company advanced its Commercialization Pilot near Cameron, Texas, by securing a drilling permit from the Texas Railroad Commission and initiating well pad construction. Operational progress included selection as the sole industrial partner on three U.S. Department of Energy grants for artificial intelligence-enabled nuclear waste repository analysis. As of September 30, 2026, the company held $16.5 million in available cash with 57.77 million common shares outstanding.
  154. NTWKNov 13, 2:39 PMNETSOL Technologies reported fiscal first quarter 2027 revenue of $16.4 million, representing a 9.3% increase from the prior-year period. The company achieved a gross margin of 50.5%, an expansion of over 1,100 basis points, driven by revenue mix changes and the capitalization of $1.0 million in software development costs. GAAP net income attributable to NETSOL turned positive at $0.16 million, or $0.01 per diluted share, compared to a net loss of $2.36 million in the same period last year. Additionally, adjusted EBITDA attributable to NETSOL improved to $0.48 million from a negative $1.66 million in the prior year, while cash and cash equivalents stood at $19.7 million as of September 30, 2026.Technology
  155. INUVNov 13, 2:29 PMInuvo reported a 70% year-over-year decline in net revenue to $6.8 million for the third quarter of 2026, driven by an 80% drop in Legacy Search revenue and a 24% decrease in Audience Modeling revenue. The company recorded a net loss of $5.0 million, or $0.28 per share, with operating expenses totaling $7.8 million that included a $2.4 million non-cash impairment charge. Despite the revenue contraction, Inuvo highlighted a stabilizing Legacy Search segment and an expanding sales pipeline for its IntentKey privacy-first AI solutions across automotive, travel, healthcare, and financial sectors. Management expects fourth-quarter Audience Modeling revenue to increase supported by the growing pipeline, while Legacy Search revenue and margins are projected to remain consistent with the third quarter.Communication Services
  156. Nov 13, 1:36 PMVaragon Capital Corporation reported a net asset value of $8.93 per share and net investment income of $0.23 per share for the third quarter of 2026, resulting in an annualized yield of 10.2%. The company declared a fourth-quarter distribution of $0.23 per share, maintaining the same rate as the previous quarter, while total investments at fair value stood at $819 million across 121 portfolio companies. Credit quality remained robust with approximately 90% of investments rated as low risk, although three portfolio companies were placed on non-accrual status by the end of the period.
  157. INBPNov 13, 12:12 PMIntegrated BioPharma, Inc. reported revenue of $9.9 million for the quarter ended September 30, 2026, a 22% decrease from the $12.7 million recorded in the same period of 2025. The company posted an operating loss of $1.0 million and a net loss of approximately $0.7 million, or $0.02 per share, compared to an operating income of $0.2 million and net income of $0.1 million in the prior year quarter. Revenue concentration remained high, with the two largest customers in the Contract Manufacturing Segment accounting for approximately 88% of total revenue in the current quarter.Consumer Defensive
  158. DYAINov 13, 11:57 AMDyadic International, Inc. reported a net loss of $1,357,041 for the third quarter ended September 30, 2026, driven by a 61.4% decline in total revenue to $449,101. The company achieved a significant milestone by recording its first direct commercial product sales of recombinant transferrin and DNase I, while also expanding distribution through Integrated Biotherapeutics. Strategic partnerships advanced with Proliant promoting AlbuFree DX and Inzymes commercializing a second chymosin product, alongside continued progress on the C1 biopharmaceutical platform for vaccine and antibody development. As of September 30, 2026, the company held $6,046,083 in cash and equivalents, reflecting a decrease from the previous year-end balance.Healthcare
  159. INLXNov 13, 11:15 AMIntellinetics, Inc. reported a narrowed GAAP net loss of $239,163 for the third quarter of 2026, compared to a loss of $369,765 in the same period the previous year. Total revenue for the quarter increased 0.7% year-over-year to $4.03 million, driven by growth in Software as a Service and storage services, while professional services revenue declined. The company achieved positive Adjusted EBITDA of $144,821, marking a sequential improvement of approximately $516,000 from the second quarter. For the nine-month period ended September 30, 2026, the company recorded a net loss of $2.5 million and total revenue of $11.88 million, with management revising its full-year SaaS growth outlook to single-digit year-over-year increases.Technology
  160. UWHRNov 13, 10:02 AMUwharrie Capital Corp reported total assets of $1.23 billion as of September 30, 2026, representing a $15 million increase from the prior year. Net income for the nine-month period ended September 30, 2026, reached $10 million, an increase of nearly 21% compared to the same period in 2025. The company's loan portfolio grew by $27 million to $709 million, supported by a $14 million year-over-year increase in core deposits. In response to this financial progress, the Board of Directors declared a 3% stock dividend payable on November 23, 2026, to shareholders of record as of November 5, 2026.
  161. MOBXNov 13, 9:50 AMMobix Labs reported preliminary fourth-quarter revenue of approximately $1.81 million, a 129% sequential increase that exceeded its guidance range. The company's gross margin expanded significantly to 44.5% from 12.9% in the prior quarter, while the GAAP operating loss narrowed by 11% to $6.56 million. Balance sheet improvements included a 21% reduction in total liabilities and a $5.2 million increase in stockholders' equity compared to the previous year. Management anticipates continued revenue growth as the company addresses working capital constraints and builds on its operational recovery.Technology
  162. BCGNov 13, 9:29 AMBinah Capital Group reported third-quarter 2026 results showing a 5.0% year-over-year increase in assets under management to $31.4 billion. Total revenue for the quarter rose 9.4% to $50.6 million, while GAAP net income increased 44.4% to $2.6 million. The company also reported EBITDA growth of 74.1% to $4.7 million and Adjusted EBITDA of $4.9 million. As of September 30, 2026, Binah held $13.2 million in cash and cash equivalents against $16.7 million in outstanding long-term debt.Financial Services
  163. ALOYNov 13, 9:28 AMREalloys Inc. reported a net loss of $30.5 million for the third quarter of 2026, driven primarily by $25.3 million in non-cash stock-based compensation, while net revenues increased to $0.4 million. The company executed a non-binding term sheet with the U.S. Army to establish a heavy rare earth processing facility at Tooele Army Depot, targeting commissioning in early 2028 with a capacity of 50 tonnes of dysprosium and terbium oxide annually. REalloys aims to achieve initial U.S.-based production of approximately 3,000 tonnes of sintered NdFeB magnets by 2030, supported by a planned $10 million investment in research and development through 2027. As of September 30, 2026, the company maintained a cash balance of $116.2 million and a virtually debt-free balance sheet.Basic Materials
  164. LFWDNov 13, 9:25 AMLifeward reported third-quarter 2026 revenue of $5.4 million, a 12% decrease from the prior year, driven by an 18% year-over-year increase in AlterG revenue to $3.6 million offset by lower ReWalk sales during its transition to a channel-partner distribution model. The company posted a net loss of $5.1 million, or $1.32 per share, compared to a net loss of $3.2 million in the same period last year, with gross margin declining to 27.4% due to foreign exchange fluctuations and acquisition-related expenses. Lifeward is advancing its strategic shift for ReWalk to expand patient access through established distributors while maintaining coverage under Medicare and major insurance plans. Additionally, the company strengthened its clinical evidence base with two new peer-reviewed studies and continues to develop AI-enabled rehabilitation technologies alongside its Protein Oral Delivery platform.Healthcare
  165. CTGONov 13, 9:00 AMContango Silver & Gold reported a net loss of $23.0 million for the third quarter of 2026, driven primarily by increased exploration expenditures and lower income from its Peak Gold Joint Venture. The company's Manh Choh mine transitioned from the north pit to the south pit, resulting in reduced gold production for the quarter but improved mill recovery rates to 86.5%. Contango received a $6 million cash distribution from the JV in October and expects to complete its 2026 production guidance of 40,000 gold equivalent ounces with the fourth campaign. Additionally, the company advanced permitting and drilling at its Kitsault Valley, Johnson Tract, and Lucky Shot projects while repaying debt and eliminating most hedge delivery obligations.Basic Materials
  166. RMIXNov 13, 8:36 AMSuncrete, Inc. reported third-quarter 2026 revenue of $141.0 million, representing a 163% increase compared to the same period in 2025 and a 45% rise from the second quarter of 2026. The company achieved an Adjusted EBITDA of $22.4 million and a Supplemental Adjusted EBITDA of $23.3 million, while total ready-mix concrete yards delivered increased by 32% quarter-over-quarter. Despite the revenue growth, the company reported a net loss of $78,000 for the quarter, contrasting with a net loss of $37.1 million in the previous quarter. Suncrete has revised its full-year 2026 outlook to project revenue between $408.0 million and $434.0 million and Adjusted EBITDA between $60.0 million and $64.0 million.Basic Materials
  167. MTVANov 13, 8:35 AMMetaVia Inc. reported a net loss of $4.6 million for the third quarter of 2026, driven by increased research and development expenses related to its lead candidate DA-1726. The company announced positive interim data from a Phase 1 study showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss, supporting plans for a Phase 2 trial in MetALD and ALD expected to begin in late 2027. Additionally, MetaVia appointed Sarah Browne, M.D., as Chief Medical Officer to lead clinical development while advancing its second candidate, vanoglipel, in combination with resmetirom for MASH.Healthcare
  168. XBIONov 13, 8:35 AMXenetic Biosciences reported a net loss of approximately $1.7 million for the third quarter of 2026, driven by a 138% increase in general and administrative expenses related to a proposed share exchange transaction. The company entered into a definitive agreement to acquire Santersus AG in an all-stock deal expected to close in early 2027, creating a Nasdaq-listed entity named Santersus Bio, Inc. focused on targeting neutrophil extracellular traps across multiple therapeutic areas. Strategic highlights include the initiation of a Phase I clinical study combining Xenetic's DNase I technology with CAR T-cell therapy for large B-cell lymphoma and the advancement of preclinical research demonstrating DNase I's ability to enhance antitumor activity.Healthcare
  169. SGRPNov 13, 8:33 AMSPAR Group, Inc. reported a net income of $50,000 for the third quarter of fiscal 2026, marking the second consecutive quarter of profitability despite a 19.0% year-over-year decline in net revenues to $33.5 million. Gross margins expanded to 18.9% driven by a shift toward higher-quality services, while selling, general, and administrative expenses decreased by 39.0% to $5.6 million due to cost reduction initiatives. The company generated $1.4 million in Adjusted EBITDA for the quarter and $4.3 million for the nine-month period, ending the quarter with $4.7 million in cash and cash equivalents. Additionally, SPAR Group announced a new three-year services agreement with a national retailer to begin in 2027 and adjusted its full-year 2026 revenue guidance to a range of $125 million to $130 million.Industrials
  170. BKYINov 13, 8:30 AMBIO-key International reported a 39% year-over-year increase in Q3 2026 software license fee revenue to $1.3 million, marking its third consecutive quarter of double-digit growth driven by momentum in the Middle East and Europe. The company's total revenue for the quarter was $1.48 million, while its gross margin improved to 90% and net loss narrowed to $886,000 compared to the prior year period. During the quarter, BIO-key retired its remaining note payable, leaving the company effectively debt-free, and working capital increased to $3.1 million. Looking ahead, the company anticipates a strong finish to 2026 and a robust start to 2027 supported by new government contracts and expanding deployments.Industrials
  171. QUCYNov 13, 8:18 AMQuantum Cyber N.V. reported its first revenue of approximately $966,833 for the third quarter of 2026, generated by its precision metal stamping operations at the Bridgeport, Connecticut facility. The company secured an $8.0 million funding commitment from CEO David Lazar to support the expansion of its autonomous defense manufacturing capabilities and the development of its Project LightShift quantum antenna technology. Additionally, the company resolved a legacy legal claim with Boustead Securities for $250,000 and expanded the licensed field of use for its quantum antenna to include unmanned surface and underwater vehicles. Shareholders' equity increased significantly to approximately $16.2 million by September 30, 2026, driven by $15.2 million in proceeds from warrant exercises and $6.0 million from preferred share issuances.Healthcare
  172. AARDNov 13, 8:18 AMAardvark Therapeutics received FDA approval to lift the clinical hold on its investigational drug ARD-101 for treating hyperphagia in Prader-Willi Syndrome, allowing the company to proceed with an open-label trial at a dose of 200 mg twice daily. The company plans to meet with the FDA in the first quarter of 2027 to finalize its clinical development strategy and expects to resume clinical activities in PWS during 2027. Financial results for the third quarter of 2026 showed a net loss of $19.2 million, with the company maintaining $60.3 million in cash and short-term investments to fund operations through 2027.Healthcare
  173. CNVSNov 13, 8:15 AMCineverse reported second-quarter fiscal 2027 revenue of $26.0 million, representing a 110% increase from the prior year quarter, driven primarily by technology and media services streams which now account for 55% of total revenue. The company achieved a net income of $3.2 million, or $0.11 per diluted share, marking a significant turnaround from a $5.7 million net loss in the same period last year, while Adjusted EBITDA rose to $1.7 million for the third consecutive positive quarter. Operational progress included the full integration of Giant Worldwide and IndiCue, resulting in a consolidated product portfolio on the Matchpoint platform and a 300 basis point sequential improvement in direct operating margin. Cineverse reaffirmed its full-year fiscal 2027 guidance of $115 to $120 million in revenue and $10 to $20 million in Adjusted EBITDA, citing strong momentum in advertising technology and content distribution.Communication Services
  174. BFRINov 13, 8:10 AMBiofrontera Inc. reported net product revenue of $9.1 million for the third quarter of 2026, representing a 29.8% increase from the prior-year period. The company achieved a gross margin of 74.4% and a net loss of $6.4 million, or $0.42 per share, during the quarter. Key developments included FDA approval of Ameluz for superficial basal cell carcinoma and a U.S. Customs ruling allowing the import of the redesigned XL-C lamp. For the nine months ended September 30, 2026, revenue grew 26.6% to $31.2 million while the net loss narrowed to $11.8 million.Healthcare
  175. OWLTNov 13, 8:05 AMOwlet reported third-quarter 2026 revenue of $30.4 million, a 4.9% decrease from the prior year, driven by lower hardware sales but offset by a 140% increase in subscription revenue to $3.6 million. The company achieved a gross margin of 53.8% and reported a net income of $1.4 million for the quarter. However, Owlet withdrew its full-year 2026 financial outlook following a safety incident involving exposed camera cables, which necessitates a free replacement program for all camera owners. Anticipated remediation expenses, potential retailer returns, and near-term demand uncertainty are expected to impact the fourth quarter results.Healthcare
  176. PDSBNov 13, 8:05 AMPDS Biotechnology Corporation reported a net loss of $7.6 million, or $0.11 per share, for the third quarter ended September 30, 2026, compared to a $9.0 million loss in the same period the previous year. The company announced the initial closing of a PIPE financing of up to $22.3 million led by Nant Capital, LLC, which included the appointment of Dr. Patrick Soon-Shiong and James Banaag to its Board of Directors. During the quarter, research and development expenses decreased to $2.1 million from $4.6 million in the prior year period, primarily due to reduced clinical trial costs. As of September 30, 2026, the company held $15.2 million in cash and cash equivalents while continuing to prioritize its lead program, PDS0301, and advancing its Versamune cancer vaccine platform.Healthcare
  177. PAVMNov 13, 8:05 AMPAVmed reported preliminary third-quarter 2026 financial results showing operating expenses of approximately $6.8 million and a non-GAAP adjusted net loss of $1.2 million. Its subsidiary Lucid Diagnostics began receiving Medicare payments for its EsoGuard test in October and recognized $1.2 million in revenue for the quarter. Veris Health achieved a design freeze for its implantable physiological monitor and initiated a 90-day GLP animal study ahead of an expected early 2027 FDA submission. Additionally, PAVmed engaged with the FDA regarding its PortIO and Octeris products, with Octeris preparing to submit an initial pre-submission package.Healthcare
  178. FBIONov 13, 8:05 AMFortress Biotech reported third-quarter 2026 net revenue of $19.2 million, representing a 9% increase from the prior year period, driven primarily by $18.9 million in product revenue. The company fully repaid its $15.0 million senior secured credit facility with Oaktree in September 2026, leaving it with no outstanding debt at the parent level. Key corporate developments included the in-licensing of FB-607 for irritable bowel syndrome, the approval of anselamimab in Japan for amyloidosis, and a $130 million Series B financing for partner Crystalys Therapeutics. Financial results for the quarter showed a net loss attributable to common stockholders of $7.9 million, while consolidated cash and cash equivalents rose to $152.2 million.Healthcare
  179. BNTCNov 13, 8:02 AMBenitec Biopharma reported positive interim clinical results for its BB-301 therapy in a Phase 1b/2a study for Oculopharyngeal Muscular Dystrophy, showing a 100% responder rate across all patients in Cohort 1 and Cohort 2 with no serious adverse events. The company announced a net loss of $12.9 million for the first quarter ended September 30, 2026, while maintaining approximately $176.5 million in cash and cash equivalents. Benitec plans to finalize the design for its pivotal BB-301 trial in the first quarter of 2027, with the study on track to begin in mid-2027. Additionally, the company intends to transition its fiscal year-end from June 30 to December 31, presenting operational guidance on a calendar-year basis and financial guidance on a fiscal-year basis.Healthcare
  180. IMUXNov 13, 8:00 AMImmunic, Inc. reported a net loss of $42.3 million for the third quarter of 2026, driven by increased research and development and general and administrative expenses. The company's Phase 3 ENSURE-1 and ENSURE-2 trials for vidofludimus calcium in relapsing multiple sclerosis remain on track to report top-line data in December 2026. Immunic is also initiating a Phase 3 PROTECT-MS trial for progressive multiple sclerosis, with the first patient enrollment expected in the first half of 2027. To support regulatory and commercial readiness, the company appointed a Chief Data and Digital Officer and a Chief People Officer during the quarter.Healthcare
  181. HURANov 13, 7:50 AMTuHURA Biosciences reported third-quarter 2026 financial results showing $1.9 million in cash and cash equivalents alongside $3.7 million in research and development expenses. The company announced preliminary data from its IFx-2.0 and Keytruda study in metastatic Merkel cell carcinoma patients, demonstrating major objective tumor responses in the first three subjects. TuHURA also received FDA clearance to initiate a Phase 1b trial for its VISTA-inhibiting antibody TBS-2025 in relapsed or refractory acute myeloid leukemia and secured new patents for its VISTA inhibitor and Delta Opioid Receptor technology. To support these initiatives, the company accessed $5.6 million in non-dilutive financing from its Parkview credit facility during the quarter.Healthcare
  182. NDLSNov 13, 7:45 AMNoodles & Company reported a 9.5% increase in system-wide comparable restaurant sales for the third quarter of 2026, driven by a 10.7% rise at company-owned locations and a 4.9% rise at franchise locations. The company posted a net loss of $2.1 million for the quarter, a significant improvement from the $9.2 million loss recorded in the same period of 2025, while operating margin expanded to 0.1% from (5.2)%. Restaurant contribution margin improved to 16.7% and Adjusted EBITDA increased by 34.3% to $8.7 million. Management has tightened its full-year 2026 guidance, projecting total revenue between $485 million and $495 million and Adjusted EBITDA between $35 million and $37 million.Consumer Cyclical
  183. DGXXNov 13, 7:45 AMDigi Power X Inc. reported third-quarter 2026 revenue of $12.25 million, representing an 85% increase from the previous quarter and a 50% year-over-year rise. AI-related revenue reached $5.66 million, accounting for 46% of total revenue, driven by a 400% surge in GPU rental income and the launch of the NeoCloudz Token Factory. The company ended the quarter with $119.6 million in cash and digital currencies, no outstanding borrowings, and a net income of $1.0 million. Looking ahead, Digi Power X anticipates an annualized revenue run-rate of $250 million to $300 million by the end of Q3 2027, supported by the upcoming billing for its Columbiana Phase 1 colocation facility and a planned $200 million debt financing.Utilities
  184. MISTNov 13, 7:36 AMMilestone Pharmaceuticals reported third-quarter 2026 net product revenue of $1.0 million for its FDA-approved drug CARDAMYST, representing a 73% increase from the previous quarter. To extend its cash runway into late 2028, the company implemented cost-efficiency measures that reduce operating expenses by approximately 30%, including bringing its sales force in-house and reducing its headquarters workforce. Consequently, Chief Financial Officer Amit Hasija and Chief Medical Officer Dr. David Bharucha have departed the leadership team, while the company maintains full funding for its Phase 3 AFib-RVR trial with data expected in the second half of 2028. As of September 30, 2026, the company held $145.4 million in cash and equivalents, providing sufficient resources to cover operations well beyond the anticipated Phase 3 readout.Healthcare
  185. XTIANov 13, 7:30 AMXTI Aerospace reported third-quarter 2026 revenue of $35.3 million, representing an 8.8% sequential increase and a 46.1% rise compared to the prior year's proforma revenue. The company achieved an adjusted EBITDA of $1.6 million, a significant improvement from a negative $4.9 million in the second quarter, driven by cost realignment initiatives and tariff recovery benefits. Management has completed its strategic pivot to focus exclusively on the Drone Nerds business, discontinuing the XTI aircraft operations while expanding its portfolio with new programs for pressure washing, airport detection, and first responders. Looking ahead, XTI Aerospace has reiterated its full-year 2026 revenue guidance of $125 million to $130 million and expects to transition to positive ongoing operating cash flows by the fourth quarter.Technology
  186. JBIONov 13, 7:20 AMJade Biosciences reported a net loss of $35.1 million for the third quarter ended September 30, 2026, driven by increased research and development and general and administrative expenses. The company holds $475.7 million in cash, cash equivalents, and investments, providing a runway into the fourth quarter of 2028. Key pipeline updates include the expected initiation of the Phase 3 EVERGREEN trial for JADE101 in the fourth quarter of 2026 and the planned start of the Phase 1 JADE301 trial in dermatomyositis during the same period. Additionally, the company expanded Brad Dahms' role to include Chief Business Officer responsibilities alongside his position as Chief Financial Officer.Healthcare
  187. TVRDNov 13, 7:05 AMTvardi Therapeutics reported a net loss of $6.1 million for the third quarter ended September 30, 2026, driven by increased research and development expenses related to its TTI-101 program. The company plans to advance its lead candidate TTI-109 into clinical trials for ulcerative colitis in 2027, pending Investigational New Drug clearance and additional funding. TTI-101 is currently being evaluated in a Phase 1b/2 study for hepatocellular carcinoma, with topline data expected in the early first quarter of 2027. As of September 30, 2026, Tvardi held $22.3 million in cash and cash equivalents, which is projected to fund operations through the third quarter of 2027.Healthcare
  188. PWCMNov 13, 7:00 AMPowerCompute reported a net income of $0.4 million for the third quarter of 2026, driven by a $6.7 million fair value gain on digital assets receivable as Bitcoin prices rose approximately 43% during the period. The company mined 23.9 Bitcoin, representing a 35.8% increase in production compared to the same quarter in 2025, while its mining margin improved to 50.7% from 29.0% in the previous quarter. Significant balance sheet improvements were achieved by repaying and terminating its Bitcoin-backed credit facility, which reduced secured debt by 94% to $1.25 million and eliminated pledged Bitcoin. Additionally, PowerCompute purchased 600 new Bitmain Antminer S21++ units for $1.0 million, which are expected to increase the company's active hashrate by approximately 10% by mid-December 2026.Financial Services
  189. SBCNov 13, 6:50 AMSBC Medical Group Holdings reported third-quarter 2026 total revenues of $59 million, representing a 35% year-over-year increase driven by service fee revisions and the consolidation of Waqoo. Net income attributable to the company rose 22% to $16 million, while Adjusted EBITDA surged 66% to $28 million, resulting in an Adjusted EBITDA margin of 47%. The company's clinic network expanded to 293 locations with 7.06 million patient visits over the trailing twelve months, and it held $198 million in cash and cash equivalents as of September 30, 2026.Industrials
  190. MXCNov 12, 5:28 PMMexco Energy Corporation reported a net income of $945,152, or $0.45 per diluted share, for the six months ended September 30, 2026, representing a 67% increase from the same period in the prior year. Operating revenues rose 21% to $4,102,157, driven primarily by a 43% increase in average oil prices despite a 23% decline in natural gas prices and a 7% drop in oil production. During this period, the company invested approximately $3.2 million in acquiring oil and gas royalty interests and plans to drill 55 horizontal wells and complete 20 others in the fiscal year ending March 31, 2027.Energy
  191. LGLNov 12, 5:27 PMThe LGL Group, Inc. reported total revenues of $1.464 million for the third quarter of 2026, representing a 32.1% increase from the same period in 2025. Net loss attributable to common stockholders was $45,000 for the quarter, a significant decline from the $772,000 net income recorded in 2025, primarily due to a reversal of a previously recorded uncertain tax position. The company's backlog in the Electronic Instruments segment grew substantially to $6.5 million as of September 30, 2026, up from $625,000 at the end of 2025. Cash and cash equivalents, along with marketable securities, increased to $87.0 million, driven largely by a rights offering that generated $41.5 million in net proceeds in July 2026.Technology
  192. BMTMNov 12, 5:27 PMBright Mountain Media, Inc. reported revenue of $11.6 million for the third quarter of 2026, a 17% decrease from the same period in 2025, while net loss narrowed to $3.0 million from $2.8 million. For the nine months ended September 30, 2026, revenue totaled $39.2 million, down 10% year-over-year, with the net loss improving by 26% to $7.5 million compared to $10.1 million in the prior period. Adjusted EBITDA increased to $1.5 million for the quarter and $3.6 million for the nine-month period, reflecting a 10% and 88% improvement respectively. The company's balance sheet showed total assets of $32.75 million and a stockholders' deficit of $84.09 million as of September 30, 2026.
  193. ROCNov 12, 5:21 PMRank One Computing Corporation reported record third-quarter 2026 revenue of $8.0 million, representing a 50% year-over-year increase and achieving its first quarterly net income of approximately $0.6 million. The company secured a historic $64.3 million federal contract with the Department of Justice for its ROC Evidence platform and a $5.1 million contract for ROC ABIS, while product revenue grew 24% to $5.7 million driven by strong performance in ROC SDK and ROC ABIS. Gross margin improved to 90% due to a favorable mix of high-margin software licensing, and the company completed the acquisition of Zuccaro Technical Consulting to expand its digital forensics capabilities.Technology
  194. AKTXNov 12, 5:21 PMAkari Therapeutics initiated GLP toxicology studies for its lead candidate AKTX-101, a TROP2-targeted antibody-drug conjugate utilizing the novel PH1 payload, to support a planned Phase 1 clinical trial in mid-2027. New preclinical data demonstrated that AKTX-101 exhibited significant tumor growth inhibition in urothelial cancer models resistant to existing therapies like Padcev and Trodelvy. The company reported third-quarter 2026 financial results showing $5.7 million in cash, a net loss of $4.8 million, and the full repayment of $0.7 million in convertible notes. Additionally, Akari strengthened its business development capabilities with the appointment of a new Chief Business Officer and expanded its intellectual property portfolio with a new patent application covering PH1's RNA splicing modulation mechanisms.Healthcare
  195. ITHUFNov 12, 5:21 PMiAnthus Capital Holdings reported fiscal third quarter 2026 revenue of $38.4 million, representing a sequential increase of $3.0 million from the previous quarter. The company achieved a gross profit of $16.7 million with a gross margin of 43.5%, while reporting a net loss of $13.2 million. Adjusted EBITDA for the quarter reached $5.2 million, an increase from $4.4 million in the second quarter and $2.5 million in the prior year's third quarter. Additionally, the company appointed Macias Gini & O'Connell LLP as its new independent registered public accounting firm effective November 12, 2026, following the resignation of PKF O'Connor Davies.
  196. ELTPNov 12, 5:20 PMElite Pharmaceuticals, Inc. reported consolidated revenues of $40.1 million for the second quarter of fiscal year 2027, representing a 10.4% increase from the prior year period. This growth was primarily driven by higher sales from the company's amphetamine and naltrexone product lines under the Elite label. The company recorded income from operations of $9.9 million and net income attributable to common shareholders of $17.3 million for the quarter. Management is scheduled to host a conference call on November 13, 2026, to discuss these financial results and recent business developments.Healthcare
  197. TBNNov 12, 5:18 PMTamboran Resources achieved first gas sales from its Shenandoah South Pilot Project in the Beetaloo Basin in September 2026, delivering 40 TJ/d to the Northern Territory Government under a fixed-price contract. Initial production tests on wells SS2-3H and SS2-5H confirmed average IP30 rates of 8.8 and 10.0 MMcf/d, while the SS2-2H ST1 well demonstrated a cleaned-up rate of 10.2 MMcf/d. The company reported US$1.8 million in gas sales revenue for the first quarter of fiscal year 2027, maintaining a pro forma cash balance of approximately US$180 million. Tamboran continues to advance its development strategy with ongoing drilling programs and strategic partnerships aimed at scaling production across its 2.8 million net prospective acres.Energy
  198. SLNDNov 12, 5:17 PMSouthland Holdings reported third-quarter 2026 revenue of $233.8 million, an increase from $213.3 million in the same period the prior year, driven by strong demand in its Civil and Transportation segments. The company achieved a gross profit of $20.6 million with an 8.8% margin, a significant improvement over the 0.9% margin recorded in the previous year, largely due to a $28.7 million settlement gain with Liberty Mutual. Net income attributable to stockholders reached $33.7 million, or $0.62 per diluted share, contrasting sharply with a net loss of $75.3 million in the prior year quarter. Additionally, Southland's backlog grew to $1.71 billion, reflecting continued execution of its strategic plan and operational improvements.Industrials
  199. LGVNNov 12, 5:11 PMLongeveron Inc. reported a net loss of $6.1 million for the third quarter ended September 30, 2026, driven by research and development expenses of $4.0 million and general and administrative costs of $3.3 million. The company's Phase 2b ELPIS II clinical trial for hypoplastic left heart syndrome did not meet its primary efficacy endpoint, prompting a request for a meeting with the FDA to determine future development steps. Concurrently, Longeveron is evaluating strategic alternatives, including potential partnerships, mergers, or sales, with Lucid Capital Markets retained as financial advisor to maximize stockholder value. The company implemented a 1-for-10 reverse stock split in August and currently holds $7.2 million in cash, which is expected to fund operations into the first quarter of 2027.Healthcare
  200. VGZNov 12, 5:10 PMVista Gold Corp. announced a consolidated net loss of $6.4 million, or $0.05 per share, for the quarter ended September 30, 2026, while maintaining cash reserves of $43.5 million with no debt. On September 20, 2026, the company entered into an arrangement agreement with Artemis Gold Inc. to be acquired via a court-approved plan of arrangement. Under the proposed terms, each Vista common share will be exchanged for 0.0966 of an Artemis common share, resulting in Vista shareholders collectively owning approximately 5% of the combined entity. The transaction aims to leverage Artemis's resources to advance the development of Vista's Mt Todd gold project while expanding the Blackwater operation.Basic Materials
  201. NNUPNov 12, 5:08 PMNocopi Technologies reported a 763% increase in third-quarter 2026 revenues to $3.329 million, driven by a renewed license agreement and sales from the acquired Polymeric business. The company achieved a net income of $1.397 million for the quarter, a significant turnaround from the net loss recorded in the same period of the previous year. Operating expenses rose to $0.982 million due to the inclusion of Polymeric's operations and elevated professional fees associated with the acquisition. As of September 30, 2026, the company maintained a strong balance sheet with $10.278 million in cash and investments and no outstanding debt.
  202. PALNov 12, 5:03 PMProficient Auto Logistics reported third-quarter 2026 total operating revenue of $149.0 million, a 30.3% increase from the prior year period, driven by the inclusion of Hansen & Adkins following its acquisition on August 13, 2026. The company delivered 839,036 units, representing a 38.6% year-over-year growth, though total operating income declined to a loss of $3.9 million compared to a $0.1 million loss in the previous year. Adjusted operating income for the quarter was $0.3 million, with the adjusted operating ratio rising to 99.8% due to elevated costs in insurance, wages, and fuel surcharge under-recovery. The integration of Hansen & Adkins is progressing on schedule, with the company now identifying a synergy opportunity range of $20 million to $30 million, significantly higher than the initial estimate.Industrials
  203. KIDZNov 12, 5:00 PMKIDZ AI Inc. reported a 40% sequential increase in third-quarter 2026 revenue, marking its first quarter-over-quarter growth in the year. The company achieved a gross margin of 65.9% and narrowed its net loss to $654,057, while strengthening its balance sheet with stockholders' equity rising 349% to $16.9 million. As of September 30, 2026, the firm maintained a net cash position of approximately $14.9 million, representing roughly 12 times its market capitalization. During the quarter, KIDZ AI repurchased 74,082 shares of Class B common stock at an average price of $3.36 per share.Consumer Defensive
  204. CWDNov 12, 5:00 PMCaliber reported a third quarter 2026 platform revenue of $3.8 million and a platform net loss of $4.3 million, resulting in a positive platform Adjusted EBITDA of $0.1 million for the second consecutive quarter. The company revised its full-year 2026 total platform revenue guidance down to a range of $15.0 million to $17.0 million due to tighter credit conditions, while reaffirming its profitability guidance. During the quarter, Caliber completed the tokenization of three additional real estate projects, bringing the total tokenized offerings to four with up to $110 million in combined offered equity. Additionally, the company held 229,203 LINK tokens valued at $3.3 million, which contributed a $1.6 million gain from changes in fair value.Financial Services
  205. MSGMNov 12, 5:00 PMMotorsport Games reported third-quarter 2026 revenues of $3.8 million, representing a 21.8% increase from the prior year period, driven by growth in Le Mans Ultimate downloadable content and RaceControl subscriptions. The company achieved its seventh consecutive quarter of profitability with net income of $0.7 million and expanded its gross profit margin to 88.0%. Le Mans Ultimate surpassed two million combined unit sales and set a new concurrent player record of 11,941 during a special event in October. Additionally, the company strengthened its balance sheet, ending the quarter with $5.4 million in cash and deferred revenue, while RaceControl subscription revenues grew by 186.2% over the nine-month period.Communication Services
  206. BGMSNov 12, 5:00 PMBio Green Med Solution, Inc. reported a net loss of $0.4 million for the third quarter ended September 30, 2026, narrowing from a $1.0 million loss in the prior-year period. The company's fire safety business generated $454,000 in product revenue, representing a significant increase from $81,000 in the same period last year, while general and administrative expenses decreased by 37% year over year. As of September 30, 2026, the company held $3.5 million in cash and cash equivalents, which management estimates will fund operations through the second quarter of 2027. Additionally, the company announced that its Form S-4 regarding a proposed business combination with Future NRG Sdn. Bhd. was declared effective in October, with a shareholder special meeting planned for November 2026.Industrials
  207. DIODNov 12, 5:00 PMDiodes, Inc. reported record third-quarter 2026 revenue of $532.6 million, representing a 36% year-over-year increase and a 20% sequential rise. The company achieved a gross margin of 36.1%, driven by strong demand in automotive, industrial, and AI-related computing sectors, alongside capacity expansion and product mix improvements. Management projects fourth-quarter revenue to reach approximately $550 million with a non-GAAP gross margin of 37%, aiming to exceed its three-year financial goals.Technology
  208. PRSONov 12, 4:58 PMPeraso Inc. reported third-quarter 2026 total net revenue of $0.3 million, a significant decline from $1.3 million in the prior quarter and $3.2 million in the same period last year, driven by reduced shipments to fixed wireless access customers. The company posted a GAAP net loss of $2.7 million, or $0.18 per share, while achieving a gross margin of 78.5% due to a favorable product mix and a one-time inventory accrual reversal. Management noted early signs of renewed demand in the fourth quarter, highlighted by a production order exceeding $2 million received in October, and announced a private placement with Nant Capital that raised approximately $10 million to support strategic initiatives in defense and drone communications.Technology
  209. SPRUNov 12, 4:52 PMSpruce Power reported a net income of $6.0 million for the third quarter of 2026, marking a significant turnaround from a net loss of $0.9 million in the same period the previous year. Operating EBITDA increased by 3% year-over-year to $27.0 million, driven by a 23% reduction in SG&A expenses resulting from streamlining efforts and labor savings initiatives. The company ended the quarter with $87.3 million in cash and cash equivalents, reduced its outstanding debt principal by $21.9 million, and finalized a non-binding term sheet to refinance key facilities extending their maturity to January 2027.Technology
  210. NSPRNov 12, 4:45 PMInspireMD, Inc. reported a net loss of $9.76 million for the third quarter of 2026, driven by a decline in total revenue to $2.24 million due to a voluntary U.S. recall of its CGuard Prime delivery system. The company received FDA approval for its CGuard Prime TransCarotid Stent System for TCAR procedures, which is expected to expand its addressable market by over 35,000 annual procedures and commence U.S. sales in the fourth quarter of 2026. International revenue grew by 9.1% to $2.21 million, offsetting the loss of U.S. sales, while the company continues to advance its SwitchGuard neuroprotection system and plans to submit a PMA supplement for an enhanced CAS delivery system in December 2026.Healthcare
  211. ALMUNov 12, 4:45 PMAeluma, Inc. reported a net loss of $3.8 million for the first quarter of fiscal 2027, with revenue declining to $0.6 million from $1.4 million in the prior year period. The company finalized a purchase agreement with Aixtron to acquire a new 200 mm capable MOCVD system, aiming to expand manufacturing capacity for non-indium-phosphide photonics. Aeluma continues to advance technology readiness for the AI datacom market through the development of high-speed photodetectors and quantum dot lasers while engaging with customers for potential high-volume demand. Additionally, the company is in negotiations with the U.S. Department of Commerce for up to $30 million in CHIPS R&D funding to support the commercialization of photonics for AI and advanced computing.Technology
  212. STRONov 12, 4:45 PMSutro Biopharma reported third-quarter 2026 financial results showing $9.1 million in revenue and a net loss of $31.5 million, while maintaining a cash balance of $142.2 million expected to fund operations through the first half of 2028. The company advanced its STRO-004 ADC program with encouraging early clinical data and initiated dosing for the STRO-006 ITGB6-targeting ADC, with both programs scheduled for further clinical updates in 2027. Additionally, the STRO-227 dual-payload ADC is set to enter clinical trials in early 2027, and a collaboration with Astellas triggered a $10 million milestone payment following the dosing of a second dual-payload program.Healthcare
  213. SPRONov 12, 4:43 PMSpero Therapeutics announced its third-quarter 2026 financial results, reporting a net loss of $44.3 million and research and development expenses of $38.2 million, which included a $35 million upfront payment for the in-licensing of SP001 from Innovent Biologics. The company secured $105 million in non-recourse financing in July 2026, bringing its cash and cash equivalents to $107.9 million as of September 30, 2026, sufficient to fund operations into the second half of 2029. SP001, a third-generation anti-CD40L antibody, is advancing toward a Phase 2 study in IgG4-related disease scheduled for the second quarter of 2027. Spero has also strengthened its leadership team with new appointments for Chief Medical Officer, Chief Regulatory and Quality Officer, and a new Board member to support its clinical development strategy.Healthcare
  214. LSFNov 12, 4:42 PMLaird Superfood reported third-quarter 2026 net sales of $42.0 million, representing a 225% increase from the prior year period, driven by the integration of Navitas Organics and Terrasoul Superfoods. The company achieved a net income of $1.7 million and an Adjusted EBITDA of $2.1 million, while e-commerce sales grew 268% to account for 54% of total revenue. For the full fiscal year 2026, the company maintains a revenue guidance range of $135 million to $140 million and an Adjusted EBITDA range of $5 million to $6 million. As of September 30, 2026, Laird Superfood held $17.3 million in cash with no outstanding debt.Consumer Defensive
  215. BATLNov 12, 4:41 PMBattalion Oil Corporation reported third quarter 2026 sales volumes of 11,359 barrels of oil equivalent per day, with average daily production of 4,915 net barrels of oil. The company generated $45.6 million in operating revenue, driven by a $5.13 per Boe increase in average realized prices, while reporting a net loss of $41.1 million largely due to $44.8 million in net losses on derivative contracts. Financial highlights include $92.1 million in cash and cash equivalents, a reduction in net debt to $70.4 million, and the commencement of drilling operations under a joint exploration agreement ahead of schedule. Additionally, the company executed a midstream transaction to transition crude transportation from trucking to pipeline and appointed John Juneau to its board of directors.Energy
  216. DMACNov 12, 4:40 PMDiaMedica Therapeutics reported a net loss of $11.3 million for the third quarter of 2026, with total cash, cash equivalents, and short-term investments standing at $34.9 million as of September 30, 2026. The company completed enrollment in the first two cohorts of its Phase 2 trial for early-onset fetal growth restriction and surpassed the 200-participant threshold for its ReMEDy2 acute ischemic stroke trial. Regulatory progress includes conditional authorization from the European Medicines Agency and Health Canada for early-onset preeclampsia studies, while the company continues to address FDA feedback regarding nonclinical reproductive toxicity data for a U.S. Investigational New Drug application. Management anticipates the ReMEDy2 interim analysis to be completed in the first quarter of 2027 and expects current cash reserves to fund operations through the fourth quarter of 2027.Healthcare
  217. DDSNov 12, 4:39 PMDillard's, Inc. reported net income of $130.9 million for the third quarter ended October 31, 2026, representing a 1% increase in total retail sales compared to the prior year period. For the 39 weeks ended October 31, 2026, the company achieved net income of $479.1 million, driven by a 2% increase in total retail sales and significant non-operating gains from tariff refunds and a litigation settlement. The retailer maintained a retail gross margin of 45.3% for the quarter and 44.0% for the year-to-date period, while operating expenses rose due to higher payroll costs. Additionally, Dillard's announced the closure of its Boynton Beach Mall Clearance Center in January 2027 and operates 272 stores across 30 states.Consumer Cyclical
  218. GEMINov 12, 4:35 PMGemini Space Station, Inc. reported third-quarter 2026 total revenue of $40.9 million, a 19% decrease from the prior year, driven by a 73% decline in platform spot trading volume. Total operating expenses fell 30% year-over-year to $119.9 million, resulting in a net loss of $58.6 million, which represents a 63% improvement over the same period in 2025. Services revenue and interest income accounted for 59% of net revenue, while exchange revenue dropped 47% to $13.4 million due to reduced retail trading activity. The company maintained disciplined cost management with lower compensation and marketing spend, despite a 38% increase in transaction losses primarily attributed to credit card charge-offs.Financial Services
  219. WHKNov 12, 4:34 PMWhiteHawk Minerals Corp. reported third-quarter 2026 net production of 71.3 million cubic feet equivalent per day, representing a 10% year-over-year increase. The company announced the signing of 13 acquisitions totaling $45.5 million in core Appalachian and Haynesville mineral interests, which are expected to generate approximately $5.6 million in incremental cash flow in 2027. For the quarter, WhiteHawk declared a quarterly dividend of $0.50 per share, achieved net income of $6.9 million, and reported adjusted EBITDA of $21.1 million.Energy
  220. CVNov 12, 4:34 PMCapsoVision reported third-quarter 2026 revenue of $3.6 million, a slight increase from $3.5 million in the same period of 2025, while net loss narrowed to $7.3 million from $7.9 million. The company received FDA clearance for its AI Highlights tool in September 2026 and launched it commercially in November, alongside completing enrollment for its CapsoCam Colon study with an expected FDA submission by year-end. Financial results reflected a gross margin decline to 49% due to higher material costs and inventory charges, though operating expenses decreased to $9.1 million. To support its operations and development pipeline, CapsoVision raised approximately $19.5 million in net proceeds through a registered direct offering and an at-the-market program during the quarter.Healthcare
  221. UPXINov 12, 4:31 PMUpexi, Inc. reported fiscal first quarter 2027 net income of $89.1 million, or $0.68 per diluted share, driven primarily by $102.0 million in unrealized gains on digital assets. Total revenue for the quarter reached $3.5 million, with digital asset revenue accounting for $3.1 million and product revenue declining to $0.4 million as the company shifted away from legacy consumer product lines. The company strengthened its balance sheet by increasing its Solana treasury to approximately 2.35 million SOL and raising cash on hand to $6.4 million, while also reducing the interest rate on its BitGo borrowings from 11.5% to 7.5%. Stockholders' equity improved significantly to $49.2 million as of September 30, 2026, reversing a deficit of $53.8 million recorded at the end of the previous quarter.Communication Services
  222. SPCENov 12, 4:31 PMVirgin Galactic reported a net loss of $59 million for the third quarter of 2026, driven by $59 million in operating expenses and revenue of $0.4 million. The company holds $184 million in cash and marketable securities as of September 30, 2026, while its first commercial spaceflight is expected in early 2027. Operational updates include the completion of a rocket motor production facility in Arizona and the opening of limited bookings for spaceflight expeditions at $850,000 per seat. Additionally, Virgin Galactic projects a high-cadence launch hangar opening in late 2028 to increase annual spaceflight capacity to 150.Industrials
  223. PROPNov 12, 4:30 PMPrairie Operating Co. reported third-quarter 2026 sales volumes of 2.4 million barrels of oil equivalent, representing a 21% increase from the prior quarter and driving revenue to $129.5 million. The company generated $65.3 million in Adjusted EBITDA, a 92% quarter-over-quarter increase, while reducing lease operating expenses per barrel of oil equivalent by 17%. Year-to-date through September 30, 2026, total revenue reached $311.8 million, an increase of approximately 97% compared to the same period in 2025. Production reached approximately 32,287 barrels of oil equivalent per day by early October, following the online status of the Burnett and Castor development pads.Energy
  224. AEMDNov 12, 4:30 PMAethlon Medical, Inc. reported a net loss of $2.62 million for the second quarter ended September 30, 2026, with operating expenses rising 77.2% to $2.7 million primarily due to professional fees associated with a proposed merger. On September 17, 2026, the company entered into a merger agreement with North Immunology, Inc., under which the combined entity will operate as North Immunology and shareholders will receive contingent value rights tied to the legacy Hemopurifier business. During the quarter, the company treated its second patient in the final dosing cohort of its Phase 1 oncology study in Australia and implemented workforce reductions to align with the merger timeline. As of September 30, 2026, the company held approximately $6.5 million in cash and cash equivalents.Healthcare
  225. LGCYNov 12, 4:30 PMLegacy Education Inc. reported a record student population of 3,684 for the first quarter of fiscal 2027, representing a 5.4% increase from the prior year. The company achieved $20.0 million in revenue and $0.9 million in net income, while expanding its footprint with a new campus lease in Houston, Texas. Strategic investments in faculty, facilities, and new programs drove educational services expenses up by 13.0%, resulting in a lower net income margin compared to the previous year. Additionally, the company recorded an estimated $0.7 million legal settlement expense and maintained a strong balance sheet with $21.7 million in cash and minimal debt.Consumer Defensive
  226. PLNHNov 12, 4:28 PMPlanet 13 Holdings Inc. reported a net loss of $6.4 million and revenue of $23.1 million for the third quarter of 2026. The company achieved a gross profit margin of 56.2%, a significant increase from the prior year, driven by the exit from California wholesale operations and a reduction in inventory reserves. Adjusted EBITDA improved to a loss of $0.2 million, reflecting better cost control and higher gross margins despite lower tourist traffic in Nevada. Additionally, the company announced that its Form S-4 merger registration with Vireo Growth Inc. was declared effective, with a shareholder vote scheduled for December 10, 2026.
  227. VRCANov 12, 4:27 PMVerrica Pharmaceuticals reported third-quarter 2026 total revenue of $6.9 million, driven by a record $5.7 million in net product revenue from YCANTH, which represents an 11.9% increase over the previous quarter. The company completed enrollment in its first pivotal Phase 3 trial for common warts and achieved milestones to unlock an additional $15.0 million in non-dilutive growth capital, extending its cash runway into the fourth quarter of 2027. Additionally, Verrica announced it is exploring the development of its oncolytic peptide, VP-315, for the treatment of Gorlin syndrome, a rare genetic disease characterized by frequent basal cell carcinomas.Healthcare
  228. NKTRNov 12, 4:25 PMNektar Therapeutics reported a net loss of $55.7 million for the third quarter of 2026, driven by increased research and development expenses totaling $44.1 million as the company advances its lead candidate rezpegaldesleukin into Phase 3 trials for atopic dermatitis and alopecia areata. Revenue for the quarter declined to $9.4 million from $11.8 million in the same period the previous year, while cash and investments rose significantly to $952.9 million. The company has initiated all three global registrational trials for the ZENITH AD program and expects topline data in mid-2028, with a target Biologics License Application submission in 2029.Healthcare
  229. ARMPNov 12, 4:24 PMArmata Pharmaceuticals reported a net income of $54.9 million for the third quarter of 2026, driven primarily by a $69.6 million gain from changes in the fair value of its convertible loan. The company advanced preparations for its pivotal Phase 3 superiority study of AP-SA02, receiving FDA Breakthrough Therapy designation and securing an additional $3.7 million in non-dilutive funding from the U.S. Department of War. Operating expenses for the quarter totaled $10.5 million, while the company held $18.3 million in unrestricted cash and cash equivalents as of September 30, 2026.Healthcare
  230. FGINov 12, 4:24 PMFGI Industries reported third-quarter 2026 total revenue of $31.7 million, an 11.6% decrease from the prior year, driven by softness in housing and remodeling activity. The company posted a gross profit of $8.7 million with an expanded gross margin of 27.6%, while operating and net losses were recorded at $0.5 million and $0.9 million, respectively. Revenue declined across core categories including sanitaryware and shower systems, though the custom kitchen cabinetry segment grew by 32.8%. Consequently, FGI revised its full-year 2026 net revenue guidance downward to a range of $120-127 million and adjusted its operating and net income forecasts to reflect continued market challenges.Consumer Cyclical
  231. XOSNov 12, 4:23 PMXos, Inc. reported a third consecutive quarter of positive GAAP gross profit for the period ended September 30, 2026, with the nine-month GAAP gross margin expanding to 26.9% from 13.3% in the prior year. Revenue for the quarter increased 17.0% sequentially to $5.5 million on 33 units delivered, while operating expenses were reduced by 10.0% year-over-year to $25.8 million for the nine-month period. The company delivered its first Xos Hub units internationally to support Waymo's autonomous vehicle operations in London and now has over 1,000 units in the field. Xos revised its full-year 2026 outlook to project revenue between $25 million and $35 million and unit deliveries between 185 and 250 units.Consumer Cyclical
  232. ENSCNov 12, 4:22 PMEnsysce Biosciences reported a net loss of $82.3 million for the third quarter of 2026, primarily driven by a $79.9 million non-cash charge for acquired in-process research and development related to the Cy Biopharma acquisition. The company completed the acquisition of Cy Biopharma in August, adding the CY200 pipeline asset for Complex Regional Pain Syndrome, and submitted a Phase 2a protocol for this candidate to the UK's MHRA in September. Additionally, Ensysce finished enrollment in the final stage of its PF614-MPAR-102 study for its abuse-deterrent opioid and ended the quarter with $29.7 million in cash and cash equivalents.Healthcare
  233. INVNov 12, 4:21 PMInnventure, Inc. reported a net loss of $333.8 million for the third quarter of 2026, driven primarily by a $323.5 million goodwill impairment charge. The company is executing a strategic repositioning that includes reducing parent-level headcount from 40 to 15 and transitioning its AeroFlexx and Refinity businesses away from reliance on Innventure capital. During the nine-month period ended September 30, 2026, Innventure generated $3.9 million in revenue while utilizing $74.5 million in operating cash flows. Management aims to preserve and maximize the value of its interest in Accelsius through disciplined capital allocation and cost reductions.Financial Services
  234. CRDFNov 12, 4:21 PMCardiff Oncology reported a net loss of $30.4 million for the nine months ended September 30, 2026, driven by $32.0 million in operating expenses. The company's Phase 2 trial for onvansertib in first-line RAS-mutated metastatic colorectal cancer remains ongoing, with median progression-free survival not yet reached in the 30 mg onvansertib plus FOLFIRI/bev arm compared to approximately 11 months in standard-of-care arms. As of late September 2026, all patients in the 30 mg onvansertib arm have exceeded 21 months on treatment, with the longest duration surpassing 29 months. Cardiff holds approximately $33.8 million in cash and cash equivalents as of September 30, 2026, and plans to initiate a registrational Phase 3 trial in the first quarter of 2027.Healthcare
  235. VATENov 12, 4:21 PMINNOVATE Corp. reported third-quarter 2026 consolidated revenue of $495.5 million, a 42.8% increase from the prior year, driven primarily by its Infrastructure segment. The company completed the sale of DBM Global to IES Holdings for approximately $413 million in cash and stock, and sold a controlling interest in HC2 Broadcasting to CONX Corp., retaining a 25% stake. Net income attributable to common stockholders rose to $15.8 million in the quarter, compared to a net loss of $9.4 million in the same period last year, largely due to a $32.9 million gain on the sale of the broadcasting interest. Total Adjusted EBITDA for the quarter reached $40.5 million, more than doubling the $19.8 million reported in the previous year.Industrials
  236. LVLUNov 12, 4:21 PMLulus reported a 20% year-over-year decline in third-quarter 2026 net revenue to $58.6 million, driven by a 20% drop in total orders placed and higher return rates. The company posted a net loss of $4.3 million and an adjusted EBITDA loss of $1.8 million, while successfully reducing inventory by 17% and improving gross margin by 230 basis points to 44.9%. Management revised its full-year 2026 outlook downward due to the continued impact of historical assortment decisions, though it anticipates revenue decline rates to moderate in fiscal 2027. Additionally, the company expects capital expenditures for 2026 to range between $1.5 million and $2.0 million.Consumer Cyclical
  237. CDXSNov 12, 4:20 PMCodexis, Inc. reported third-quarter 2026 total revenues of $19.3 million, a significant increase from $8.6 million in the same period of 2025, driven by higher product revenue from newly approved customer products. The company achieved a product gross margin of 74.5% for the quarter and reduced its net loss to $8.1 million, or $0.08 per share, compared to a $19.6 million loss in the prior year period. Financial stability was strengthened through a $25 million equity raise completed in July and a $60 million senior secured loan facility with Trinity Capital, which included a $42.5 million drawdown used to refinance existing debt. Codexis reiterated its full-year 2026 revenue guidance of $72 million to $76 million and expects its cash and investments to fund operations through the end of 2028.Healthcare
  238. YSSNov 12, 4:20 PMYork Space Systems reported third-quarter 2026 revenue of $84.2 million, a 7% decrease from the prior year, while recording a net loss of $807.4 million largely driven by a $749.7 million non-cash goodwill impairment charge. The company's backlog stood at $581.0 million as of September 30, 2026, supported by new contract wins and modifications, and its identified pipeline expanded by over 30% to $14.9 billion. York announced the permanent appointment of Brian Frantz as Chief Financial Officer and outlined strategic initiatives including the proposed acquisition of Outlook Industries to enter the unmanned systems market. Full-year 2026 revenue guidance was narrowed to a range of $380 million to $400 million, with the company maintaining total liquidity of $459 million.Industrials
  239. SCTXNov 12, 4:20 PMScribe Therapeutics reported third-quarter 2026 financial results, recording a net loss of $9.9 million and holding $174.2 million in cash, cash equivalents, and marketable securities as of September 30, 2026. The company completed an upsized initial public offering in July 2026, raising approximately $155.5 million in aggregate gross proceeds, which extends its funding runway into the first half of 2029. Clinical progress includes ongoing enrollment in the first-in-human Phase 1 trial for STX-1150, an epigenetic silencing therapy targeting LDL-C lowering, with initial data expected in the first half of 2027. Additionally, Scribe expanded its strategic collaboration with Sanofi to include access to its ELXR epigenetic silencing technology alongside its existing gene-editing platform.Healthcare
  240. CRWSNov 12, 4:19 PMCrown Crafts, Inc. reported second-quarter fiscal 2027 net sales of $19.0 million, a decrease from $23.7 million in the prior-year period. The company achieved a gross profit margin of 32.0%, an increase from 27.7% in the previous year, driven by $0.4 million in tariff refunds and offset by $0.2 million in severance expenses. Net income for the quarter rose to $1.3 million, or $0.12 per diluted share, compared to $1.2 million, or $0.11 per share, in the prior year. Additionally, the Board of Directors declared a quarterly cash dividend of $0.03 per share on the Series A common stock.Consumer Cyclical
  241. RMRNov 12, 4:19 PMThe RMR Group Inc. announced its financial results for the fiscal quarter ended September 30, 2026. The company, a leading U.S. alternative asset management firm focused on commercial real estate, manages approximately $37 billion in assets through over 800 professionals across more than 30 offices. A conference call to discuss these results was scheduled for November 13, 2026, at 11:00 a.m. Eastern Time, with a live webcast and replay options available.Real Estate
  242. GROWNov 12, 4:18 PMU.S. Global Investors reported a 18% increase in operating revenues to $2.7 million for the first quarter of fiscal 2027, ending the period with an operating income of $55,000 compared to a loss in the prior year. Average assets under management grew 14% to $1.6 billion, driven by a 45% surge in gold and precious metals strategies. The company also highlighted growth in its defense-focused WAR ETF and shipping-focused SEA ETF, while maintaining a shareholder yield of 8.33% and a strong liquidity position with $35.4 million in net working capital.Financial Services
  243. PMNNov 12, 4:17 PMProMIS Neurosciences reported a net loss of $8.2 million for the third quarter of 2026, with cash reserves totaling $44.1 million as of September 30, 2026. The company's lead Alzheimer's candidate, PMN310, remains on track to deliver unblinded 12-month topline data from the PRECISE-AD Phase 1b trial in the first quarter of 2027. Recent interim data showed no amyloid-related imaging abnormalities with edema and a 4.4% rate of hemorrhage, all of which were mild and asymptomatic. Ivana Rubino, Ph.D., a former senior executive at Biogen and Roche, was appointed Chief Commercial Officer effective October 5, 2026, to guide the company's late-stage development and commercial strategy.Healthcare
  244. PARKNov 12, 4:17 PMPark Dental Partners reported third-quarter 2026 revenue of $64.9 million, representing a 6.0% increase from the prior year, driven by same-practice growth and acquisitions. The company achieved net income of $1.7 million and adjusted EBITDA of $5.0 million for the quarter, while supporting 225 affiliated doctors across 88 practices. Full-year 2026 revenue is now projected to range between $262.0 million and $265.0 million, incorporating the expected contribution from the recently acquired Village Family DSO. Additionally, the company completed the acquisition of Village Family DSO in November 2026, with integration activities commencing immediately.Healthcare
  245. PROKNov 12, 4:17 PMProKidney Corp. reported third-quarter 2026 financial results, ending the period with $141.9 million in cash and cash equivalents to support operations through mid-2027. The company's pivotal Phase 3 PROACT 1 trial is on track to deliver eGFR slope topline results in the second quarter of 2027, with full enrollment expected to exceed 500 patients by the first quarter of 2027. During the quarter, research and development expenses rose to $40.8 million, driven primarily by increased clinical study and manufacturing costs associated with the ongoing trial. Additionally, the company presented eight new data abstracts at the ASN Kidney Week 2026 to further support the mechanistic and clinical evidence for its lead candidate, rilparencel.Healthcare
  246. ETRANov 12, 4:17 PMElectra Therapeutics reported a net loss of $23.9 million for the third quarter of 2026, supported by a cash position of $402.5 million following a $350 million IPO. The company is advancing its lead candidate, ipsoprubart, through a global registrational program for secondary hemophagocytic lymphohistiocytosis with enrollment completion expected in the second half of 2027. Additionally, ipsoprubart is being evaluated in a Phase 1 trial for T/NK cell malignancies, while the second candidate, ELA822, has initiated a Phase 1 trial in healthy volunteers with data expected in early 2027.Healthcare
  247. CTSONov 12, 4:16 PMCytoSorbents Corporation reported third-quarter 2026 revenue of $9.7 million, representing a 3% increase from the prior year, while achieving positive operating cash flow of approximately $43,000 excluding restructuring payments. The company improved its gross margin to 75% and reduced total operating expenses by 11% to $8.5 million, resulting in a net loss of $1.8 million compared to $3.2 million in the same period last year. Management highlighted progress on four strategic value drivers, including sustaining cash flow breakeven, revitalizing the core CytoSorb franchise in Germany, advancing the DrugSorb-ATR submission to the FDA for the U.S. market, and exploring commercial opportunities for the HemoDefend-BGA technology.Healthcare
  248. DFLINov 12, 4:16 PMDragonfly Energy reported third-quarter 2026 net sales of $12.2 million, a 23.8% decrease year-over-year, driven by softness in the recreational vehicle market despite heavy-duty trucking revenue more than doubling sequentially to $1.3 million. The company recorded a net loss attributable to common stockholders of $6.7 million and an adjusted EBITDA loss of $2.3 million, while completing the acquisition of the Dakota Lithium brand to expand its product portfolio. Management projects fourth-quarter 2026 net sales of approximately $12.5 million with adjusted EBITDA expected to reach breakeven, supported by continued fleet adoption and cost-reduction initiatives.Industrials
  249. ANABNov 12, 4:16 PMAnaptysBio reported fiscal first quarter 2027 results showing Jemperli global net sales of $1.0 billion for the nine months ended September 30, 2026, representing 29% year-over-year growth. The company received $30.3 million in collaboration revenue for the quarter, driven by Jemperli royalties, while net income from continuing operations was $3.9 million. Regulatory updates include FDA approval for Jemperli in locally advanced rectal cancer and an expected PDUFA decision for Quimilza in December 2026. Additionally, a post-trial hearing in the litigation with GSK and Tesaro was held on October 20, 2026, with a judgment anticipated in late 2026 or early 2027.Healthcare
  250. MSAINov 12, 4:16 PMMultiSensor AI Holdings, Inc. reported third-quarter 2026 net revenue of $1.5 million, a decrease from $1.6 million in the same period of 2025, driven by lower hardware sales and the discontinuation of inspection services. Software subscriptions now constitute the majority of revenue, accounting for 58% of the total, while the company posted a net loss of $1.9 million for the quarter. The company ended the period with $20.4 million in cash and cash equivalents, having reduced its cash burn rate through disciplined spending and strong collections. Strategic progress included the launch of a 14-site rollout in North America for a major global distributor and the expansion of deployments with Manchester Airports Group and a new pilot in the Asia-Pacific region.Technology
  251. WATTNov 12, 4:16 PMEnergous Wireless Power Solutions reported third-quarter 2026 revenue of approximately $3.4 million, representing a 167% increase compared to the same period in 2025. Year-to-date revenue for the nine months ended September 30, 2026, reached $9.6 million, a 270% rise over the prior year that exceeded the company's full-year 2025 revenue of $5.6 million. The company achieved a gross margin of 14% in the third quarter, improving from 3% in the second quarter, while shipping over 69,500 transmitters since 2024. Energous maintained a net loss of approximately $2.5 million for the quarter, or $0.45 per share, and held $28.8 million in cash and cash equivalents as of September 30, 2026.Technology
  252. RNANov 12, 4:16 PMAtrium Therapeutics reported third-quarter 2026 financial results, recording $15.3 million in collaboration revenue primarily from a milestone payment with Bristol Myers Squibb. The company dosed the first patient in its Corventis Phase 1/2 clinical trial for ATR 1072, a treatment targeting the root cause of PRKAG2 syndrome, following nonclinical data showing the drug reversed cardiac glycogen accumulation. A $50 million private placement closed in October, bringing the pro-forma cash balance to $293.6 million and extending the company's operational runway through 2028. For the quarter, the company reported research and development expenses of $13.8 million and general and administrative expenses of $8.2 million.Healthcare
  253. AMPGNov 12, 4:16 PMAmpliTech Group reported third-quarter 2026 revenue of $6.58 million, an 8.0% increase year-over-year, with gross margin expanding sequentially to 34.2%. The company achieved a nine-month gross profit growth of 41.1% to $7.07 million while narrowing its net loss to $1.89 million for the quarter. Following quarter-end, AmpliTech announced record bookings near $25 million in October, pushing its total backlog to over $52 million. Management revised its full-year 2026 revenue outlook to at least $28 million, citing supply-chain constraints and deployment delays that prevented the achievement of a previously withdrawn $50 million target.Technology
  254. TNONNov 12, 4:15 PMTenon Medical, Inc. reported third-quarter 2026 revenue of $1.4 million, representing a 22% increase compared to the same period in 2025. The company achieved a gross profit of $1.0 million with a gross margin of 66.3% and ended the quarter with $8.3 million in cash and cash equivalents. During the quarter, Tenon raised approximately $15.6 million in gross proceeds, fully repaid its senior convertible notes, and launched the 3D-printed lateral screw for its SImmetry+ SI Joint Fusion System. Additionally, the company added eight new U.S. patents to its portfolio, bringing the total to 38 issued patents.Healthcare
  255. VNRXNov 12, 4:15 PMVolitionRx Limited reported third-quarter 2026 revenue of approximately $1.6 million, a 157% increase from the prior year, driven by deferred revenue recognition. The company narrowed its operating loss to $3.3 million and reduced its net loss to $3.8 million while strengthening its balance sheet with $2.4 million in cash and the full repayment of a $7.5 million convertible note. Strategic progress includes the launch of the DETECSEPS program for sepsis detection, active licensing discussions for its Capture-Seq technology targeting a combined market over $36 billion, and a pending reimbursement submission for its lung cancer test in France. Additionally, the CEO and board voluntarily reduced their compensation by 50% to align with the company's cost-reduction efforts and commitment to securing licensing agreements.Healthcare
  256. RCKTNov 12, 4:15 PMRocket Pharmaceuticals reported a net loss of $49.2 million for the third quarter of 2026, with cash, cash equivalents, and investments totaling $279.4 million as of September 30, 2026. The company received FDA alignment to complete its pivotal Phase 2 trial of RP-A501 for Danon disease, with dosing expected to finish by mid-2027. Additionally, dosing has begun in the Phase 1 trial for RP-A701 targeting BAG3-associated dilated cardiomyopathy, and the commercial product KRESLADI achieved readiness with activated treatment centers on October 1, 2026.Healthcare
  257. QXONov 12, 4:15 PMQXO, Inc. reported a net loss of $123 million for the third quarter of 2026, with net sales reaching $4.90 billion. Despite the GAAP loss, the company achieved an Adjusted Net Income of $229 million and Adjusted EBITDA of $557 million, driven by a 2.2% year-over-year pricing increase and strong demand in mechanical insulation and data centers. The company serves 194,000 customers across its integrated legacy businesses and has authorized a $500 million share repurchase program. Management projects reaching $4 billion in adjusted EBITDA and $50 billion in annual revenue by 2030 through organic growth and acquisitions.Industrials
  258. GCTSNov 12, 4:15 PMGCT Semiconductor Holding, Inc. reported third-quarter 2026 net revenues of $1.1 million, representing a 148.6% increase from the prior year period, driven by shipments of over 3,200 5G chipsets. The company achieved a net loss of $7.4 million, a 46.7% decrease year-over-year, which included $6.2 million in gains from changes in the fair value of warrant liabilities. Cash and cash equivalents stood at $17.2 million as of September 30, 2026, while the company extended the maturities of $26.5 million in loans during the quarter. Management expects 5G shipment volumes to ramp significantly into the first half of 2027 as customer integration schedules progress.Technology
  259. NEOVNov 12, 4:15 PMNeoVolta Inc. reported revenue of $2.8 million for the quarter ended September 30, 2026, a significant increase from the previous quarter driven by initial sales through its third-party ownership residential platform. The company achieved a gross profit of $1.0 million, reversing a prior gross loss, while reporting a GAAP net loss of $7.7 million and adjusted EBITDA of negative $5.5 million. Financial results were supported by a $20 million senior secured term loan, bringing total cash and restricted cash to $28.8 million. Strategic progress included the ramp-up of the Pendergrass, Georgia manufacturing facility, a $116 million master purchase agreement for utility-scale products, and a supply collaboration with SK On for 9 GWh of battery cells.Industrials
  260. CBIONov 12, 4:15 PMCrescent Biopharma completed dose escalation in its Phase 1/2 ASCEND trial for CR-001, having dosed over 125 patients across the United States, Europe, and South Korea, with initial monotherapy data expected in the first quarter of 2027. The company has also dosed the first patient in the global APOLLO trial for CR-002, a PD-L1-targeted ADC, while multiple Phase 2 studies of CR-001 combinations with sacituzumab tirumotecan are ongoing in China. Financially, Crescent reported a net loss of $37.7 million for the third quarter of 2026, with cash and cash equivalents totaling $289.4 million as of September 30, 2026.Healthcare
  261. FLONov 12, 4:15 PMFlowers Foods, Inc. reported third-quarter 2026 net sales of $1.169 billion, a 4.7% decrease from the prior year, driven by a 7.0% decline in volume that outweighed a 2.3% favorable price and mix. Net income fell 63.6% to $14.4 million, while adjusted net income decreased 56.0% to $21.4 million, resulting in diluted earnings per share of $0.07. The company cited challenging market conditions, including pressure on household budgets and higher logistics costs, as key factors impacting performance. Consequently, Flowers Foods revised its full-year 2026 guidance downward, projecting net sales between $5.016 billion and $5.063 billion and adjusted diluted EPS between $0.63 and $0.68.Consumer Defensive
  262. BLSMNov 12, 4:15 PMBlossomHill Therapeutics reported a net loss of $24.0 million for the third quarter of 2026, driven by increased research and development expenses related to its lead candidate BH-30643. The company aligned with the FDA on a recommended Phase 2 dose of 50 mg twice daily for BH-30643 and announced the upcoming SOLARA-2 pivotal trial, which is expected to dose its first patient in the first quarter of 2027. Additionally, BlossomHill plans to submit an Investigational New Drug application for its pan-KRAS inhibitor, BH-501284, in the first quarter of 2027. As of September 30, 2026, the company held $224.9 million in cash and cash equivalents, which is projected to fund operations through the second quarter of 2028.Healthcare
  263. AZTRNov 12, 4:15 PMAzitra, Inc. reported a net loss of $3.0 million for the quarter ended September 30, 2026, with total operating expenses reaching $2.9 million. The company announced positive ex vivo results for its ATR-COSF program, demonstrating a 50% reduction in fine lines and improved skin elasticity, and plans to initiate a first-in-human cosmetic study with results expected by year-end. Additionally, Azitra completed Cohort 1 of its ATR-04 Phase 1/2 trial and received approval to proceed to Cohort 2, which will expand eligibility to include patients with KRAS and MEK inhibitor-associated rashes. As of September 30, 2026, the company held $3.8 million in cash and cash equivalents.Healthcare
  264. IMMXNov 12, 4:15 PMImmix Biopharma reported a 89% complete response rate across all 45 patients in its NEXICART-2 clinical trial for NXC-201, with potential for up to 98% complete response. The company appointed David He as Senior Vice President of Technical Operations and Karin McIntosh as Senior Vice President of Regulatory Affairs to advance commercial launch preparations. Immix plans to submit a Biologics License Application in mid-2027 and initiate the NEXICART-3 front-line trial in the first half of 2027. For the third quarter ended September 30, 2026, the company reported $340.9 million in cash and marketable securities, providing an operating runway into mid-2028, alongside $15.9 million in operating expenses.Healthcare
  265. HKHCNov 12, 4:15 PMHorizon Kinetics Holding Corporation reported a net loss of $18.4 million for the third quarter of 2026, driven by unrealized declines in the fair value of key investment holdings. Management and advisory fees remained flat at $17.8 million for the quarter, while assets under management decreased 7.3% to $10.0 billion. The company declared a $0.13 per share cash dividend and authorized a $25 million share repurchase program. Year-to-date results showed a net income of $35.8 million, reflecting unrealized gains that offset the quarterly losses.
  266. KLCNov 12, 4:15 PMKinderCare Learning Companies reported a net loss of $85.0 million for the third quarter of 2026, driven by $83.4 million in impairment losses and a 5.9% decline in enrollment at its early childhood education centers. Total revenue for the period decreased 1.7% to $665.3 million, while adjusted EBITDA fell to $42.5 million compared to the prior year quarter. The company closed 20 centers as part of an optimization initiative and updated its full-year 2026 revenue guidance to a range of $2.64 billion to $2.66 billion.Consumer Defensive
  267. MRLNNov 12, 4:14 PMMerlin, Inc. reported a third quarter 2026 GAAP net income of $73.8 million, a significant turnaround from the $58.4 million loss in the second quarter of 2026. Total revenue for the quarter reached $3.5 million, while the company ended the period with $161.6 million in cash, cash equivalents, and short-term investments and no outstanding debt. The company secured an $8.9 million task order from USSOCOM for its C-130J autonomy program and a $500,000 contract from USAFRICOM for an autonomous casualty evacuation demonstration. Looking ahead, Merlin plans to reduce 2027 operating expenses by focusing investment on funded programs with clear revenue paths to preserve its balance sheet.Industrials
  268. NTLANov 12, 4:14 PMIntellia Therapeutics has submitted a Biologics License Application for lonvo-z, an investigational one-time in vivo CRISPR gene editing therapy for hereditary angioedema (HAE), with a PDUFA goal date of March 10, 2027. Phase 3 HAELO trial data demonstrated a 62% reduction in mean attack rates and an 87% reduction in attack-free weeks compared to placebo, with benefits sustained for up to four years in long-term follow-up. The treatment permanently inactivates the KLKB1 gene to stop excess kallikrein production, offering a potential cure that eliminates the need for chronic long-term prophylaxis and significantly reduces the disease burden for patients.Healthcare
  269. TACTNov 12, 4:13 PMTransAct Technologies reported preliminary third-quarter 2026 net sales of $14.4 million, representing a 10% increase year-over-year driven by a 33% rise in Food Service Technology revenue. The company recorded a net loss of $440 thousand for the quarter, with adjusted EBITDA reaching $289 thousand, while revising its full-year 2026 revenue guidance to between $55 million and $56 million. Management highlighted strong growth in FST software revenue and online unit installations, though the Casino and Gaming segment experienced a decline due to cyclicality. Additionally, the Board has initiated a strategic review of the Casino and Gaming business, potentially including a sale of the FST division, to maximize stockholder value.Technology
  270. SERNov 12, 4:13 PMSerina Therapeutics reported a net loss of $7.9 million for the third quarter of 2026, driven by increased research and development expenses related to clinical activities. The company advanced its investigational Parkinson's disease treatment, SER-252, to Cohort 2 of its registrational study following a positive safety review by an independent committee. Cash and cash equivalents increased to $19.4 million as of September 30, 2026, supported by financing activities. Topline data from the single-ascending-dose portion of the SER-252 trial is expected in the first half of 2027.Healthcare
  271. SSTINov 12, 4:12 PMSoundThinking, Inc. reported third-quarter 2026 revenues of $25.0 million, a slight decrease from the prior year, while GAAP net loss widened to $8.5 million compared to $2.0 million in the same period of 2025. The company announced a definitive merger agreement with Transom Capital Group to be acquired for $8.00 per share in cash plus contingent value rights, with an expected closing in the fourth quarter of 2026. Due to the pending transaction, SoundThinking will not provide forward-looking guidance or host an earnings conference call for this quarter or future quarters. Adjusted EBITDA for the quarter totaled $2.2 million, down from $3.5 million in the previous year, driven by increased acquisition-related costs and higher operating expenses.Technology
  272. OFRMNov 12, 4:12 PMOnce Upon a Farm reported third-quarter 2026 net sales of $89.1 million, representing a 34.9% increase from the prior year period. The company posted a net loss of $3.8 million and an adjusted EBITDA loss of $1.0 million, driven by trade investments and cooler placement costs that reduced gross margin to 36.1%. As of September 30, 2026, the company held $106.4 million in cash and cash equivalents with no outstanding debt. Consequently, the company updated its full-year 2026 outlook, lowering net sales guidance to $290–$300 million and adjusting the adjusted EBITDA loss forecast to $4.5–$7 million due to the impact of a voluntary product recall.Consumer Defensive
  273. SRTSNov 12, 4:12 PMSensus Healthcare reported third-quarter 2026 revenues of $6.0 million, a 13% decrease from the prior year, driven by a shift toward lower-priced SRT-100 systems and the absence of sales to a historically large customer. Despite lower revenue, gross profit increased to $3.3 million as the gross margin improved to 55% due to a favorable product mix and lower cost of sales. The company shipped 26 systems during the quarter, including eight carried over from the previous quarter, and announced the sale of its 1,000th SRT system subsequent to the quarter end. Net loss for the period was $1.5 million, or $0.09 per share, while adjusted EBITDA improved to a negative $1.5 million from negative $2.4 million in the prior year.Healthcare
  274. BOLTNov 12, 4:11 PMBolt Biotherapeutics completed the acquisition of Prana Therapies in a stock-for-stock reverse merger and secured $120 million in concurrent private placement financing. The company has designated the INSPIRE-built pipeline, led by the Phase 2 bispecific antibody PRA-216, as its primary development focus for treating asthma, atopic dermatitis, and chronic obstructive pulmonary disease. PRA-216 Phase 1 data demonstrated the potential for at-home maintenance dosing every 8 to 12 weeks, with initial Phase 2 proof-of-concept data expected in the second quarter of 2027. For the third quarter of 2026, the company reported a net loss of $4.4 million and operating expenses of $4.7 million, while its cash runway is projected to extend into 2028.Healthcare
  275. BCDANov 12, 4:11 PMBioCardia, Inc. reported a net loss of $1.8 million for the third quarter of 2026, with total operating expenses reaching $1.8 million. The company successfully completed regulatory interactions with Japan's PMDA regarding its CardiAMP autologous cell therapy and expects to submit for approval in Japan during late 2026 or early 2027. Additionally, the FDA accepted the company's pre-submission minutes for the Helix transendocardial delivery system, with a full De Novo submission targeted for the first quarter of 2027. BioCardia ended the quarter with $2.2 million in cash and cash equivalents, providing an anticipated runway into 2027.Healthcare
  276. MGNXNov 12, 4:11 PMMacroGenics reported a net loss of $20.1 million for the third quarter of 2026, with total revenue declining to $18.7 million from $53.0 million in the same period last year. The company's cash position increased to $287.7 million as of September 30, 2026, supported by milestone payments from partners and the sale of its GMP manufacturing operations. Clinical progress included the completion of Phase 1 dose escalation for MGC028, the reporting of interim results for MGC026 and lorigerlimab at ESMO 2026, and the dosing of the first patient in the Phase 1 study for MGC030. Additionally, the Board of Directors was strengthened by the appointment of two new independent directors with oncology expertise, and Gilead Sciences exercised an option to license a preclinical bispecific program, triggering a $10 million payment.Healthcare
  277. FDMTNov 12, 4:11 PM4D Molecular Therapeutics completed enrollment and randomization for the 4FRONT-2 Phase 3 clinical trial of its lead candidate 4D-150 in wet age-related macular degeneration, with topline data expected in the second half of 2027. The company also initiated the global 4SIGHT Phase 3 trial for 4D-150 in diabetic macular edema and presented two-year data from PRISM and SPECTRA trials demonstrating durable clinical activity and a favorable safety profile. Financially, the company reported a net loss of $78.1 million for the third quarter of 2026, driven by increased research and development expenses, while maintaining a cash position of $375 million expected to fund operations through the second half of 2028.Healthcare
  278. PLRXNov 12, 4:11 PMPliant Therapeutics reported a net loss of $24.4 million for the third quarter of 2026, with research and development expenses remaining flat at $17.9 million despite the termination of its bexotegrast program. The company's lead candidate, PLN-101095, continues to enroll ahead of schedule in the FORTIFY Phase 1b trial for immune checkpoint inhibitor-refractory solid tumors, with interim data expected in 2027. Pliant also announced the appointment of David Raben as Chief Medical Officer and Craig Blanchette as Senior Vice President of Research to lead its RNAi initiatives. The company's proprietary integrin-mediated delivery platform has demonstrated over 75% target gene knockdown in non-human primate studies while avoiding liver exposure, supporting plans to target neuromuscular and cardiac diseases. As of September 30, 2026, Pliant held $142.6 million in cash and short-term investments, which is projected to fund operations through mid-2028.Healthcare
  279. ALMSNov 12, 4:11 PMAlumis Inc. reported a net loss of $94.9 million for the third quarter of 2026, driven by $80.8 million in research and development expenses and $20.2 million in general and administrative costs. The company highlighted new Phase 3 data for its lead candidate envudeucitinib in plaque psoriasis, which demonstrated rapid and durable improvements in skin clearance and itch resolution, supporting a planned New Drug Application submission in the fourth quarter of 2026. Conversely, the Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus did not meet its primary endpoints in the overall population, though robust responses were observed in a subgroup with high interferon gene signatures. As of September 30, 2026, Alumis held $431.3 million in cash and marketable securities, which is expected to fund operations through the fourth quarter of 2027.Healthcare
  280. CBUSNov 12, 4:11 PMCibus reported a net loss of $21.9 million for the third quarter of 2026, with cash used in operating activities decreasing by approximately 19% year-over-year to $9.3 million. The company advanced its Rice herbicide-tolerance traits into customer field trials in Ecuador and initiated manufacturing for two biofragrance products, which represent a potential $100 million peak annual revenue opportunity. Regulatory progress included U.S. FDA clearance for an altered-lignin Alfalfa trait and European Union legislation treating precise genomic edits as conventional breeding. Cibus anticipates exiting 2026 with an annualized net cash usage run rate of approximately $35 million, supported by a cash balance of $10.7 million as of September 30, 2026.Healthcare
  281. INVENov 12, 4:11 PMINVE Technologies reported third-quarter 2026 revenue of $3.1 million, a decrease from $5.0 million in the prior year, driven by lower RFID unit sales and the divestiture of its IoT business to Trackonomy. The company achieved a GAAP net income of $0.6 million, or $0.02 per share, compared to a net loss of $3.5 million in the same period last year, primarily due to gains recognized on the asset sale and the dissolution of a foreign subsidiary. Following the September 15, 2026, sale of its IoT business, INVE Technologies currently has no commercial revenue and has suspended financial guidance. Non-GAAP operating expenses decreased to $4.0 million from $4.5 million in the prior year, reflecting disciplined cost control despite higher strategic transaction-related costs.Technology
  282. AAWHNov 12, 4:10 PMAscend Wellness Holdings reported third-quarter 2026 net revenue of $130.0 million, representing a 4.2% year-over-year increase and a 3.1% sequential rise. The company generated $31.1 million in Adjusted EBITDA, achieving a margin of 23.9%, while net cash provided by operating activities reached $5.4 million despite a $19.1 million semi-annual interest payment. Retail operations expanded to 61 stores, exceeding the year-end target of 60, and the company maintained its position as the number two brand house across Illinois, New Jersey, and Massachusetts. Additionally, Ascend secured $11 million in non-dilutive mortgage loans and entered a brand licensing agreement to introduce its products to the Canadian market in early 2027.
  283. LFMDNov 12, 4:10 PMLifeMD reported third-quarter 2026 revenue of $44.6 million, representing a 7% decline from the prior year, while adjusting its full-year revenue guidance downward to a range of $188 million to $191 million. The company achieved an adjusted EBITDA loss of approximately $0.4 million, a significant sequential improvement driven by a 34% reduction in selling and marketing expenses. Total active subscribers grew 13% year-over-year to 350,000, and the pharmacy division saw shipment volume increase by 58.3%. Strategic developments included new dispensing agreements for branded GLP-1 medications with Novo Nordisk and Eli Lilly, as well as an exclusive partnership with AT&T to serve its customer base.Healthcare
  284. RLMDNov 12, 4:10 PMRelmada Therapeutics reported a net loss of $13.9 million for the third quarter of 2026, with research and development expenses rising to $9.2 million. The company holds approximately $202.1 million in cash and short-term investments as of September 30, 2026, which is projected to fund operations through 2029. Clinical updates indicate that 86% of patients in the NDV-01 Phase 2 study who achieved a complete response at 12 months remained in complete response at 18 months. Relmada remains on track to submit Investigational New Drug applications for both NDV-01 and sepranolone by the end of 2026, with the registrational Phase 3 SPECTRUM program for NDV-01 expected to commence upon clearance.Healthcare
  285. OPHCNov 12, 4:10 PMOptimumBank Holdings, Inc. reported net income of $7.2 million, or $0.30 per share, for the third quarter of 2026, marking an increase from the previous quarter and the same period last year. The company's gross loan portfolio grew by $150.2 million to $1.37 billion, while total deposits rose by $128.8 million to $1.34 billion during the quarter. Net interest income increased to $16.8 million, driven by higher yields on loans and securities, resulting in a net interest margin of 4.63%. Additionally, the company strengthened its capital position through a $35.0 million subordinated debt offering and maintained strong asset quality with net charge-offs of only $11,000.Financial Services
  286. UAMYNov 12, 4:10 PMUnited States Antimony Corporation reported third-quarter 2026 revenues of $10.1 million, a 16% increase from the prior year, driven by a 68% rise in antimony pounds sold. The company achieved a gross profit margin of 42%, up from 23% in the previous year, resulting in $4.3 million in gross profit despite a net loss of $9.5 million due to non-cash stock-based compensation and an unrealized loss on an equity investment. Antimony sales included approximately 162,000 pounds of metal ingots accepted by the Defense Logistics Agency, contributing $5.1 million in revenue, while industrial sales volumes increased 10% year-over-year. The company provided full-year 2026 guidance for antimony sales volumes between 1.68 million and 1.81 million pounds, representing a 24% increase over 2025, and maintained significant liquidity with $51.0 million in cash and U.S. Treasury securities.Basic Materials
  287. PEWNov 12, 4:10 PMGrabAGun Digital Holdings reported third-quarter 2026 net revenues of $21.2 million, a 4.7% decrease from the prior year, driven by lower firearms and non-firearms sales. Despite the revenue decline, the company achieved a 44% increase in gross profit and expanded its gross margin by 480 basis points to 14.4%, supported by improved average selling prices and sourcing. The company posted a net loss of $3.0 million for the quarter and $6.7 million for the first nine months, while maintaining $96.0 million in cash and minimal debt. Subsequent to the quarter, GrabAGun completed the acquisition of Camfour, a New England-based wholesale distributor, to broaden its distribution capabilities.Industrials
  288. FLNTNov 12, 4:10 PMFluent, Inc. reported third-quarter 2026 revenue of $53.6 million, a 14% increase year-over-year, driven by Commerce Media Solutions revenue doubling to $37.5 million. The company's Commerce Media Solutions segment now accounts for 70% of total revenue with an annual run rate exceeding $145 million and a gross margin of 30%. Net loss for the quarter narrowed to $3.1 million from $7.6 million in the prior year period, while adjusted EBITDA reached near-breakeven at $0.0 million. Fluent expects full-year 2026 to deliver double-digit revenue growth on aggregate continuing businesses and improved adjusted EBITDA.Communication Services
  289. SMTINov 12, 4:10 PMSanara MedTech Inc. reported third-quarter 2026 net revenue of $28.4 million, an 8% increase from the prior year, driven by growth in soft tissue repair products. The company posted a net loss from continuing operations of $1.3 million, or $0.15 per diluted share, compared to a net income of $0.8 million in the same period last year. Adjusted EBITDA for the quarter rose to $5.6 million, while the company updated its full-year 2026 revenue guidance to a range of $110 million to $115 million. Additionally, Sanara continues to advance its pending merger with MiMedx Group, Inc., which received shareholder approval in September.Healthcare
  290. SNALNov 12, 4:10 PMSnail, Inc. reported third-quarter 2026 net revenues of $33.1 million, representing a 139.2% increase from the prior year period, driven primarily by strong sales of ARK: Survival Ascended and its downloadable content. The company achieved a net income of $6.7 million for the quarter, a significant turnaround from a net loss of $7.9 million in the same period last year, while total units sold rose 73.3% to 2.0 million. Key operational highlights included the launch of new ARK content updates, the release of titles such as Bellwright and Honeycomb: The World Beyond, and the unveiling of upcoming AAA projects like 9 Yin Sutra and For The Stars. Looking ahead, Snail expects continued momentum from its established ARK content pipeline extending through 2027 and the anticipated release of ARK: Dragontopia in December 2026.Communication Services
  291. EQNov 12, 4:10 PMEquillium, Inc. initiated a Phase 1 clinical trial for its investigational drug EQ504 in October 2026, with proof-of-mechanism data expected in the second quarter of 2027. The company reported cash and cash equivalents of $53.3 million as of September 30, 2026, and secured an additional $20 million in financing later that month, extending its cash runway into 2029. For the third quarter of 2026, Equillium recorded a net loss of $4.6 million, driven by research and development expenses of $2.5 million and general and administrative expenses of $2.6 million. EQ504 is a selective aryl hydrocarbon receptor modulator designed to treat ulcerative colitis and other inflammatory disorders through a non-immunosuppressive mechanism.Healthcare
  292. LCTXNov 12, 4:10 PMLineage Cell Therapeutics reported a net income of $4.2 million for the third quarter of 2026, driven primarily by a non-cash gain from the fair value remeasurement of warrant liabilities. The company acquired NeuroAirmid Therapeutics, adding the HUNT1 clinical-stage cell therapy candidate for Huntington's Disease to its pipeline, and secured a U.S. patent for its AlloSCOPE 5D manufacturing technology. Financial results showed total revenues of $1.4 million and operating expenses of $8.8 million, with cash and marketable securities totaling $45.2 million expected to fund operations through the second quarter of 2028. Key program updates include the advancement of the ReSonance hearing loss therapy into the second year of its collaboration with William Demant Invest and the initiation of preclinical testing for the COR1 corneal endothelial disease program.Healthcare
  293. ELDNNov 12, 4:10 PMEledon Pharmaceuticals reported a net loss of $3.9 million for the third quarter of 2026, driven by $17.8 million in research and development expenses, while maintaining $69.7 million in cash and short-term investments sufficient to fund operations into the second quarter of 2027. The company received FDA Fast Track designation for tegoprubart in kidney transplantation and cleared an IND application for a registrational study in islet cell transplantation for type 1 diabetes. Clinical updates included new patient-reported outcome data showing improved quality of life and symptom burden for tegoprubart compared to tacrolimus in kidney transplant recipients, alongside long-term data demonstrating sustained eGFR advantages. Upcoming milestones include the initiation of the global Phase 3 LEGACY trial for kidney transplantation in the fourth quarter of 2026 and the start of a registrational path study for islet cell transplantation.Healthcare
  294. RKDANov 12, 4:09 PMArcadia Biosciences reported third-quarter 2026 total revenues of $1.619 million, representing a 24% year-over-year increase driven by strong summer program volumes. The company achieved net income of $1.755 million for the quarter, a significant improvement from the $856,000 net income recorded in the same period of 2025, largely due to a $2.6 million gain from changes in the fair value of warrant and option liabilities. Zola brand revenues reached their highest quarterly sales ever, with a new 1-liter espresso formulation beginning shipments and slim can variants scheduled for launch in early 2027. Operating expenses for the nine-month period decreased by 23% compared to the prior year, offset by a $2.7 million reduction in other operating income related to the absence of prior-year patent transfer gains.Consumer Defensive
  295. ACCVNov 12, 4:08 PMAccelevation Holdings Corp. reported third-quarter 2026 revenue of $202.2 million, representing a 65.9% year-over-year increase, while bookings surged 364% to $768.9 million. The company achieved a backlog of $1.7 billion and an adjusted EBITDA of $37.7 million, with operating cash flow turning positive to $62.5 million. Following its initial public offering in October 2026, the company entered into a new $650 million senior secured credit agreement to reduce leverage. Management has issued full-year 2026 guidance projecting revenue between $905 million and $915 million and adjusted EBITDA between $155 million and $165 million.Industrials
  296. REKRNov 12, 4:08 PMRekor Systems reported a net loss of $2.9 million for the third quarter of 2026, narrowing from $4.1 million in the prior year period, while recurring revenue grew 16% to $7.5 million. The company reduced its nine-month operating cash use by 49% to $10.6 million following a major rightsizing initiative that eliminated approximately $9.7 million in lease liabilities. Recent business developments include a potential $1.4 million five-year contract with the Oregon Department of Transportation and a 94% increase in the contract ceiling with the Florida Department of Transportation. Additionally, Rekor expanded its Born Authentic product line to include audio authentication and is actively pursuing refinancing for its $15 million Series A Prime Revenue Sharing Notes due in December 2026.Technology
  297. ERASNov 12, 4:08 PMErasca, Inc. reported a net loss of $51.3 million for the third quarter ended September 30, 2026, while maintaining a cash position of $947.8 million. The company's lead candidate, ERAS-0015, received FDA Fast Track Designation for metastatic pancreatic adenocarcinoma in August 2026. Erasca is advancing toward three potentially registration-enabling trials in pancreatic and lung cancers, with preliminary data for ERAS-4001 expected in the second half of 2026. Additionally, the firm completed an upsized public offering in July 2026 that raised approximately $632.5 million to fund its development pipeline.Healthcare
  298. OBXNov 12, 4:07 PMObsidian Therapeutics reported third-quarter 2026 financial results showing a net loss of $50.7 million and cash reserves of $324.4 million as of September 30, 2026. The company presented updated efficacy data for its lead candidate amsoki-cel in advanced melanoma, demonstrating a 67% objective response rate and a median progression-free survival of 8.3 months in the registration-enabling cohort of the Agni-01 study. Enrollment in this cohort is expected to conclude by the end of the first quarter of 2027, with topline data anticipated by the end of 2027. Corporate updates include the completion of a $350 million financing round, the closing of a transaction with Galera Therapeutics, and the appointment of Mark Reisenauer to the Board of Directors.Healthcare
  299. SHIMNov 12, 4:07 PMShimmick Corporation reported a net income of $1 million for the third quarter ended October 2, 2026, marking its first positive net income since the third quarter of 2023. Revenue for the quarter reached $136 million, driven entirely by Shimmick Projects which saw a 28% increase quarter-over-quarter, while Adjusted EBITDA rose 106% to $9 million. The company's liquidity increased by $20 million to $53 million, and its backlog stands at approximately $907 million with Shimmick Projects representing 98% of the total. Management reaffirmed full-year 2026 Adjusted EBITDA guidance between $20 million and $25 million and raised revenue expectations to a range of $500 million to $525 million.Industrials
  300. IDNNov 12, 4:07 PMIntellicheck reported a net income of $0.5 million for the third quarter of 2026, marking its fifth consecutive quarter of profitability. Revenue for the period totaled $5.7 million, while Adjusted EBITDA increased to $0.9 million, representing the sixth consecutive quarter of positive performance. The company ended the quarter with $13.2 million in cash and no debt, its highest cash balance since the end of 2021. Banking and lending remained the fastest-growing vertical, with momentum also observed in emerging sectors such as cargo, freight, and automotive credit.Technology

Earnings Call Transcripts

More →
  1. MLKNINTAPP, INC Annual Meeting of Stockholders - MILLERKNOLL INC The company held its annual stockholder meeting on September 22, 2026, with 76,694,785 shares outstanding and 89% of voting power represented. Three key governance proposals were voted on: the election of Class III directors Martine Finchner and John Hall, the ratification of Deloitte & Touche LLP as the independent auditor for fiscal 2027, and an advisory vote on executive compensation. The meeting adopted a digital format to enhance accessibility and concluded with a brief session for stockholder questions, with final results to be reported in a Form 8-K within four business days. No financial metrics, business segment data, or forward-looking guidance were disclosed during the proceedings. 1d ago
  2. PHINSTEPHENS ANNUAL INVESTMENT CONFERENCE | NASH2026 - PHINIA INC Finia's Q3 revenue growth and increased guidance are driven by the Stoba acquisition and strong performance in its resilient aftermarket segment, which now accounts for approximately 36% of total revenue. The company is strategically diversifying beyond light passenger vehicles to target GDP-plus growth by expanding its aerospace, defense, and off-highway portfolios while leveraging its propulsion-agnostic technology to adapt to various fuel types. Management aims to increase market capitalization to $3-4 billion through disciplined capital allocation, including share buybacks and opportunistic M&A, while reducing cyclicality by capitalizing on an aging global vehicle fleet and tightening emissions regulations. 1d ago
  3. TIGJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - TIGENIX NV The company is investing approximately ¥100 billion in commercial activities to support the full-year launch of three new products while executing a cost-saving transformation program to fund these efforts. Net debt is targeted to decrease from 2.5x to 2.0x before the U.S. entry of a biosimilar, and operating margins are being protected in the current phase with profit accretion expected only after new assets reach scale. Key pipeline assets include Mimrylo and Zurzo, which are already performing well, and Zazacitinib, which is pending approval for psoriasis and undergoing evaluation for inflammatory bowel disease indications. 1d ago
  4. ADUSSTEPHENS ANNUAL INVESTMENT CONFERENCE | NASH2026 - ADDUS HOMECARE CORP The company reported strong financial results in 2026 across Personal Care Services, Home Health, and Hospice, with the Home Health division returning to growth and Hospice achieving high-single-digit organic expansion. Management projects 2027 revenue growth driven by a 2.4% national rate increase for Home Health, the anticipated $280 million annual contribution from the AccentCare acquisition, and strategic efforts to increase the clinical service revenue mix to 25-30%. Primary operational focus includes overcoming caregiver supply constraints through technology-enabled scheduling efficiency and a bridge program designed to cross-sell clinical services to Personal Care clients. The organization maintains a clean balance sheet with leverage near 1.0x, positioning it to pursue additional mergers and acquisitions while navigating a favorable regulatory environment. 1d ago
  5. COGTJeffries Global Healthcare Conference in London - COGENT BIOSCIENCES INC The company is transitioning from an R&D organization to a commercial entity with a pre-revenue status, focusing on the imminent launch of its lead asset, bezuclastinib. This selective KIT inhibitor targets advanced systemic mastocytosis, non-advanced systemic mastocytosis, and imatinib-resistant GIST, with pending PDUFA action dates scheduled for late 2026 and mid-2027. Clinical data indicates significant efficacy in the GIST segment when combined with sunitinib and potential advantages over competitors in the SM segment regarding central nervous system toxicity. Despite investor concerns over potential liver toxicity warnings, management maintains confidence in the drug's safety profile and has established a unified commercial strategy with a dedicated sales force to address both indications. 1d ago
  6. CRNXJefferies Global Healthcare Conference in London - CRINETICS PHARMACEUTICALS INC Vertex Pharmaceuticals projects non-Cystic Fibrosis revenue exceeding $500 million annually starting in 2026, driven by the acquisition of Krenetics and the launches of Gernavix and Casgevy. The company is advancing a renal-focused pipeline with povitacicept awaiting a PDUFA decision for IgA nephropathy and anaxiplin targeting APOL1-mediated kidney disease, while aiming to secure global regulatory approvals through a 2-year EGFR endpoint. Strategic initiatives include leveraging a large commercial field force, partnering with Ono Pharma and ZaiLab for international markets, and addressing pricing pressures via external partners to maintain flexibility. 1d ago
  7. NVAXNOVAVAX, INC. - JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - NOVAVAX INC The company secured a $30 million upfront payment from Pfizer and a $125 million milestone from Sanofi for a combination COVID-flu vaccine, with potential for an additional $225 million upon the first U.S. commercial sale. Operating expenses have been reduced by 80–90% while maintaining research capabilities, positioning the firm to achieve non-GAAP profitability by 2029 with a lean cost structure. The organization is transitioning from a single-asset commercial model to a technology platform strategy, leveraging its MatrixM adjuvant for partnerships in infectious diseases and early-stage oncology exploration. 1d ago
  8. ALLNDATABRICKS CEO: AGI IS ALREADY HERE, WHY COMPANIES ARE BEHIND, AND THE SUPERINTELLIGENCE DEBATE - All-In Podcast Databricks projects reaching a $7 billion revenue run rate by August 2026, driven by an 80% year-over-year growth rate fueled by enterprise adoption of agentic AI. The company differentiates itself by solving data sovereignty and context challenges, allowing organizations to deploy AI agents without exposing sensitive information to public models. While token costs are rising exponentially, Databricks aims to maintain margins through cost-optimization tools and model routing strategies. Management forecasts a 10-15 year timeline for full AI integration into core enterprise operations, citing organizational inertia as a primary constraint on immediate transformation. 1d ago
  9. SPECIAL MEETING OF STOCKHOLDERS - SYNAPTICS INCORPORATED Synaptics stockholders convened on November 17, 2026, to vote on a proposed merger where Sonic Acquisition Corp. will merge into Synaptics, making it a wholly owned subsidiary of On Semiconductor Corporation. The Board of Directors and CEO Rahul Patel unanimously recommended approval, stating the transaction is in the best interest of the company and its stockholders. All three proposals were addressed, with the merger agreement and advisory compensation approval passing, while the adjournment proposal was declared moot. Dissenting stockholders were informed of their right to seek appraisal under Delaware General Corporation Law Section 262. Final voting results are expected to be reported via a Form 8-K within four business days. 1d ago
  10. PRKAnnual Meeting of Stockholders - PARK NATIONAL CORP The 2026 Annual Meeting of Shareholders served as a procedural record for corporate governance matters rather than a financial earnings call. During the event, directors Eileen Owen and Jan Sternreid were elected, Deloitte & Touche LLP was ratified as auditors, and executive compensation was approved. Chairman Howard Donnelly retired following the company's transformation, with incoming Chair Eileen Owen expressing strong confidence in the future leadership of new CEO Eric Honroth. The meeting concluded with the amendment of the 2020 Equity Incentive Plan, and the results are scheduled to be filed on Form 8K within four business days. 1d ago
  11. NKENIKE, Inc. Investor Day 2026 - NIKE INC Nike projects FY27 revenue to decline in the high single-digit range due to deliberate inventory and marketplace resets, with growth expected to return to market pace by FY29 and accelerate thereafter. The company aims to generate $5 billion in incremental revenue by FY31 while expanding operating income margins to 12–14% through $2.5 billion in PACE savings and improved marketplace health. Strategic initiatives include diversifying beyond legacy franchises like Air Force 1 and Jordan, focusing on performance sports and localized innovation in key markets such as China and India, and returning $12 billion to shareholders via dividends through FY31. 1d ago
  12. CRNXJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - CRINETICS PHARMACEUTICALS INC The company projects non-CF revenue exceeding $500 million in 2026, driven by the Krenetics acquisition and launches of Gernavix and Casgevi, with continued growth anticipated through 2027. A definitive PDUFA decision for the kidney therapy povitacicept is expected on November 30th, while multiple clinical data readouts for anaxiplin, suzetrogene, and DM1 are scheduled for 2026 and 2027. Management is executing a renal renaissance strategy to diversify beyond cystic fibrosis, leveraging an 80% patient services utilization rate and strategic partnerships in Japan and China to support a pipeline of four disease-modifying kidney therapies. 1d ago
  13. ADUSSTEPHENS ANNUAL INVESTMENT CONFERENCE | NASH2026 - ADDUS HOMECARE CORP AddisCare delivered strong financial performance in 2026 across its Personal Care, Home Health, and Hospice segments, with no significant negative impact from OB3 or Medicaid work requirements. The company expects to close the AccentCare transaction in February 2027, adding approximately $280 million in annual revenue while maintaining a leverage ratio of 1.0x. Long-term growth targets include 3-5% annual organic growth, with specific plans to increase the clinical services portion of the business to 25-30% and achieve upper-80s fill rates in Personal Care through technology integration. 1d ago
  14. PSQHEVENTS WILL COME IN WAVES ONE AFTER ANOTHER, SMALL ATTACKS HERE AND THERE, BUILDS INTO MAJOR EVENT - PSQ HOLDINGS INC The content describes a forecast of imminent systemic failures including the collapse of power grids, internet, banking, and communication networks in the United States. It predicts a timeline of events for mid-November involving emergency alerts and widespread civil unrest, alongside claims of coordinated cyber attacks orchestrated by a shadowy government elite. The narrative urges individuals to prepare for a prolonged period of societal collapse by stockpiling resources, fleeing major urban centers, and avoiding specific political regions. 1d ago
  15. LMNDLemonade Investor Day 2026 - LEMONADE INC Lemonade projects its first full-year GAAP operating cash flow positivity in 2026, with EBITDA expected to turn positive in 2027 and net income in 2028. The company's revenue and in-force premium are on a trajectory to double approximately every 2.5 years, driven by an AI-native operating system that automates 80% of customer service interactions and 70% of claims. By prioritizing long-term compounding over short-term harvesting, Lemonade aims to reach $10 billion in in-force premium and $1 billion in EBITDA by 2032-2033 while maintaining industry-leading loss ratios and cost efficiencies. 1d ago
  16. NAVITD COWEN 2026 FINANCIALS & FINTECH CONFERENCE - SLM Corporation The company reported full-year originations growth of 12-14%, driven by a doubling of graduate lending originations following the elimination of federal caps. Net charge-offs increased by approximately $45 million due to operational adjustments and specific delinquent groups, though this remains within the annual budget. Management anticipates originations could eventually grow up to 70% as new federal regulations phase in, with loan sales expected to resume as a key funding pillar in 2027. 1d ago
  17. ALXOALX Oncology - UBS Global Biopharma Conference - ALX ONCOLOGY HOLDINGS INC The company reported sufficient cash reserves to sustain operations through mid-2028 following a $150 million capital raise in January. It is currently advancing two clinical candidates, ALX2004 and EvorPRECEP, with Phase 1 data for the EGFR ADC expected in early December and Phase 2 data for the CD47 inhibitor projected for late 2027. Management aims to initiate two registrational studies within the next 12 months by targeting specific biomarker-driven populations in head and neck, non-small cell lung cancer, and HER2-positive metastatic breast cancer. 1d ago
  18. TXG10X GENOMICS, INC. JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - 10X GENOMICS INC The company's single-cell consumables revenue grew mid-single digits sequentially in Q3, driven by robust demand despite the launch of the new Terra platform. Terra instruments are experiencing significant backlog due to manufacturing and field service constraints, with management targeting 50 sales by year-end and a ramp to 50 units per quarter by Q1. While the strategic shift to the lower-cost Apex platform temporarily compresses average reaction pricing, the company anticipates equilibrium within a few quarters as volume increases. Management projects Terra will become the primary workhorse for large-scale spatial biology and AI foundation model training, with initial orders attracting a diverse mix of new customers beyond existing spatial biology users. 1d ago
  19. WGSJefferies Global Healthcare Conference in London - GENEDX HOLDINGS CORP The company is on track to deliver nearly 30% total volume growth for the year, with Q3 sample sessions increasing by 25% and average selling prices rising mid-single digits. Gross margins remain solidified in the 30s range as the business achieves profitability, driven by improved genome collection rates and a strategic shift from Exome to Genome sequencing. Management expects further sequential ASP growth in Q4 and anticipates that a multi-year revenue cycle transformation will align sample submissions with report volumes, eventually bridging the gap between high payer coverage rates and current collection rates. Long-term growth strategies include expanding into general pediatrics and the NICU segment, aiming to reduce the average age of rare disease diagnosis from 14 years to 5 years. 1d ago
  20. INGRSTEPHENS ANNUAL INVESTMENT CONFERENCE | NASH2026 - INGREDION INC The Argo plant's operational issues resulted in a $40 million operating income loss in Q1 2025 and are projected to cost another $40 million for the full year, with yields expected to lag industry averages by approximately 5 percentage points in the near term. Despite these challenges, the Texture and Healthful Solutions segment has recorded ten consecutive quarters of volume growth while the company anticipates $130 million in annual synergies from its planned acquisition of Tate & Lyle, which is targeted to close in the second half of 2026. Corporate operating income is forecast to improve in 2026 and 2027 as maintenance costs normalize and Argo yields recover, supporting a strategic pivot toward sustainable packaging and high-value health solutions. 1d ago
  21. PRKAnnual Meeting of Stockholders - PARK NATIONAL CORP The company held a virtual annual shareholder meeting on October 6, 2026, where three proposals were approved: the election of eight directors, advisory approval of executive compensation, and the ratification of KPMG LLP as the independent auditor for fiscal 2027. The newly formed board includes executives with backgrounds in the semiconductor and technology sectors from companies such as TSMC, AMD, and Cisco. No financial metrics, forward-looking guidance, or operational details were disclosed during the proceedings, which focused exclusively on corporate governance and voting procedures. The meeting transcript contains an inconsistency, referring to the entity by two different names, Standis Corporation and Sandys Corporation. 1d ago
  22. SNDKANNUAL MEETING OF STOCKHOLDERS - SANDISK CORP Standis Corporation held its virtual Annual Meeting of Stockholders on September 21, 2026, where shareholders approved the election of eight new directors, the advisory compensation of named executive officers, and the ratification of KPMG LLP as the independent registered public accounting firm for fiscal 2027. The meeting was conducted procedurally by CEO David Gekler, who addressed logistics and voting protocols without providing financial performance data, business segment updates, or future growth guidance. All three proposals received favorable preliminary voting results, with final vote tabulation and Form 8K filings scheduled to occur within four business days. 1d ago
  23. POWLPowell Industries Fiscal 2026 Q4 Earnings Conference Call - POWELL INDUSTRIES INC Fiscal 2026 revenue reached a record $1.3 billion, driven by a 124% year-over-year increase in new orders to $2.6 billion and a backlog growth to $2.7 billion. The company reported diluted earnings per share of $6.04 for the full year and expanded its gross margin to 31.3%, supported by strong project execution and favorable closeouts. Management projects fiscal 2027 revenue growth fueled by a balanced backlog mix, with capacity expansions in Ohio, Texas, and Jacinto Port expected to support over $100 million in incremental annualized revenue. Key growth drivers include the LNG sector, electric utility projects, and a strategic shift toward configured-to-order models in the commercial and data center markets. 1d ago
  24. STOKJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - STOKE THERAPEUTICS INC The company is advancing Zirivenersen, an antisense oligonucleotide targeting Dravet syndrome, through a Phase III clinical trial with 162 patients and zero dropouts. Primary data readouts for the pivotal study are expected in the third quarter of the following year, with the trial powered to detect a 46% treatment difference in seizure reduction. Unlike current therapies that only reduce seizures, Zirivenersen aims to address the root cause of the condition by upregulating the NAV1.1 protein to improve neurodevelopmental cognition and behavior. Management has secured FDA agreement to use a composite MC4 cognitive scoring method to evaluate the drug's multi-domain effects, moving away from previously proposed hierarchical testing requirements. 1d ago
  25. OCSLOCSL 4Q2026 Earnings Call - OAKTREE SPECIALTY LENDING CORP In the fourth fiscal quarter, adjusted net investment income decreased to $29.6 million per share, while full-year 2026 adjusted net investment income totaled $131.7 million. The company declared dividends of $1.39 per share for the year, representing 108% of its adjusted net investment income, and maintained net leverage at 1.00x. Non-accruals in the debt portfolio were reduced by 44% to 1.8% of total fair value, driven by the resolution of specific credit issues and the restructuring of BioXL Therapeutics. Looking ahead, management anticipates that recent Federal Reserve rate hikes will positively impact net investment income starting in the December quarter, with 91% of debt investments floating or swapped. 1d ago
  26. PCVXVaxcyte Inc - 1781026 - VAXCYTE INC Scribe Therapeutics is a pre-revenue clinical-stage biotechnology company utilizing two distinct platforms, Elixir and X-Editor, to develop curative therapies for cardiovascular diseases. The company's lead program employs epigenetic silencing to lower LDL-C, while its genome editing programs target Lp(a) and triglycerides with the goal of achieving long-lasting, one-time treatments. Recent IPO funding and grants support the advancement of these programs toward Phase 1 clinical trials, which aim to address the limitations of current chronic dosing therapies by offering durable, preventative solutions. 1d ago
  27. ALLNEarnings Call Databricks is a private company projecting an annual revenue run rate of approximately $7 billion by August 2026, driven by an 80% year-over-year growth rate fueled by consumption-based pricing for data governance and security. The company differentiates itself by focusing on the integration of AI with legacy enterprise data and security rather than building foundational models, with a strategic roadmap centered on its Genie AI agent system for automating organizational intelligence. Management anticipates a slow macroeconomic adoption curve for AI, estimating a 10 to 15-year timeline for significant GDP impact, while prioritizing long-term execution over immediate public market entry. 1d ago
  28. SNDKSANDISK CORPORATION ANNUAL MEETING OF STOCKHOLDERS - SANDISK CORP The 2026 Annual Stockholder Meeting served as a procedural record focused exclusively on corporate governance and voting matters. Eight directors were elected, and stockholders unanimously approved executive compensation on an advisory basis while ratifying KPMG LLP as the independent registered public accounting firm for fiscal 2027. The meeting featured no financial performance data, forward guidance, or analyst Q&A sessions, with the CEO facilitating an orderly administrative process. Final voting results are scheduled to be filed in a Form 8K within four business days following the event. 1d ago
  29. NBIXJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - NEUROCRINE BIOSCIENCES INC Neurocrine Biosciences has diversified its revenue model, with commercial sales annualizing at approximately $4.5 billion driven by Ingresa and Chronicity, reducing reliance on a single product to 30% of total revenue. The company anticipates double-digit volume growth for Ingresa through 2028 despite modest IRA-related price concessions, while 2027 is identified as a critical catalyst year for multiple Phase 3 readouts including Osevamator for major depressive disorder. Strategic initiatives include transitioning to a next-generation oral VMAT2 inhibitor and long-acting injectables for tardive dyskinesia, alongside pediatric expansion for Chronicity in congenital adrenal hyperplasia to maintain market leadership against potential competitors. 1d ago
  30. ZVIASTEPHENS ANNUAL INVESTMENT CONFERENCE | NASH2026 - ZEVIA PBC The company has established a solid financial foundation with a base adjusted EBITDA margin of approximately 5% and is executing a $20 million cost reduction initiative. Management plans to transition from a defensive optimization strategy to an aggressive growth offensive in 2027, prioritizing single-serve formats and e-commerce expansion to unlock significant market share. Recent partnerships and packaging modernization have strengthened brand visibility, while the business aims to capitalize on white space in club stores and mass merchandisers without requiring further price increases. 1d ago
  31. BOOTBoot Barn Holdings at Stephens Annual Investment Conference | Nash2026 - BOOT BARN HOLDINGS INC The company reported revenue growth driven by strong performance in Western wear, work boots, and apparel, with the work category seeing double-digit comparable sales increases. Merchandise margins expanded due to exclusive brand sourcing efficiencies and third-party pricing strategies, supporting an expected operating margin of 13.3% to 14.0% and a long-term target of 15%. Store opening guidance was raised to 75-80 locations for the fiscal year, while the Workforce B2B segment is projected to grow rapidly through digital platform digitization. Management forecasts continued merchandise margin expansion and plans to return the majority of future free cash flow to shareholders via accelerated share repurchases. 1d ago
  32. OLMAUBS Global Biopharma Conference - OLEMA PHARMACEUTICALS INC The company is developing palazestrin, an oral selective estrogen receptor degrader, targeting both ESR1 mutant and wild-type metastatic breast cancer populations with a combined market opportunity of $5 billion. Phase III trials are underway, with OPERA-01 evaluating the drug as a monotherapy in second- and third-line settings and APRO-02 assessing it in combination with ribociclib for first-line treatment. Management anticipates readouts for the second- and third-line study in the first quarter of next year, aiming to demonstrate statistically significant efficacy in the 60% of patients who are ESR1 wild-type, a segment where competitors have previously failed. 1d ago
  33. OLMAOlema Oncology - 1781054 - OLEMA PHARMACEUTICALS INC Alema Pharmaceuticals is developing palazestrin, a selective estrogen receptor degrader, for metastatic breast cancer with primary Phase III data expected in Q1 2027. The company targets both ESR1 mutant and wild-type populations, aiming to be the first agent to demonstrate statistically significant activity in the wild-type subset where competitors have previously failed. Strategic partnerships with Novartis support a first-line combination study, while management anticipates that positive second-line results will significantly increase the probability of success in adjuvant settings. 1d ago
  34. ABCLAbCellera - 1782193 - ABCELLERA BIOLOGICS INC The company transitioned from a service-based model to a traditional biotech development strategy in 2023, focusing on its lead asset ABCL635, a first-in-class NK3R antagonist for treating menopausal hot flashes. Recent Phase 2 data demonstrated an approximately 80% reduction in hot flash frequency and a 50% reduction compared to placebo, with efficacy and safety profiles superior to current small-molecule competitors like Veozah and Linbit. The company plans to initiate Phase 3 trials for Menopausal Vasomotor Symptoms in mid-2027, targeting a once-monthly 300mg auto-injector dose, while also developing a half-life extended analog, ABCL992, to lower manufacturing costs and enable self-pay models in international markets. 1d ago
  35. ABCLAbCellera - 1782193 - ABCELLERA BIOLOGICS INC The company recently raised $1.5 billion via an IPO to transition from a service-based model to a capital-intensive biotech focused on developing proprietary assets. Its lead asset, ABCL635, is a first-in-class antibody antagonist showing approximately 80% reduction in hot flash frequency in Phase 2 trials, with Phase 3 initiation targeted for mid-to-late 2027. Management plans to advance the drug independently to retain value, targeting a market of 12 million US women with vasomotor symptoms while leveraging a superior safety profile compared to existing small molecule competitors. 1d ago
  36. IMCRUBS Global Biopharma Conference - IMMUNOCORE HOLDINGS PLC Immunocore maintains strong liquidity with over $900 million in cash while its ChemTrack therapy for uveal melanoma achieves over 70% market penetration and a stabilized treatment duration of approximately 14 months. The company is advancing a combination therapy of ChemTrack and Bernanfusp, which demonstrated superior efficacy over monotherapy in Phase 1 data, and is conducting a Phase 3 Tebiam study for metastatic melanoma with registration data expected in Q2 2027. Future development includes an HIV program targeting functional cure with high-dose safety data anticipated in 2026 and a Type 1 Diabetes initiative aiming to preserve C-peptide levels, with plans to partner in non-oncology sectors while retaining oncology assets in-house. 1d ago
  37. XERSXERIS BIOPHARMA HOLDINGS, INC. Jefferies Global Healthcare Conference in London - XERIS BIOPHARMA HOLDINGS INC The company has raised its full-year 2024 revenue guidance to $395–$405 million, driven by RecorLiv sales reaching approximately $71 million and maintaining profitability with 88% gross margins. It has updated its 2030 revenue outlook to over $1 billion, accelerating the projected timeline for RecorLiv to reach $1 billion in sales to 3–4 years. Strategic focus includes expanding market access for RecorLiv and Gvoke through updated clinical guidelines, initiating Phase 3 trials for the hypothyroidism product 8121 by year-end, and evaluating business development activities supported by strong cash flow. 1d ago
  38. LQDAJefferies Global Healthcare Conference in London - LIQUIDIA CORP The company achieved over 30% market share in the PAH inhaled prostacyclin market by September 2026 and entered Q4 2026 with approximately $400 million in cash reserves. It has committed to net settlement payments totaling $380 million to United Therapeutics, with the final payment due in April 2027, removing all future royalty obligations. The firm plans to initiate 10 clinical trials by late 2027, including three registrational studies for L606 in PH-COPD, PH-ILD, and systemic sclerosis, while aiming to complete enrollment for the L606 Amplify PAH study by 2028. Management projects over 50% operating margins by 2027 and intends to establish L606 as the dominant treatment for PAH while positioning Eutrepia for niche indications like systemic sclerosis. 1d ago
  39. SYRESPYRE THERAPEUTICS, INC. JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - SPYRE THERAPEUTICS INC Spire is a pre-revenue biotechnology company developing co-formulated long-acting antibody therapies for Inflammatory Bowel Disease and Hidradenitis Suppurosa. The company has enrolled over 600 patients in its pivotal Phase 2 combination study and expects to read out primary data for three pairwise combinations in the third quarter of next year. Spire aims to capture market share in the $40 billion IBD sector by offering products with superior efficacy and convenience compared to current monotherapies. Management plans to advance multiple combination therapies to Phase 3, targeting a biologic-like price point to compete against established players like AbbVie and J&J. 1d ago
  40. ENREnergizer Holdings, Inc. Fourth Quarter and FY 2026 Results - ENERGIZER HOLDINGS INC Energizer reported a 13% increase in full-year 2026 adjusted EBITDA and a 30% rise in adjusted EPS, with free cash flow tripling to approximately $229 million. The company is transitioning from a cost-reduction transformation phase to a sustainable growth strategy, projecting fiscal 2027 EBITDA between $560 million and $580 million while exiting lower-margin private label business in the Auto Care segment. Despite anticipated cost pressures of 200 to 300 basis points, management expects gross margins to remain stable near 40% through targeted pricing and cost savings. Long-term goals include normalizing capital expenditures to 2% of revenue and achieving healthy single-digit organic growth by 2028 as the portfolio evolution in super-premium segments matures. 1d ago
  41. XERSJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - XERIS BIOPHARMA HOLDINGS INC The company raised its full-year revenue guidance to $395–$405 million, driven by approximately $71 million in third-quarter Recorlev sales. It has increased its 2030 revenue outlook to over $1 billion, with Recorlev projected to reach peak sales of $1 billion within three to four years. The company is expanding its commercial footprint for Recorlev and G-Voke while initiating a Phase 3 trial for its hypothyroidism product, 8121, with approval expected by 2030. 1d ago
  42. KITTNauticus Robotics 2026 Q3 Earnings Call - NAUTICUS ROBOTICS INC In the third quarter of 2026, the company reported revenue of $2.2 million and a net loss of $4.9 million, reflecting improved financial performance driven by disciplined cost management and reduced non-cash debt extinguishment losses. Strategic initiatives focus on transitioning from short-term tactical contracts to long-term agreements in offshore wind, subsea cable laying, and defense sectors, with specific growth anticipated in the Gulf of America market during 2027. The organization is advancing its Nauticus Toolkit integration and Aquanaut autonomous platform while finalizing regulatory approvals for a new manufacturing hub in the UAE to support regional commercial and defense demands. 1d ago
  43. TWSTTwist Bioscience Corporation at Jefferies Global Healthcare Conference in London - TWIST BIOSCIENCE CORP Twist Bioscience achieved $590 million in revenue for 2026, representing a 175% year-over-year increase from $210 million in 2025, while reaching EBITDA break-even for the first time. The company's AI drug discovery segment generated $59 million in 2026 and is guided to exceed $100 million in 2027, supported by a shift from lumpy pilot orders to recurring production revenue. With a total addressable market expanding to $7 billion and a long-term target of $13 billion, Twist plans to invest $150 million in manufacturing capacity over the next two years to address current supply constraints and support triple-digit growth in its AI and MRD business lines. 1d ago
  44. TWSTJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - TWIST BIOSCIENCE CORP The company reported FY2026 revenue of $59 million for its AI-driven drug discovery segment, contributing to total company revenue of $459 million and achieving its first quarterly EBITDA break-even. Management projects FY2027 total revenue between $550 million and $560 million, with AI segment revenue guided to reach at least $100 million as the business transitions from pilot orders to recurring production models. To support this growth, the firm plans a $150 million capital expenditure program over the next two years to expand its DNA synthesis capacity from 10 to 16 units, addressing current constraints that limit further revenue realization. 1d ago
  45. NEOStephens Annual Investment Conference - NEOGENOMICS INC The company's clinical revenue grew 13% year-over-year, driven by a 29% increase in Next-Generation Sequencing (NGS) business which now accounts for approximately 33% of total revenue. Adjusted EBITDA improved by 53% as the organization shifts focus toward high-margin molecular oncology products like the PanTracer family and MRD testing, while exiting low-margin non-clinical work. Full-year NGS growth is guided to exceed 25% in 2026, supported by new product launches, sales team expansion, and anticipated commercial coverage for additional MRD indications. Management projects continued momentum through 2027 and 2028 as liquid testing adoption matures in community settings and the Heme NGS portfolio transitions to more efficient sequencing technology. 1d ago
  46. DNLIUBS Global Biopharma Conference - DENALI THERAPEUTICS INC In Q3 2026, the company reported revenue of approximately $18 million, driven by accelerated payer access and patient switching from competitor Elaprase for Hunter syndrome treatment. Management projects Q4 2026 revenue between $30 million and $32 million, with a strategic goal to capture the majority of the eligible US Hunter syndrome market by 2027. The company's pipeline includes Zafi for Sanfilippo Type A, expected to present pivotal data in early 2027, and Alzheimer's programs targeting A-beta and Tau with Phase 1b results anticipated in 2027. Future pipeline programs across rare diseases and Alzheimer's are projected to generate peak revenues of $3 billion to $4 billion, supported by a transport vehicle platform enabling intravenous and subcutaneous administration. 1d ago
  47. NUVBJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - NUVATION BIO INC The company reported approximately $100 million in first-year-to-date revenue driven by the commercial launch of Ibtrozi, achieving 18% quarter-over-quarter sales growth despite a 20% decline in new patient alerts for ROS1 testing. Ibtrozi holds market leadership in the first-line ROS1 space with a 90% response rate and 50-month duration of response, while Safucitinib demonstrates superior efficacy in glioma trials compared to competitors. The firm maintains a strong balance sheet with $660 million in cash, supporting a path to profitability and potential adjuvant label expansion for Ibtrozi by late 2027. 1d ago
  48. FUBOFubo 4Q26 Earnings Call - FUBOTV INC FuboTV reported fiscal Q4 2026 North American revenue of approximately $1.5 billion, a 22% year-over-year increase driven by improved advertising metrics, while achieving a pro forma net loss of $134 million for the full year. The company generated positive free cash flow of $36.1 million in the quarter and strengthened its liquidity position to $272.4 million, marking a strategic shift away from subscriber count growth toward profitability and adjusted EBITDA. Management reaffirmed a long-term target of at least $300 million in adjusted EBITDA by fiscal 2028 and highlighted key initiatives including the integration of Hulu Live into the Disney+ app and the development of AI-driven capabilities to enhance operational efficiency. 1d ago
  49. PRKThe Estée Lauder Companies Inc. Annual Meeting of Shareholders - PARK NATIONAL CORP The company reported improved fiscal year 26 results while reaffirming its 2030 ambition to become a sustainable growth entity with enhanced profitability. Strategic priorities include accelerating innovation across four main categories, expanding distribution in high-potential markets, and increasing consumer-facing investments to acquire and retain customers globally. Management emphasized a cultural shift toward a bolder, more entrepreneurial approach while maintaining core values of quality and social support for girls and women. The transition from strategic ambition to execution was highlighted as a key focus, with a multi-pronged plan addressing distribution, innovation, and cultural evolution to drive future performance. 1d ago
  50. ILOGThe Trust Phase: What Does it actually Take to Trust Agentic NetOps - ILOG SA IBM Network Intelligence (INI) is an operational agentic layer designed for autonomous network investigation and remediation, functioning through a Sense, Reason, Govern, Act loop that integrates with existing observability tools. Market trends indicate a shift in 2026 from feature capability to trust and security, with 55% of IT organizations requiring AI capabilities while only 31% completely trust current AI network tools. Primary barriers to deployment include security risks, data quality issues, and the need for transparent architectures, as organizations prefer assisted operations where AI recommends actions for human approval rather than fully autonomous execution. To address reliability decay and non-determinism, the system employs digital twin verification, continuous real-time evaluation, and human-in-the-loop governance to ensure auditability and reproducibility. 1d ago

Research Reports

Technology →

Oct 4, 2026 to Nov 18, 2026 · 413 companies

Technology Earnings Report — 2026-10-04 to 2026-11-18

Report generated: 2026-11-18 13:35:12 EST

Overview

Companies reported: 413 (2026-10-04 - 2026-11-18). Technology sector results were overwhelmingly positive, driven by surging demand for AI infrastructure that fueled record revenue and profit growth across semiconductor, networking, and data center segments. Major players like NVIDIA (NVDA), Super Micro Computer (SMCI), and CoreWeave (CRWV) led the rally with triple-digit year-over-year gains, while companies pivoting to recurring revenue models and expanding capital expenditures further amplified the sector's momentum. Conversely, a distinct bifurcation emerged as legacy hardware and consumer electronics firms faced headwinds from macroeconomic softness and inventory corrections, resulting in significant revenue declines and liquidity challenges for outliers such as GoPro (GPRO) and Veritone (VERI).

Leaderboard

Top 5 by Revenue Growth (YoY)

# Company Ticker Revenue Growth YoY Revenue
1 Ainos AIMD 29,567% $642,889
2 Boost Run BRUN 496% $39.9 million
3 FiEE FIEE 382.1% $9.6 million
4 QumulusAI QMLS 376% $14.8 million
5 IonQ IONQ 336% $173.8 million

Revenue growth for Ainos (AIMD) is derived from a base of $2,170 in the prior year period.

Top 5 by Net Income Growth (YoY)

# Company Ticker Net Income Growth YoY Net Income
1 Super Micro Computer Inc SMCI 849.1% $1,594 million
2 Strategy Inc MSTR 599.7% $19.53 billion
3 NVIDIA Corp NVDA 105% $65.3 billion
4 CoreWeave Inc CRWV n/a $(709) million
5 Netlist Inc NLST n/a $85.4 million

Net income growth for Strategy Inc (MSTR) and Super Micro Computer Inc (SMCI) is derived from net income figures including significant non-cash gains (digital assets and warrant liability adjustments) or revenue surges; CoreWeave (CRWV) reports a net loss despite revenue growth.

Themes

  • AI infrastructure demand continues to drive record revenue growth and margin expansion across semiconductor, networking, and data center infrastructure segments, with major players like NVIDIA (NVDA), AMD (AMD), and Super Micro Computer (SMCI) reporting double-digit to triple-digit year-over-year gains driven by hyperscaler and enterprise compute needs.
  • Companies are aggressively expanding capital expenditures and securing long-term power and capacity commitments to support AI workloads, as evidenced by CoreWeave (CRWV) raising billions in debt and expanding active power to over 1.7 GW, while others like Cerebras (CBRS) and Boost Run (BRUN) secure massive GPU deployments and data center capacity.
  • A significant trend involves the pivot toward recurring revenue models and software-as-a-service (SaaS) structures, with firms like Duos Technologies (DUOT), Veritone (VERI), and Palantir (PLTR) emphasizing subscription growth, ARR expansion, and the transition from project-based to platform-based monetization.
  • Strategic acquisitions and M&A activity are accelerating to integrate AI capabilities and expand market reach, including NVIDIA's (NVDA) acquisition of Hugging Face, Microsoft's (MSFT) continued investment in OpenAI, and numerous deals in the semiconductor and software sectors to acquire specialized IP or customer bases.
  • Cost discipline and operational restructuring remain critical themes, with many companies implementing headcount reductions, exiting unprofitable lines of business, and focusing on high-margin opportunities to improve profitability, as seen with Phunware (PHUN), Latch (LTCH), and XTI Aerospace (XTIA).
  • Balance sheet management is a key focus, with firms utilizing share repurchases, dividends, and debt refinancing to optimize capital structure, while others face liquidity challenges requiring equity raises or debt-for-equity exchanges to maintain solvency and fund growth.
  • Supply chain constraints and component availability continue to impact production and delivery timelines, particularly in the semiconductor and hardware sectors, leading to extended lead times and inventory buildups, though some companies like Diodes (DIOD) and Monolithic Power (MPWR) report strong demand outpacing supply.
  • Regulatory and geopolitical factors, including export controls, tariffs, and trade restrictions, are influencing revenue guidance and market access, with companies like NVIDIA (NVDA) excluding China data center revenue and others adjusting strategies to navigate complex international compliance landscapes.
  • The transition to agentic AI and autonomous systems is driving new product launches and service offerings, with companies like Unity (U), ServiceNow (NOW), and Fortinet (FTNT) integrating AI agents into their platforms to enhance automation and customer value propositions.
  • Financial performance is increasingly bifurcated between companies successfully capitalizing on the AI supercycle and those facing headwinds from macroeconomic softness, legacy product declines, or the need to restructure for profitability, highlighting the importance of strategic execution in the current market environment.

Market Outlook & Trends

  • Revenue growth in the sector is heavily driven by AI infrastructure demand, with companies like NVIDIA (NVDA), CoreWeave (CRWV), and Cerebras (CBRS) reporting record quarterly revenues and multi-year backlogs exceeding $100 billion, while others such as Super Micro Computer (SMCI) and Arista Networks (ANET) are scaling gigawatt-scale datacenter solutions to meet hyperscaler needs.
  • Demand for semiconductor equipment and materials is accelerating, evidenced by record bookings and revenue surges at Applied Materials (AMAT), KLA (KLAC), and Onsemi (ON), though supply chain constraints and extended lead times persist for critical components, as noted by Diodes (DIOD) and Micron (MU).
  • Backlog levels are reaching historic highs across the sector, with companies like Clearfield (CLFD), M-tron Industries (MPTI), and BlackSky (BKSY) citing multi-year order books that support 2027 revenue visibility, while others such as Axcelis (ACLS) and Teradyne (TER) report strong order inflows driven by AI and advanced packaging requirements.
  • Pricing power and margin expansion are evident in segments with high demand, such as the software and infrastructure sectors where NetSuite (NOW), Datadog (DDOG), and Fortinet (FTNT) are achieving double-digit revenue growth alongside expanding non-GAAP operating margins, though some hardware manufacturers like Netgear (NTGR) and Key Tronic (KTCC) face margin pressure from rising component costs and inventory write-downs.
  • Cost expectations are mixed, with many firms like Intel (INTC) and AMD (AMD) investing heavily in R&D and capacity expansion, while others such as Veritone (VERI) and Phunware (PHUN) are executing cost-reduction plans and headcount reductions to improve operating leverage and achieve profitability targets.
  • Capital allocation strategies are shifting toward aggressive share repurchases and dividends, with Apple (AAPL), Microsoft (MSFT), and Broadcom (AVGO) returning billions to shareholders, although companies facing liquidity constraints like AMC Robotics (AMCI) and Algorhythm Holdings (RIME) are prioritizing debt management and restructuring over capital returns.
  • Risks identified by management include geopolitical tensions affecting supply chains and export controls, as highlighted by Intel (INTC) and Marvell (MRVL), alongside regulatory uncertainties and litigation costs impacting firms like Grindr (GRND) and GoPro (GPRO).
  • Strategic pivots toward AI-native models and platform consolidation are underway, with companies like Unity (U), Atlassian (TEAM), and ServiceNow (NOW) integrating agentic AI capabilities, while others such as Duos Technologies (DUOT) and Axe Compute (AGPU) are restructuring to focus on pure-play GPU infrastructure or colocation models.
  • M&A activity remains active, with major transactions including NVIDIA's acquisition of Hugging Face, Microsoft's investment in OpenAI, and various consolidations in the semiconductor and software sectors, though some deals like the proposed merger of PTC (PTC) with Schneider Electric have led to the suspension of forward guidance.
  • Forward-looking statements indicate a bifurcated outlook where AI leaders expect sustained double-digit growth through 2027, while traditional hardware and consumer electronics segments face headwinds from macroeconomic softness, inventory corrections, and delayed customer deployments, as seen in reports from Sonos (SONO) and Turtle Beach (TBCH).

Key Numbers

  • NVIDIA (NVDA) reported record Q3 revenue of $115.8 billion, up 103% year-over-year, driven by a 110% surge in Data Center revenue to $107.6 billion, while GAAP net income rose 105% to $65.3 billion.
  • Super Micro Computer (SMCI) posted Q1 FY27 net sales of $19.9 billion, a 298% year-over-year increase, with net income surging to $1.594 billion compared to $168 million in the prior year quarter.
  • CoreWeave (CRWV) saw Q3 revenue jump 168% year-over-year to $3.66 billion, with Adjusted EBITDA rising 169% to $2.26 billion, though net loss widened to $709 million due to aggressive infrastructure build-out.
  • Arista Networks (ANET) achieved Q3 revenue of $3.66 billion, up 58.5% year-over-year, with non-GAAP diluted EPS increasing to $1.20 from $0.77 in the prior year period.
  • AMD (AMD) reported record Q3 revenue of $13.4 billion, up 45% year-over-year, driven by a 97% surge in Data Center revenue to $8.5 billion, while GAAP net income rose 95% to $2.4 billion.
  • Apple (AAPL) recorded Q4 revenue of $114.5 billion, a 12% year-over-year increase, with iPhone revenue reaching a September quarter record of $57.6 billion and Services revenue hitting an all-time high of $31.6 billion.
  • Microsoft (MSFT) reported Q1 FY27 revenue of $92.3 billion, up 19% year-over-year, with Azure revenue surging 48% and commercial remaining performance obligations increasing 73% to $677 billion.
  • Cisco Systems (CSCO) reached record Q1 FY27 revenue of $18.5 billion, up 24% year-over-year, with product revenue surging 32% to $14.7 billion and GAAP net income rising 59% to $4.6 billion.
  • Datadog (DDOG) posted Q3 revenue of $1.20 billion, up 35% year-over-year, marking the first quarter of positive GAAP operating income at $75 million, while free cash flow reached $251 million.
  • Palantir (PLTR) reported Q3 revenue of $2.313 billion, a 96% year-over-year increase, with GAAP net income of $1.128 billion and adjusted free cash flow of $1.216 billion.

Outliers

  • NVIDIA (NVDA) posted the strongest report with 103% YoY revenue growth to $115.8 billion and 105% net income growth, driven by a 110% surge in Data Center revenue.
  • CoreWeave (CRWV) delivered exceptional growth with 168% YoY revenue reaching $3.66 billion and a 169% increase in Adjusted EBITDA to $2.26 billion.
  • Super Micro Computer (SMCI) reported the highest absolute revenue growth, surging 298% YoY to $19.9 billion with net income rising to $1.594 billion.
  • i3 Verticals (IIIV) issued the weakest report as full-year net income declined 27.2% to $4.1 million, driven by a Q4 net loss of $5.1 million and a significant drop in cash reserves.
  • GoPro (GPRO) faced severe distress with net revenue falling 41% to $96 million, a gross margin contraction to 12.7%, and substantial doubt regarding its ability to continue as a going concern.
  • Veritone (VERI) reported the weakest top-line performance with a 30.1% YoY revenue decline to $18.6 million, accompanied by a 12.6% drop in ARR and a sharp reduction in cash reserves to $7.3 million.

VC News

More →
  1. AI agents drive >50% of 2026 internet traffic. Linq, a leading infrastructure platform, powers this with DoorDash partnership on Apple Messages. Founded 2020 in Alabama, now in SF, Linq leads Series B & hires. Andreessen Horowitz · 1h ago
  2. Boltz revolutionizes drug discovery with AI models adopted by top pharma. Usage-based token model grew 50x in 4 months. Deployed at Pfizer, GSK, Takeda, BMS. Secured $110M Series A to scale research & compute. Andreessen Horowitz · 3h ago
  3. Zenity pivots to AI agent security as adoption outpaces cloud. Agents breach fixed perimeters, risking data theft & attacks. Co-founders urge full-speed AI growth with dynamic guardrails & human-on-loop strategies to defend against AI threats using AI. SoftBank Vision Fund · 1d ago
  4. Gopuff, founded 2013 by Gola & Ilishayev, uses a vertically integrated model with micro-fulfillment centers to deliver in 15 mins. Achieving 99.5% order accuracy via AI, the firm prioritizes unit economics to remain profitable while expanding globally & partnering with Uber, DoorDash, & Starbucks. SoftBank Vision Fund · 1d ago
  5. Fountain & Netradyne pivot to gen AI for core friction. CMT.AI builds custom models for sensor data. Hybrid build-or-buy with narrow pilots is key. AI coding cuts dev cycles to days. Avoid chasing AI for its own sake. Audit data, define moats, & evaluate unit economics before scaling. SoftBank Vision Fund · 1d ago
  6. Lightspeed led Compute Desk's $45M seed for a GPU clearing platform replacing outdated contracts with standardized trading & trusted price indices. Founders bring derivatives & quant expertise to a market where AI capex hits $1.5T by 2030, enabling potential $20-40T annual volume. Lightspeed Venture Partners · 1d ago
  7. Boring Co. hit $23B valuation after Sept 2026 $3B round. CEO Davis targets D.C.-Las Vegas hyperloop. Cost down to <$10M/mile. Vegas Loop moved 4M+ riders. Austin-San Antonio trip to drop to <30 mins. ZPIT mining enables full autonomy. Andreessen Horowitz · 1d ago
  8. First Person Labs builds Second, a device-local personal model giving users total control over AI data. Founders Ken Liu & Erik Chi bring AI & security expertise. This infrastructure ensures privacy & portability, preventing third-party influence over agent actions. Andreessen Horowitz · 1d ago
  9. 2026 security sees 1990s exploit speed via AI. Worms target API keys & ransomware. Enterprises must accelerate patching & shift to continuous AI red-teaming. New startups will harden legacy stacks. Defense needs AI-native layers & agentic security to counter collapsing vulnerability windows. Andreessen Horowitz · 2d ago
  10. Eli Lilly hits $1T cap driven by $17B Q3 GLP-1 sales. Pharma relies on top 25% of hits for 85% revenue. AI aims to slash 13-year, $2B development costs. Bio-AI matures to GPT-3 levels with major partnerships. Valuation shifts toward discovery engines over approved portfolios. Andreessen Horowitz · 5d ago
  11. AI accelerates attacks requiring machine-speed defense. White House plan targets 5 critical sectors: power, banking, water, comms, hospitals. Focus is containment over replacement. CEOs accountable via monthly scorecards & board attestations. Goal: contain top targets in 6 months using AI & digital twins. Andreessen Horowitz · 5d ago
  12. Gaming archetypes: indie, toolmakers & world-builders. AI accelerates all three by bridging skill gaps & expanding production. New models enable end-to-end design & decompilation. Leaders reorganize for AI-assisted dev. Studios shorten cycles to risk more IP. AI tools foster a new generation of developers. Andreessen Horowitz · 6d ago
  13. SE3 secures $30M Series A to build sovereign spatial intelligence for EU defense, capitalizing on €800B spending plans & MOSA shift. The Munich-founded firm partners with HENSOLDT, Ukraine, & Germany's forces to enable autonomous ops where GPS fails. Accel · 6d ago
  14. Taneja warns AI's top risk is a trust-driven prisoner's dilemma. General Catalyst backs both closed & open models, highlighting a resilience premium markets undervalue. Summa Health adoption rose from 20% to 80% post-acquisition. Breaking the cycle requires costly first moves & rules for cooperation. Founders must build at the frontier without relying on one lab to ensure no single entity can switch off the AI economy. General Catalyst · 6d ago
  15. Fractile secures Series C co-led by Exponential. Its chip-first approach solves AI inference bottlenecks via stacked DRAM, promising 10x speed & lower cost. With 80% of future AI spend targeting inference, Fractile's vertically integrated stack targets a $100B+ market. Lightspeed Venture Partners · 1w ago
  16. Edelbyte, spun from Microsoft's Kusto team, rethinks data platforms for AI agents. Founders include ex-Microsoft engineers. Like Confluent, it targets B2B with 10x query efficiency. We led their seed round. Sequoia Capital · 1w ago
  17. Invest in General Translation, a Series A AI localization firm. It integrates into React, GitHub, Figma, Slack to fix brittle workflows. Clients include Cursor, Ramp, Clickhouse. Founder Archie McKenzie, ex-Princeton CS. Martin joins board. Andreessen Horowitz · 1w ago
  18. AI agents now drive majority web traffic, author half of articles & generate most code. Shopify & Vercel report 8x-28x growth. B2A economy emerging: treat agents as customers or face obsolescence. Andreessen Horowitz · 1w ago
  19. US infrastructure faces extreme delays & cost overruns, with manufacturing share dropping from 25% to 16%. NEPA is the primary obstacle, not environmental safety. A bipartisan consensus forms around the 2026 Bipartisan American Affordability & Jobs Act to reform permitting through hard deadlines & streamlined reviews. Andreessen Horowitz · 1w ago
  20. Lightspeed leads Nominal's Series C to modernize hardware testing. Legacy inefficiencies plague engineers, but Nominal unifies sensor data & video on one timeline. AI agents handle debugging, safety, & planning in air-gapped environments. Clients include Hermeus w/ $53M Air Force contract. Targets $100B annual labor savings for aerospace & chemical engineers. Lightspeed Venture Partners · 1w ago
  21. SoftBank, Grab & PETROS commit $1.85B to AI infrastructure across Sarawak & Peninsular Malaysia. Long-term target: 5GW+ capacity. SoftBank locks up Grab shares for 5 years. Initiative supports Malaysia's AI Nation 2030 ambition to address surging regional demand. SoftBank Group · 1w ago
  22. SoftBank leads $1B AI infrastructure deal in Sarawak with Grab & PETROS. Target: 5GW compute capacity. Aligned with Malaysia's AI Nation 2030. Aims to become Asia's largest AI site serving gov & multinationals. SoftBank Group · 1w ago
  23. Exploit costs dropped while patching stalled, creating a widening gap. Remediation times hit 252 days in 2025. AI generates exploits in hours. 94% of ransomware attacks target backups but only 28% recovered data in 2026. Future defense requires removing exposure, virtual patching, memory-safe code, or making patching unnecessary. Andreessen Horowitz · 1w ago
  24. SoftBank agreed Oct 8, 2025 to buy ABB robotics. Nov 4, 2026, China blocked the deal. Both firms continue dialogue despite the prohibition. SoftBank Group · 1w ago
  25. AI slashed exploit time to days before disclosure, hitting 395 orgs in hours. Patching lags at 43 days median, leaving schools & critical infrastructure exposed. Ransomware payments dropped as attackers target small victims with destructive attacks. Defenders must shift to isolation & segmentation where updates are impossible. Andreessen Horowitz · 1w ago
  26. Tech buyouts face structural stress from debt & rates, lacking fixer-uppers. Venture outperforms innovation cycles; 2007-2016 top VC funds hit 5.3x DPI vs 3.5x for buyouts. 70% of recent debt foreclosures stem from 2021-2022 deals. $140B in risky PE loans mature in 2028. Andreessen Horowitz · 2w ago
  27. Industry practice now favors full desktop access for AI agents. Phaze delivers high-performance remote desktops for OS-specific apps & latency-sensitive workloads. Founded by ex-Parsec creators with backing from prior investors to enable seamless agent access. Andreessen Horowitz · 2w ago
  28. Accrual co-founders Nicolaescu & Chandrasekaran target accounting with AI automating 90-99% of tax prep. The 20-person team avoids AI wrappers by focusing on complex multiplayer workflows. Strategy includes model-agnostic tech & acquiring a firm for cultural shifts. General Catalyst · 2w ago
  29. Longevity went mainstream via AI & pandemic. A healthcare home race is underway. Non-toxic product spending surges. Peptides grow but GLP-1s dominate at $44B. Cholesterol management evolves with new drugs. Wearables focus on biomarkers. Neurotech shifts to consumer use. Founders should build tools for actionable behaviors. Andreessen Horowitz · 2w ago
  30. Cresta, founded 2017 at Stanford, joined Salesforce after Ping Wu led it from stealth to AI agent autonomy. The acquisition transitions Cresta from research to mission-critical business infrastructure, leveraging Salesforce's global platform for enterprise scaling. Sequoia Capital · 2w ago
  31. Tutor Intelligence leads Series B with robots prioritizing task completion over specific models. Deploying via teleoperators, they target 1,000 units by 2027. Hourly pricing shifts costs to Opex for SMBs, large logistics, & mid-market firms. Co-founders Gruenstein & Kosowsky leverage MIT expertise for ROI-driven adoption. Andreessen Horowitz · 2w ago
  32. Lower inference costs demand pricing on value units, not tokens. Buyers need 96% adoption & 34% speed gains to justify premiums. 94% expect spending growth in 2026. Vendors must make context cheaper to rent than rebuild while widening app advantages faster than model progress. Andreessen Horowitz · 2w ago
  33. a16z welcomes Andy Baker as advisor to Global Affairs. Baker, former Deputy NSA to Trump & NSA to VP Vance, brings 10+ years as Foreign Service Officer. Goal: help founders in AI, defense, cybersecurity, energy, & infrastructure navigate geopolitics & government priorities. Andreessen Horowitz · 2w ago
  34. a16z prioritizes founder backgrounds for its $1M Speedrun checks with an SF residency deadline Nov 1. AI empowers solo founders but teams may still outperform on scaling. Non-technical founders can prototype yet lack technical judgment. Domain experts understand pain points but lack outsider perspective. Young founders leverage AI but lack enterprise experience. Content creators face viral-to-sustainable challenges. Investor preferences shift with tech cycles. Evaluate how AI changes capabilities rather than inverting old rules. Andreessen Horowitz · 2w ago
  35. SoftBank delays LINE MAN capital increase to Jan 2027 due to coordination needs. Deal involves 12.4M new shares for $130M. Impact on current fiscal results minimal. Post-completion SoftBank will hold 63.7% voting rights in LINE MAN. SoftBank Group · 2w ago
  36. LLMs treat file systems as native behaviors. Using bash & files as external memory cuts token costs & prevents context rot. Vercel cut agent costs 75% this way. Start local, add DBs only for scale. Files offer audit trails & interface abstraction, but lack concurrency guarantees. Lightspeed Venture Partners · 2w ago
  37. AI accelerates cyber threats, driving 87% of CISOs to boost 2027 spending. Security headcount rises as AI governance becomes top priority. Only 18% use AI SOC tools now, yet startups lead innovation while incumbents lag in addressing AI-specific gaps. Andreessen Horowitz · 3w ago
  38. VC shifted to specialized teams applying traditional finance to early-stage tech, often ignoring that tech waves precede business models. Four philosophies: Financial (metrics), Productive (tech as market creator), Frontier (founders), Speculative (perception). Align philosophy with deal stages to avoid the grab bag trap. Andreessen Horowitz · 3w ago
  39. Databricks hit $7B run rate w/ 80% YoY growth. Its Lakehouse & Lakebase unify data & ops. CEO Ghodsi proposes SORA for agents, shifting humans from execution to strategy. The firm rejected a $6B offer to build the future OS. AI triggers a Second Managerial Revolution. Andreessen Horowitz · 3w ago
  40. Amjad Khatib notes early AI agent adoption mirrors historical tech chaos like PCs and spreadsheets. This disorder signals deep alignment. Future success depends on Replit's Agent Habitat, which structures chaos to let employees generate code and drive productivity without stifling ownership. Andreessen Horowitz · 3w ago
  41. SoftBank resolved to pay JPY 5.50 interim dividend per share, record date Sept 30, payable Dec 2. Total cash: JPY 31.3B. FY27 forecast: JPY 16.50 total. FY26 actual: JPY 27.50. Share split effective Jan 1, 2026. SoftBank Group · 3w ago
  42. SoftBank Group Corp. fully redeemed its EUR 2.875% Senior Notes due Jan 2027. Redemption finalized Oct 21, 2026. All notes are now canceled & no longer outstanding. SoftBank Group · 3w ago
  43. Zetwerk listed after 8 years, growing from 200 suppliers to 7k across 26 countries. Revenue hit ₹15,913 cr (~$1.68B) with ₹12,370 cr order book. Energy is now the largest segment driven by AI & solar. 80% revenue from returning clients. Accel · 3w ago
  44. DualEntry founder Santiago Nestares raised $90M Series A to replace legacy ERPs like NetSuite with an AI-native platform. The system automates bookkeeping & lets firms scale past $100M revenue with tiny finance teams. Expanding into real estate, tech & manufacturing. Lightspeed Venture Partners · 3w ago
  45. Warp launched Series A led by Lightspeed to build AI robotic labs for US drug discovery. The team includes ex-OpenAI & ex-Meta AI leaders. Warp records failures to train models & reduce reliance on offshore partners amid BIOSECURE Act pressures. Lightspeed Venture Partners · 3w ago
  46. a16z renames Crypto fund to Frontier, expanding scope from crypto to broader frontier tech. Strategy targets AI wave, new devices like autonomous machines & bio tech. Firm defines companies by activities, not tech. Led by authors & founders with focus on full-stack startups & programmable rails. Andreessen Horowitz · 3w ago
  47. Serval automates IT, HR & finance workflows by generating code from natural language. Co-founded by Jake Stauch & Alex McLeod, it launched April 2024 with customers including Perplexity, Mercor & Ramp. The platform covers 13 departments per customer using proactive agents to resolve issues before tickets are filed. General Catalyst · 3w ago
  48. Legora doubled revenue quarterly after pausing sales to refine AI. It onboards 1k lawyers daily, uses agentic AI for due diligence, & targets global scale from NY, London, & Stockholm. Users average 90 mins daily. CEO aims to empower lawyers in a supply-constrained market. General Catalyst · 4w ago
  49. Whop hit $500M run-rate, adding 10k daily businesses. Sequoia leads Series D. AI lowers entry barriers as the team launches a decision engine for merchant profits. Sequoia Capital · 4w ago
  50. Dev bottlenecks shifted from coding to verification. Anthropic saw 25x CI surge. Blacksmith accelerates CI 2x at 60% less cost. 10k+ firms use it; weekly jobs up 18x to 90M. ARR grew 17x in 2026. Founders from Cockroach Labs. Leading Series C for agent-speed validation. Sequoia Capital · 4w ago

Press Releases

More →
  1. MDGLKaplan Fox & Kilsheimer LLP is Investigating Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) for Potential Securities Law Violations Kaplan Fox investigating MDGL for potential securities violations & whistleblower retaliation under Sarbanes-Oxley. Madrigal disputes claims & plans vigorous defense. Stock fell 8.08% to $396.32 on Nov 3 following disclosure. Investors with losses may contact firm. GlobeNewswire · 10m ago
  2. GTNGray Announces Participation in Upcoming Investor Events Gray Media (NYSE: GTN) announces participation in 4 investor conferences Nov 2026-Mar 2027, including Furey, Singular Research, BofA, & J.P. Morgan. The Atlanta-based media giant serves 37% of US TV households via 117 markets & largest Telemundo group. Contact Alan Gould for meetings. GlobeNewswire · 25m ago
  3. EXLSEXL Recognized as a Leader in the Everest Group Fraud Management Operations Services PEAK Matrix® Assessment 2026 EXLS (EXL) named Leader in 2026 Fraud Management PEAK Matrix by Everest Group. Recognition highlights AI-enabled fraud ops, advanced analytics & graph intelligence. EXL also ranked Major Contender in FCC Ops for 2nd year. Global data & AI firm with 74k+ employees. GlobeNewswire · 31m ago
  4. KFYKorn Ferry to Participate in the 2026 UBS Global Technology and AI Conference Korn Ferry (KFY) confirms participation in UBS Global Tech & AI Conf on Nov 30. CFO Robert Rozek & Head of AI Bryan Ackermann will lead fireside chat at 11:35 AM EST. Event will be broadcast live on KFY IR site. KFY serves as LA28 Official Talent Partner supporting 5,000 personnel. Business Wire · 54m ago
  5. CZRCaesars Palace Launches Second Major Renovation of Bacchanal Buffet, Reimagining Its Global Kitchens Caesars Palace Bacchanal Buffet closes Jan 4 2027 for renovations led by MUKU design studio. Expect modern metallic accents & 250 dishes in 25k sq ft space. Reopening summer 2027. Reservations open until closure via caesars.com. Business Wire · 55m ago
  6. KDKyndryl Named a Leader in the 2026 Gartner® Magic Quadrant™ for Outsourced Digital Workplace Services for the 3rd Consecutive Time Kyndryl (KD) named Gartner ODWS Leader for 3rd year, topping Execution & leading in Vision. AI-native model shifts to proactive productivity protection via Digital Twin & Bridge tech. Largest IT infrastructure provider serving 60+ countries. PR Newswire · 1h ago
  7. NXTNextpower Awarded New U.S. Patent for NX Horizon-XTR Terrain-following Technology Nextpower secured U.S. Patent 12,803,495 for its NX Horizon-XTR terrain-following solar tracker. The design adjusts to elevation changes, minimizing grading & enabling efficient deployment on challenging sites. This is the second patent in this family, supporting Nextpower's 1,600+ issued patents & pending applications. Business Wire · 1h ago
  8. NSCNorfolk Southern celebrates 200 years of railroading, unveils anniversary campaign and commemorative locomotives Norfolk Southern launched its 200-year celebration with the NS 200 Locomotive series & GeneratioNS campaign. Heritage Days tour begins spring 2027 across its 22-state network. The company collaborates with Atlanta History Center & Virginia Museum of History & Culture to preserve archives while avoiding 15 million tons of annual carbon emissions. PR Newswire · 1h ago
  9. BLBDBlue Bird to Report Fiscal 2026 Fourth Quarter and Full Year Results on December 2, 2026 Blue Bird (BLBD) releases FY26 Q4 & full year results Dec 2 at 4:30 PM ET. CEO Wyskiel & CFO Radulescu lead webcast with slides & dial-in on IR site. Replay available 2 hours post-call. Company has sold 25k+ propane, natural gas, electric buses since 1927. Business Wire · 1h ago
  10. FIVNFive9 Announces Winners of the 2026 New Era of CX Awards Five9 2026 CX Awards winners include CVS Health, IAA, TruConnect, Advia Credit Union, Wells Fargo, Doctor Care Anywhere, & First Tech FCU. Winners reduced wait times, boosted NPS, & automated interactions via Genius AI across 4,000+ customers. Business Wire · 1h ago
  11. TMUST-Mobile Adds New AI-Powered Intelligence and Resilience To Make Its 5G Network Even Stronger T-Mobile expanded AI AutoPilot & Dynamic CX to boost 5G resilience in 2026. Hybrid generators extend uptime 50% during outages. Satellite & deployable assets supported Hurricane Lala with 144K messages in Hawaii. T-Priority ensures first responder connectivity. ACCESS Newswire · 1h ago
  12. NXSTNexstar Media Group to Participate in Three Upcoming Investor Conferences Nexstar Media Group Inc. (NXST) confirms exec participation in three Dec 2026 conferences: BofA on Dec 2, UBS on Dec 7, & Wells Fargo on Dec 9. CFO Lee Ann Gliha joins CEO Perry Sook & COO Michael Biard. Webcasts available at nexstar.tv. Business Wire · 1h ago
  13. PRKSSPLASH DOWN! BUSCH GARDENS TAMPA BAY TO DEBUT EXHILARATING NEW WATER RIDE - NORTH AMERICA'S FIRST AND WORLD'S FASTEST LAUNCHED WATER COASTER Busch Gardens Tampa, owned by PRKS, unveils Simbi Rush, North America's first launched water coaster. Debuting 2027 at 40mph, it's part of a $200M investment. Passes offer 60% off Black Friday. PR Newswire · 1h ago
  14. PNCPNC Grow Up Great Wins Gold Anthem Award in K-12 Education Innovation PNC Grow Up Great won Gold Anthem Award for K-12 Education Innovation. The $500M+ bilingual initiative has helped 11.5M children access early education over 20 years. Funded by PNC Financial Services Group (NYSE:PNC). ACCESS Newswire · 1h ago
  15. MDLNMedline launches right-sized Ranpak packaging solutions in two key distribution centers Medline & Ranpak deployed Cut'it! EVO & Form'it! tech at Grayslake & Katy facilities to cut shipping costs & boost sustainability. These upgrades join a 3rd site in Montgomery, N.Y., optimizing high volumes across 45 U.S. centers without strict order-to-box matching. PR Newswire · 1h ago
  16. BBWBuild-A-Bear Workshop Appoints Holly Tybor as SVP Chief Product and Innovation Officer Build-A-Bear (BBW) named Holly Tybor SVP Chief Product & Innovation. Tybor brings 20+ years exp from Victoria's Secret & Knitwell. She will lead product strategy & innovation across 650+ locations. BBW posted $529.8M revenue in FY2025, its 5th consecutive record year. PR Newswire · 1h ago
  17. PEGALaunchpad® from Pega Makes it Faster and Easier for Software Companies to Go from Idea to Production with Conversational AI Pega launches free AI Assistant on Launchpad.io to generate visual models & prototypes from text. It supports building, enhancing, or replacing apps without upfront costs or server management. Providers upload docs to build workflows & logic instantly. The tool leverages 40+ years of experience for secure, agentic enterprise applications. Business Wire · 1h ago
  18. MSFTMicrosoft and Intel Deepen Collaboration to Deliver Differentiated Azure Infrastructure Microsoft & Intel expanded their long-term Azure collaboration, leveraging Intel Foundry's EMIB tech for first-party silicon. The deal secures next-gen Xeon CPUs & CXL integration, boosting Azure M-series v4 performance by 2.3x. New QAT VMs deliver 2.5x faster SQL backups while TDX enhances confidential computing for scalable, resilient infrastructure. PR Newswire · 2h ago
  19. BIOANew three-year real-world data on Leqembi® presented at CTAD 2026 Eisai's LEADER study shows Leqembi reduced Alzheimer's progression by 76% over 36 months. 81% remained stable or improved. 95% stayed in early stages. SC maintenance showed 77% amyloid-negative. No ARIA events reported on SC. Safety consistent with prior data. BioArctic holds Nordic rights. PR Newswire · 2h ago
  20. BIOANew three-year real-world data on Leqembi® presented at CTAD 2026 Eisai's LEADER study at CTAD shows Leqembi patients had 76% lower progression vs natural history. 95% stayed in early AD stages. Subcutaneous maintenance showed zero ARIA events. Safety profile improved vs Phase 3 data. BioArctic retains Nordic rights while Eisai handles global commercial activities. PR Newswire · 2h ago
  21. TDTHTrident Signs MOU to Acquire 51% Controlling Stake in Malaysia’s Guang Yao Development, Entering Hydrogen Power and Battery Energy Storage for Data Centres Trident Digital Tech (TDTH) signed MOU to acquire 51% of Guang Yao for $15.3M. Guang Yao supplies hydrogen & battery storage for data centers. Deal targets completion by Dec 18, 2026. Trident will appoint board majority. Aim: integrate energy supply into AI & digital tax platforms. GlobeNewswire · 2h ago
  22. HBANCapstone Partners Advances Firmwide Growth, Names Ji Sang Lee Head of Buy-Side Advisory and Michael Mathews Head of Technology & Digital Advisory Capstone Partners, a Huntington Bancshares subsidiary, appointed 4 MDs including Ji Sang Lee & Michael Mathews. The hires add 30+ years of experience, positioning the 300+ firm to better serve middle market clients. PR Newswire · 2h ago
  23. ONDSOndas and Aston Martin Aramco Formula One Team Launch Multi-Year Partnership Built for "Speed to Decision" Ondas (ONDS) signs multi-year global F1 partnership with Aston Martin Aramco through 2029. Branding debuts on the car at the 2026 Las Vegas GP, with race suits in 2027. Annual engineering workshops begin at Silverstone in 2027. The deal leverages F1's rapid-decision environment to showcase Ondas' autonomous systems & mission-critical tech for defense, public safety, & industrial markets. ACCESS Newswire · 2h ago
  24. ALKAlaska Air Group Refreshes Atmos™ Rewards Visa® Business Card with Bank of America, Offering Higher Earn Rates and New Travel Benefits Alaska Air & BofA launched refreshed Atmos Visa Business Nov 18. Earns 10x on qualifying flights, 20x+ with status. $195 flat annual fee covers all employees. New benefits include 4 lounge passes, Global Entry credit, status points for spending, 50% off flight codes, & free point sharing. PR Newswire · 2h ago
  25. GNTXGentex Wins 2026 Pace Award for Groundbreaking Dimmable Sun Visor Technology Gentex (GNTX) wins 2026 PACE Award for dimmable sun visor using patented electrochromic tech. Shipping to first customer next year. This marks ninth award, reinforcing leadership in automotive & aerospace optics. GlobeNewswire · 2h ago
  26. AWKCalifornia American Water Brings New Groundwater Treatment and Production Capacity Online on the Monterey Peninsula California American Water launched ASR Well 4 in Pacific Grove, adding 1,400 gpm capacity. New mercury treatment ensures compliance with CA standards. Project boosts system resilience for Monterey Peninsula. Subsidiary of American Water, the largest US regulated utility serving 14M people. PR Newswire · 2h ago
  27. NVDACantor Sets the Record Straight on Nvidia: Positions Are Hedges in Connection with Client Transactions, Not Material Proprietary Investments Cantor clarifies no material Nvidia prop position; holdings stem from client equity swaps, not proprietary bets. Decline since 2025 reflects hedge unwinding. No Nvidia compensation received. Southeast Asia banking is ordinary-course business, unrelated to U.S. policy. Firm asserts all operations ethical & compliant. Business Wire · 2h ago
  28. ONTFH2O.ai Appoints Steven Vattuone as Chief Financial Officer H2O.ai appoints ex-ON24 CFO Steven Vattuone. The firm holds FedRAMP High certification & its TimeH2O-v1 model ranked first on fev-bench. Trusted by 20k orgs including half the Fortune 500. Demand grows from banks, telecoms, & governments to own AI infrastructure. Business Wire · 2h ago
  29. BIIBNew Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026 Eisai & Biogen report 3-year LEADER data: LEQEMBI reduced progression 76%. 81% stable/improved, 95% stayed early-stage, 77% amyloid clearance. Persistence high at 87.5%. SC maintenance showed no ARIA. Safety aligns with real-world meta-analysis of 5k patients showing 12.4% total ARIA rate. PR Newswire · 2h ago
  30. FOXFFox Factory Celebrates Seventh Consecutive Baja 1000 Victory and 2026 SCORE Championship Sweep Fox Factory secured 7th consecutive Baja 1000 overall victory. FOX Live Valve tech dominated UTV class with top 5 sweep & Method wheels claimed 12 podiums. FOX athletes swept all four 2026 SCORE International events. CEO Grimm says motorsports innovation drives product engineering. GlobeNewswire · 2h ago
  31. BIIBNew Three-Year Real-World LEQEMBI® Data Presented at CTAD 2026 Eisai & Biogen report LEADER study 3-year real-world data: LEQEMBI shows 76% lower progression risk vs natural history. 95% projected stable 3 yrs; 77% amyloid-negative. High persistence (87.5%) & favorable safety profile with low ARIA rates across IV & SC maintenance. GlobeNewswire · 2h ago
  32. CVLTCommvault Expands Microsoft Security Integration to Turn Threat Intelligence into Recovery Action Commvault integrates Threat Scan with Microsoft Defender for Endpoint to automate backup threat detection. IDC notes only 35% of orgs have automated safety checks. General availability today requires both tools at no price change. Builds on existing Sentinel integration. PR Newswire · 2h ago
  33. ZBRAPurpose-Driven Innovation, Frontline AI Place Zebra Technologies Among TIME's Top Manufacturers in America Zebra named to TIME's inaugural America's Top Manufacturers 2027 list. Qualified via revenue, innovation & safety pillars. Invests 10% of sales in R&D for AI, vision & RFID. Highlights strong shareholder value, resiliency & high retention. Business Wire · 2h ago
  34. CCSCentury Communities to Host November Grand Opening for Six Model Homes at Two New Florence, AZ Communities Century Communities hosts Nov 21 Grand Opening in Florence, AZ. 6 model homes across Sage Grove, Vistas, Foothills. Prices start low $300s. 275+ homesites, 3-5 bed, 1,299-2,935 sq ft. USDA eligible. Upgrades include quartz, LG appliances, smart home. Amenities: pools, trails. Online buying via Inspire Home Loans. PR Newswire · 3h ago
  35. TDACProLogium and TDAC Announce Prospective Investments of $85 Million ProLogium & TDAC signed term sheets for $85M PIPE at $10/share to fund Dunkirk gigafactory expansion. Deal closes Dec 2026, listing on Nasdaq as PRLG. Funds target 4GW capacity, unlocking $1.5B French subsidies for drone markets. GlobeNewswire · 3h ago
  36. NMRKNewmark Investor Solutions Launches Hotel Asset Management Business Led by Industry Veterans Dan Falvey and Steve Kakaty Newmark launches Hotel Asset Management led by Dan Falvey & Steve Kakaty. The unit aligns hotel performance with ownership goals using senior pros & data. Launches with a Downtown Atlanta luxury project. Excludes investment banking functions. PR Newswire · 3h ago
  37. NMRKNewmark Investor Solutions Launches Hotel Asset Management Business Led by Industry Veterans Dan Falvey and Steve Kakaty Newmark Group launched Hotel Asset Management under co-heads Falvey & Kakaty, offering independent oversight for hotel owners. The team integrates revenue optimization & capital project management with access to Newmark's broader ecosystem. This initiative supports a flagship Atlanta project while the firm reported $3.7B revenue for 12 months ended Sept 30, 2026. PR Newswire · 3h ago
  38. CVLTGC AI Hits $40 Million ARR and 2,200 Company Customers in 36 Months With Legal Intelligence GC AI hit $40M ARR 3 years post-2023 launch, 4x YoY growth. 2,200 clients include 55+ Forbes Global 2000 firms. 97% revenue from in-house legal teams. 80 NPS, 139% net revenue retention. Outpaced Glean, Shopify, Twilio, Intercom. Ranked 2026 SaaS Awards. Business Wire · 3h ago
  39. TRVGtrivago N.V.: Dr. Mathias Hansen, Vesting of Restricted Share Units. trivago GC Dr. Mathias Hansen notified of 47,683.5 USD RSU vesting on 15 Nov at 4.15 USD/share. Transaction occurred outside trading venue. ISIN US89686D3035. GlobeNewswire · 3h ago
  40. CNTNFairmint Outlines Onchain Ownership Priorities in Support of SEC Transfer Agent Modernization Fairmint TA supports SEC transfer agent modernization. Onchain registers must match traditional accountability for errors & records. Principles include onchain master files, issuer token authority, distinct key possession & single accountable agent. Recommendations draw from CNTN tokenized stock experience & ensure complete ownership history. GlobeNewswire · 3h ago
  41. TRVGtrivago N.V.: Dr. Wolf Schmuhl, Vesting of Restricted Share Units. Dr. Wolf Schmuhl notified vesting of 53,003.80 USD in trivago N.V. shares on Nov 15, 2026. Price was 4.15 USD per unit. Transaction was outside a trading venue under an employee share participation program. This marks the initial disclosure for this specific event. GlobeNewswire · 3h ago
  42. TRVGtrivago N.V.: Brandon Pedersen, Vesting of Restricted Share Units. trivago admin member Brandon Pedersen reported RSU vesting on Nov 15. 55,493.80 USD volume at 4.15 USD/share. ISIN US89686D3035. GlobeNewswire · 3h ago
  43. NUEE-Waste Is Rising Five Times Faster Than Documented Recycling E-waste hits 62M tons in 2022, recycling lags. MDRN raised $40M to build NC facility targeting 40k gold oz/year from waste 100x richer than ore. Gold costs rose 22% to $1,930/oz. IRM, RSG, NUE, KGC also reported strong Q3 2026 results. GlobeNewswire · 3h ago
  44. CCLPrincess Cruises Selected as a Good Housekeeping 2027 Travel Awards Winner, with Star Princess Named One of the Year's Best Ships Star Princess, a 177,800-ton Princess Cruises vessel debuting Oct 2025, won a 2027 Good Housekeeping Travel Award for dining, entertainment, & experiences. Operating in the Caribbean & Alaska, it features The Sanctuary Collection, 8 specialty restaurants, & original arena shows. Parent company Carnival Corp has served 345 destinations for 60+ years. PR Newswire · 3h ago
  45. GESupersonic Rule and Launch Corridor Push Shift Focus to Inland Test Airspace Four entities signed LOI for 250nm high-speed flight corridor. FAA rulemakings may lift Mach 1 overland ban. Starfighters plans Dec test; SpaceX Q3 rev $14.6B, $100B LA spaceport. Lockheed Q3 sales $20.7B, X-59 hit Mach 1.1. GE orders +49% to $19B. Howmet rev +29% to $2.7B, buyback +$5B. GlobeNewswire · 3h ago
  46. PRTHFragmented Financial Systems Mean More Work, Less Visibility for Finance Teams 70% of finance leaders use 4+ tools but only 26% have seamless integration. 77% can't track idle cash accurately; 37% lack real-time transit visibility. Priority Commerce (PRTH) offers a unified platform to solve these cash flow pain points. Business Wire · 3h ago
  47. BNEDBarnes & Noble Education to Host Fiscal 2027 Second Quarter Earnings Call on December 9, 2026 Barnes & Noble Education reports Q2 FY27 results after market close Dec 8, 2026. Conference call at 8:30 a.m. ET Dec 9. Dial-in: 888-506-0062 or 973-528-0011, code 319635. Webcast at investor.bned.com under Events & Presentations. GlobeNewswire · 3h ago
  48. BYByline Bank Named to 2027 America’s Best Workplaces by Best Companies Group Byline Bank, a $9.9B Chicago lender with 40+ branches, earned 2027 America's Best Workplace status. Rankings rely on algorithmic analysis of policies, demographics, & employee surveys. The bank serves SMBs, financial sponsors, & consumers with commercial banking, leasing, & SBA loans. GlobeNewswire · 3h ago
  49. IIICriteria and Options Expand for Enterprises Choosing Cloud Platforms, ISG says ISG 2026 buyers guides show enterprises now prioritize sovereignty & latency over provider size. Microsoft leads global cloud; T-Systems tops sovereign. Demand for regional & sovereign services expected to grow by 2028 to meet data rules. Report ranks 49 providers across 4 categories without sponsorships. Business Wire · 3h ago
  50. HSYHershey's Celebrates Its Story with Five-Cent Milk Chocolate Bars Ahead of the HERSHEY Movie Hershey sells classic 5c bars Nov 25 for HERSHEY movie. Locations: Chocolate World, Times Square, Walmart, Amazon. Limits apply. Vintage packaging now available. No discounts on 5c offer. PR Newswire · 3h ago

FDA Approvals

More →
  1. HIMSHims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy CNBC · 4h ago
  2. TOMZTOMI Environmental Solutions Expands SteraMist iHP in Meat, Poultry and Dairy Processing as Enterprise Food Producers Evaluate Multi-Facility Standardization GlobeNewswire · 5h ago
  3. NNOXNanox to Showcase Its Innovative Technology and Advances Across Nanox.ARC X and Nanox.AI at RSNA 2026 GlobeNewswire · 5h ago
  4. TELOTelomir Pharmaceuticals Selects Linical to Advance FDA-Cleared Phase 1/2 Clinical Trial of Telomir-Zn in Triple-Negative Breast Cancer GlobeNewswire · 5h ago
  5. RXRXRecursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis GlobeNewswire · 8h ago
  6. CDIOCardio Diagnostics to Unveil Non-Obstructive Coronary Artery Disease Data, FDA Breakthrough Device Designation Strategy, and India Launch Update on December 10 Investor Call Business Wire · 1d ago
  7. MAIAMAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung Cancer GlobeNewswire · 1d ago
  8. CNXUConexeu Sciences Announces Early-Stage Development of W.A.F.E.R.™ Sheet and W.A.F.E.R.™ Lattice, Fabricated Formats of Its Investigational CXU™ Platform GlobeNewswire · 1d ago
  9. NRXPNRx Pharmaceuticals (Nasdaq: NRXP) Reports Third Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire · 1d ago
  10. NTRBNutriband Announces USPTO Notice of Allowance for Commercial Brand Name Trademarks for Its Abuse-Deterrent Fentanyl Transdermal System GlobeNewswire · 1d ago
  11. MDTMedtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system PR Newswire · 1d ago
  12. CGONBiotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection PR Newswire · 1d ago
  13. RHHBYFDA Approves Genentech’s WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer Business Wire · 1d ago
  14. AEONAEON Biopharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire · 1d ago
  15. IDYAIDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas PR Newswire · 1d ago
  16. CADLPRISM MarketView Highlights Seven Small-Cap Lung Cancer Developers for Lung Cancer Awareness Month GlobeNewswire · 2d ago
  17. MMEDFDA Clears MiniMed Fit™ -- World's First and Only Tubeless Insulin Pump with Up to Seven-Day Wear and Zero Interruptions PR Newswire · 2d ago
  18. EOCNEocene and Barcode Nanotech Report Progress in the Development of Tumor Microenvironment-Targeted Lipid Nanoparticles Formulation of Aramchol PR Newswire · 2d ago
  19. OCSOculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses GlobeNewswire · 2d ago
  20. OCSOculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses GlobeNewswire · 2d ago
  21. RHHBYGenentech’s Gazyva Becomes the First FDA-Approved Treatment for Primary Membranous Nephropathy Business Wire · 2d ago
  22. SMMTSummit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application Business Wire · 3d ago
  23. BYSIBeyondSpring Reports Third-Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire · 4d ago
  24. CINGWCingulate Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA Resubmission GlobeNewswire · 4d ago
  25. VTGNVistagen Reports Fiscal Year 2027 Second Quarter Financial Results and Provides Corporate Update GlobeNewswire · 4d ago
  26. NTHINeOnc Showcases Two Brain Cancer Drug Programs at SNO as FDA Meetings Approach GlobeNewswire · 5d ago
  27. TNDMTandem Mobi Now FDA Cleared as World’s First and Only Tubeless AID System with up to Seven Days of Wear Business Wire · 5d ago
  28. AARDAardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates GlobeNewswire · 5d ago
  29. RVPHReviva Reports Third Quarter 2026 Financial Results and Recent Business Highlights GlobeNewswire · 5d ago
  30. YDESYD Bio Announces FDA Grant of INTERACT Meeting Request for YDB-LMSCEV-001, an Investigational Extracellular Vesicle Candidate for Dry Eye Disease GlobeNewswire · 5d ago

BNN Bloomberg

More →
  1. Bausch Health discontinued Retin-A in Canada for business reasons, not safety. Stock lasts until March or depletion. Experts warn alternatives cost over $100 vs the $40 price point, urging patients to consult pharmacists instead of stockpiling as other effective treatments remain available. 23m ago
  2. TGTXNasdaq down 10% from Oct high; S&P 500 at 18x earnings. Top picks: TG Therapeutics (MS drug sales), Medpace (R&D recovery), UNFI (cash flow). AI spending supported, but inflation risks loom. Feb picks: Merck +23%, Citigroup -0.3%, Celestica -18%. 33m ago
  3. Culture Minister Marc Miller declined to discuss confidential Meta talks to end Canada's news blackout. Meta proposed commercial deals & funding 2 roles for an Online News Act exemption. The proposal was part of collapsed U.S.-Canada trade talks. Meta blocked news after 2023, while Google paid $100M. Report published Nov 18, 2026. 59m ago
  4. Metro Q4 profit fell to $201.9M from $217M as a 6-month strike cost $132M for FY26. CEO Giroux noted freshness & assortment issues. Total sales rose 1.4% to $5.18B but food same-store sales dropped 1.9%. Pharmacy sales grew 5.5%. Plans include expanding discount banners Food Basics & Super C. 59m ago
  5. Bausch Health discontinued Retin-A cream & gel in Canada for business reasons, not safety. Inventory lasts until March. Alternatives exist but cost more, e.g., Retin-A Micro over $100 vs $40. Patients should consult providers & verify insurance to avoid treatment gaps & system strain. 1h ago
  6. Porter pilots vote on strike mandate amid first contract talks. 200 picketing; key issues are wages & scheduling. Federal conciliation ends Sunday. Potential strike begins Dec 14. Company faces fuel cost pressure from Iran war & $125M bailout. 1h ago
  7. Housing Minister Robertson declined to reaffirm the 2025 pledge to double annual home building to 500,000 over a decade. The PBO says Ottawa is not on track for that goal, which was absent from the recent federal budget. Focus now shifts to boosting supply, stabilizing Toronto & Vancouver markets, tripling non-market housing, & ending homelessness. 1h ago
  8. TSX fell 651 pts to 34,663 on mining, energy, & financial losses. Dow dropped 617 to 50,141. S&P 500 slid 39 to 7,301. Nasdaq dropped 42 to 24,286. CAD weakened to 69.77 US cents. Crude fell $1.74 to $82.91. Gold dropped $114 to $3,750.20. 2h ago
  9. ANTAnthropic IPO priced Wednesday at $1.4T valuation, 40x sales. Strong institutional demand persists despite high multiples vs Amazon or Alphabet. Concerns over rates, regulation, & AI productivity. Insiders may sell 29% after 180 days. Share performance could dictate OpenAI IPO outlook. 2h ago
  10. Trump meets Putin & Xi in Shenzhen to discuss nuclear limits & Ukraine, expecting no breakthroughs. Personal diplomacy drives agenda amid AI security fears & $1T China surplus. U.S. outages claimed unrelated to cyberattacks. 2h ago
  11. PM Carney says Canada-Taiwan trade deal finalized March 2025 may be signed soon at APEC Shenzhen Nov 18. Docs confirm provinces consulted. Bloc Québécois accuses delay to avoid China upset. Commons foreign affairs committee recommends signing aligns with Indo-Pacific strategy. 3h ago
  12. PM Carney says telecom decisions must drive competition, lower prices & better service. He addressed Quebecor's Telus takeover at APEC, noting fewer players could boost competition. Telus calls the unsolicited bid undervalued amid regulatory hurdles. Report dated Nov 18, 2026. 3h ago
  13. Bausch Health discontinued Retin-A in Canada for business reasons. Stock lasts until March. Alternatives exist but cost over $100 vs prior $40. Experts warn against stockpiling & note rising patient burdens in a stretched healthcare system. 3h ago
  14. TTWOTake-Two shares up 6% as GTA VI launches. Wells Fargo raised FY sales forecast to 65M units, bookings to $9.76B. Oppenheimer estimates $1.85B gross in 3 days. Sensor Tower reports 17.1M units sold, surpassing GTA V pre-orders. 3h ago
  15. Global luxury sales projected to grow 2% in 2026 to €367bn, ending a decline but lagging the 5% 15-year avg. Growth to 0-4% in 2027 led by Americas as China stays subdued. Consumer base shrank to 315m. Spending shifts to experiences; jewelry outperforms fashion. European stocks fell 22% amid tech selloff. US heritage brands beat peers by 6% H1. 4h ago
  16. Target beats 3rd qtr estimates with 5.6% comp sales growth & 6% 2026 forecast. CEO invested $5B to lower prices & expand grocery. Apparel down 3.8% while hardlines surged 27% on toy demand. Digital up 9.8% despite inflation. Analysts note apparel recovery may take a year. 4h ago
  17. Nvidia shares rose 4% on revenue doubling to $116B despite CEO departure reports, lifting chipmakers. S&P 500 futures gained 0.6% while oil declined on rising inventories. Fed minutes suggest rate hike risk as 10Y yield nears 5.15%. Europe slipped on inflation; Asia mixed. 5h ago
  18. Carney met Trump in Shenzhen to advance trade deal while rejecting Putin's claim that sanctions are obsolete. Leaders agreed to respect Canadian sovereignty & culture. Carney noted US concerns over China ties were not a top priority. He also encouraged Asian investment as Canada's global standing strengthens. 5h ago
  19. NVDANvidia shares rose 3.5% on $130B Q4 forecast. CoreWeave & Nebius jumped 5.4% & 7% as major chip stocks advanced. AI sector faces regulatory hurdles post-election, yet demand remains strong. Focus shifts to Anthropic IPO valuing up to $1.4T. 5h ago
  20. Metro Inc. Q4 profit fell to $201.9M vs $217M last year due to resolved Quebec strike. Revenue rose 1.4% to $5.18B. Food same-store sales down 1.9%, pharmacy up 5.5% driven by prescriptions. EPS 97 cents vs $1.13 prior year. 5h ago
  21. La Caisse leads talks to buy up to 50% of Bain's Bridge Data Centres, potentially valuing the stake at $4B-$5B. BDC serves AI demand in SE Asia despite chip curbs & debt concerns. Deal expected soon. 6h ago
  22. NVDANvidia shares rose 4% on strong Q4 guidance despite $700B value drop after CEO Huang resigned following intelligence investigation. Interim CEO Kress pledged discipline & confirmed TSMC support as board rejected Huang's return. 6h ago
  23. Carney met Trump in Shenzhen, noting China ties aren't a top US priority. He urged Chinese investment in Canadian megaprojects as global order shifts. Putin claimed sanctions are ineffective, but Carney insisted they remain real & increasing. Business leaders report improved Canada standing in APEC & Asia. 6h ago
  24. Toronto's new council features housing activists aiming to fix affordability. McNally will revive rights committees; Padovani seeks rent limits. Homelessness fell 8% locally since 2022 but remains an emergency. Fed budget allocates $30B nationally. Mayor Chow moved 15k to housing. Nearly half Toronto rents. Activists must learn compromise to drive change. 7h ago
  25. Carney declared Canada-China relations fully resumed after meeting Xi. New trade concessions cut tariffs on pork, seafood, & beef, boosting exports to nearly $8B. China suspended tariffs through 2028. Carney sought auto investments but EV limits remain. US adviser Navarro criticized the strategy. 7h ago
  26. World shares mixed as AI stocks recovered. Oil fell with Brent down 1.6% to $91.67. UK inflation hit 3.6% in Oct. S&P 500 futures up 0.6%. Nvidia shares volatile ahead of earnings; new board committee for trade compliance. 10-year yield at 5.10%. 7h ago
  27. Canada's Justice Dept spent $3.45M on legal costs challenging Quebec's Bill 21. The Bloc Québécois criticized the expense as federal funds used against provincial law. The Supreme Court is reviewing the use of the notwithstanding clause while the Court of Appeal upheld most of the 2019 statute. 7h ago
  28. Grand Theft Auto VI launches Thursday, marking a major franchise milestone with 470M+ total sales. The 212GB game features Vice City, dual protagonists, & record marketing hype. Miami secured a $3.9M promotional deal despite local criticism. Rockstar awaits global player feedback as details emerge. 7h ago
  29. Trump visited China to boost tech leadership despite US outages at Microsoft & JPMorgan. Rubio blames patching, not hackers. Trump hugged Xi in Shenzhen; Putin arrived separately. Trilateral talks with Xi & Putin aim to discuss Ukraine & nukes but expect no breakthroughs. AI security concerns persist after Nvidia CEO Jensen Huang removal. Trump hesitant to cut off China's chips. 7h ago
  30. PM Carney says Canada must emulate China's growth while safeguarding against interference. Canada lifts steel/aluminum restrictions for ag access & announces an AI partnership. Despite US backlash, Ottawa seeks to diversify away from US dependence via Asia-Pacific ties. 8h ago
  31. Disability Can, formerly March of Dimes Canada, rebrands to reflect 75 years of evolution & a modern view that barriers limit achievement. Founded in 1951 for polio research, it now serves 30k+ people with 2,500 staff. Report by The Canadian Press on Nov 17, 2026. 8h ago
  32. Carney met Trump in Shenzhen, noting China ties aren't a top priority. He urged Asian investors to fund Canadian megaprojects, citing an ambitious infrastructure push. Carney rejected Putin's claims that sanctions are irrelevant, asserting they will increase as long as the war in Ukraine continues. Canada's standing in Asia is stronger than in years. 8h ago
  33. Canada & India near finalizing FTA after 16 years. Trade targets $70B by 2030 vs $30.4B in 2025. Modi visits Dec 11-12 for potential defence deal. Talks resumed Nov 2025; ministers met 10 times since May 2025. 17h ago
  34. Health Canada recalled 4 Pendopharm PegLyte Powder lots (260303-260306) over foreign matter risk. Consumers must verify lot numbers. Those with affected products should consult a healthcare provider before stopping use. Report side effects via official systems. 18h ago
  35. Apple, NSA, United, JPMorgan, Equinor, \& IIHF faced recent outages. Officials attribute most disruptions to system upgrades or maintenance, not coordinated cyber attacks. Experts warn interconnected risks remain high. 18h ago
  36. Carney met Xi at APEC to discuss Chinese auto investment if US trade talks fail. Thomas warns of data risks calling EVs computers on wheels. Ford urges caution. Navarro calls engagement offensive. Jan 2026 deal allows 49k EVs at 6.1% tariff. No new import announcements made. 18h ago
  37. Jody Thomas warns Chinese EVs pose data risks to Beijing. PM Carney explores Chinese auto investment as a fallback if U.S. talks fail, citing a Jan 2026 deal lowering tariffs. Ontario Premier Ford urges caution while Trump advisers call engagement offensive. 19h ago
  38. Joly meets Stellantis CEO in Toronto amid scrutiny over Brampton sale to Roshel. 2,200 workers remain laid off. Officials knew of deal months prior despite initial "betrayal" claims. Gov offered $529M in 2022; Stellantis to repay $24M. Carney now calls it partial solution. 19h ago
  39. Nvidia board won't reinstate CEO Huang. He offered to return if board deems it best for shareholders, country. House lawmakers scheduled interviews Dec 1 regarding national security & suspected Chinese intel asset. New oversight committee created with 3 board members & experts. Trump endorsed committee. 20h ago
  40. Canadian Trade Minister LeBlanc defends PM Carney's account of trade talks with Trump, citing US demands on foreign deals, French rules & auto tariffs. Ottawa & Washington blamed each other for collapse. LeBlanc says retaliatory tariffs protect domestic industries. 20h ago
  41. CA DMV bans Waymo on freeways citing safety hazards after incursions into construction zones. Waymo halted freeway ops pending review but continues surface street service in CA. Restriction lifts only after corrective actions prove effective. 21h ago
  42. NVDANvidia Q4 revenue forecast $130B beats $125.25B estimates despite Jensen Huang resignation amid China security probe. Interim CEO Colette Kress leads as board adds national security committee. China chip sales excluded. Vera Rubin expected to drive 20% of data center revenue. 21h ago
  43. Jensen Huang removed as Nvidia CEO last week. He issued a statement admitting personal mistakes & cooperating with the board. Huang thanked supporters & expressed willingness to return as CEO if the board deems it best for shareholders & America. 23h ago
  44. Apple services, NSA internal networks, US banks, United Airlines & Microsoft systems faced disruptions. No cyberattack evidence found; officials confirm no crisis or security threat. 23h ago
  45. Anthropic IPOs this month with a unique Long-Term Benefit Trust holding Class T stock to elect 3 board directors, prioritizing AI safety over profits despite no economic rights. Critics warn measuring public benefit is hard & Chinese open-source models may pressure safety guardrails. 23h ago
  46. Apple services faced outages Tuesday. Affected platforms included App Store, Apple Music & AppleCare on Device. System status site confirmed disruptions. Further details pending. 1d ago
  47. PEPS&P 500 earnings up 30% but free cash flow down. Equity supply rising, weighing on large caps. Equal-weight led Oct-Nov, widest gap since 2009. Top picks: WSP (14x 2027 earnings), PepsiCo (4% yield, 54 yrs dividend growth), Alphabet (cloud growth, AI risks). All held in Cobb's personal portfolio. 1d ago
  48. 178 orgs including Zoom, HSBC, & Salesforce hit by malicious JS via Optimizely. Attackers targeted crypto wallets & payment data. Optimizely patched vulnerability; Equifax halted platform use. Total impact unclear as third-party risks rise alongside $22.3B in crypto thefts since 2021. 1d ago
  49. Canada S&P/TSX fell 337 pts to 35,384 on tech losses. US markets declined: Dow -752 to 50,855, S&P500 -85 to 7,332, Nasdaq -306 to 24,203. CAD rose to 70.03 US cents. Dec crude up $1.34 to $87.06; gold up $21.50 to $3,874.50/oz. 1d ago
  50. DB Ventures sues Coty in NY for unauthorized discount sales damaging Beckham fragrance brand. Seeking $41M damages. Coty seeks dismissal citing lack of jurisdiction & claims suit aims to exit deal for Interparfums. Both parties dispute claims. 1d ago

Earnings Reports

More →
  1. BNEDBarnes & Noble Education reports Q2 FY27 results after market close Dec 8, 2026. Conference call at 8:30 a.m. ET Dec 9. Dial-in: 888-506-0062 or 973-528-0011, code 319635. Webcast at investor.bned.com under Events & Presentations. 3h ago
  2. SAICSAIC reports Q3 FY2027 results before market open Dec 3, 2026. Management discusses financials via webcast at 10:00 a.m. ET. The company serves defense, space, civilian & intelligence markets with 23,000 employees & $7.3B annual revenue. 5h ago
  3. PREPrenetics Q3 2026 revenue hit $64.1M, up 228% YoY, beating guidance. IM8 revenue reached $62.9M. Adjusted EBITDA loss narrowed to 20% of revenue. Adjusted free cash flow was positive at $4.1M. FY2026 revenue guidance reaffirmed at $220-230M. H2 2026 EBITDA loss raised to $30-35M to fund growth. 5h ago
  4. NVDANvidia shares rose 4% on strong Q4 guidance despite $700B value drop after CEO Huang resigned following intelligence investigation. Interim CEO Kress pledged discipline & confirmed TSMC support as board rejected Huang's return. 6h ago
  5. TJXTJX Q3 sales rose 6% to $16B; comp sales up 4% vs plan. EPS $1.39 beat expectations. Margins expanded 30bps. Returned $1.5B to shareholders. Full-year sales growth outlook 4%. Inventory flat. Expanding footprint with 64 new stores. 6h ago
  6. OMSEOMSE reports H1 FY2027 results Nov 25 pre-market. Conference call at 8am ET. Replay on ir.omsos.com. Company manufactures wellhead systems & tubular goods across Asia Pacific, Middle East, North Africa. 6h ago
  7. TGTTarget Q3 2026: Sales +7.1% to $27.1B; Comp sales +5.6%. EPS $2.65 vs $1.51. Raised FY guidance to $10.65-$11.40 EPS. Capex $5-6B for 2027. Margins at 6.2%. Dividend up 1.8%, $251M buybacks. 7h ago
  8. LOWLowe's Q3 EPS: $3.10 adj. Sales up 9.3% to $22.8B. $250M tariff benefit boosted earnings. FY26 outlook: $12.25 EPS, $92.5B sales. Maintains Dividend Aristocrat status. Conference call Nov 18. 7h ago
  9. NVDANvidia stock rose 3% premarket after Q3 revenue hit $115.8B vs $109.1B est. Q4 guidance of $130B beat $125.1B consensus. CoreWeave, Nebius, Iren shares also jumped. Board chair Jones confirmed no plan to reinstate Huang as CEO despite his openness to return. 9h ago
  10. TGTTarget reports Q3 results Wednesday, up 60% YTD. Raised full-year outlook after lowering prices on 10k items. EPS expected $2.07, revenue $26.56B. CEO notes work remains as apparel lags. Morgan Stanley sees encouraging quarter but questions durability. 13h ago
  11. NVDANvidia Q3 rev $115.84B beats exp; Q4 guide $130B tops consensus. 2028 growth raised to 75%. China excluded from data center outlook. Supply commitments hit $390B. Shares up 5% despite CEO search volatility. New US export rules target 5 Asian/Latin American nations. 14h ago
  12. NVDAJensen Huang resigned after 33 years. Interim CEO Kress reported $115.8B revenue, up 2x, with 75% growth forecast. Shares rose 5% on strong demand. Board chair Jones confirmed Huang won't return. Vera Rubin AI sales hit $20B. New rules limit Chinese chip access. 15h ago
  13. NVDANvidia beat earnings & revenue as Colette Kress raised outlook, lifting shares 4%. Cramer sees results as phenomenal but urges share buybacks over unrelated spending, noting the firm can thrive without Huang. 19h ago
  14. GLADGladstone Capital Q4 net investment income $0.49/share, up to $2.00 for 2026. Coverage 100% of quarterly distributions & 104.5% for fiscal 2026. Non-accruals at 2.8% of debt. Portfolio $956M, up 11.7%. New leadership effective Oct 2026. Call Nov 18 at 8:30 a.m. ET. 21h ago
  15. NVDANVIDIA Q3 FY27 revenue hit $115.8B, up 103% YoY. Data Center grew 110% to $107.6B. Gross margin 74.8%. Raised buyback by $150B. Acquired Hugging Face. Q4 revenue guidance $130B. 21h ago
  16. WOOFPetco Q3 FY26 results & call Dec 8 at 4pm ET. Webcast on IR page. Firm operates 1,500+ US, Mexico, PR stores. Petco Love founded 1999, placed 7M+ animals. 21h ago
  17. CASYCasey's General Stores (CASY) will report Q2 2027 results after market close Dec 8, 2026, with a webcast call following on Dec 9 at 7:30am CT. The Fortune 500 convenience & pizza retailer operates nearly 3,000 stores. 23h ago
  18. POWLFiscal 2026 revenue reached a record $1.3 billion, driven by a 124% year-over-year increase in new orders to $2.6 billion and a backlog growth to $2.7 billion. The company reported diluted earnings per share of $6.04 for the full year and expanded its gross margin to 31.3%, supported by strong project execution and favorable closeouts. Management projects fiscal 2027 revenue growth fueled by a balanced backlog mix, with capacity expansions in Ohio, Texas, and Jacinto Port expected to support over $100 million in incremental annualized revenue. Key growth drivers include the LNG sector, electric utility projects, and a strategic shift toward configured-to-order models in the commercial and data center markets. 1d ago
  19. OCSLIn the fourth fiscal quarter, adjusted net investment income decreased to $29.6 million per share, while full-year 2026 adjusted net investment income totaled $131.7 million. The company declared dividends of $1.39 per share for the year, representing 108% of its adjusted net investment income, and maintained net leverage at 1.00x. Non-accruals in the debt portfolio were reduced by 44% to 1.8% of total fair value, driven by the resolution of specific credit issues and the restructuring of BioXL Therapeutics. Looking ahead, management anticipates that recent Federal Reserve rate hikes will positively impact net investment income starting in the December quarter, with 91% of debt investments floating or swapped. 1d ago
  20. ALLNDatabricks is a private company projecting an annual revenue run rate of approximately $7 billion by August 2026, driven by an 80% year-over-year growth rate fueled by consumption-based pricing for data governance and security. The company differentiates itself by focusing on the integration of AI with legacy enterprise data and security rather than building foundational models, with a strategic roadmap centered on its Genie AI agent system for automating organizational intelligence. Management anticipates a slow macroeconomic adoption curve for AI, estimating a 10 to 15-year timeline for significant GDP impact, while prioritizing long-term execution over immediate public market entry. 1d ago
  21. KITTIn the third quarter of 2026, the company reported revenue of $2.2 million and a net loss of $4.9 million, reflecting improved financial performance driven by disciplined cost management and reduced non-cash debt extinguishment losses. Strategic initiatives focus on transitioning from short-term tactical contracts to long-term agreements in offshore wind, subsea cable laying, and defense sectors, with specific growth anticipated in the Gulf of America market during 2027. The organization is advancing its Nauticus Toolkit integration and Aquanaut autonomous platform while finalizing regulatory approvals for a new manufacturing hub in the UAE to support regional commercial and defense demands. 1d ago
  22. FUBOFuboTV reported fiscal Q4 2026 North American revenue of approximately $1.5 billion, a 22% year-over-year increase driven by improved advertising metrics, while achieving a pro forma net loss of $134 million for the full year. The company generated positive free cash flow of $36.1 million in the quarter and strengthened its liquidity position to $272.4 million, marking a strategic shift away from subscriber count growth toward profitability and adjusted EBITDA. Management reaffirmed a long-term target of at least $300 million in adjusted EBITDA by fiscal 2028 and highlighted key initiatives including the integration of Hulu Live into the Disney+ app and the development of AI-driven capabilities to enhance operational efficiency. 1d ago
  23. TOPSTOP Ships Q3 2026 net income $4.3M, rev $14.6M vs prior year. 9-mo net income $10.8M, rev $40M. Fleet util 100%, TCE $28,723. 12 newbuildings ordered. $1.07B revenue backlog. Reverse split Nov 6. Cash $10.7M. 1d ago
  24. HDHome Depot reported Q3 2026 total sales of $43.4 billion, reflecting a 4.9% year-over-year increase with comparable sales growing 2.2%. Adjusted diluted earnings per share rose 3.2% to $3.86, while gross and operating margins contracted slightly due to rising input costs and strategic mix shifts. The company updated its full-year fiscal 2026 guidance to anticipate sales growth of approximately 4.5% and adjusted EPS growth of 2%, despite headwinds in the roofing sector and a pressured housing market. Online sales continued to accelerate with 13% growth, driven by AI-enabled search and expanded fulfillment options, while the Pro business maintained positive momentum across all cohorts. 1d ago
  25. SRFiscal 2026 adjusted earnings per share rose 20% to $4.02, driven by utility earnings growth and a $257.6 million after-tax gain from the divestiture of the Mississippi storage and marketing business. The company has transitioned to a fully regulated portfolio following the acquisition of Spire Tennessee and is projecting fiscal 2027 adjusted EPS between $5.05 and $5.25. An $11.8 billion capital plan spanning 2027 to 2036 aims to support approximately 7% annual rate base growth, anchored by the MoGas pipeline expansion and new regulatory frameworks in Missouri, Tennessee, and Alabama. 1d ago
  26. AUTanzania gold exports up 37.4% to $5.67B in FY2026. Mining now 10.1% of GDP. Lake Victoria Gold started Imwelo drilling; Tembo project holds 580k oz NI 43-101. AngloGold Q3 output 120k oz at $1,349/oz cash cost. Barrick secured North Mara licenses after $5.3B investment. B2Gold Q3 produced 193k oz. 1d ago
  27. HDNRF forecasts 4.2% holiday growth to $1.013T. Adobe expects record $275.1B online spend. Home Depot, Lowe's, Walmart & TJX all report strong Q2 sales & raised full-year guidance, signaling robust consumer demand for the 2026 season. 1d ago
  28. BLGOBioLargo Q3 rev $1.09M down 1%, net loss $3.8M down 47%. Clyra drove 57% of 9-mo loss. PFAS AEC tech validated in NJ. New distributors added for ViaCLYR. 9-mo rev $3.45M down 52%. No earnings call; annual meeting Dec 1. 1d ago
  29. DISDisney reported 7% revenue growth and 16% adjusted EPS growth for fiscal 2026, driven by strong performance in domestic parks and double-digit Disney+ SVOD revenue growth. The company plans to merge Disney+ and Hulu into a unified app by December while increasing content spending by 9% to $26 billion in fiscal 2027. Major expansions for Disney Experiences, including new park lands and a cruise fleet of 13 ships, are scheduled for 2027 and 2028, supported by a $3 billion annual savings target from an efficiency program. Management remains optimistic about long-term growth, citing a unique IP flywheel advantage and the recent hiring of a Chief Technology Officer to lead AI and product innovation. 1d ago
  30. ACMThe company reported record fiscal 2026 results with Net Services Revenue growth driven by design and international segments, while adjusted EBITDA margins reached a record 19.2%. Full-year adjusted earnings per share grew 20%, and free cash flow exceeded prior guidance despite an anticipated $500 million cash outflow for two Construction Management projects in fiscal 2027. Looking ahead, fiscal 2027 revenue growth is forecast between 4% and 6%, with margins expected to expand as Construction Management projects ramp up in the second half of the year. Management maintains a long-term target to exit fiscal 2028 with margins above 20% and has increased the quarterly dividend by 10%. 1d ago
  31. LUXEGroup net sales increased 8.5% in constant currency to €250.8 million, marking the strongest growth since the YNAB acquisition, while adjusted EBITDA margin improved to +2.1% for the fourth consecutive profitable quarter. All three business segments, including MyTheresa, Net-a-Porter & Mr. Porter, and Jukes, delivered positive financial results driven by full-price selling strategies, top customer engagement, and significant cost reductions. The company has raised its full-year FY27 net sales growth guidance to a range of +6% to +9% and adjusted EBITDA margin guidance to +2.5% to +3.5%, citing accelerated growth and successful operational transformations across its portfolio. 1d ago
  32. TGTTarget hosts Q3 earnings call Nov 18 at 7 a.m. CT. Access via Corporate.Target.com/Investors under Events & Presentations. The retailer operates 2,000+ U.S. stores with 400,000+ team members. 1d ago
  33. CPRTCopart (CPRT) Q1 FY27 earnings Dec 1 before open. Call at 8am ET. Webcast at copart.com/investorrelations. Global auction leader with 250+ locations in 11 countries. Sold 4M+ units in 2026. 1d ago
  34. LUXEThe group achieved record net sales growth of 8.5% to €610.4 million, driven by a 590 basis point expansion in adjusted EBITDA margin to 2.1% and significant SG&A cost reductions. All three business segments, including MyTheresa, Net-a-Porter & Mr. Porter, and Ux, delivered improved profitability through a strategy focused on top customers, full-price selling, and operational discipline. Management has raised its full-year 2027 adjusted EBITDA margin guidance to 2.5%–3.5% and net sales growth guidance to 6%–9%, while targeting EBITDA break-even for the Ux business by fiscal year 2028. 1d ago
  35. OPRAIn Q3 2026, the company reported revenue of $182.8 million, representing a 20% year-over-year increase driven by a 22% rise in Average Revenue Per User. Advertising revenue reached $116.8 million, with gaming emerging as a material contributor showing double-digit growth, while query revenue totaled $65 million. The company achieved an adjusted EBITDA margin of 24% and returned $73.3 million to shareholders through dividends and share repurchases. Full-year 2026 revenue guidance was raised to $735–$742 million, reflecting confidence in cross-channel capabilities and the expansion of connected TV and gaming verticals. 1d ago
  36. DISDisney beat EPS at $1.77 vs $1.67 forecast. Revenue rose 16% to $25.9B. Board approved 33% dividend hike to $2/share. Plans to spend 9% more on content while cutting $3B in expenses by 2029. CEO D'Amaro targets streaming & parks growth. Double-digit EPS growth expected in 2027. 1d ago
  37. NXTNextpower raised 2030 revenue target to over $7.5B & adj EPS to $8. Upgrades driven by power conversion, storage & eBOS growth. US inverter capacity ramps to 10GW by 2027 with shipments starting summer 2027. 1d ago
  38. DBIDesigner Brands Q3 2026 earnings on Dec 8. Management call at 8:30 AM ET. The retailer operates 660+ stores & a billion-dollar digital business. Since 2018, it donated 13M+ shoes to Soles4Souls. 1d ago
  39. MOVMovado Group inc FY27 Q3 earnings call Nov 24 at 9am ET. CEO Grinberg & CFO DeMarsilis present. Press release pre-market. Dial 877-407-0784 ID 13763847. Live webcast at movadogroup.com. Replay available until Dec 8. 1d ago
  40. CTRNCiti Trends (CTRN) reports Q3 2026 earnings Dec 1 before market open. Conference call at 9:00 a.m. ET. Dial-in 1-877-407-0779. Replay available for one year at ir.cititrends.com. The retailer operates 597 stores across 33 states. 1d ago
  41. NVDANvidia drops 4% amid China claims & Trump trade concerns; Intel down 3%. Disney earnings expected with $109B AI revenue forecast. Deutsche Bank slips on tax leak & Epstein links. Anthropic IPO demand nears SpaceX. Aschenbrenner buys AI; Eisman turns cautious. 1d ago
  42. HDHome Depot beats Q3 EPS to $3.86 & revenue to $43.4B. Richard McPhail replaces Ted Decker as CEO. Ann-Marie Campbell becomes COO. Jordan Broggi appointed CFO. Full year sales expected up 4.5%. Online comps up 13%. Focus remains on pros & AI. 1d ago
  43. NVDANvidia shares fell 0.56% to lowest since July 2025 after Jensen Huang resigned following espionage allegations. Board rejects reinstatement despite 190k signatures. U.S. lawmakers increasing scrutiny on chip access while Commerce Dept. issues rules to block remote Chinese access. 1d ago
  44. DISDisney Q4 earnings Tuesday. Focus on streaming, parks & D'Amaro's strategy. Layoffs cut costs by 20%. LSEG expects $1.67 EPS, $25.18B revenue. Wall Street seeks DTC subscriber & ad growth data. Company no longer reports quarterly subs or linear TV breakdowns. Parks drove revenue last quarter despite global headwinds. 1d ago
  45. YALAIn the third quarter of 2026, the company reported total revenue of $90.4 million, a 0.9% year-over-year increase driven by a 13.7% surge in game services revenue. Non-GAAP net income reached $37.6 million, supported by a 41.4% non-GAAP net margin despite a 73.3% increase in selling and marketing expenses to fund new gaming initiatives. The company maintains a strong liquidity position with $772.2 million in cash and investments while projecting full-year 2026 revenue to remain broadly flat. Looking ahead, double-digit revenue growth is anticipated for 2027, led by the expansion of new gaming businesses and the deployment of AI-driven development tools. 1d ago
  46. AYAAya Gold & Silver amended Q3 2026 filings to correct silver ounces sold at Zgounder to 1.4M oz due to inventory error. Revenue & net income unchanged. Consolidated silver eq. sales rose to 1.89M oz. Cash costs per oz fell to $14.28. Morocco operations continue with Boumadine feasibility ongoing. 1d ago
  47. DISDisney releases FY2026 & Q4 2026 results Nov 17 at 6:30 a.m. ET. Webcast follows at 8:30 a.m. ET. Materials & replay at disney.com/investors. Forward-looking info included. 1d ago
  48. BAERBridger Air reported Q3 2026 revenue of $76.4 million, a 16% year-over-year increase, while year-to-date net income fell to $4.1 million due to slower European fire season adoption and King Air modification delays. The company has lowered its full-year 2026 revenue guidance to $124–$128 million and adjusted EBITDA guidance to $36–$39 million, citing weather-dependent volume shortfalls and operational delays. Management is executing a strategic pivot to refocus on core aerial services, including workforce reductions and the repatriation of European scoopers, while securing long-term contracts with Meditech and Texas A&M to support a 2027 outlook. 1d ago
  49. SLIThe company reported a $36.7 million net loss for the third quarter of 2026, primarily driven by a $41 million non-cash fair value remeasurement loss on contingent payments from Equinor following a delay in the Southwest Arkansas project's Final Investment Decision. The FID target has been pushed to the end of the first quarter of 2027, with construction expected to commence shortly thereafter on a two-to-three-year timeline. Despite the accounting loss, the company secured binding off-take agreements totaling 20,000 tons annually and increased its senior secured debt financing target to over $1.2 billion. The firm maintains a cash balance of $118.1 million and continues to advance resource definition for its East Texas Franklin project while validating its technology through partnerships with major industry players. 1d ago
  50. RCATIn the third quarter of 2026, the company reported revenue of $11.8 million, a 22% year-over-year increase, while recording a net loss of $40.4 million due to inventory scrap, warranty expenses, and unabsorbed overhead. Gross margins contracted significantly to 0.6% as the organization restructured its FlightWave division and reduced its workforce by 10% to consolidate operations. Despite withdrawing full-year revenue guidance caused by delayed defense funding and the non-selection of its FANG FPV offering, management maintains a funded pipeline of approximately $2.4 billion across the U.S. and Indo-Pacific regions. The company holds $242.7 million in cash and is advancing the acquisition of Steyr Motors to secure internal engine manufacturing capabilities, with significant revenue ramping anticipated in 2027. 1d ago